

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
3 October 2002 (03.10.2002)

PCT

(10) International Publication Number
WO 02/077183 A2

(51) International Patent Classification⁷: **C12N**

(21) International Application Number: PCT/US02/09107

(22) International Filing Date: 21 March 2002 (21.03.2002)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

09/815,242	21 March 2001 (21.03.2001)	US
09/948,993	6 September 2001 (06.09.2001)	US
60/342,923	25 October 2001 (25.10.2001)	US
10/072,851	8 February 2002 (08.02.2002)	US
60/362,699	6 March 2002 (06.03.2002)	US

(71) Applicant (for all designated States except US): **ELITRA PHARMACEUTICALS, INC.** [US/US]; 3510 Dunhill Street, Suite A, San Diego, CA 92121 (US).

(72) Inventors; and

(75) Inventors/Applicants (for US only): **WANG, Liangsu** [CA/US]; 4204 Calle Isabelino, San Diego, CA 92130


(US). **ZAMUDIO, Carlos** [US/US]; 8724 Villa La Jolla, #88, La Jolla, CA 92037 (US). **MALONE, Cheryl** [US/US]; 8798 Wahl Street, Santee, CA 92071 (US). **HASELBECK, Robert** [US/US]; 4672 El Cerrito Drive, San Diego, CA 92115 (US). **OHLSEN, Kari, L.** [US/US]; 3560 Vista De La Orilla, San Diego, CA 92117 (US). **ZYSKIND, Judith, W.** [US/US]; 8415 La Jolla Scenic Drive, La Jolla, CA 92037 (US). **WALL, Daniel** [US/US]; 3734 Brookshire Street, San Diego, CA 92111 (US). **TRAWICK, John, D.** [US/US]; 7975 Michelle Drive, La Mesa, CA 91942 (US). **CARR, Grant, J.** [US/US]; 2210 Sonrisa Glen, Escondido, CA 92029 (US). **YAMAMOTO, Robert** [US/US]; 3725 Notre Dame Avenue, San Diego, CA 92122 (US). **FORSYTH, R., Allyn** [US/US]; 1135 Beryl Street, San Diego, CA 92109 (US). **XU, H., Howard** [US/US]; 14695 Penasquitos Drive, San Diego, CA 92129 (US).

(74) Agent: **HUNT, Dale, C.**; KNOBBE, MARTENS, OLSON & BEAR, LLP, 16th Floor, 620 Newport Center Drive, Newport Beach, CA 92660 (US).

(81) Designated States (national): AE, AG, AL, AM, AT, AT (utility model), AU, AZ, BA, BB, BG, BR, BY, BZ, CA,

[Continued on next page]

(54) Title: IDENTIFICATION OF ESSENTIAL GENES IN MICROORGANISMS



(57) Abstract: The sequences of antisense nucleic acids which inhibit the proliferation of prokaryotes are disclosed. Cell-based assays which employ the antisense nucleic acids to identify and develop antibiotics are also disclosed. The antisense nucleic acids can also be used to identify proteins required for proliferation, express these proteins or portions thereof, obtain antibodies capable of specifically binding to the expressed proteins, and to use those expressed proteins as a screen to isolate candidate molecules for rational drug discovery programs. The nucleic acids can also be used to screen for homologous nucleic acids that are required for proliferation in cells other than *Staphylococcus aureus*, *Salmonella typhimurium*, *Klebsiella pneumoniae*, and *Pseudomonas aeruginosa*. The nucleic acids of the present invention can also be used in various assay systems to screen for proliferation required genes in other organisms.



CH, CN, CO, CR, CU, CZ, CZ (utility model), DE, DE (utility model), DK, DK (utility model), DM, DZ, EC, EE, EE (utility model), ES, FI, FI (utility model), GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SK (utility model), SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW.

(84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent

(BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

- *without international search report and to be republished upon receipt of that report*
- *with sequence listing part of description published separately in electronic form and available upon request from the International Bureau*

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

IDENTIFICATION OF ESSENTIAL GENES IN MICROORGANISMSSequence Listing

The present application is being filed along with quadruplicate copies of a CD-ROM marked "Copy 1 - SEQUENCE LISTING PART," "Copy 2 - SEQUENCE LISTING PART,"
5 "Copy 3 - SEQUENCE LISTING PART," and "CRF" containing a Sequence Listing in electronic format. The quadruplicate copies of the CD-ROM each contain a file entitled 034VPC_final.ST25.txt, created on March 15, 2002, which is 181,323,311 bytes in size.

Background of the Invention

Since the discovery of penicillin, the use of antibiotics to treat the ravages of bacterial
10 infections has saved millions of lives. With the advent of these "miracle drugs," for a time it was popularly believed that humanity might, once and for all, be saved from the scourge of bacterial infections. In fact, during the 1980s and early 1990s, many large pharmaceutical companies cut back or eliminated antibiotics research and development. They believed that infectious disease caused by bacteria finally had been conquered and that markets for new drugs were limited.
15 Unfortunately, this belief was overly optimistic.

The tide is beginning to turn in favor of the bacteria as reports of drug resistant bacteria become more frequent. The United States Centers for Disease Control announced that one of the most powerful known antibiotics, vancomycin, was unable to treat an infection of the common *Staphylococcus aureus* (staph). This organism is commonly found in our environment and is
20 responsible for many nosocomial infections. The import of this announcement becomes clear when one considers that vancomycin was used for years to treat infections caused by *Staphylococcus* species as well as other stubborn strains of bacteria. In short, bacteria are becoming resistant to our most powerful antibiotics. If this trend continues, it is conceivable that we will return to a time when what are presently considered minor bacterial infections are fatal diseases.

25 Over-prescription and improper prescription habits by some physicians have caused an indiscriminate increase in the availability of antibiotics to the public. The patients are also partly responsible, since they will often improperly use the drug, thereby generating yet another population of bacteria that is resistant, in whole or in part, to traditional antibiotics.

The bacterial pathogens that have haunted humanity remain, in spite of the development of
30 modern scientific practices to deal with the diseases that they cause. Drug resistant bacteria are now an increasing threat to the health of humanity. A new generation of antibiotics is needed to once again deal with the pending health threat that bacteria present.

Discovery of New Antibiotics

As more and more bacterial strains become resistant to the panel of available antibiotics,
35 new antibiotics are required to treat infections. In the past, practitioners of pharmacology would have to rely upon traditional methods of drug discovery to generate novel, safe and efficacious compounds for the treatment of disease. Traditional drug discovery methods involve blindly testing potential drug candidate-molecules, often selected at random, in the hope that one might prove to be

an effective treatment for some disease. The process is painstaking and laborious, with no guarantee of success. Today, the average cost to discover and develop a new drug exceeds US \$500 million, and the average time from laboratory to patient is 15 years. Improving this process, even incrementally, would represent a huge advance in the generation of novel antimicrobial agents.

5 Newly emerging practices in drug discovery utilize a number of biochemical techniques to provide for directed approaches to creating new drugs, rather than discovering them at random. For example, gene sequences and proteins encoded thereby that are required for the proliferation of a cell or microorganism make excellent targets since exposure of bacteria to compounds active against these targets would result in the inactivation of the cell or microorganism. Once a target is
10 identified, biochemical analysis of that target can be used to discover or to design molecules that interact with and alter the functions of the target. Use of physical and computational techniques to analyze structural and biochemical properties of targets in order to derive compounds that interact with such targets is called rational drug design and offers great potential. Thus, emerging drug discovery practices use molecular modeling techniques, combinatorial chemistry approaches, and
15 other means to produce and screen and/or design large numbers of candidate compounds.

Nevertheless, while this approach to drug discovery is clearly the way of the future, problems remain. For example, the initial step of identifying molecular targets for investigation can be an extremely time consuming task. It may also be difficult to design molecules that interact with the target by using computer modeling techniques. Furthermore, in cases where the function of the
20 target is not known or is poorly understood, it may be difficult to design assays to detect molecules that interact with and alter the functions of the target. To improve the rate of novel drug discovery and development, methods of identifying important molecular targets in pathogenic cells or microorganisms and methods for identifying molecules that interact with and alter the functions of such molecular targets are urgently required.

25 *Escherichia coli* represents an excellent model system to understand bacterial biochemistry and physiology. The estimated 4288 genes scattered along the 4.6×10^6 base pairs of the *Escherichia coli* (*E. coli*) chromosome offer tremendous promise for the understanding of bacterial biochemical processes. In turn, this knowledge will assist in the development of new tools for the diagnosis and treatment of bacteria-caused human disease. The entire *E. coli* genome has been
30 sequenced, and this body of information holds a tremendous potential for application to the discovery and development of new antibiotic compounds. Yet, in spite of this accomplishment, the general functions or roles of many of these genes are still unknown. For example, the total number of proliferation-required genes contained within the *E. coli* genome is unknown, but has been variously estimated at around 200 to 700 (Armstrong, K.A. and Fan, D.P. Essential Genes in the
35 *metB-malB* Region of *Escherichia coli* K12, 1975, J. Bacteriol. 126: 48-55).

Staphylococcus aureus is a Gram positive microorganism which is the causative agent of many infectious diseases. Local infection by *Staphylococcus aureus* can cause abscesses on skin and cellulitis in subcutaneous tissues and can lead to toxin-related diseases such as toxic shock and

scalded skin syndromes. *Staphylococcus aureus* can cause serious systemic infections such as osteomyelitis, endocarditis, pneumonia, and septicemia. *Staphylococcus aureus* is also a common cause of food poisoning, often arising from contact between prepared food and infected food industry workers. Antibiotic resistant strains of *Staphylococcus aureus* have recently been
5 identified, including those that are now resistant to all available antibiotics, thereby severely limiting the options of care available to physicians.

Pseudomonas aeruginosa is an important Gram negative opportunistic pathogen. It is the most common Gram negative found in nosocomial infections. *P. aeruginosa* is responsible for 16% of nosocomial pneumonia cases, 12% of hospital-acquired urinary tract infections, 8% of surgical
10 wound infections, and 10% of bloodstream infections. Immunocompromised patients, such as neutropenic cancer and bone marrow transplant patients, are particularly susceptible to opportunistic infections. In this group of patients, *P. aeruginosa* is responsible for pneumonia and septicemia with attributable deaths reaching 30%. *P. aeruginosa* is also one of the most common and lethal pathogens responsible for ventilator-associated pneumonia in intubated patients, with directly
15 attributable death rates reaching 38%. Although *P. aeruginosa* outbreaks in burn patients are rare, it is associated with 60% death rates. In the AIDS population, *P. aeruginosa* is associated with 50% of deaths. Cystic fibrosis patients are characteristically susceptible to chronic infection by *P. aeruginosa*, which is responsible for high rates of illness and death. Current antibiotics work poorly for CF infections (Van Delden & Igelwsky. 1998. Emerging Infectious Diseases 4:551-560;
20 references therein).

The gram negative enteric bacterial genus, *Salmonella*, encompasses at least 2 species. One of these, *S. enterica*, is divided into multiple subspecies and thousands of serotypes or serovars (Brenner, et al. 2000 J. Clin. Microbiol. 38:2465-2467). The *S. enterica* human pathogens include serovars Typhi, Paratyphi, Typhimurium, Choleraesuis, and many others deemed so closely related
25 that they are variants of a widespread species. Worldwide, disease in humans caused by *Salmonella* is a very serious problem. In many developing countries, *S. enterica* ser. Typhi still causes often-fatal typhoid fever. This problem has been reduced or eliminated in wealthy industrial states. However, enteritis induced by *Salmonella* is widespread and is the second most common disease caused by contaminated food in the United States (Edwards, BH 1999 "Salmonella and Shigella
30 species" Clin. Lab Med. 19(3):469-487). Though usually self-limiting in healthy individuals, others such as children, seniors, and those with compromising illnesses can be at much greater risk of serious illness and death.

Some *S. enterica* serovars (e.g. Typhimurium) cause a localized infection in the gastrointestinal tract. Other serovars (i.e. Typhi and Paratyphi) cause a much more serious systemic
35 infection. In animal models, these roles can be reversed which has allowed the use of the relatively safe *S. enterica* ser. Typhimurium as a surrogate in mice for the typhoid fever agent, *S. enterica* ser. Typhi. In mice, *S. enterica* ser Typhimurium causes a systemic infection similar in outcome to typhoid fever. Years of study of the *Salmonella* have led to the identification of many determinants

of virulence in animals and humans. *Salmonella* is interesting in its ability to localize to and invade the intestinal epithelium, induce morphologic changes in target cells via injection of certain cell-remodeling proteins, and to reside intracellularly in membrane-bound vesicles (Wallis, TS and Galyov, EE 2000 "Molecular basis of *Salmonella*-induced enteritis." Molec. Microb. 36:997-1005; Falkow, S "The evolution of pathogenicity in *Escherichia*, *Shigella*, and *Salmonella*," Chap. 149 in Neidhardt, et al. eds pp 2723-2729; Gulig, PA "Pathogenesis of Systemic Disease," Chap. 152 in Neidhardt, et al. ppp 2774-2787). The immediate infection often results in a severe watery diarrhea but *Salmonella* also can establish and maintain a subclinical carrier state in some individuals. Spread is via food contaminated with sewage.

10 The gene products implicated in *Salmonella* pathogenesis include type three secretion systems (TTSS), proteins affecting cytoplasmic structure of the target cells, many proteins carrying out functions necessary for survival and proliferation of *Salmonella* in the host, as well as "traditional" factors such as endotoxin and secreted exotoxins. Additionally, there must be factors mediating species-specific illnesses. Despite this most of the genomes of *S. enterica* ser. Typhi (see
15 http://www.sanger.ac.uk/Projects/S_typhi/ for the genome database) and *S. enterica* ser. Typhimurium (see <http://genome.wustl.edu/gsc/bacterial/salmonella.shtml> for the genome database) are highly conserved and are mutually useful for gene identification in multiple serovars. The *Salmonella* are a complex group of enteric bacteria causing disease similar to but distinct from other gram negative enterics such as *E. coli* and have been a focus of biomedical research for the
20 last century.

Enterococcus faecalis, a Gram positive bacterium, is by far the most common member of the enterococci to cause infections in humans. *Enterococcus faecium* generally accounts for less than 20% of clinical isolates. Enterococci infections are mostly hospital-acquired though they are also associated with some community-acquired infections. Of nosocomial infections enterococci
25 account for 12% of bacteremia, 15% of surgical wound infections, 14% of urinary tract infections, and 5 to 15% of endocarditis cases (Huycke, M. M., D. F., Sahm and M. S. Gilmore. 1998. Emerging Infectious Diseases 4:239-249). Additionally enterococci are frequently associated with intraabdominal and pelvic infections. Enterococci infections are often hard to treat because they are resistant to a vast array of antimicrobial drugs, including aminoglycosides, penicillin, ampicillin
30 and vancomycin. The development of multiple-drug resistant (MDR) enterococci has made this bacteria a major concern for treating nosocomial infections.

 Current drug discovery methods involve screening large number of prospective therapeutic compounds to identify those that are effective therapeutic agents or that can be optimized to provide an effective therapeutic agents. For example, the compounds to be evaluated for therapeutic
35 activity may be members of a library of compounds generated by combinatorial chemistry or members of a library of natural products.

 Unfortunately, current methods are laborious and time consuming and may yield compounds which have already been identified or which act on gene products which are already

targeted by an existing therapeutic agent. In addition, a large number of compounds have been identified which have antimicrobial activity but which cannot be administered to individuals suffering from infection due to the fact that their targets are unknown.

The above reasons underscore the urgency of developing new antibiotics that are effective
5 against *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*,
Pseudomonas aeruginosa, and *Salmonella typhimurium*. Accordingly, there is an urgent need for
more novel methods to identify and characterize bacterial genomic sequences that encode gene
products involved in proliferation, and are thereby potential new targets for antibiotic development.
Likewise, there is a need for rapid screening techniques which yield novel compounds or
10 compounds which act on novel targets as well as a need for methods which permit the identification
of the target on which a compound with antimicrobial activity acts.

Prior to the present invention, the discovery of *Escherichia coli*, *Staphylococcus aureus*,
Enterococcus faecalis, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Salmonella*
typhimurium genes required for proliferation of the microorganism was a painstaking and slow
15 process. Rapid screening techniques for identifying novel targets on which novel compounds act
were undeveloped. While the detection and identification of new cellular drug targets within a
Escherichia coli, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*,
Pseudomonas aeruginosa, and *Salmonella typhimurium* cell is key for novel antibiotic development
and effective treatment, the current methods of drug target discovery available prior to this
20 invention have required painstaking processes requiring years of effort.

Summary of the Invention

Some aspects of the present invention are described in the numbered paragraphs below.

1. A purified or isolated nucleic acid sequence comprising a nucleotide sequence
consisting essentially of one of SEQ ID NOs: 1-6213, wherein expression of said nucleic acid
25 inhibits proliferation of a cell.

2. The nucleic acid sequence of Paragraph 1, wherein said nucleotide sequence is
complementary to at least a portion of a coding sequence of a gene whose expression is required for
proliferation of a cell.

3. The nucleic acid of Paragraph 1, wherein said nucleic acid sequence is
30 complementary to at least a portion of a nucleotide sequence of an RNA required for proliferation
of a cell.

4. The nucleic acid of Paragraph 3, wherein said RNA is an RNA comprising a
sequence of nucleotides encoding more than one gene product.

5. A purified or isolated nucleic acid comprising a fragment of one of SEQ ID NOs.:
35 1-6213, said fragment selected from the group consisting of fragments comprising at least 10, at
least 20, at least 25, at least 30, at least 50 and more than 50 consecutive nucleotides of one of SEQ
ID NOs: 1-6213.

6. The fragment of Paragraph 5, wherein said fragment is included in a nucleic acid obtained from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

7. The fragment of Paragraph 5, wherein said fragment is included in a nucleic acid obtained from an organism other than *Escherichia coli*.

8. A vector comprising a promoter operably linked to the nucleic acid of any one of Paragraphs 1-7.

9. The vector of Paragraph 8, wherein said promoter is active in a microorganism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,

Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
 5 *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*,
 10 *Yersinia pestis* and any species falling within the genera of any of the above species.

10. A host cell containing the vector of Paragraph 8 or Paragraph 9.

11. A purified or isolated antisense nucleic acid comprising a nucleotide sequence complementary to at least a portion of an intragenic sequence, intergenic sequence, sequences spanning at least a portion of two or more genes, 5' noncoding region, or 3' noncoding region
 15 within an operon comprising a proliferation-required gene whose activity or expression is inhibited by an antisense nucleic acid comprising the nucleotide sequence of one of SEQ ID NOs.: 1-6213.

12. The purified or isolated antisense nucleic acid of Paragraph 11, wherein said antisense nucleic acid is complementary to a nucleic acid from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*,
 20 *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
 25 *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
 30 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
 35 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma*

urealyticum, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

13. The purified or isolated antisense nucleic acid of Paragraph 11, wherein said nucleotide sequence is complementary to a nucleotide sequence of a nucleic acid from an organism other than *E. coli*.

14. The purified or isolated antisense nucleic acid of Paragraph 11, wherein said proliferation-required gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

15. A purified or isolated nucleic acid comprising a nucleotide sequence having at least 70% identity to a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, fragments comprising at least 25 consecutive nucleotides of SEQ ID NOs.: 1-6213, the nucleotide sequences complementary to SEQ ID NOs.: 1-6213 and the sequences complementary to fragments comprising at least 25 consecutive nucleotides of SEQ ID NOs.: 1-6213 as determined using BLASTN version 2.0 with the default parameters.

16. The purified or isolated nucleic acid of Paragraph 15, wherein said nucleic acid is obtained from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

17. The nucleic acid of Paragraph 15, wherein said nucleic acid is obtained from an organism other than *E. coli*.

18. A vector comprising a promoter operably linked to a nucleic acid encoding a polypeptide whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence of any one of SEQ ID NOs.: 1-6213.

19. The vector of Paragraph 18, wherein said nucleic acid encoding said polypeptide is
 5 obtained from an organism selected from the group consisting of *Acinetobacter baumannii*,
Anaplasma marginale, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella*
pertussis, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia*
mallei, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis*
glabrata), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*,
 10 *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia*
pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*,
Clostridium difficile, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*,
Cryptococcus neoformans, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*,
Escherichia coli, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella*
 15 *pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*,
Mycobacterium avium, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*,
Mycoplasma genitalium, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*,
Nocardia asteroides, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*,
Proteus mirabilis, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas*
 20 *syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*,
Salmonella typhi, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*,
Shigella sonnei, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
Streptococcus pneumoniae, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*,
Ureaplasma urealyticum, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia*
 25 *enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

20. The vector of Paragraph 18, wherein said nucleotide sequence encoding said polypeptide is obtained from an organism other than *E. coli*.

21. A host cell containing the vector of Paragraph 18.

22. The vector of Paragraph 18, wherein said polypeptide comprises a polypeptide
 30 comprising an amino acid sequence selected from the group consisting of SEQ ID NOs: 42398-
 78581.

23. The vector of Paragraph 18, wherein said promoter is operably linked to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

24. A purified or isolated polypeptide comprising a polypeptide whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence of any one of SEQ ID NOs.: 1-6213, or a fragment selected from the group consisting of fragments comprising at least 5,

at least 10, at least 20, at least 30, at least 40, at least 50, at least 60 or more than 60 consecutive amino acids of one of the said polypeptides.

25. The polypeptide of Paragraph 24, wherein said polypeptide comprises an amino acid sequence of any one of SEQ ID NOs.: 42398-78581 or a fragment comprising at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60 or more than 60 consecutive amino acids of a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

26. The polypeptide of Paragraph 24, wherein said polypeptide is obtained from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

27. The polypeptide of Paragraph 24, wherein said polypeptide is obtained from an organism other than *E. coli*.

28. A purified or isolated polypeptide comprising a polypeptide having at least 25% amino acid identity to a polypeptide whose expression is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, or at least 25% amino acid identity to a fragment comprising at least 10, at least 20, at least 30, at least 40, at least 50, at least 60 or more than 60 consecutive amino acids of a polypeptide whose expression is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 as determined using FASTA version 3.0t78 with the default parameters.

29. The polypeptide of Paragraph 28, wherein said polypeptide has at least 25% identity to a polypeptide comprising one of SEQ ID NOs: 42398-78581 or at least 25% identity to a fragment comprising at least 5, at least 10, at least 20, at least 30, at least 40, at least 50, at least 60 or more than 60 consecutive amino acids of a polypeptide comprising one of SEQ ID NOs.: 42398-
5 78581 as determined using FASTA version 3.0t78 with the default parameters.

30. The polypeptide of Paragraph 28, wherein said polypeptide is obtained from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.
10
15
20
25

31. The polypeptide of Paragraph 28, wherein said polypeptide is obtained from an organism other than *E. coli*.

30 32. An antibody capable of specifically binding the polypeptide of one of Paragraphs 28-31.

33. A method of producing a polypeptide, comprising introducing a vector comprising a promoter operably linked to a nucleic acid comprising a nucleotide sequence encoding a polypeptide whose expression is inhibited by an antisense nucleic acid comprising one of SEQ ID
35 NOs.: 1-6213 into a cell.

34. The method of Paragraph 33, further comprising the step of isolating said polypeptide.

35. The method of Paragraph 33, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

36. The method of Paragraph 33, wherein said nucleic acid encoding said polypeptide is obtained from an organism selected from the group consisting of *Acinetobacter baumannii*,
 5 *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*,
 10 *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*,
Clostridium difficile, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*,
Escherichia coli, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*,
 15 *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*,
Nocardia asteroides, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*,
 20 *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
Streptococcus pneumoniae, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

25 37. The method of Paragraph 33, wherein said nucleic acid encoding said polypeptide is obtained from an organism other than *E. coli*.

38. The method of Paragraph 33, wherein said promoter is operably linked to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

30 39. A method of inhibiting proliferation of a cell in an individual comprising inhibiting the activity or reducing the amount of a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 or inhibiting the activity or reducing the amount of a nucleic acid encoding said gene product.

35 40. The method of Paragraph 39, wherein said method comprises inhibiting said activity or reducing said amount of a gene product in an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*,

Burkholderia fungorum, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
 5 *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
 10 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
 15 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

20 41. The method of Paragraph 39, wherein said method comprises inhibiting said activity or reducing said amount of a gene product in an organism other than *E. coli*.

42. The method of Paragraph 39, wherein said gene product is present in an organism other than *E. coli*.

25 43. The method of Paragraph 39, wherein said gene product comprises a polypeptide comprising a sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

44. A method for identifying a compound which influences the activity of a gene product required for proliferation, said gene product comprising a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, said method comprising:

30 contacting said gene product with a candidate compound; and
 determining whether said compound influences the activity of said gene product.

45. The method of Paragraph 44, wherein said gene product is from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*,
 35 *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*,

Clostridium acetobutylicum, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*,
 5 *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
 10 *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*,
 15 *Yersinia pestis* and any species falling within the genera of any of the above species.

46. The method of Paragraph 44, wherein said gene product is from an organism other than *E. coli*.

47. The method of Paragraph 44, wherein said gene product is a polypeptide and said activity is an enzymatic activity.

20 48. The method of Paragraph 44, wherein said gene product is a polypeptide and said activity is a carbon compound catabolism activity.

49. The method of Paragraph 44, wherein said gene product is a polypeptide and said activity is a biosynthetic activity.

25 50. The method of Paragraph 44, wherein said gene product is a polypeptide and said activity is a transporter activity.

51. The method of Paragraph 44, wherein said gene product is a polypeptide and said activity is a transcriptional activity.

52. The method of Paragraph 44, wherein said gene product is a polypeptide and said activity is a DNA replication activity.

30 53. The method of Paragraph 44, wherein said gene product is a polypeptide and said activity is a cell division activity.

54. The method of Paragraph 44, wherein said gene product is an RNA.

55. The method of Paragraph 44, wherein said gene product is a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-
 35 78581.

56. A compound identified using the method of Paragraph 44.

57. A method for identifying a compound or nucleic acid having the ability to reduce the activity or level of a gene product required for proliferation, said gene product comprising a

gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, said method comprising:

(a) contacting a target gene or RNA encoding said gene product with a candidate compound or nucleic acid; and

(b) measuring an activity of said target.

58. The method of Paragraph 57, wherein said target gene or RNA is from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

59. The method of Paragraph 57, wherein said target gene or RNA is from an organism other than *E. coli*.

60. The method of Paragraph 57, wherein said gene product is from an organism other than *E. coli*.

61. The method of Paragraph 57, wherein said target is a messenger RNA molecule and said activity is translation of said messenger RNA.

62. The method of Paragraph 57, wherein said target is a messenger RNA molecule and said activity is transcription of a gene encoding said messenger RNA.

63. The method of Paragraph 57, wherein said target is a gene and said activity is transcription of said gene.

64. The method of Paragraph 57, wherein said target is a nontranslated RNA and said activity is processing or folding of said nontranslated RNA or assembly of said nontranslated RNA into a protein/RNA complex.

65. The method of Paragraph 57, wherein said target is a messenger RNA molecule encoding a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

66. The method of Paragraph 57, wherein said target comprises a nucleic acid selected from the group consisting of SEQ ID NOS.: 6214-42397.

67. A compound or nucleic acid identified using the method of Paragraph 57.

68. A method for identifying a compound which reduces the activity or level of a gene product required for proliferation of a cell, wherein the activity or expression of said gene product is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, said method comprising the steps of:

(a) providing a sublethal level of an antisense nucleic acid comprising a nucleotide sequence complementary to a nucleic acid comprising a nucleotide sequence encoding said gene product in a cell to reduce the activity or amount of said gene product in said cell, thereby producing a sensitized cell;

(b) contacting said sensitized cell with a compound; and

(c) determining the degree to which said compound inhibits proliferation of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

69. The method of Paragraph 68, wherein said determining step comprises determining whether said compound inhibits the growth of said sensitized cell to a greater extent than said compound inhibits the growth of a nonsensitized cell.

70. The method of Paragraph 68, wherein said cell is a Gram positive bacterium.

71. The method of Paragraph 68, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

72. The method of Paragraph 68, wherein said bacterium is *Staphylococcus aureus*.

73. The method of Paragraph 72, wherein said *Staphylococcus* species is coagulase negative.

74. The method of Paragraph 72, wherein said bacterium is selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

75. The method of Paragraph 68, wherein said cell is an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*),

Candida dubliniensis, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*,
 5 *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
 10 *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*,
 15 *Yersinia pestis* and any species falling within the genera of any of the above species.

76. The method of Paragraph 68, wherein said cell is not an *E. coli* cell.

77. The method of Paragraph 68, wherein said gene product is from an organism other than *E. coli*.

20 78. The method of Paragraph 68, wherein said antisense nucleic acid is transcribed from an inducible promoter.

79. The method of Paragraph 68, further comprising the step of contacting said cell with a concentration of inducer which induces transcription of said antisense nucleic acid to a sublethal level.

25 80. The method of Paragraph 68, wherein growth inhibition is measured by monitoring optical density of a culture growth solution.

81. The method of Paragraph 68, wherein said gene product is a polypeptide.

82. The method of Paragraph 81, wherein said polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

30 83. The method of Paragraph 68, wherein said gene product is an RNA.

84. The method of Paragraph 68, wherein nucleic acid encoding said gene product comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

85. A compound identified using the method of Paragraph 68.

35 86. A method for inhibiting cellular proliferation comprising introducing an effective amount of a compound with activity against a gene whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 or a compound with activity against the product of said gene into a population of cells expressing said gene.

87. The method of Paragraph 86, wherein said compound is an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, or a proliferation-inhibiting portion thereof.

88. The method of Paragraph 86, wherein said proliferation inhibiting portion of one of
5 SEQ ID NOs.: 1-6213 is a fragment comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 51 consecutive nucleotides of one of SEQ ID NOs.: 1-6213.

89. The method of Paragraph 86, wherein said population is a population of Gram positive bacteria.

90. The method of Paragraph 89, wherein said population of Gram positive bacteria is
10 selected from the group consisting of a population of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

91. The method of Paragraph 86, wherein said population is a population of *Staphylococcus aureus*.

92. The method of Paragraph 91, wherein said population is a population of a
15 bacterium selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

93. The method of Paragraph 86, wherein said population is a population of a bacterium selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*,
25 *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*,
30 *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
35 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

94. The method of Paragraph 86, wherein said population is a population of an organism other than *E. coli*.

95. The method of Paragraph 86, wherein said product of said gene is from an organism other than *E. coli*.

5 96. The method of Paragraph 86, wherein said gene encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

97. The method of Paragraph 86, wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

10 98. A composition comprising an effective concentration of an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, or a proliferation-inhibiting portion thereof in a pharmaceutically acceptable carrier.

99. The composition of Paragraph 98, wherein said proliferation-inhibiting portion of one of SEQ ID NOS.: 1-6213 comprises at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOS.: 1-6213.

15 100. A method for inhibiting the activity or expression of a gene in an operon required for proliferation wherein the activity or expression of at least one gene in said operon is inhibited by an antisense nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOS.: 1-6213, said method comprising contacting a cell in a cell population with an antisense nucleic acid complementary to at least a portion of said operon.

20 101. The method of Paragraph 100, wherein said antisense nucleic acid comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 or a proliferation-inhibiting portion thereof.

102. The method of Paragraph 100, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
 25 *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
 30 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,

Salmonella choleraesuis, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

103. The method of Paragraph 100, wherein said cell is not an *E. coli* cell.
104. The method of Paragraph 100, wherein said gene is from an organism other than *E. coli*.
105. The method of Paragraph 100, wherein said cell is contacted with said antisense nucleic acid by introducing a plasmid which expresses said antisense nucleic acid into said cell population.
106. The method of Paragraph 100, wherein said cell is contacted with said antisense nucleic acid by introducing a phage which encodes said antisense nucleic acid into said cell population.
107. The method of Paragraph 100, wherein said cell is contacted with said antisense nucleic acid by expressing said antisense nucleic acid from the chromosome of cells in said cell population.
108. The method of Paragraph 100, wherein said cell is contacted with said antisense nucleic acid by introducing a promoter adjacent to a chromosomal copy of said antisense nucleic acid such that said promoter directs the transcription of said antisense nucleic acid.
109. The method of Paragraph 100, wherein said cell is contacted with said antisense nucleic acid by introducing a retron which expresses said antisense nucleic acid into said cell population.
110. The method of Paragraph 100, wherein said cell is contacted with said antisense nucleic acid by introducing a ribozyme into said cell-population, wherein a binding portion of said ribozyme comprises said antisense nucleic acid.
111. The method of Paragraph 100, wherein said cell is contacted with said antisense nucleic acid by introducing a liposome comprising said antisense nucleic acid into said cell.
112. The method of Paragraph 100, wherein said cell is contacted with said antisense nucleic acid by electroporation of said antisense nucleic acid into said cell.
113. The method of Paragraph 100, wherein said antisense nucleic acid is a fragment comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOS.: 1-6213.
114. The method of Paragraph 100 wherein said antisense nucleic acid is a synthetic oligonucleotide.
115. The method of Paragraph 100, wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

116. A method for identifying a gene which is required for proliferation of a cell comprising:

- (a) contacting a cell with an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, wherein said cell is a cell other than the organism from which said nucleic acid was obtained;
- (b) determining whether said nucleic acid inhibits proliferation of said cell; and
- (c) identifying the gene in said cell which encodes the mRNA which is complementary to said antisense nucleic acid or a portion thereof.

117. The method of Paragraph 116, wherein said cell is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

118. The method of Paragraph 116 wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

119. The method of Paragraph 116, wherein said cell is not *E. coli*.

120. The method of Paragraph 116, further comprising operably linking said antisense nucleic acid to a promoter which is functional in said cell, said promoter being included in a vector, and introducing said vector into said cell.

121. A method for identifying a compound having the ability to inhibit proliferation of a cell comprising:

(a) identifying a homolog of a gene or gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 in a test cell, wherein said test cell is not the cell from which said nucleic acid was obtained;

(b) identifying an inhibitory nucleic acid sequence which inhibits the activity of said homolog in said test cell;

(c) contacting said test cell with a sublethal level of said inhibitory nucleic acid, thus sensitizing said cell;

(d) contacting the sensitized cell of step (c) with a compound; and

(e) determining the degree to which said compound inhibits proliferation of said sensitized cell relative to a cell which does not contain said inhibitory nucleic acid.

122. The method of Paragraph 121, wherein said determining step comprises determining whether said compound inhibits proliferation of said sensitized test cell to a greater extent than said compound inhibits proliferation of a nonsensitized test cell.

123. The method of Paragraph 121, wherein step (a) comprises identifying a nucleic acid homologous to a gene or gene product whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213 or a nucleic acid encoding a homologous polypeptide to a polypeptide whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213 by using an algorithm selected from the group consisting of BLASTN version 2.0 with the default parameters and FASTA version 3.0t78 algorithm with the default parameters to identify said homologous nucleic acid or said nucleic acid encoding a homologous polypeptide in a database.

124. The method of Paragraph 121 wherein said step (a) comprises identifying a homologous nucleic acid or a nucleic acid comprising a sequence of nucleotides encoding a homologous polypeptide by identifying nucleic acids which hybridize to said nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213 or the complement of said nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213.

125. The method of Paragraph 121 wherein step (a) comprises expressing a nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213 in said test cell.

126. The method of Paragraph 121, wherein step (a) comprises identifying a homologous nucleic acid or a nucleic acid encoding a homologous polypeptide in a test cell selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida*

pseudotropicalis), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*,
 5 *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
 10 *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*,
 15 *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

127. The method of Paragraph 121, wherein step (a) comprises identifying a homologous nucleic acid or a nucleic acid encoding a homologous polypeptide in a test cell other than *E. coli*.

20 128. The method of Paragraph 121, wherein said inhibitory nucleic acid is an antisense nucleic acid.

129. The method of Paragraph 121, wherein said inhibitory nucleic acid comprises an antisense nucleic acid to a portion of said homolog.

25 130. The method of Paragraph 121, wherein said inhibitory nucleic acid comprises an antisense nucleic acid to a portion of the operon encoding said homolog.

131. The method of Paragraph 121, wherein the step of contacting the cell with a sublethal level of said inhibitory nucleic acid comprises directly contacting the surface of said cell with said inhibitory nucleic acid.

30 132. The method of Paragraph 121, wherein the step of contacting the cell with a sublethal level of said inhibitory nucleic acid comprises transcribing an antisense nucleic acid complementary to at least a portion of the RNA transcribed from said homolog in said cell.

133. The method of Paragraph 121, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

35 134. The method of Paragraph 121, wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

135. A compound identified using the method of Paragraph 121.

136. A method of identifying a compound having the ability to inhibit proliferation comprising:

(a) contacting a test cell with a sublethal level of a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 or a portion thereof which inhibits the proliferation of the cell from which said nucleic acid was obtained, thus sensitizing said test cell;

(b) contacting the sensitized test cell of step (a) with a compound; and

(c) determining the degree to which said compound inhibits proliferation of said sensitized test cell relative to a cell which does not contain said nucleic acid.

137. The method of Paragraph 136, wherein said determining step comprises determining whether said compound inhibits proliferation of said sensitized test cell to a greater extent than said compound inhibits proliferation of a nonsensitized test cell.

138. A compound identified using the method of Paragraph 136.

139. The method of Paragraph 136, wherein said test cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

140. The method of Paragraph 136, wherein the test cell is not *E. coli*.

141. A method for identifying a compound having activity against a biological pathway required for proliferation comprising:

(a) sensitizing a cell by providing a sublethal level of an antisense nucleic acid complementary to a nucleic acid encoding a gene product required for proliferation, wherein the activity or expression of said gene product is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID

5 NOs.: 1-6213, in said cell to reduce the activity or amount of said gene product;

(b) contacting the sensitized cell with a compound; and

(c) determining the degree to which said compound inhibits the growth of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

142. The method of Paragraph 141, wherein said determining step comprises
10 determining whether said compound inhibits the growth of said sensitized cell to a greater extent than said compound inhibits the growth of a nonsensitized cell.

143. The method of Paragraph 141, wherein said cell is selected from the group consisting of bacterial cells, fungal cells, plant cells, and animal cells.

144. The method of Paragraph 141, wherein said cell is a Gram positive bacterium.

15 145. The method of Paragraph 144, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

146. The method of Paragraph 145, wherein said Gram positive bacterium is *Staphylococcus aureus*.

20 147. The method of Paragraph 146, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

148. The method of Paragraph 141, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*,
25 *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*,
30 *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*,
35 *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella*

typhimurium, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*,

5 *Yersinia pestis* and any species falling within the genera of any of the above species.

149. The method of Paragraph 141, wherein said cell is not an *E. coli* cell.

150. The method of Paragraph 141, wherein said gene product is from an organism other than *E. coli*.

151. The method of Paragraph 141, wherein said antisense nucleic acid is transcribed
10 from an inducible promoter.

152. The method of Paragraph 141, further comprising contacting the cell with an agent which induces transcription of said antisense nucleic acid from said inducible promoter, wherein said antisense nucleic acid is transcribed at a sublethal level.

153. The method of Paragraph 141, wherein inhibition of proliferation is measured by
15 monitoring the optical density of a liquid culture.

154. The method of Paragraph 141, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

155. The method of Paragraph 141, wherein said nucleic acid encoding said gene
20 product comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

156. A compound identified using the method of Paragraph 141.

157. A method for identifying a compound having the ability to inhibit cellular proliferation comprising:

25 (a) contacting a cell with an agent which reduces the activity or level of a gene product required for proliferation of said cell, wherein said gene product is a gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213;

(b) contacting said cell with a compound; and

30 (c) determining whether said compound reduces proliferation of said contacted cell by acting on said gene product.

158. The method of Paragraph 157, wherein said determining step comprises determining whether said compound reduces proliferation of said contacted cell to a greater extent than said compound reduces proliferation of cells which have not been contacted with said agent.

35 159. The method of Paragraph 157, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida*

glabrata (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*,
 5 *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
 10 *pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
 15 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

160. The method of Paragraph 157, wherein said cell is not an *E. coli* cell.
- 20 161. The method of Paragraph 157, wherein said gene product is from an organism other than *E. coli*.
162. The method of Paragraph 157, wherein said agent which reduces the activity or level of a gene product required for proliferation of said cell comprises an antisense nucleic acid to a gene or operon required for proliferation.
- 25 163. The method of Paragraph 157, wherein said agent which reduces the activity or level of a gene product required for proliferation of said cell comprises a compound known to inhibit growth or proliferation of a cell.
164. The method of Paragraph 157, wherein said cell contains a mutation which reduces the activity or level of said gene product required for proliferation of said cell.
- 30 165. The method of Paragraph 157, wherein said mutation is a temperature sensitive mutation.
166. The method of Paragraph 157, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.
- 35 167. A compound identified using the method of Paragraph 157.
168. A method for identifying the biological pathway in which a proliferation-required gene or its gene product lies, wherein said gene or gene product comprises a gene or gene product

whose activity or expression is inhibited by an antisense nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs.: 1-6213, said method comprising:

(a) providing a sublethal level of an antisense nucleic acid which inhibits the activity of said proliferation-required gene or gene product in a test cell;

(b) contacting said test cell with a compound known to inhibit growth or proliferation of a cell, wherein the biological pathway on which said compound acts is known; and

(c) determining the degree to which said proliferation of said test cell is inhibited relative to a cell which was not contacted with said compound.

169. The method of Paragraph 168, wherein said determining step comprises determining whether said test cell has a substantially greater sensitivity to said compound than a cell which does not express said sublethal level of said antisense nucleic acid.

170. The method of Paragraph 168, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

171. The method of Paragraph 168, wherein said test cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

172. The method of Paragraph 168, wherein said test cell is not an *E. coli* cell.

173. The method of Paragraph 168, wherein said gene product is from an organism other than *E. coli*.

174. A method for determining the biological pathway on which a test compound acts comprising:

- 5 (a) providing a sublethal level of an antisense nucleic acid complementary to a proliferation-required nucleic acid in a first cell, wherein the activity or expression of said proliferation-required nucleic acid is inhibited by an antisense nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOs.: 1-6213 and wherein the biological pathway in which said proliferation-required nucleic acid or a protein encoded
10 by said proliferation-required nucleic acid lies is known,
- (b) contacting said first cell with said test compound; and
- (c) determining the degree to which said test compound inhibits proliferation of said first cell relative to a cell which does not contain said antisense nucleic acid.

175. The method of Paragraph 174, wherein said determining step comprises
15 determining whether said first cell has a substantially greater sensitivity to said test compound than a cell which does not express said sublethal level of said antisense nucleic acid.

176. The method of Paragraph 174, further comprising:

- (d) providing a sublethal level of a second antisense nucleic acid complementary to a second proliferation-required nucleic acid in a second cell, wherein said second
20 proliferation-required nucleic acid is in a different biological pathway than said proliferation-required nucleic acid in step (a); and
- (e) determining whether said second cell does not have a substantially greater sensitivity to said test compound than a cell which does not express said sublethal level of said second antisense nucleic acid, wherein said test compound is specific for the biological
25 pathway against which the antisense nucleic acid of step (a) acts if said first cell has a substantially greater sensitivity to said test compound than said second cell.

177. The method of Paragraph 174, wherein said first cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*,
30 *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*,
35 *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,

Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
5 *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
Staphylococcus aureus, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*,
10 *Yersinia pestis* and any species falling within the genera of any of the above species.

178. The method of Paragraph 174, wherein said first cell is not an *E. coli* cell.

179. The method of Paragraph 174, wherein said proliferation-required nucleic acid is from an organism other than *E. coli*.

180. A purified or isolated nucleic acid comprising a sequence selected from the group
15 consisting of SEQ ID NOs.: 1-6213.

181. A compound which interacts with a gene or gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence of one of SEQ ID NOs.: 1-6213 to inhibit proliferation.

182. The compound of Paragraph 181, wherein said gene product is a polypeptide
20 comprising one of SEQ ID NOs.: 42398-78581.

183. The compound of Paragraph 181, wherein said gene comprises a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397.

184. A compound which interacts with a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence of one of SEQ ID NOs.: 1-6213 to
25 inhibit proliferation.

185. A method for manufacturing an antibiotic comprising the steps of:
screening one or more candidate compounds to identify a compound that reduces the activity or level of a gene product required for proliferation, said gene product comprising a gene product whose activity or expression is inhibited by an antisense nucleic acid comprising a
30 nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213; and
manufacturing the compound so identified.

186. The method of Paragraph 185, wherein said screening step comprises performing any one of the methods of Paragraphs 44, 68, 121, 136, 141, and 157.

187. The method of Paragraph 185, wherein said gene product is a polypeptide
35 comprising one of SEQ ID NOs.: 42398-78581.

188. A method for inhibiting proliferation of a cell in a subject comprising administering an effective amount of a compound that reduces the activity or level of a gene product required for proliferation of said cell, said gene product comprising a gene product whose activity or expression

is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 to said subject.

189. The method of Paragraph 188 wherein said subject is selected from the group consisting of vertebrates, mammals, avians, and human beings.

5 190. The method of Paragraph 188, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

191. The method of Paragraph 188, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
10 *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
15 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
20 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

30 192. The method of Paragraph 188, wherein said cell is not *E. coli*.

193. The method of Paragraph 188, wherein said gene product is from an organism other than *E. coli*.

194. A purified or isolated nucleic acid consisting essentially of the coding sequence of one of SEQ ID NOs: 6214-42397.

35 195. A fragment of the nucleic acid of Paragraph 8, said fragment comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOs: 6214-42397.

196. A purified or isolated nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, fragments comprising at least 25 consecutive nucleotides of SEQ ID NOs.: 6214-42397, the nucleotide sequences complementary to SEQ ID NOs.: 6214-42397, and the
 5 nucleotide sequences complementary to fragments comprising at least 25 consecutive nucleotides of SEQ ID NOs.: 6214-42397 as determined using BLASTN version 2.0 with the default parameters.

197. The nucleic acid of Paragraph 196, wherein said nucleic acid is from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus*
 10 *fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*,
 15 *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
 20 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
 25 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

30 198. The nucleic acid of Paragraph 196, wherein said nucleic acid is from an organism other than *E. coli*.

199. A method of inhibiting proliferation of a cell comprising inhibiting the activity or reducing the amount of a gene product in said cell or inhibiting the activity or reducing the amount of a nucleic acid encoding said gene product in said cell, wherein said gene product is selected from
 35 the group consisting of a gene product having having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at

least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs:1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213.

200. The method of Paragraph 199, wherein said method comprises inhibiting said activity or reducing said amount of said gene product or inhibiting the activity or reducing the amount of a nucleic acid encoding said gene product in an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

201. The method of Paragraph 199, wherein said method comprises inhibiting said activity or reducing said amount of said gene product or inhibiting the activity or reducing the amount of a nucleic acid encoding said gene product in an organism other than *E. coli*.

202. The method of Paragraph 199, wherein said gene product is from an organism other than *E. coli*.

203. The method of Paragraph 199, wherein said gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42398-78581.

204. The method of Paragraph 199, wherein said gene product is encoded by a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

205. A method for identifying a compound which influences the activity of a gene product required for proliferation comprising:

contacting a candidate compound with a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented

by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213; and

determining whether said candidate compound influences the activity of said gene product.

5 206. The method of Paragraph 205, wherein said gene product is from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*,
10 *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
15 *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*,
20 *Yersinia pestis* and any species falling within the genera of any of the above species.

207. The method of Paragraph 205, wherein said gene product is from an organism other than *E. coli*.

208. The method of Paragraph 205, wherein said gene product is a polypeptide selected
30 from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42398-78581.

209. The method of Paragraph 205, wherein said gene product is encoded by a nucleic
35 acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID

NOS.: 6214-42397 under stringent conditions, and a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

210. A compound identified using the method of Paragraph 205.

211. A method for identifying a compound or nucleic acid having the ability to reduce
5 the activity or level of a gene product required for proliferation comprising:

(a) providing a target that is a gene or RNA, wherein said target comprises a nucleic acid that encodes a gene product selected from the group consisting of a gene product having having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is
10 inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleic acid identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group
15 consisting of SEQ ID NOS.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, a gene product
20 encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID
25 NOS.: 1-6213;

(b) contacting said target with a candidate compound or nucleic acid; and

(c) measuring an activity of said target.

212. The method of Paragraph 211, wherein said target gene or RNA is from an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*,
30 *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*,
35 *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*,

Listeria monocytogenes, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
5 *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma*
10 *urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

213. The method of Paragraph 211, wherein said target gene or RNA is from an organism other than *E. coli*.

214. The method of Paragraph 211, wherein said gene product is from an organism other
15 than *E. coli*.

215. The method of Paragraph 211, wherein said target is a messenger RNA molecule and said activity is translation of said messenger RNA.

216. The method of Paragraph 211, wherein said compound is a nucleic acid and said activity is translation of said gene product.

217. The method of Paragraph 211, wherein said target is a gene and said activity is
20 transcription of said gene.

218. The method of Paragraph 211, wherein said target is a nontranslated RNA and said activity is processing or folding of said nontranslated RNA or assembly of said nontranslated RNA into a protein/RNA complex.

219. The method of Paragraph 211, wherein said target gene is a messenger RNA
25 molecule encoding a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42398-78581.

220. The method of Paragraph 11, wherein said target gene comprises a nucleic acid
30 selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.:
35 6214-42397 under stringent conditions, and a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

221. A compound or nucleic acid identified using the method of Paragraph 211.

222. A method for identifying a compound which reduces the activity or level of a gene product required for proliferation of a cell comprising:

- 5 (a) providing a sublethal level of an antisense nucleic acid complementary to a nucleic acid encoding said gene product in a cell to reduce the activity or amount of said gene product in said cell, thereby producing a sensitized cell, wherein said gene product is selected from the group consisting of a gene product having having at least 70% nucleic acid identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213;
- 10 25 (b) contacting said sensitized cell with a compound; and
- (c) determining the degree to which said compound inhibits the growth of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

223. The method of Paragraph 222, wherein said determining step comprises determining whether said compound inhibits the growth of said sensitized cell to a greater extent than said compound inhibits the growth of a nonsensitized cell.

224. The method of Paragraph 222, wherein said sensitized cell is a Gram positive bacterium.

225. The method of Paragraph 224, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

226. The method of Paragraph 225, wherein said bacterium is *Staphylococcus aureus*.

227. The method of Paragraph 224, wherein said *Staphylococcus* species is coagulase negative.

228. The method of Paragraph 226, wherein said bacterium is selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

229. The method of Paragraph 222, wherein said sensitized cell is an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

230. The method of Paragraph 222, wherein said cell is an organism other than *E. coli*.

231. The method of Paragraph 222, wherein said gene product is from an organism other than *E. coli*.

232. The method of Paragraph 222, wherein said antisense nucleic acid is transcribed from an inducible promoter.

233. The method of Paragraph 222, further comprising the step of contacting said cell with a concentration of inducer which induces transcription of said antisense nucleic acid to a sublethal level.

234. The method of Paragraph 222, wherein growth inhibition is measured by monitoring optical density of a culture medium.

235. The method of Paragraph 222, wherein said gene product is a polypeptide.

236. The method of Paragraph 235, wherein said polypeptide comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of

SEQ ID NOS.: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42398-78581.

237. The method of Paragraph 222, wherein said gene product is an RNA.

238. The method of Paragraph 222, wherein said nucleic acid encoding said gene
5 product comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleic acid identity as determined using BLASTN version 2.0 with the default parameters to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid which hybridizes to a sequence selected from the group consisting of
10 SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

239. A compound identified using the method of Paragraph 222.

240. A method for inhibiting cellular proliferation comprising introducing a compound
15 with activity against a gene product or a compound with activity against a gene encoding said gene product into a population of cells expressing said gene product, wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product
20 whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited
25 by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of
30 SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the
35 gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS: 1-6213.

241. The method of Paragraph 240, wherein said compound is an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, or a
35 proliferation-inhibiting portion thereof.

242. The method of Paragraph 240, wherein said proliferation inhibiting portion of one of SEQ ID NOS.: 1-6213 is a fragment comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 51 consecutive nucleotides of one of SEQ ID NOS.: 1-6213.

243. The method of Paragraph 240, wherein said population is a population of Gram positive bacteria.

244. The method of Paragraph 243, wherein said population of Gram positive bacteria is selected from the group consisting of a population of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

245. The method of Paragraph 243, wherein said population is a population of *Staphylococcus aureus*.

246. The method of Paragraph 245, wherein said population is a population of a bacterium selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

247. The method of Paragraph 240, wherein said population is a population of a bacterium selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

248. The method of Paragraph 240, wherein said population is a population of an organism other than *E. coli*.

249. The method of Paragraph 240, wherein said product of said gene is from an organism other than *E. coli*.

250. The method of Paragraph 240, wherein said gene product is selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using

FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42398-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS.: 42398-78581.

251. The method of Paragraph 240, wherein said gene comprises a nucleic acid selected
5 from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic
10 acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

252. A preparation comprising an effective concentration of an antisense nucleic acid in a pharmaceutically acceptable carrier wherein said antisense nucleic acid is selected from the group consisting of a nucleic acid comprising a sequence having at least 70% nucleotide sequence identity
15 as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 or a proliferation-inhibiting portion thereof, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group
20 consisting of SEQ ID NOS.: 1-6213 under moderate conditions.

253. The preparation of Paragraph 252, wherein said proliferation-inhibiting portion of one of SEQ ID NOS.: 1-6213 comprises at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOS.: 1-6213.

254. A method for inhibiting the activity or expression of a gene in an operon which
25 encodes a gene product required for proliferation comprising contacting a cell in a cell population with an antisense nucleic acid comprising at least a proliferation-inhibiting portion of said operon in an antisense orientation, wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic
30 acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product having at least
35 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the

group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213.

255. The method of Paragraph 254, wherein said antisense nucleic acid comprises a nucleotide sequence having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a proliferation inhibiting portion thereof, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, and a nucleic acid which comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions.

256. The method of Paragraph 254, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

257. The method of Paragraph 254, wherein said cell is not an *E. coli* cell.

258. The method of Paragraph 254, wherein said gene is from an organism other than *E. coli*.

259. The method of Paragraph 254, wherein said cell is contacted with said antisense nucleic acid by introducing a plasmid which transcribes said antisense nucleic acid into said cell population.

260. The method of Paragraph 254, wherein said cell is contacted with said antisense nucleic acid by introducing a phage which transcribes said antisense nucleic acid into said cell population.

261. The method of Paragraph 254, wherein said cell is contacted with said antisense nucleic acid by transcribing said antisense nucleic acid from the chromosome of cells in said cell population.

262. The method of Paragraph 254, wherein said cell is contacted with said antisense nucleic acid by introducing a promoter adjacent to a chromosomal copy of said antisense nucleic acid such that said promoter directs the synthesis of said antisense nucleic acid.

263. The method of Paragraph 254, wherein said cell is contacted with said antisense nucleic acid by introducing a retron which expresses said antisense nucleic acid into said cell population.

264. The method of Paragraph 254, wherein said cell is contacted with said antisense nucleic acid by introducing a ribozyme into said cell-population, wherein a binding portion of said ribozyme is complementary to said antisense oligonucleotide.

265. The method of Paragraph 254, wherein said cell is contacted with said antisense nucleic acid by introducing a liposome comprising said antisense oligonucleotide into said cell.

266. The method of Paragraph 254, wherein said cell is contacted with said antisense nucleic acid by electroporation of said antisense nucleic acid into said cell.

267. The method of Paragraph 254, wherein said antisense nucleic acid has at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence comprising at least 10, at least 20, at least 25, at least 30, at least 50 or more than 50 consecutive nucleotides of one of SEQ ID NOS.: 1-6213.

268. The method of Paragraph 254 wherein said antisense nucleic acid is a synthetic oligonucleotide.

269. The method of Paragraph 254, wherein said gene comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

270. A method for identifying a gene which is required for proliferation of a cell comprising:

(a) contacting a cell with an antisense nucleic acid selected from the group consisting of a nucleic acid at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 or a proliferation-inhibiting portion thereof, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, wherein said cell is a cell other than the organism from which said nucleic acid was obtained;

(b) determining whether said nucleic acid inhibits proliferation of said cell; and

(c) identifying the gene in said cell which encodes the mRNA which is complementary to said antisense nucleic acid or a portion thereof.

271. The method of Paragraph 270, wherein said cell is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

272. The method of Paragraph 270 wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

273. The method of Paragraph 270, wherein said cell is not *E. coli*.

274. The method of Paragraph 270, further comprising operably linking said antisense nucleic acid to a promoter which is functional in said cell, said promoter being included in a vector, and introducing said vector into said cell.

275. A method for identifying a compound having the ability to inhibit proliferation of a
5 cell comprising:

(a) identifying a homolog of a gene or gene product whose activity or level is inhibited by an antisense nucleic acid in a test cell, wherein said test cell is not the microorganism from which the antisense nucleic acid was obtained, wherein said antisense nucleic acid is selected from the group consisting of a nucleic acid having at least 70%
10 nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected
15 from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions;

(b) identifying an inhibitory nucleic acid sequence which inhibits the activity of said homolog in said test cell;

(c) contacting said test cell with a sublethal level of said inhibitory nucleic acid, thus sensitizing said cell;

20 (d) contacting the sensitized cell of step (c) with a compound; and

(e) determining the degree to which said compound inhibits proliferation of said sensitized cell relative to a cell which does not express said inhibitory nucleic acid.

276. The method of Paragraph 275, wherein said determining step comprises determining whether said compound inhibits proliferation of said sensitized test cell to a greater
25 extent than said compound inhibits proliferation of a nonsensitized test cell.

277. The method of Paragraph 275, wherein step (a) comprises identifying a homologous nucleic acid to a gene or gene product whose activity or level is inhibited by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID
30 NOs. 1-6213 or a nucleic acid encoding a homologous polypeptide to a polypeptide whose activity or level is inhibited by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 by using an algorithm selected from the group consisting of BLASTN version 2.0 with the default parameters and FASTA version 3.0t78
35 algorithm with the default parameters to identify said homologous nucleic acid or said nucleic acid encoding a homologous polypeptide in a database.

278. The method of Paragraph 275 wherein said step (a) comprises identifying a homologous nucleic acid or a nucleic acid encoding a homologous polypeptide by identifying

nucleic acids comprising nucleotide sequences which hybridize to said nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 or the complement of the nucleotide sequence of said nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213.

279. The method of Paragraph 275 wherein step (a) comprises expressing a nucleic acid having at least 70% nucleic acid identity as determined using BLASTN version 2.0 with the default parameters to a sequence selected from the group consisting of SEQ ID NOs. 1-6213 in said test cell.

280. The method of Paragraph 275, wherein step (a) comprises identifying a homologous nucleic acid or a nucleic acid encoding a homologous polypeptide in a test cell selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

281. The method of Paragraph 275, wherein step (a) comprises identifying a homologous nucleic acid or a nucleic acid encoding a homologous polypeptide in a test cell other than *E. coli*.

282. The method of Paragraph 275, wherein said inhibitory nucleic acid is an antisense nucleic acid.

283. The method of Paragraph 275, wherein said inhibitory nucleic acid comprises an antisense nucleic acid to a portion of said homolog.

284. The method of Paragraph 275, wherein said inhibitory nucleic acid comprises an antisense nucleic acid to a portion of the operon encoding said homolog.

5 285. The method of Paragraph 275, wherein the step of contacting the cell with a sublethal level of said inhibitory nucleic acid comprises directly contacting said cell with said inhibitory nucleic acid.

286. The method of Paragraph 275, wherein the step of contacting the cell with a sublethal level of said inhibitory nucleic acid comprises expressing an antisense nucleic acid to said
10 homolog in said cell.

287. The method of Paragraph 275, wherein said gene product comprises a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

288. The method of Paragraph 275, wherein said gene comprises a nucleic acid selected
15 from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid
20 comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate condtions.

289. A compound identified using the method of Paragraph 275.

290. A method of identifying a compound having the ability to inhibit proliferation comprising:

25 (a) sensitizing a test cell by contacting said test cell with a sublethal level of an antisense nucleic acid, wherein said antisense nucleic acid is selected from the group consisting of a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs. 1-6213 or a portion thereof which inhibits the
30 proliferation of the cell from which said nucleic acid was obtained, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditionst;

35 (b) contacting the sensitized test cell of step (a) with a compound; and

(c) determining the degree to which said compound inhibits proliferation of said sensitized test cell relative to a cell which does not contain said antisense nucleic acid.

291. The method of Paragraph 290, wherein said determining step comprises determining whether said compound inhibits proliferation of said sensitized test cell to a greater extent than said compound inhibits proliferation of a nonsensitized test cell.

292. A compound identified using the method of Paragraph 290.

5 293. The method of Paragraph 290, wherein said test cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*,
15 *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
20 *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*,
25 *Yersinia pestis* and any species falling within the genera of any of the above species.

294. The method of Paragraph 290, wherein the test cell is not *E. coli*.

295. A method for identifying a compound having activity against a biological pathway required for proliferation comprising:

30 (a) sensitizing a cell by providing a sublethal level of an antisense nucleic acid complementary to a nucleic acid encoding a gene product required for proliferation, wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.:
35 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid

comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213;

(b) contacting the sensitized cell with a compound; and

(c) determining the extent to which said compound inhibits the growth of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

296. The method of Paragraph 295, wherein said determining step comprises determining whether said compound inhibits the growth of said sensitized cell to a greater extent than said compound inhibits the growth of a nonsensitized cell.

297. The method of Paragraph 295, wherein said cell is selected from the group consisting of bacterial cells, fungal cells, plant cells, and animal cells.

298. The method of Paragraph 295, wherein said cell is a Gram positive bacterium.

299. The method of Paragraph 298, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus* species, *Streptococcus* species, *Enterococcus* species, *Mycobacterium* species, *Clostridium* species, and *Bacillus* species.

300. The method of Paragraph 299, wherein said Gram positive bacterium is *Staphylococcus aureus*.

301. The method of Paragraph 298, wherein said Gram positive bacterium is selected from the group consisting of *Staphylococcus aureus* RN450 and *Staphylococcus aureus* RN4220.

302. The method of Paragraph 295, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria*

monocytogenes, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
 5 *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma*
 10 *urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

303. The method of Paragraph 295, wherein said cell is not an *E. coli* cell.

304. The method of Paragraph 295, wherein said gene product is from an organism other than *E. coli*.

15 305. The method of Paragraph 295, wherein said antisense nucleic acid is transcribed from an inducible promoter.

306. The method of Paragraph 305, further comprising contacting the cell with an agent which induces expression of said antisense nucleic acid from said inducible promoter, wherein said antisense nucleic acid is expressed at a sublethal level.

20 307. The method of Paragraph 295, wherein inhibition of proliferation is measured by monitoring the optical density of a liquid culture.

308. The method of Paragraph 295, wherein said gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

25 309. The method of Paragraph 295, wherein said nucleic acid encoding said gene product comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to
 30 a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

310. A compound identified using the method of Paragraph 295.

35 311. A method for identifying a compound having the ability to inhibit cellular proliferation comprising:

(a) contacting a cell with an agent which reduces the activity or level of a gene product required for proliferation of said cell, wherein said gene product is selected from

the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213;

(b) contacting said cell with a compound; and

(c) determining the degree to which said compound reduces proliferation of said contacted cell relative to a cell which was not contacted with said agent.

312. The method of Paragraph 311, wherein said determining step comprises determining whether said compound reduces proliferation of said contacted cell to a greater extent than said compound reduces proliferation of cells which have not been contacted with said agent.

313. The method of Paragraph 311, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella*

haemolytica, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
 5 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

314. The method of Paragraph 311, wherein said cell is not an *E. coli* cell.

10 315. The method of Paragraph 311, wherein said gene product is from an organism other than *E. coli*.

316. The method of Paragraph 311, wherein said agent which reduces the activity or level of a gene product required for proliferation of said cell comprises an antisense nucleic acid to a gene or operon required for proliferation.

15 317. The method of Paragraph 311, wherein said agent which reduces the activity or level of a gene product required for proliferation of said cell comprises a compound known to inhibit growth or proliferation of a cell.

318. The method of Paragraph 311, wherein said cell contains a mutation which reduces the activity or level of said gene product required for proliferation of said cell.

20 319. The method of Paragraph 311, wherein said mutation is a temperature sensitive mutation.

320. The method of Paragraph 311, wherein said gene product comprises a gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to an amino acid sequence selected from the group
 25 consisting of SEQ ID NOs.: 42398-78581.

321. A compound identified using the method of Paragraph 311.

322. A method for identifying the biological pathway in which a proliferation-required gene product or a gene encoding a proliferation-required gene product lies comprising:

(a) providing a sublethal level of an antisense nucleic acid which inhibits the
 30 activity or reduces the level of said gene encoding a proliferation-required gene product or said said proliferation-required gene product in a test cell, wherein said proliferation-required gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic
 35 acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid

comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS: 1-6213;

(b) contacting said test cell with a compound known to inhibit growth or proliferation of a cell, wherein the biological pathway on which said compound acts is known; and

(c) determining the degree to which said compound inhibits proliferation of said test cell relative to a cell which does not contain said antisense nucleic acid.

323. The method of Paragraph 322, wherein said determining step comprises determining whether said test cell has a substantially greater sensitivity to said compound than a cell which does not express said sublethal level of said antisense nucleic acid.

324. The method of Paragraph 322, wherein said gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to an amino acid sequence selected from the group consisting of SEQ ID NOS.: 42398-78581.

325. The method of Paragraph 322, wherein said test cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,

Pseudomonas aeruginosa, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

326. The method of Paragraph 322, wherein said test cell is not an *E. coli* cell.

327. The method of Paragraph 322, wherein said gene product is from an organism other than *E. coli*.

328. A method for determining the biological pathway on which a test compound acts comprising:

(a) providing a sublethal level of an antisense nucleic acid complementary to a proliferation-required nucleic acid in a cell, thereby producing a sensitized cell, wherein said antisense nucleic acid is selected from the group consisting of a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOs:1-6213 or a proliferation-inhibiting portion thereof, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions and wherein the biological pathway in which said proliferation-required nucleic acid or a protein encoded by said proliferation-required polypeptide lies is known,

(b) contacting said cell with said test compound; and

(c) determining the degree to which said compound inhibits proliferation of said sensitized cell relative to a cell which does not contain said antisense nucleic acid.

329. The method of Paragraph 328, wherein said determining step comprises determining whether said sensitized cell has a substantially greater sensitivity to said test compound than a cell which does not express said sublethal level of said antisense nucleic acid.

330. The method of Paragraph 328, further comprising:

(d) providing a sublethal level of a second antisense nucleic acid complementary to a second proliferation-required nucleic acid in a second cell, wherein said second proliferation-required nucleic acid is in a different biological pathway than said proliferation-required nucleic acid in step (a); and

(e) determining whether said second cell does not have a substantially greater sensitivity to said test compound than a cell which does not express said sublethal level of said second antisense nucleic acid, wherein said test compound is specific for the biological

pathway against which the antisense nucleic acid of step (a) acts if said sensitized cell has substantially greater sensitivity to said test compound than said second cell.

331. The method of Paragraph 328, wherein said sensitized cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*,
 5 *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium*
 10 *acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
 15 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella*
 20 *typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

25 332. The method of Paragraph 328, wherein said sensitized cell is not an *E. coli* cell.

333. The method of Paragraph 328, wherein said proliferation-required nucleic acid is from an organism other than *E. coli*.

334. A compound which inhibits proliferation by interacting with a gene encoding a gene product required for proliferation or with a gene product required for proliferation, wherein
 30 said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using
 35 BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product

whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213.

335. The compound of Paragraph 334, wherein said gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

336. The compound of Paragraph 334, wherein said gene comprises a nucleic acid selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

337. A method for manufacturing an antibiotic comprising the steps of:
screening one or more candidate compounds to identify a compound that reduces the activity or level of a gene product required for proliferation wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the

gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213 ; and

manufacturing the compound so identified.

338. The method of Paragraph 337, wherein said screening step comprises performing
5 any one of the methods of Paragraphs 205, 211, 222, 275, 290, 295, 311.

339. The method of Paragraph 337, wherein said gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

10 340. A method for inhibiting proliferation of a cell in a subject comprising administering an effective amount of a compound that reduces the activity or level of a gene product required for proliferation of said cell, wherein said gene product is selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic
15 acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least
20 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a
25 nucleic acid comprising a nucleotide sequence which hybridizes to a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs: 1-6213.

341. The method of Paragraph 340 wherein said subject is selected from the group
30 consisting of vertebrates, mammals, avians, and human beings.

342. The method of Paragraph 340, wherein said gene product comprises a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581.

35 343. The method of Paragraph 340, wherein said cell is selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida*

glabrata (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*,
 5 *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
 10 *pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
 15 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

344. The method of Paragraph 340, wherein said cell is not *E. coli*.

20 345. The method of Paragraph 340, wherein said gene product is from an organism other than *E. coli*.

346. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

25 obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

30 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

35 identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

347. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

348. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

349. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide

sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

350. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

351. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining a culture comprising a plurality of strains wherein each strain in said culture overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the
10 group consisting of SEQ ID NOs: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on
15 which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture.

20 352. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said culture includes at least one strain which does not overexpresses a gene product which is essential for proliferation of said organism.

353. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said strains which overexpress said gene products comprise a nucleic acid encoding said gene product which is
25 essential for proliferation of said organism operably linked to a regulatable promoter.

354. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said strains which overexpress said gene products a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a constitutive promoter.

355. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said
30 identification step comprises determining the nucleotide sequence of a nucleic acid encoding said gene product in said cell which proliferated more rapidly in said culture.

356. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said identification step comprises performing an amplification reaction to identify the nucleic acid encoding said gene product in said cell which proliferated more rapidly in said cell culture.

35 357. The method of Paragraph 356, wherein the products of said amplification reaction are labeled with a detectable dye.

358. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said identification step comprises performing a hybridization procedure.

359. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said identification step comprises contacting a nucleic acid array with a nucleic acid encoding said gene product in said cell which proliferated more rapidly in said cell culture.

360. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said organism is
5 selected from the group consisting of bacteria, fungi, and protozoa.

361. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*,
10 *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*,
15 *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
25 *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

362. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said compound is obtained from a library of natural compounds.

30 363. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said compound is obtained from a library of synthetic compounds.

364. The method of Paragraph 346, 347, 348, 349, 350 or 351, wherein said compound is present in a crude or partially purified state.

365. The method of Paragraph 346, 347, 348, 349, 350 or 351, further comprising
35 determining whether said gene product in said strain which proliferated more rapidly in said culture has a counterpart in at least one other organism.

366. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

367. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed;

contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

368. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed;

contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

369. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression
10 is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the
15 group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide
20 sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide
25 sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not
30 overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

370. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

35 obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid

comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of
5 SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed;

contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene
10 product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

15 371. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining an array of strains on a solid growth medium wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide
20 selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42938-78581 is overexpressed;

25 contacting said array of strains with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

30 identifying the gene product which is overexpressed in a strain which proliferated more rapidly on said solid medium.

372. The method of Paragraph 366, 367, 368, 369, 370 or 371, wherein at least one strain in said array does not overexpresses a gene product which is essential for proliferation of said organism.

35 373. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for

proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting each of said cultures with a different concentration of said compound;

5 and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

374. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

10 obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed;

15 contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

20 375. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed;

25 contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

30 376. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene

product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS: 1-6213 is overexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

377. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS: 6214-42397 under moderate conditions is overexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

378. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining a plurality of cultures, wherein each culture comprises a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group
10 consisting of SEQ ID NOs: 42938-78581 is overexpressed;
contacting each of said cultures with a different concentration of said compound;
and
identifying the gene product which is overexpressed in a strain whose proliferation is inhibited by said compound.

15 379. The method of Paragraph 373, 374, 375, 376, 377 or 378, wherein at least one strain in said plurality of cultures does not overexpress a gene product which is essential for proliferation of said organism.

380. A method of profiling a compound's activity comprising:
performing the method of Paragraph 346 on a first culture using a first compound;
20 performing the method of Paragraph 346 on a second culture using a second compound; and
comparing the strains identified in said first culture to the strains identified in said second culture.

381. A method of profiling a compound's activity comprising:
25 performing the method of Paragraph 347 on a first culture using a first compound;
performing the method of Paragraph 347 on a second culture using a second compound; and
comparing the strains identified in said first culture to the strains identified in said second culture.

30 382. A method of profiling a compound's activity comprising:
performing the method of Paragraph 348 on a first culture using a first compound;
performing the method of Paragraph 348 on a second culture using a second compound; and
comparing the strains identified in said first culture to the strains identified in said
35 second culture.

383. A method of profiling a compound's activity comprising:
performing the method of Paragraph 349 on a first culture using a first compound;

performing the method of Paragraph 349 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

5 384. A method of profiling a compound's activity comprising:
performing the method of Paragraph 350 on a first culture using a first compound;
performing the method of Paragraph 350 on a second culture using a second compound; and

10 comparing the strains identified in said first culture to the strains identified in said second culture.

385. A method of profiling a compound's activity comprising:
performing the method of Paragraph 351 on a first culture using a first compound;
performing the method of Paragraph 351 on a second culture using a second compound; and

15 comparing the strains identified in said first culture to the strains identified in said second culture.

386. A method of profiling a first compound's activity comprising:
growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

25 comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

387. A method of profiling a first compound's activity comprising:
growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

35 comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

388. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

389. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

390. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

391. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein each strain in said array overexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 is overexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

392. The method of any one of Paragraphs 380, 381, 382, 383, 384, 385, 386, 387, 388, 389, 390 or 391, wherein said first compound is present in a crude or partially purified state.

393. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

394. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

395. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

396. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

397. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid

comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

398. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42938-78581 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress said gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture.

399. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein at least one strain in said culture does not underexpresses a gene product which is essential for proliferation of said organism.

400. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said strains which underexpresses said gene products comprise a nucleic acid complementary to at least a portion of a gene encoding said gene product which is essential for proliferation of said organism operably linked to a regulatable promoter.

401. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said strains which underexpress said gene products express an antisense nucleic acid complementary to at least

a portion of a gene encoding said gene product which is essential for proliferation of said organism, wherein expression of said antisense nucleic acid reduces expression of said gene product in said strain.

402. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said
5 identification step comprises determining the nucleotide sequence of a nucleic acid encoding said gene product in said strain which proliferated more slowly.

403. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said identification step comprises performing an amplification reaction to identify the nucleic acid encoding said gene product in said cell which proliferated more slowly.

10 404. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein the products of said amplification reaction are labeled with a detectable dye.

405. The method of Paragraph 404, wherein said identification step comprises performing a hybridization procedure.

406. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said
15 identification step comprises contacting a nucleic acid array with a nucleic acid encoding said gene product in said cell which proliferated more slowly.

407. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said organism is selected from the group consisting of bacteria, fungi, protozoa.

408. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said culture is a
20 culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr*
25 (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*,
30 *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*,
35 *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*,

Ureaplasma urealyticum, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

409. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said compound is obtained from a library of natural compounds.

5 410. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said compound is obtained from a library of synthetic compounds.

411. The method of Paragraph 393, 394, 395, 396, 397 or 398, wherein said compound is present in a crude or partially purified state.

412. The method of Paragraph 393, 394, 395, 396, 397 or 398, further comprising
10 determining whether said gene product in said strain which proliferated more slowly in said culture has a counterpart in at least one other organism.

413. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, each culture comprising a plurality of strains
15 wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting each of said cultures with a different concentration of said compound;
20 and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

414. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

25 obtaining a plurality of cultures, each culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed;

30 contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

415. A method for identifying the gene product on which a compound which inhibits
35 proliferation of an organism acts comprising:

obtaining a plurality of cultures, each culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene

product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

contacting each of said cultures with a different concentration of said compound;
and

5 identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

416. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, each culture comprising a plurality of strains
10 wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a
15 nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-
20 6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group
25 consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group
30 consisting of SEQ ID NOs: 1-6213 is underexpressed;

contacting each of said cultures with a different concentration of said compound;
and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

35 417. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, each culture comprising a plurality of strains
wherein each strain underexpresses a different gene product which is essential for

proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

418. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures, each culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is underexpressed;

contacting each of said cultures with a different concentration of said compound; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

419. A method of profiling a compound's activity comprising:

performing the method of Paragraph 393 on a first culture using a first compound; performing the method of Paragraph 393 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

420. A method of profiling a compound's activity comprising:

performing the method of Paragraph 394 on a first culture using a first compound; performing the method of Paragraph 394 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

421. A method of profiling a compound's activity comprising:

performing the method of Paragraph 395 on a first culture using a first compound;

performing the method of Paragraph 395 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

422. A method of profiling a compound's activity comprising

performing the method of Paragraph 396 on a first culture using a first compound;

performing the method of Paragraph 396 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

423. A method of profiling a compound's activity comprising

performing the method of Paragraph 397 on a first culture using a first compound;

performing the method of Paragraph 397 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

424. A method of profiling a compound's activity comprising

performing the method of Paragraph 398 on a first culture using a first compound;

performing the method of Paragraph 398 on a second culture using a second compound; and

comparing the strains identified in said first culture to the strains identified in said second culture.

425. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

426. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain
5 in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the
10 pattern of strains which grow on said second solid medium.

427. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product
15 which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the
20 pattern of strains which grow on said second solid medium.

428. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product
25 which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.:
30 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA
35 version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group

consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

429. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

430. A method of profiling a first compound's activity comprising:

growing an array of strains on a first solid medium comprising said first compound and on a second solid medium comprising a second compound, wherein said array comprises a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of an organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed, and wherein said first compound and said second compound inhibit the proliferation of said organism; and

comparing the pattern of strains which grow on said first solid medium with the pattern of strains which grow on said second solid medium.

431. The method of any one of Paragraphs 419, 420, 421, 422, 423, 424, 425, 426, 427, 428, 429 or 430, wherein said first compound is present in a crude or partially purified state.

5 432. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

10 contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

15 identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

433. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

20 obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed;

25 contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

30 434. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

35 obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

435. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product
10 whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide
15 sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.:
20 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

30 identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

436. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

35 obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as

determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

437. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a plurality of cultures comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 is underexpressed;

contacting each of said plurality of cultures with a varying concentration of a regulatory agent which regulates the level of expression of said gene products which are essential for proliferation of said organism; and

identifying the gene product which is underexpressed in a strain whose rate of proliferation is reduced by said compound.

438. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 is overexpressed.

439. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 is overexpressed.

440. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture

comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed.

441. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture
5 comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a
10 gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide
15 sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose
20 activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed.

442. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture
25 comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected
30 from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed.

443. A culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism, wherein said culture
35 comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581

and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed.

444. The culture of Paragraph 438, 439, 440, 441, 442 or 443, wherein said strains which overexpress said gene products comprise a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a regulatable promoter.

445. The culture of Paragraph 438, 439, 440, 441, 442 or 443, wherein said strains which overexpress said gene products comprise a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a constitutive promoter.

446. The culture of Paragraph 438, 439, 440, 441, 442 or 443, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

447. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed.

448. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture

comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed.

449. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture
5 comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed.

450. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product
10 having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a
15 gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a
20 nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid
25 comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed.

451. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide
30 sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic
35 acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed.

452. A culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism, wherein said culture

comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is underexpressed.

453. The culture of Paragraph 447, 448, 449, 450, 451 or 452, wherein said strains which underexpress said gene products comprise a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a regulatable promoter.

454. The culture of Paragraph 447, 448, 449, 450, 451 or 452, wherein said strains which underexpress said gene products comprise a nucleic acid encoding said gene product which is essential for proliferation of said organism operably linked to a constitutive promoter.

455. The culture of Paragraph 447, 448, 449, 450, 451 or 452, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

456. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so

as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

457. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

458. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

459. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

460. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

5 obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain
10 in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID
15 NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed;

20 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

25 identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

461. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

30 obtaining a culture comprising a plurality of strains wherein each strain overexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the overexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the overexpressed genes, wherein said culture comprises a strain
35 in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which do not overexpress said gene product on which said compound acts, such that strains which overexpress said gene product on which said compound acts proliferate more rapidly than strains which do not overexpress said gene product on which said compound acts; and

identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

462. The method of Paragraph 456, 457, 458, 459, 460 or 461, wherein the nucleotide sequence of each of the genes encoding an overexpressed gene product has been altered by replacing the native promoters of said genes with promoters which facilitate overexpression of said gene products.

463. The method of Paragraph 456, 457, 458, 459, 460 or 461, wherein the nucleotide sequence of each of the genes encoding an overexpressed gene product has been altered by inserting a regulatory element into the native promoters of said genes with a promoter which facilitates overexpression of said gene products.

464. The method of Paragraph 463, wherein said regulatory element is selected from the group consisting of a regulatable promoter, an operator which is recognized by a repressor, a nucleotide sequence which is recognized by a transcriptional activator, a transcriptional terminator, a nucleotide sequence which introduces a bend in the DNA and an upstream activating sequence.

465. The method of Paragraph 456, 457, 458, 459, 460 or 461, wherein the step of identifying the gene product which is overexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene comprises performing an amplification reaction and detecting a unique amplification product corresponding to said gene.

466. The method of Paragraph 462, wherein the native promoter of each of the genes encoding a gene product essential for proliferation is replaced with the same promoter.

467. The method of Paragraph 462, wherein the native promoters of the genes encoding gene products essential for proliferation are replaced with a plurality of promoters selected to give a desired expression level for each gene product.

468. The method of Paragraph 462, wherein said promoters which replaced the native promoters in each strain comprise regulatable promoters.

469. The method of Paragraph 462, wherein said promoters which replaced the native promoters in each strain each strain comprise constitutive promoters.

470. The method of Paragraph 456, 457, 458, 459, 460 or 461, wherein said organism is selected from the group consisting of bacteria, fungi, and protozoa.

471. The method of Paragraph 456, 457, 458, 459, 460 or 461, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*,

Campylobacter jejuni, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium*
 5 *perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma*
 10 *genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*,
 15 *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

472. A method for identifying the gene product on which a compound which inhibits
 20 proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product
 25 corresponding to each of the underexpressed genes and wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit
 30 the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated
 35 more rapidly in said culture by detecting the unique product corresponding to said gene.

473. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the underexpressed genes and wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

474. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the underexpressed genes, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

475. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the underexpressed genes, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at

least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is underexpressed;

contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress the gene product on which said compound acts; and

identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

476. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the underexpressed genes, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent

conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is underexpressed;

5 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress the gene product on which said compound acts; and

10 identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

477. A method for identifying the gene product on which a compound which inhibits proliferation of an organism acts comprising:

15 obtaining a culture comprising a plurality of strains wherein each strain underexpresses a different gene product which is essential for proliferation of said organism and wherein the nucleotide sequence of each of the underexpressed genes has been altered so as to include a nucleotide sequence which can be used to generate a unique product corresponding to each of the underexpressed genes, wherein said culture comprises a strain in which a gene product comprises a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version
20 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 is underexpressed;

25 contacting said culture with a sufficient concentration of said compound to inhibit the proliferation of strains of said organism which underexpress said gene product on which said compound acts, such that strains which underexpress said gene product on which said compound acts proliferate more slowly than strains which do not underexpress the gene product on which said compound acts; and

30 identifying the gene product which is underexpressed in a strain which proliferated more rapidly in said culture by detecting the unique product corresponding to said gene.

478. The method of Paragraph 472, 473, 474, 475, 476 or 477, wherein the nucleotide sequence of each of the genes encoding an underexpressed gene product has been altered by replacing the native promoters of said genes with promoters which facilitate underexpression of said gene products.

35 479. The method of Paragraph 472, 473, 474, 475, 476 or 477, wherein the nucleotide sequence of each of the genes encoding an underexpressed gene product has been altered by inserting a regulatory element into the native promoters of said genes with a promoter which facilitates underexpression of said gene products.

480. The method of Paragraph 479, wherein said regulatory element is selected from the group consisting of a regulatable promoter, an operator which is recognized by a repressor, a nucleotide sequence which is recognized by a transcriptional activator, a transcriptional terminator, a nucleotide sequence which introduces a bend in the DNA and an upstream activating sequence.

5 481. The method of Paragraph 472, 473, 474, 475, 476 or 477, wherein the step of identifying the gene product which is underexpressed in a strain which proliferated more slowly in said culture by detecting the unique product corresponding to said gene comprises performing an amplification reaction and detecting a unique amplification product corresponding to said gene.

10 482. The method of Paragraph 478, wherein the native promoter of each of the genes encoding a gene product essential for proliferation is replaced with the same promoter.

483. The method of Paragraph 478, wherein the native promoters of the genes encoding gene products essential for proliferation are replaced with a plurality of promoters selected to give a desired expression level for each gene product.

15 484. The method of Paragraph 478, wherein said promoters which replaced the native promoters in each strain comprise regulatable promoters.

485. The method of Paragraph 478, wherein said promoters which replaced the native promoters in each strain each strain comprise constitutive promoters.

486. The method of Paragraph 472, 473, 474, 475, 476 or 477, wherein said organism is selected from the group consisting of bacteria, fungi, and protozoa.

20 487. The method of Paragraph 472, 473, 474, 475, 476 or 477, wherein said culture is a culture of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*),
25 *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*,
30 *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*,
35 *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,

Streptococcus pneumoniae, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* and any species falling within the genera of any of the above species.

488. A method for determining the extent to which each of a plurality of strains are
5 present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or
collection of strains wherein said culture or collection of strains comprises a plurality of
strains wherein each strain overexpresses or underexpresses a different gene product which
is required for proliferation of said organism wherein said culture comprises a strain in
10 which a gene product whose activity or level is inhibited by a nucleic acid comprising a
nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is
overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are
complementary to nucleotide sequences within or adjacent to the genes which encode said
15 gene products, wherein the members of said set of primer pairs are designed such that each
primer pair would yield an amplification product having a length distinguishable from the
lengths of the amplification products from the other primer pairs if a strain comprising the
nucleotide sequences complementary to said primer pair is present in said culture or
collection of strains; and

20 determining the lengths of the amplification products obtained in said amplification
reaction.

489. A method for determining the extent to which each of a plurality of strains are
present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or
25 collection of strains wherein said culture or collection of strains comprises a plurality of
strains wherein each strain overexpresses or underexpresses a different gene product which
is required for proliferation of said organism, wherein said culture comprises a strain in
which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected
from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed or
30 underexpressed;

performing an amplification reaction using a set of primer pairs which are
complementary to nucleotide sequences within or adjacent to the genes which encode said
gene products, wherein the members of said set of primer pairs are designed such that each
primer pair would yield an amplification product having a length distinguishable from the
35 lengths of the amplification products from the other primer pairs if a strain comprising the
nucleotide sequences complementary to said primer pair is present in said culture or
collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

490. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

5 obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group
10 consisting of SEQ ID NOs.: 42938-78581 is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the
15 lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

20 491. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which
25 is required for proliferation of said organism, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.:
30 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA
35 version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group

consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

492. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

493. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

5 obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism, wherein said culture comprises a strain in which a gene product comprising a polypeptide selected from the group consisting of a
10 polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed or underexpressed;

performing an amplification reaction using a set of primer pairs which are
15 complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or
20 collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction.

494. The method of Paragraph 488, 489, 490, 491, 492 or 493, wherein one member of each primer pair for each of said genes is labeled with a detectable dye.

25 495. The method of Paragraph 488, 489, 490, 491, 492 or 493, wherein:

said nucleic acid sample is divided into N aliquots; and

said amplification reaction is performed on each aliquot using primer pairs complementary to nucleotide sequences within or adjacent to 1/N of the genes which encode said gene products, wherein one of the members of each primer pair in each aliquot
30 is labeled with a dye and wherein the dyes on the primers in each aliquot are distinguishable from one another.

496. The method of Paragraph 494, further comprising pooling the amplification products from each of the aliquots prior to determining the lengths of the amplification products.

497. The method of Paragraph 488, 489, 490, 491, 492 or 493, wherein the native
35 promoters of said genes which encode said gene products have been replaced with a regulatable promoter and one of the primers in said primer pairs is complementary to a nucleotide sequence within said regulatable promoter.

498. The method of Paragraph 496, wherein the native promoters for each of said genes were replaced with the same regulatable promoter.

499. The method of Paragraph 496, wherein more than one regulatable promoter was used to replace the promoters of said genes such that some of said genes are under the control of a
5 different regulatable promoter.

500. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of
10 strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the
15 same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a
20 length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding
30 to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second
35 cultures or collection of strains comprise a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

501. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second cultures or collection of strains comprise a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed or underexpressed.

502. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which

is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second cultures or collection of strains comprise a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed or underexpressed.

503. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second cultures or collection of strains comprise a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

504. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second cultures or collection of strains comprise a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from

the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed.

505. A method for identifying the target of a compound which inhibits the proliferation of an organism comprising:

5 obtaining a first nucleic acid sample comprising nucleic acids from a first culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains wherein each strain overexpresses or underexpresses a different gene product which is required for proliferation of said organism and wherein said culture or collection of strains has been contacted with said compound;

10 obtaining a second nucleic acid sample comprising nucleic acids from a second culture or collection of strains wherein said culture or collection of strains comprises the same strains as said first culture or collection of strains wherein said second culture or collection of strains has not been contacted with said compound;

15 performing a first amplification reaction on said first nucleic acid sample using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains;

20 performing a second amplification reaction on said second nucleic acid sample using the same set of primer pairs used in said first amplification reaction;

25 and comparing the amount of each amplification product in said first amplification reaction to the amount of that amplification product in said second amplification reaction, wherein an increased level of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products and a decreased level of of an amplification product in said first amplification reaction relative to said second amplification reaction indicates that
30 the gene product corresponding to said amplification product is the target of said compound if said culture or strain overexpresses said gene products, wherein said first and second culture or collection of strains comprise a strain in which a gene product comprising a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the
35 group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS: 42938-78581 is overexpressed or underexpressed.

506. The method of Paragraph 500, 501, 502, 503, 504 or 505, wherein one member of each primer pair for each of said genes is labeled with a detectable dye.

507. The method of Paragraph 500, 501, 502, 503, 504 or 505, wherein the native promoters of said genes which encode said gene products have been replaced with a regulatable promoter and one of the primers in said primer pairs is complementary to a nucleotide sequence within said regulatable promoter.

508. The method of Paragraph 500, 501, 502, 503, 504 or 505, wherein the native promoters for each of said genes were replaced with the same regulatable promoter.

509. The method of Paragraph 500, 501, 502, 503, 504 or 505, wherein more than one regulatable promoter was used to replace the promoters of said genes such that some of said genes are under the control of a different regulatable promoter.

510. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

511. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length

distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed or underexpressed.

512. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed or underexpressed.

513. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

514. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as

determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed.

515. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which transcribe an antisense nucleic acid complementary to a different gene product which is required for proliferation of said organism;

performing an amplification reaction using a set of primer pairs which are complementary to nucleotide sequences within or adjacent to the nucleic acids which encode said antisense nucleic acids, wherein the members of said set of primer pairs are designed such that each primer pair would yield an amplification product having a length distinguishable from the lengths of the amplification products from the other primer pairs if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

determining the lengths of the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product comprising a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 is overexpressed or underexpressed.

516. The method of Paragraph 510, 511, 512, 513, 514 or 515, wherein one member of each primer pair for each of said genes is labeled with a detectable dye.

517. The method of Paragraph 510, 511, 512, 513, 514 or 515, wherein:

said nucleic acid sample is divided into N aliquots; and

said amplification reaction is performed on each aliquot using primer pairs complementary to nucleotide sequences within or adjacent to 1/N of the genes which encode said gene products, wherein one of the members of each primer pair in each aliquot is labeled with a dye and wherein the dyes on the primers in each aliquot are distinguishable from one another.

518. The method of Paragraph 517, further comprising pooling the amplification products from each of the aliquots prior to determining the lengths of the amplification products.

519. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the a basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed.

520. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the a basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397 is overexpressed or underexpressed.

521. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of

strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the a basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed or underexpressed.

522. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the a basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide

sequence selected from the group consisting of SEQ ID NOS.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213 is overexpressed or underexpressed.

523. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed.

524. A method for determining the extent to which each of a plurality of strains are present in a culture or collection of strains comprising:

obtaining a nucleic acid sample comprising nucleic acids from a culture or collection of strains wherein said culture or collection of strains comprises a plurality of

strains which overexpress or underexpress a different gene product which is required for proliferation of said organism;

performing an amplification reaction using primer pairs which are complementary to nucleotide sequences within or adjacent to the genes which encode said gene products, wherein said primer pairs are designed such that each primer pair would yield an amplification product which is distinguishable from the amplification products produced by the other primer pairs on the basis selected from the group consisting of length, detectable label and both length and detectable label if a strain comprising the nucleotide sequences complementary to said primer pair is present in said culture or collection of strains; and

identifying the amplification products obtained in said amplification reaction, wherein said culture comprises a strain in which a gene product comprising a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed or underexpressed.

525. The method of Paragraph 519, 520, 521, 522, 523 or 524, wherein said primer pairs are divided into at least two sets, each primer pair comprises a primer which is labeled with a distinguishable dye, and the distinguishable dye used to label each set of primer pairs is distinguishable from the dye used to label the other sets of primer pairs.

526. The method of Paragraph 519, 520, 521, 522, 523 or 524, wherein:

said nucleic acid sample is divided into N aliquots; and

said amplification reaction is performed on each aliquot using primer pairs complementary to nucleotide sequences within or adjacent to 1/N of the genes which encode said gene products, wherein one of the members of each primer pair in each aliquot is labeled with a dye and wherein the dyes on the primers in each aliquot are distinguishable from one another.

527. The method of Paragraph 526, further comprising pooling the amplification products from each of the aliquots prior to determining the lengths of the amplification products.

528. The method of Paragraph 519, 520, 521, 522, 523 or 524, wherein the native promoters of said genes which encode said gene products have been replaced with a regulatable promoter and one of the primers in said primer pairs is complementary to a nucleotide sequence within said regulatable promoter.

529. The method of Paragraph 528, wherein the native promoters for each of said genes were replaced with the same regulatable promoter.

530. The method of Paragraph 528, wherein more than one regulatable promoter was used to replace the promoters of said genes such that some of said genes are under the control of a different regulatable promoter.

Definitions

By “biological pathway” is meant any discrete cell function or process that is carried out by a gene product or a subset of gene products. Biological pathways include anabolic, catabolic, enzymatic, biochemical and metabolic pathways as well as pathways involved in the production of cellular structures such as cell walls. Biological pathways that are usually required for proliferation of cells or microorganisms include, but are not limited to, cell division, DNA synthesis and replication, RNA synthesis (transcription), protein synthesis (translation), protein processing, protein transport, fatty acid biosynthesis, electron transport chains, cell wall synthesis, cell membrane production, synthesis and maintenance, and the like.

By “inhibit activity of a gene or gene product” is meant having the ability to interfere with the function of a gene or gene product in such a way as to decrease expression of the gene, in such a way as to reduce the level or activity of a product of the gene or in such a way as to inhibit the interaction of the gene or gene product with other biological molecules required for its activity. Agents which inhibit the activity of a gene include agents that inhibit transcription of the gene, agents that inhibit processing of the transcript of the gene, agents that reduce the stability of the transcript of the gene, and agents that inhibit translation of the mRNA transcribed from the gene. In microorganisms, agents which inhibit the activity of a gene can act to decrease expression of the operon in which the gene resides or alter the folding or processing of operon RNA so as to reduce the level or activity of the gene product. The gene product can be a non-translated RNA such as ribosomal RNA, a translated RNA (mRNA) or the protein product resulting from translation of the gene mRNA. Of particular utility to the present invention are antisense RNAs that have activities against the operons or genes to which they specifically hybridize.

By “activity against a gene product” is meant having the ability to inhibit the function or to reduce the level or activity of the gene product in a cell. This includes, but is not limited to, inhibiting the enzymatic activity of the gene product or the ability of the gene product to interact with other biological molecules required for its activity, including inhibiting the gene product’s assembly into a multimeric structure.

By “activity against a protein” is meant having the ability to inhibit the function or to reduce the level or activity of the protein in a cell. This includes, but is not limited to, inhibiting the enzymatic activity of the protein or the ability of the protein to interact with other biological molecules required for its activity, including inhibiting the protein’s assembly into a multimeric structure.

By “activity against a nucleic acid” is meant having the ability to inhibit the function or to reduce the level or activity of the nucleic acid in a cell. This includes, but is not limited to, inhibiting the ability of the nucleic acid interact with other biological molecules required for its activity, including inhibiting the nucleic acid’s assembly into a multimeric structure.

By “activity against a gene” is meant having the ability to inhibit the function or expression of the gene in a cell. This includes, but is not limited to, inhibiting the ability of the gene to interact with other biological molecules required for its activity.

By “activity against an operon” is meant having the ability to inhibit the function or reduce the level of one or more products of the operon in a cell. This includes, but is not limited to, inhibiting the enzymatic activity of one or more products of the operon or the ability of one or more products of the operon to interact with other biological molecules required for its activity.

By “antibiotic” is meant an agent which inhibits the proliferation of a cell or microorganism.

By “*E. coli* or *Escherichia coli*” is meant *Escherichia coli* or any organism previously categorized as a species of *Shigella* including *Shigella boydii*, *Shigella flexneri*, *Shigella dysenteriae*, *Shigella sonnei*, *Shigella 2A*.

By “homologous coding nucleic acid” is meant a nucleic acid homologous to a nucleic acid encoding a gene product whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 or a portion thereof. In some embodiments, the homologous coding nucleic acid may have at least 97%, at least 95%, at least 90%, at least 85%, at least 80%, or at least 70% nucleotide sequence identity to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42,397 and fragments comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides thereof. In other embodiments the homologous coding nucleic acids may have at least 97%, at least 95%, at least 90%, at least 85%, at least 80%, or at least 70% nucleotide sequence identity to a nucleotide sequence selected from the group consisting of the nucleotide sequences complementary to one of SEQ ID NOS.: 1-6213 and fragments comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides thereof. Identity may be measured using BLASTN version 2.0 with the default parameters or tBLASTX with the default parameters. (Altschul, S.F. et al. Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs, Nucleic Acid Res. 25: 3389-3402 (1997). Alternatively a “homologous coding nucleic acid” could be identified by membership of the gene of interest to a functional orthologue cluster. All other members of that orthologue cluster would be considered homologues. Such a library of functional orthologue clusters can be found at <http://www.ncbi.nlm.nih.gov/COG>. A gene can be classified into a cluster of orthologous groups or COG by using the COGNITOR program available at the above web site, or by direct BLASTP comparison of the gene of interest to the members of the COGs and analysis of these results as described by Tatusov, R.L., Galperin, M.Y., Natale, D. A. and Koonin, E.V. (2000) The COG database: a tool for genome-scale analysis of protein functions and evolution. Nucleic Acids Research v. 28 n. 1, pp33-36.

Homologous coding nucleic acids and the homologous polypeptides which they encode may also be identified using a “reciprocal” best-hit analysis. To facilitate the identification of homologous coding nucleic acids and homologous polypeptides, paralogous genes within each of

51 organisms are identified and clustered prior to comparison to other organisms. Briefly, the polypeptide sequence of each polypeptide encoded by each open reading frame (ORF) in a given organism is compared to the polypeptide sequence encoded by every other ORF for that organism for each of the 51 pathogenic organisms (PathoSeq Sept 2001 release) using BLASTP 2.09 algorithm without filtering. Simultaneously, the polypeptide sequence encoded by each ORF of an organism is compared to the polypeptide sequences encoded by each of the ORFs in the remaining 51 organisms. Those polypeptides within a single organism that shared a higher degree of sequence identity to one another than to polypeptide sequences obtained from any other organisms are clustered as "paralog" sequences for "reciprocal" best-hit analysis.

For each reference organism, the 50 homologous coding nucleic acids (and the 50 homologous polypeptides which they encode) can be determined by identifying the ORFs in each of the 50 comparison organisms which encode a polypeptide sharing the highest degree of amino acid sequence identity to the polypeptide encoded by the ORF from the reference organism. The accuracy of the identification of the predicted homologous coding nucleic acids (and the homologous polypeptides which they encode) is confirmed by a "reciprocal" BLAST analysis in which the polypeptide sequence of the predicted homologous polypeptide is compared against the polypeptides encoded by each of the ORFS in the reference organism using BLASTP 2.09 algorithm without filtering. Only those polypeptides that share the highest degree of amino acid sequence identity in each portion of the two-way comparison are retained for further analysis.

The term "homologous coding nucleic acid" also includes nucleic acids comprising nucleotide sequences which encode polypeptides having at least 99%, 95%, at least 90%, at least 85%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40% or at least 25% maino acid identity or similarity to a polypeptide comprising the amino acid sequence of one of SEQ ID NOs: 42,398-78,581 or to a polypeptide whose expression is inhibited by a nucleic acid comprising a nucleotide sequence of one of SEQ ID NOs: 1-6213 or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof as determined using the FASTA version 3.0t78 algorithm with the default parameters. Alternatively, protein identity or similarity may be identified using BLASTP with the default parameters, BLASTX with the default parameters, TBLASTN with the default parameters, or tBLASTX with the default parameters. (Altschul, S.F. et al. Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs, Nucleic Acid Res. 25: 3389-3402 (1997).

Additionally, homologous coding nucleic acids and the homologous polypeptides which they encode may be identified using a "reciprocal" best-hit analysis. To facilitate the identification of homologous coding nucleic acids and homologous polypeptides, paralogous genes within each of 51 organisms are identified and clustered prior to comparison to other organisms. Briefly, the polypeptide sequence of each polypeptide encoded by each open reading frame (ORF) in a given organism is compared to the polypeptide sequence encoded by every other ORF for that organism for each of the 51 pathogenic organisms (PathoSeq Sept 2001 release) using BLASTP 2.09

algorithm without filtering. Simultaneously, the polypeptide sequence encoded by each ORF of an organism is compared to the polypeptide sequences encoded by each of the ORFs in the remaining 51 organisms. Those polypeptides within a single organism that shared a higher degree of sequence identity to one another than to polypeptide sequences obtained from any other organisms are clustered as "paralog" sequences for "reciprocal" best-hit analysis.

For each reference organism, the 50 homologous coding nucleic acids (and the 50 homologous polypeptides which they encode) can be determined by identifying the ORFs in each of the 50 comparison organisms which encode a polypeptide sharing the highest degree of amino acid sequence identity to the polypeptide encoded by the ORF from the reference organism. The accuracy of the identification of the predicted homologous coding nucleic acids (and the homologous polypeptides which they encode) is confirmed by a "reciprocal" BLAST analysis in which the polypeptide sequence of the predicted homologous polypeptide is compared against the polypeptides encoded by each of the ORFS in the reference organism using BLASTP 2.09 algorithm without filtering. Only those polypeptides that share the highest degree of amino acid sequence identity in each portion of the two-way comparison are retained for further analysis.

The term "homologous coding nucleic acid" also includes coding nucleic acids which hybridize under stringent conditions to a nucleic acid selected from the group consisting of the nucleotide sequences complementary to one of SEQ ID NOS.: 6214-42,397 and coding nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of the sequences complementary to one of SEQ ID NOS.: 6214-42,397. As used herein, "stringent conditions" means hybridization to filter-bound nucleic acid in 6xSSC at about 45°C followed by one or more washes in 0.1xSSC/0.2% SDS at about 68°C. Other exemplary stringent conditions may refer, *e.g.*, to washing in 6xSSC/0.05% sodium pyrophosphate at 37°C, 48°C, 55°C, and 60°C as appropriate for the particular probe being used.

The term "homologous coding nucleic acid" also includes coding nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a nucleotide sequence selected from the group consisting of the sequences complementary to one of SEQ ID NOS.: 6214-42,397 and coding nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of the sequences complementary to one of SEQ ID NOS.: 6214-42,397. As used herein, "moderate conditions" means hybridization to filter-bound DNA in 6x sodium chloride/sodium citrate (SSC) at about 45°C followed by one or more washes in 0.2xSSC/0.1% SDS at about 42-65°C.

The term "homologous coding nucleic acids" also includes nucleic acids comprising nucleotide sequences which encode a gene product whose activity may be complemented by a gene encoding a gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213. In some embodiments, the

homologous coding nucleic acids may encode a gene product whose activity is complemented by the gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42,397. In other embodiments, the homologous coding nucleic acids may comprise a nucleotide sequence encode a gene product whose activity is
5 complemented by one of the polypeptides of SEQ ID NOS. 42,398-78,581.

The term "homologous antisense nucleic acid" includes nucleic acids comprising a nucleotide sequence having at least 97%, at least 95%, at least 90%, at least 85%, at least 80%, or at least 70% nucleotide sequence identity to a nucleotide sequence selected from the group consisting of one of the sequences of SEQ ID NOS. 1-6213 and fragments comprising at least 10, 15, 20, 25,
10 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides thereof. Homologous antisense nucleic acids may also comprising nucleotide sequences which have at least 97%, at least 95%, at least 90%, at least 85%, at least 80%, or at least 70% nucleotide sequence identity to a nucleotide sequence selected from the group consisting of the sequences complementary to one of sequences of SEQ ID NOS.: 6214-42,397 and fragments comprising at least 10, 15, 20, 25, 30, 35,
15 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides thereof. Nucleic acid identity may be determined as described above.

The term "homologous antisense nucleic acid" also includes antisense nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a nucleotide sequence complementary to one of SEQ ID NOS.: 1-6213 and antisense nucleic acids comprising
20 nucleotide sequences which hybridize under stringent conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of the sequence complementary to one of SEQ ID NOS. 1-6213. Homologous antisense nucleic acids also include antisense nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-
25 42,397 and antisense nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of one of SEQ ID NOS.: 6214-42,397.

The term "homologous antisense nucleic acid" also includes antisense nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a nucleotide
30 sequence complementary to one of SEQ ID NOS.: 1-6213 and antisense nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of the sequence complementary to one of SEQ ID NOS. 1-6213. Homologous antisense nucleic acids also include antisense nucleic acids comprising nucleotide sequences which hybridize under moderate
35 conditions to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42,397 and antisense nucleic acids which comprising nucleotide sequences hybridize under moderate conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of one of SEQ ID NOS.: 6214-42,397.

By “homologous polypeptide” is meant a polypeptide homologous to a polypeptide whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 or by a homologous antisense nucleic acid. The term “homologous polypeptide” includes polypeptides having at least 99%, 95%, at least 90%, at least 85%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40% or at least 25% amino acid identity or similarity to a polypeptide whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 or by a homologous antisense nucleic acid, or polypeptides having at least 99%, 95%, at least 90%, at least 85%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40% or at least 25% amino acid identity or similarity to a polypeptide to a fragment comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of a polypeptide whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 or by a homologous antisense nucleic acid. Identity or similarity may be determined using the FASTA version 3.0t78 algorithm with the default parameters. Alternatively, protein identity or similarity may be identified using BLASTP with the default parameters, BLASTX with the default parameters, or TBLASTN with the default parameters. (Altschul, S.F. et al. Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs, *Nucleic Acid Res.* 25: 3389-3402 (1997). Additionally, homologous coding nucleic acids and the homologous polypeptides which they encode may be identified using a “reciprocal” best-hit analysis. To facilitate the identification of homologous coding nucleic acids and homologous polypeptides, paralogous genes within each of 51 organisms are identified and clustered prior to comparison to other organisms. Briefly, the polypeptide sequence of each polypeptide encoded by each open reading frame (ORF) in a given organism is compared to the polypeptide sequence encoded by every other ORF for that organism for each of the 51 pathogenic organisms (PathoSeq Sept 2001 release) using BLASTP 2.09 algorithm without filtering. Simultaneously, the polypeptide sequence encoded by each ORF of an organism is compared to the polypeptide sequences encoded by each of the ORFs in the remaining 51 organisms. Those polypeptides within a single organism that shared a higher degree of sequence identity to one another than to polypeptide sequences obtained from any other organisms are clustered as “paralog” sequences for “reciprocal” best-hit analysis.

For each reference organism, the 50 homologous coding nucleic acids (and the 50 homologous polypeptides which they encode) can be determined by identifying the ORFs in each of the 50 comparison organisms which encode a polypeptide sharing the highest degree of amino acid sequence identity to the polypeptide encoded by the ORF from the reference organism. The accuracy of the identification of the predicted homologous coding nucleic acids (and the homologous polypeptides which they encode) is confirmed by a “reciprocal” BLAST analysis in which the polypeptide sequence of the predicted homologous polypeptide is compared against the polypeptides encoded by each of the ORFS in the reference organism using BLASTP 2.09

algorithm without filtering. Only those polypeptides that share the highest degree of amino acid sequence identity in each portion of the two-way comparison are retained for further analysis.

The term homologous polypeptide also includes polypeptides having at least 99%, 95%, at least 90%, at least 85%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40% or at least 25% amino acid identity or similarity to a polypeptide selected from the group consisting of SEQ ID NOs: 42,398-78,581 and polypeptides having at least 99%, 95%, at least 90%, at least 85%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40% or at least 25% amino acid identity or similarity to a fragment comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of a polypeptide selected from the group consisting of SEQ ID NOs: 42,398-78,581.

The invention also includes polynucleotides, preferably DNA molecules, that hybridize to one of the nucleic acids of SEQ ID NOs.: 1-6213, SEQ ID NOs.: 6214-42,397 or the complements of any of the preceding nucleic acids. Such hybridization may be under stringent or moderate conditions as defined above or under other conditions which permit specific hybridization. The nucleic acid molecules of the invention that hybridize to these DNA sequences include oligodeoxynucleotides ("oligos") which hybridize to the target gene under highly stringent or stringent conditions. In general, for oligos between 14 and 70 nucleotides in length the melting temperature (T_m) is calculated using the formula:

$$T_m (^{\circ}\text{C}) = 81.5 + 16.6(\log[\text{monovalent cations (molar)}] + 0.41 (\% \text{ G+C}) - (500/N))$$

where N is the length of the probe. If the hybridization is carried out in a solution containing formamide, the melting temperature may be calculated using the equation:

$$T_m(^{\circ}\text{C}) = 81.5 + 16.6(\log[\text{monovalent cations (molar)}] + 0.41(\% \text{ G+C}) - (0.61) (\% \text{ formamide}) - (500/N))$$

where N is the length of the probe. In general, hybridization is carried out at about 20-25 degrees below T_m (for DNA-DNA hybrids) or about 10-15 degrees below T_m (for RNA-DNA hybrids).

Other hybridization conditions are apparent to those of skill in the art (see, for example, Ausubel, F.M. *et al.*, eds., 1989, *Current Protocols in Molecular Biology*, Vol. I, Green Publishing Associates, Inc. and John Wiley & Sons, Inc., New York, at pp. 6.3.1-6.3.6 and 2.10.3.

The term, *Salmonella*, is the generic name for a large group of gram negative enteric bacteria that are closely related to *Escherichia coli*. The diseases caused by *Salmonella* are often due to contamination of foodstuffs or the water supply and affect millions of people each year. Traditional methods of *Salmonella* taxonomy were based on assigning a separate species name to each serologically distinguishable strain (Kauffmann, F 1966 The bacteriology of the *Enterobacteriaceae*. Munksgaard, Copenhagen). Serology of *Salmonella* is based on surface antigens (O [somatic] and H [flagellar]). Over 2,400 serotypes or serovars of *Salmonella* are known (Popoff, et al. 2000 Res. Microbiol. 151:63-65). Therefore, each serotype was considered to

be a separate species and often given names, accordingly (e.g. *S. paratyphi*, *S. typhimurium*, *S. typhi*, *S. enteritidis*, etc.).

However, by the 1970s and 1980s it was recognized that this system was not only cumbersome, but also inaccurate. Then, many *Salmonella* species were lumped into a single species (all serotypes and subgenera I, II, and IV and all serotypes of *Arizona*) with a second subspecies, *S. bongorii* also recognized (Crosa, et al., 1973, J. Bacteriol. 115:307-315). Though species designations are based on the highly variable surface antigens, the *Salmonella* are very similar otherwise with a major exception being pathogenicity determinants.

There has been some debate on the correct name for the *Salmonella* species. Currently (Brenner, et al. 2000 J. Clin. Microbiol. 38:2465-2467), the accepted name is *Salmonella enterica*. *S. enterica* is divided into six subspecies (I, *S. enterica* subsp. *enterica*; II, *S. enterica*, subsp. *salamae*; IIIa, *S. enterica* subsp. *arizonae*; IIIb, *S. enterica* subsp. *diarizonae*; IV, *S. enterica* subsp. *houtenae*; and VI, *S. enterica* subsp. *indica*). Within subspecies I, serotypes are used to distinguish each of the serotypes or serovars (e.g. *S. enterica* serotype Enteritidis, *S. enterica* serotype Typhimurium, *S. enterica* serotype Typhi, and *S. enterica* serotype Choleraesuis, etc.). Current convention is to spell this out on first usage (*Salmonella enterica* ser. Typhimurium) and then use an abbreviated form (*Salmonella* Typhimurium or *S. Typhimurium*). Note, the genus and species names (*Salmonella enterica*) are italicized but not the serotype/serovar name (Typhimurium). Because the taxonomic committees have yet to officially approve of the actual species name, this latter system is what is employed by the CDC (Brenner, et al. 2000 J. Clin. Microbiol. 38:2465-2467). Due to the concerns of both taxonomic priority and medical importance, some of these serotypes might ultimately receive full species designations (*S. typhi* would be the most notable).

Therefore, as used herein "*Salmonella enterica* or *S. enterica*" includes serovars Typhi, Typhimurium, Paratyphi, Choleraesuis, etc." However, appeals of the "official" name are in process and the taxonomic designations may change (*S. choleraesuis* is the species name that could replace *S. enterica* based solely on priority).

By "identifying a compound" is meant to screen one or more compounds in a collection of compounds such as a combinatorial chemical library or other library of chemical compounds or to characterize a single compound by testing the compound in a given assay and determining whether it exhibits the desired activity.

By "inducer" is meant an agent or solution which, when placed in contact with a cell or microorganism, increases transcription, or inhibitor and/or promoter clearance/fidelity, from a desired promoter.

As used herein, "nucleic acid" means DNA, RNA, or modified nucleic acids. Thus, the terminology "the nucleic acid of SEQ ID NO: X" or "the nucleic acid comprising the nucleotide sequence" includes both the DNA sequence of SEQ ID NO: X and an RNA sequence in which the thymidines in the DNA sequence have been substituted with uridines in the RNA sequence and in which the deoxyribose backbone of the DNA sequence has been substituted with a ribose backbone

in the RNA sequence. Modified nucleic acids are nucleic acids having nucleotides or structures which do not occur in nature, such as nucleic acids in which the internucleotide phosphate residues with methylphosphonates, phosphorothioates, phosphoramidates, and phosphate esters. Nonphosphate internucleotide analogs such as siloxane bridges, carbonate bridges, thioester bridges, as well as many others known in the art may also be used in modified nucleic acids. Modified nucleic acids may also comprise, α -anomeric nucleotide units and modified nucleotides such as 1,2-dideoxy-d-ribofuranose, 1,2-dideoxy-1-phenylribofuranose, and N^4 , N^4 -ethano-5-methyl-cytosine are contemplated for use in the present invention. Modified nucleic acids may also be peptide nucleic acids in which the entire deoxyribose-phosphate backbone has been exchanged with a chemically completely different, but structurally homologous, polyamide (peptide) backbone containing 2-aminoethyl glycine units.

As used herein, "sub-lethal" means a concentration of an agent below the concentration required to inhibit all cell growth.

Brief Description of the Drawings

Figure 1A illustrates a method for replacing a promoter using a promoter replacement cassette comprising a 5' region homologous to the sequence which is 5' of the natural promoter in the chromosome, the promoter which is to replace the chromosomal promoter and a 3' region which is homologous to sequences 3' of the natural promoter in the chromosome.

Figure 1B illustrates a method for replacing a promoter using a promoter replacement cassette comprising a nucleic acid encoding an identifiable or selectable marker disposed between the 5' region which is homologous to the sequence 5' of the natural promoter and the promoter which is to replace the chromosomal promoter and a transcriptional terminator 3' of the gene encoding an identifiable or selectable marker.

Figures 2A and 2B illustrate one method for identifying amplification products which are underrepresented or overrepresented in a culture.

Figures 3A and 3B illustrate another method for identifying amplification products which are underrepresented or overrepresented in a culture.

Figure 4 illustrates the results of a hybridization analysis where the antisense nucleic acid expressed by a strain in the culture is not complementary to all or a portion of the gene encoding the target of the compound (i.e. a nonspecific strain).

Figure 5 illustrates the results of a hybridization analysis where the antisense nucleic acid expressed by a strain in the culture is complementary to all or a portion of the gene encoding the target of the compound, the hybridization intensity for that strain will be intimately correlated with the concentration of the compound (i.e. a specific strain).

Figure 6 illustrates an oligonucleotide comprising a lac operator flanked on each side by 40 nucleotides homologous to the promoter is the promoter which drives expression of the *yabB yabC ftsL ftsI murE* genes in an operon for use in inserting the lac operator into the promoter.

Figure 7 is an IPTG dose response curve in *E. coli* transformed with an IPTG-inducible plasmid containing either an antisense clone to the *E. coli* ribosomal protein *rplW* (AS-*rplW*) which is required for protein synthesis and essential for cell proliferation, or an antisense clone to the *elaD* (AS-*elaD*) gene which is not known to be involved in protein synthesis and which is also essential for proliferation.

Figure 8A is a tetracycline dose response curve in *E. coli* transformed with an IPTG-inducible plasmid containing antisense to *rplW* (AS-*rplW*) in the absence (0) or presence of IPTG at concentrations that result in 20% and 50% growth inhibition.

Figure 8B is a tetracycline dose response curve in *E. coli* transformed with an IPTG-inducible plasmid containing antisense to *elaD* (AS-*elaD*) in the absence (0) or presence of IPTG at concentrations that result in 20% and 50% growth inhibition.

Figure 9 is a graph showing the fold increase in tetracycline sensitivity of *E. coli* transfected with antisense clones to essential ribosomal proteins *L23* (AS-*rplW*) and *L7/L12* and *L10* (AS-*rplLrplJ*). Antisense clones to genes known to not be directly involved in protein synthesis, *atpB/E* (AS-*atpB/E*), *visC* (AS-*visC*), *elaD* (AS-*elaD*), *yohH* (AS-*yohH*), are much less sensitive to tetracycline.

Figure 10 illustrates the results of an assay in which *Staphylococcus aureus* cells transcribing an antisense nucleic acid complementary to the *gyrB* gene encoding the β subunit of gyrase were contacted with several antibiotics whose targets were known.

Figure 11 illustrates a microtitration plate which contains antibiotic and inducer at gradient concentrations in a matrix format in 10 times excess quantity.

Figure 12 illustrates the results of an experiment demonstrating that at appropriate concentrations of inducer, cells which overexpress the *defB* gene product were able to grow at elevated concentrations of the antibiotic actinonin.

Figure 13 illustrates the results of an experiment demonstrating that at appropriate concentrations of inducer cells which overexpress the *folA* gene product were able to grow at elevated concentrations of the antibiotic trimethoprim.

Figure 14 illustrates the results of an experiment demonstrating that overexpression of the *fabI* gene confers resistance to triclosan, which acts on the gene product of the *fabI* gene, but does not confer resistance to cerulenin, trimethoprim, or actinonin, each of which act on other gene products.

Figure 15 illustrates the results of an experiment demonstrating that overexpression of the *folA* gene confers resistance to trimethoprim, which acts on the gene product of the *folA* gene but does not confer resistance to triclosan, cerulenin, or actinonin, each of which act on other gene products.

Figure 16 illustrates the results of an experiment demonstrating that overexpression of the *defB* gene conferred resistance to actinonin, which acts on the gene product of the *defB* gene but

does not confer resistance to cerulenin, trimethoprim, or triclosan, each of which act on other gene products.

Figure 17 illustrates the results of an experiment demonstrating that overexpression of the *fabF* gene conferred resistance to cerulenin, which acts on the gene product of the *fabF* gene, β keto-acyl carrier protein synthase but does not confer resistance to triclosan, trimethoprim, or actinonin, each of which act on other gene products.

Figure 18 illustrates the results of experiments in which a mixture of nine strains was grown wells in a 96 well plate in medium containing various concentrations of inducer and a sufficient concentration of actinonin, cerulenin, triclosan or trimethoprim to inhibit the growth of strains which do not overexpress the targets of these antibiotics.

Detailed Description of Embodiments of the Invention

The present invention describes a group of prokaryotic genes and gene families required for cellular proliferation. Exemplary genes and gene families from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diptheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholera* and *Yersinia pestis* are provided. A proliferation-required gene or gene family is one where, in the absence or substantial reduction of a gene transcript and/or gene product, growth or viability of the cell or microorganism is reduced or eliminated. Thus, as used herein, the terminology "proliferation-required" or "required for proliferation" encompasses instances where the absence or substantial reduction of a gene transcript and/or gene product completely eliminates cell growth as well as instances where the absence of a gene transcript and/or gene product merely reduces cell growth. These proliferation-required genes can be used as potential targets for the generation of new antimicrobial agents. To achieve that goal, the present invention also encompasses assays for analyzing proliferation-required genes and for identifying compounds which interact with the gene and/or gene products of the proliferation-required genes. In addition, the present invention contemplates the expression of genes and the purification of the proteins encoded by the nucleic acid sequences identified as required proliferation genes and reported herein. The purified proteins can be

used to generate reagents and screen small molecule libraries or other candidate compound libraries for compounds that can be further developed to yield novel antimicrobial compounds.

The present invention also describes methods for identification of nucleotide sequences homologous to these genes and polypeptides described herein, including nucleic acids comprising nucleotide sequences homologous to the nucleic acids of SEQ ID NOS.: 6214-42397 and polypeptides homologous to the polypeptides of SEQ ID NOS.: 42398-78581. For example, these sequences may be used to identify homologous coding nucleic acids, homologous antisense nucleic acids, or homologous polypeptides in microorganisms such as *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. In some embodiments, the homologous coding nucleic acids, homologous antisense nucleic acids, or homologous polypeptides are identified in an organism other than *E. coli*.

The homologous coding nucleic acids, homologous antisense nucleic acids, or homologous polypeptides, may then be used in each of the methods described herein, including methods of identifying compounds which inhibit the proliferation of the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, methods of inhibiting the growth of the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, methods of identifying compounds which influence the activity or level of a gene product required for proliferation of the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous

polypeptide, methods for identifying compounds or nucleic acids having the ability to reduce the level or activity of a gene product required for proliferation of the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, methods of inhibiting the activity or expression of a gene in an operon required for proliferation of the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, methods for identifying a gene required for proliferation of the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, methods for identifying the biological pathway in which a gene or gene product required for proliferation of the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide lies, methods for identifying compounds having activity against biological pathway required for proliferation of the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, methods for determining the biological pathway on which a test compound acts in the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, methods of replacing an endogenous promoter with a regulatable promoter which controls the expression of the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, methods of inserting an operator within or near an endogenous promoter to provide regulatable expression of the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, methods of identifying the target on which a compound acts in the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide, and methods of inhibiting the proliferation of the organism containing the homologous coding nucleic acid, homologous antisense nucleic acid or homologous polypeptide in a subject. In some embodiments of the present invention, the methods are performed using an organism, other than *E. coli* or a gene or gene product from an organism other than *E. coli*.

One embodiment of the present invention utilizes a novel method to identify proliferation-required sequences. Generally, a library of nucleic acid sequences from a given source are subcloned or otherwise inserted immediately downstream of an inducible promoter on an appropriate vector, such as a *Staphylococcus aureus*/*E. coli* or *Pseudomonas aeruginosa*/*E. coli* shuttle vector, or a vector which will replicate in both *Salmonella typhimurium* and *Klebsiella pneumoniae*, or other vector or shuttle vector capable of functioning in the intended organism, thus forming an expression library. It is generally preferred that expression is directed by a regulatable promoter sequence such that expression level can be adjusted by addition of variable concentrations of an inducer molecule or of an inhibitor molecule to the medium. For example, a number of regulatable promoters useful for regulating the expression of nucleic acid sequences over a wide range of expression levels are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001. Temperature activated promoters, such as promoters regulated by temperature sensitive repressors, such as the lambda C₁₈₅₇ repressor, are also envisioned. Although the insert nucleic acids may be derived from the chromosome

of the cell or microorganism into which the expression vector is to be introduced, because the insert is not in its natural chromosomal location, the insert nucleic acid is an exogenous nucleic acid for the purposes of the discussion herein. The term "expression" is defined as the production of a sense or antisense RNA molecule from a gene, gene fragment, genomic fragment, chromosome, operon or
5 portion thereof. Expression can also be used to refer to the process of peptide or polypeptide synthesis. An expression vector is defined as a vehicle by which a ribonucleic acid (RNA) sequence is transcribed from a nucleic acid sequence carried within the expression vehicle. The expression vector can also contain features that permit translation of a protein product from the transcribed RNA message expressed from the exogenous nucleic acid sequence carried by the expression vector. Accordingly, an
10 expression vector can produce an RNA molecule as its sole product or the expression vector can produce a RNA molecule that is ultimately translated into a protein product.

Once generated, the expression library containing the exogenous nucleic acid sequences is introduced into a population of cells (such as the organism from which the exogenous nucleic acid sequences were obtained) to search for genes that are required for bacterial proliferation. Because the
15 library molecules are foreign, in context, to the population of cells, the expression vectors and the nucleic acid segments contained therein are considered exogenous nucleic acid.

Expression of the exogenous nucleic acid fragments in the test population of cells containing the expression library is then activated. Activation of the expression vectors consists of subjecting the cells containing the vectors to conditions that result in the expression of the exogenous nucleic acid
20 sequences carried by the expression library. The test population of cells is then assayed to determine the effect of expressing the exogenous nucleic acid fragments on the test population of cells. Those expression vectors that negatively impact the growth of the cells upon induction of expression of the random sequences contained therein are identified, isolated, and purified for further study.

In some embodiments, vectors which comprises a regulatable fusion promoter selected
25 from a suite of fusion promoters, wherein the promoter suite is useful for modulating both the basal and maximal levels of transcription of a nucleic acid over a wide dynamic range thus allowing the desired level of production of a transcript, can be used to express exogenous nucleic acids, including the nucleic acids of the present invention. Such promoters are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001, the disclosure of which is
30 incorporated herein by reference in its entirety.

In some other embodiments, vectors useful for the production of stabilized mRNA having an increased lifetime (including antisense RNA) in Gram negative organisms are described in U.S. Provisional Patent Application Serial Number 60/343,512, filed December 21, 2001. Briefly, the stabilized antisense RNA may comprise an antisense RNA which was identified as inhibiting
35 proliferation as described above which has been engineered to contain at least one stem loop flanking each end of the antisense nucleic acid. In some embodiments, the at least one stem-loop structure formed at the 5' end of the stabilized antisense nucleic acid comprises a flush, double stranded 5' end. In some embodiments, one or more of the stem loops comprises a rho independent

terminator. In additional embodiments, the stabilized antisense RNA lacks a ribosome binding site. In further embodiments, the stabilized RNA lacks sites which are cleaved by one or more RNAses, such as RNase E or RNase III. In some embodiments, the stabilized antisense RNA may be transcribed in a cell which the activity of at least one enzyme involved in RNA degradation has been reduced. For example, the activity of an enzyme such as RNase E, RNase II, RNase III, polynucleotide phosphorylase, and poly(A) polymerase, RNA helicase, enolase or an enzyme having similar functions may be reduced in the cell.

Alternatively, genes required for proliferation may be identified by replacing the natural promoter for the proliferation required gene with a regulatable promoter as described above. The growth of such strains under conditions in which the promoter is active or non-repressed is compared to the growth under conditions in which the promoter is inactive or repressed. If the strains fail to grow or grow at a substantially reduced rate under conditions in which the promoter is inactive or repressed but grow normally under conditions in which the promoter is active or non-repressed, then the gene which is operably linked to the regulatable promoter encodes a gene product required for proliferation. For example, proliferation-required genes and gene products identified using promoter replacement are described in U.S. Patent Application Serial Number 09/948,993.

For example, in some embodiments, the natural promoter may be replaced using techniques which employ homologous recombination to exchange a promoter present on the chromosome of the cell with the desired promoter. In such methodology, a nucleic acid comprising a promoter replacement cassette is introduced into the cell. As illustrated in Figure 1A, the promoter replacement cassette comprises a 5' region homologous to the sequence which is 5' of the natural promoter in the chromosome, the promoter which is to replace the chromosomal promoter and a 3' region which is homologous to sequences 3' of the natural promoter in the chromosome. In some embodiments, the promoter replacement cassette may also include a nucleic acid encoding an identifiable or selectable marker disposed between the 5' region which is homologous to the sequence 5' of the natural promoter and the promoter which is to replace the chromosomal promoter. If desired, the promoter replacement cassette may also contain a transcriptional terminator 3' of the gene encoding an identifiable or selectable marker, as illustrated in Figure 1B. As illustrated in Figure 1A and 1B, homologous recombination is allowed to occur between the chromosomal region containing the natural promoter and the promoter replacement cassette. Cells in which the promoter replacement cassette has integrated into the chromosome are identified or selected. To confirm that homologous recombination has occurred, the chromosomal structure of the cells may be verified by Southern analysis or PCR.

In some embodiments, the promoter replacement cassette may be introduced into the cell as a linear nucleic acid, such a PCR product or a restriction fragment. Alternatively, the promoter replacement may be introduced into the cell on a plasmid. Figures 1A and 1B illustrates the

replacement of a chromosomal promoter with a desired promoter through homologous recombination.

In some embodiments, the cell into which the promoter replacement cassette is introduced may carry mutations which enhance its ability to be transformed with linear DNA or which enhance the frequency of homologous recombination. For example, if the cell is an *Escherichia coli* cell it may have a mutation in the gene encoding Exonuclease V of the RecBCD recombination complex. If the cell is an *Escherichia coli* cell it may have a mutation that activates the RecET recombinase of the λ prophage and/or a mutation that enhances recombination through the RecF pathway. For example, the *Escherichia coli* cells may be RecB or RecC mutants carrying an *sbcA* or *sbcB* mutation. Alternatively, the *Escherichia coli* cells may be *recD* mutants. In other embodiments the *Escherichia coli* cells may express the λ Red recombination genes. For example, *Escherichia coli* cells suitable for use in techniques employing homologous recombination have been described in Datsenko, K.A. and Wanner, B.L., PNAS 97:6640-6645 (2000); Murphy, K.C., J. Bact 180: 2053-2071 (1998); Zhang, Y., et al., Nature Genetics 20: 123-128 (1998); and Muylers, J.P.P. et al., Genes & Development 14: 1971-1982 (2000). It will be appreciated that cells carrying mutations in similar genes may be constructed in organisms other than *Escherichia coli*.

In some embodiments of the present invention, a regulatable fusion promoter selected from a suite of fusion promoters, wherein the promoter suite is useful for modulating both the basal and maximal levels of transcription of a nucleic acid over a wide dynamic range thus allowing the desired level of production of a transcript, is with the promoter replacement methods described above. Such promoters are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001, the disclosure of which is incorporated herein by reference in its entirety.

A variety of assays are contemplated to identify nucleic acid sequences that negatively impact growth upon expression. In one embodiment, growth in cultures expressing exogenous nucleic acid sequences and growth in cultures not expressing these sequences is compared. Growth measurements are assayed by examining the extent of growth by measuring optical densities. Alternatively, enzymatic assays can be used to measure bacterial growth rates to identify exogenous nucleic acid sequences of interest. Colony size, colony morphology, and cell morphology are additional factors used to evaluate growth of the host cells. Those cultures that fail to grow or grow at a reduced rate under expression conditions are identified as containing an expression vector encoding a nucleic acid fragment that negatively affects a proliferation-required gene.

Once exogenous nucleic acids of interest are identified, they are analyzed. The first step of the analysis is to acquire the nucleotide sequence of the nucleic acid fragment of interest. To achieve this end, the insert in those expression vectors identified as containing a nucleotide sequence of interest is sequenced, using standard techniques well known in the art. The next step of the process is to determine the source of the nucleotide sequence. As used herein "source" means the genomic region containing the cloned fragment.

Determination of the gene(s) corresponding to the nucleotide sequence is achieved by comparing the obtained sequence data with databases containing known protein and nucleotide sequences from various microorganisms. Thus, initial gene identification is made on the basis of significant sequence similarity or identity to either characterized or predicted *Escherichia coli*,
 5 *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, and *Salmonella typhimurium* genes or their encoded proteins and/or homologues in other species.

The number of nucleotide and protein sequences available in database systems has been growing exponentially for years. For example, the complete nucleotide sequences of *Caenorhabditis elegans* and several bacterial genomes, including *E. coli*, *Aeropyrum pernix*, *Aquifex aeolicus*,
 10 *Archaeoglobus fulgidus*, *Bacillus subtilis*, *Borrelia burgdorferi*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium tetani*, *Corynebacterium diphtheria*, *Deinococcus radiodurans*, *Haemophilus influenzae*, *Helicobacter pylori* 26695, *Helicobacter pylori* J99, *Methanobacterium thermoautotrophicum*, *Methanococcus jannaschii*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Pseudomonas aeruginosa*, *Pyrococcus abyssi*, *Pyrococcus*
 15 *horikoshii*, *Rickettsia prowazekii*, *Synechocystis* PCC6803, *Thermotoga maritima*, *Treponema pallidum*, *Bordetella pertussis*, *Campylobacter jejuni*, *Clostridium acetobutylicum*, *Mycobacterium tuberculosis* CSU#93, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pseudomonas aeruginosa*, *Pyrobaculum aerophilum*, *Pyrococcus furiosus*, *Rhodobacter capsulatus*, *Salmonella typhimurium*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Ureaplasma urealyticum* and *Vibrio cholera* are
 20 available. This nucleotide sequence information is stored in a number of databanks, such as GenBank, the National Center for Biotechnology Information (NCBI), the Genome Sequencing Center (<http://genome.wustl.edu/gsc/salmonella.shtml>), and the Sanger Centre (http://www.sanger.ac.uk/projects/S__typhi) which are publicly available for searching. A variety of computer programs are available to assist in the analysis of the sequences stored within these
 25 databases. FASTA, (W. R. Pearson (1990) "Rapid and Sensitive Sequence Comparison with FASTP and FASTA" Methods in Enzymology 183:63- 98), Sequence Retrieval System (SRS), (Etzold & Argos, SRS an indexing and retrieval tool for flat file data libraries. Comput. Appl. Biosci. 9:49-57, 1993) are two examples of computer programs that can be used to analyze sequences of interest. In one embodiment of the present invention, the BLAST family of computer
 30 programs, which includes BLASTN version 2.0 with the default parameters, or BLASTX version 2.0 with the default parameters, is used to analyze nucleotide sequences.

BLAST, an acronym for "Basic Local Alignment Search Tool," is a family of programs for database similarity searching. The BLAST family of programs includes: BLASTN, a nucleotide sequence database searching program, BLASTX, a protein database searching program where the input
 35 is a nucleic acid sequence; and BLASTP, a protein database searching program. BLAST programs embody a fast algorithm for sequence matching, rigorous statistical methods for judging the significance of matches, and various options for tailoring the program for special situations. Assistance

in using the program can be obtained by e-mail at blast@ncbi.nlm.nih.gov. tBLASTX can be used to translate a nucleotide sequence in all three potential reading frames into an amino acid sequence.

Bacterial genes are often transcribed in polycistronic groups. These groups comprise operons, which are a collection of genes and intergenic sequences under common regulation. The genes of an operon are transcribed on the same mRNA and are often related functionally. Given the nature of the screening protocol, it is possible that the identified exogenous nucleic acid corresponds to a gene or portion thereof with or without adjacent noncoding sequences, an intragenic sequence (i.e. a sequence within a gene), an intergenic sequence (i.e. a sequence between genes), a nucleotide sequence spanning at least a portion of two or more genes, a 5' noncoding region or a 3' noncoding region located upstream or downstream from the actual nucleotide sequence that is required for bacterial proliferation. Accordingly, it is often desirable to determine which gene(s) that is encoded within the operon is individually required for proliferation.

In one embodiment of the present invention, an operon is identified and then dissected to determine which gene or genes are required for proliferation. Operons can be identified by a variety of means known to those in the art. For example, the RegulonDB DataBase described by Huerta et al. (*Nucl. Acids Res.* 26:55-59, 1998), which may also be found on the website http://www.cifn.unam.mx/Computational_Biology/regulondb/, provides information about operons in *Escherichia coli*. The Subtilist database (<http://bioweb.pasteur.fr/GenoList/SubtiList>), (Moszer, I., Glaser, P. and Danchin, A. (1995) *Microbiology* 141: 261-268 and Moszer, I (1998) *FEBS Letters* 430: 28-36, may also be used to predict operons. This database lists genes from the fully sequenced, Gram positive bacteria, *Bacillus subtilis*, together with predicted promoters and terminator sites. This information can be used in conjunction with the *Staphylococcus aureus* genomic sequence data to predict operons and thus produce a list of the genes affected by the antisense nucleic acids of the present invention. The *Pseudomonas aeruginosa* web site (<http://www.pseudomonas.com>) can be used to help predict operon organization in this bacterium. The databases available from the Genome Sequencing Center (<http://genome.wustl.edu/gsc/salmonella.shtml>), and the Sanger Centre (http://www.sanger.ac.uk/projects/S__typhi) may be used to predict operons in *Salmonella typhimurium*. The TIGR microbial database has an incomplete version of the *E. faecalis* genome http://www.tigr.org/cgi-bin/BlastSearch/blast.cgi?organism=e_faecalis. One can take a nucleotide sequence and BLAST it for homologs.

A number of techniques that are well known in the art can be used to dissect the operon. Analysis of RNA transcripts by Northern blot or primer extension techniques are commonly used to analyze operon transcripts. In one aspect of this embodiment, gene disruption by homologous recombination is used to individually inactivate the genes of an operon that is thought to contain a gene required for proliferation.

Several gene disruption techniques have been described for the replacement of a functional gene with a mutated, non-functional (null) allele. These techniques generally involve the use of

homologous recombination. One technique using homologous recombination in *Staphylococcus aureus* is described in Xia et al. 1999, Plasmid 42: 144-149. This technique uses crossover PCR to create a null allele with an in-frame deletion of the coding region of a target gene. The null allele is constructed in such a way that nucleotide sequences adjacent to the wild type gene are retained.

5 These homologous sequences surrounding the deletion null allele provide targets for homologous recombination so that the wild type gene on the *Staphylococcus aureus* chromosome can be replaced by the constructed null allele. This method can be used with other bacteria as well, including *Salmonella* and *Klebsiella* species. Similar gene disruption methods that employ the counter selectable marker *sacB* (Schweizer, H. P., Klassen, T. and Hoang, T. (1996) Mol. Biol. of

10 *Pseudomonas*. ASM press, 229-237, are available for *Pseudomonas*, *Salmonella* and *Klebsiella* species. *E. faecalis* genes can be disrupted by recombining in a non-replicating plasmid that contains an internal fragment to that gene (Leboeuf, C., L. Leblanc, Y. Auffray and A. Hartke. 2000. J. Bacteriol. 182:5799-5806.

The crossover PCR amplification product is subcloned into a suitable vector having a

15 selectable marker, such as a drug resistance marker. In some embodiments the vector may have an origin of replication which is functional in *E. coli* or another organism distinct from the organism in which homologous recombination is to occur, allowing the plasmid to be grown in *E. coli* or the organism other than that in which homologous recombination is to occur, but may lack an origin of replication functional in *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella*

20 *pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*,

25 *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus*

30 *epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* such that selection of the selectable marker requires integration of the vector into the homologous region of the *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter*

35 *baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus*

faecium, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*,
 5 *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* chromosome. Usually a single crossover event is responsible for this integration event such that the *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*,
 10 *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus*
 15 *faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*,
 20 *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholera* or *Yersinia pestis* chromosome now contains a tandem duplication of the target gene consisting of one wild type allele and one deletion null allele separated by vector sequence. Subsequent resolution of the duplication results in both removal of the vector sequence and either
 25 restoration of the wild type gene or replacement by the in-frame deletion. The latter outcome will not occur if the gene should prove essential. A more detailed description of this method is provided in Example 10 below. It will be appreciated that this method may be practiced with any of the nucleic acids or organisms described herein.

Recombinant DNA techniques can be used to express the entire coding sequences of the gene
 30 identified as required for proliferation, or portions thereof. The over-expressed proteins can be used as reagents for further study. The identified exogenous sequences are isolated, purified, and cloned into a suitable expression vector using methods well known in the art. If desired, the nucleic acids can contain the nucleotide sequences encoding a signal peptide to facilitate secretion of the expressed protein.

35 Expression of fragments of the bacterial genes identified as required for proliferation is also contemplated by the present invention. The fragments of the identified genes can encode a polypeptide comprising at least 5, at least 10, at least 15, at least 20, at least 25, at least 30, at least 35, at least 40, at least 45, at least 50, at least 55, at least 60, at least 65, at least 75, or more than 75 consecutive amino

acids of a gene complementary to one of the identified sequences of the present invention. The nucleic acids inserted into the expression vectors can also contain endogenous sequences upstream and downstream of the coding sequence.

When expressing the encoded protein of the identified nucleic acid required for bacterial proliferation or a fragment thereof, the nucleic acid to be expressed is operably linked to a promoter in an expression vector using conventional cloning technology. The expression vector can be any of the bacterial, insect, yeast, or mammalian expression systems known in the art. Commercially available vectors and expression systems are available from a variety of suppliers including Genetics Institute (Cambridge, MA), Stratagene (La Jolla, California), Promega (Madison, Wisconsin), and Invitrogen (San Diego, California). If desired, to enhance expression and facilitate proper protein folding, the codon usage and codon bias of the sequence can be optimized for the particular expression organism in which the expression vector is introduced, as explained by Hatfield, et al., U.S. Patent No. 5,082,767, incorporated herein by this reference. Fusion protein expression systems are also contemplated by the present invention.

Following expression of the protein encoded by the identified exogenous nucleic acid, the protein may be purified. Protein purification techniques are well known in the art. Proteins encoded and expressed from identified exogenous nucleic acids can be partially purified using precipitation techniques, such as precipitation with polyethylene glycol. Alternatively, epitope tagging of the protein can be used to allow simple one step purification of the protein. In addition, chromatographic methods such as ion-exchange chromatography, gel filtration, use of hydroxyapatite columns, immobilized reactive dyes, chromatofocusing, and use of high-performance liquid chromatography, may also be used to purify the protein. Electrophoretic methods such as one-dimensional gel electrophoresis, high-resolution two-dimensional polyacrylamide electrophoresis, isoelectric focusing, and others are contemplated as purification methods. Also, affinity chromatographic methods, comprising antibody columns, ligand presenting columns and other affinity chromatographic matrices are contemplated as purification methods in the present invention.

The purified proteins produced from the gene encoding sequences identified as required for proliferation can be used in a variety of protocols to generate useful antimicrobial reagents. In one embodiment of the present invention, antibodies are generated against the proteins expressed from the identified exogenous nucleic acids. Both monoclonal and polyclonal antibodies can be generated against the expressed proteins. Methods for generating monoclonal and polyclonal antibodies are well known in the art. Also, antibody fragment preparations prepared from the produced antibodies discussed above are contemplated.

In addition, the purified protein, fragments thereof, or derivatives thereof may be administered to an individual in a pharmaceutically acceptable carrier to induce an immune response against the protein. Preferably, the immune response is a protective immune response which protects the individual. Methods for determining appropriate dosages of the protein and pharmaceutically acceptable carriers may be determined empirically and are familiar to those skilled in the art.

Another application for the purified proteins of the present invention is to screen small molecule libraries for candidate compounds active against the various target proteins of the present invention. Advances in the field of combinatorial chemistry provide methods, well known in the art, to produce large numbers of candidate compounds that can have a binding, or otherwise inhibitory effect on a target protein. Accordingly, the screening of small molecule libraries for compounds with binding affinity or inhibitory activity for a target protein produced from an identified gene is contemplated by the present invention.

In some embodiments of the present invention, a cell sensitized by expressing an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, an antisense nucleic acid comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a nucleic acid complementary to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a nucleic acid complementary to a nucleic acid comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a nucleic acid complementary to a nucleic acid which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a nucleic acid complementary to a nucleic acid which encodes at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of a polypeptide sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a homologous antisense nucleic acid, an antisense nucleic acid comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a homologous nucleic acid, a nucleic acid complementary to a homologous coding nucleic acid, a nucleic acid complementary to at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a homologous coding nucleic acid, a nucleic acid complementary to a nucleic acid which encodes a homologous polypeptide, or a nucleic acid complementary to a nucleic acid which encodes at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of a homologous polypeptide, is contacted with one or more candidate compounds from a small molecule library. Candidate compounds which further inhibit the proliferation of the sensitized cell may be identified as possessing inhibitory activity for a target protein or product produced by the gene to which the antisense sequence is complementary.

A number of vectors useful in the above methods are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001.

In some embodiments of the present invention, the methods for the production of stabilized RNA, as described in U.S. Patent Application Serial Number 60/343,512, can be used for the production of a stabilized transcript, which corresponds to a nucleic acid described herein, having an increased lifetime in Gram-negative organisms. Briefly, the stabilized antisense RNA may comprise an antisense RNA which was identified as inhibiting proliferation as described above

which has been engineered to contain at least one stem loop flanking each end of the antisense nucleic acid. In some embodiments, the at least one stem-loop structure formed at the 5' end of the stabilized antisense nucleic acid comprises a flush, double stranded 5' end. In some embodiments, one or more of the stem loops comprises a rho independent terminator. In additional embodiments, the stabilized antisense RNA lacks a ribosome binding site. In further embodiments, the stabilized RNA lacks sites which are cleaved by one or more RNases, such as RNase E or RNase III. In some embodiments, the stabilized antisense RNA may be transcribed in a cell which the activity of at least one enzyme involved in RNA degradation has been reduced. For example, the activity of an enzyme such as RNase E, RNase II, RNase III, polynucleotide phosphorylase, and poly(A) polymerase, RNA helicase, enolase or an enzyme having similar functions may be reduced in the cell.

The present invention further contemplates utility against a variety of other pathogenic microorganisms in addition to *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* and *Yersinia pestis*. For example, homologous coding nucleic acids, homologous antisense nucleic acids or homologous polypeptides from other pathogenic microorganisms (including nucleic acids homologous to the nucleic acids of SEQ ID NOs.: 6214-42397, nucleic acids homologous to the antisense nucleic acids of SEQ ID NOs.: 1-6213, and polypeptides homologous to the polypeptides of SEQ ID NOs.: 42398-78581) may be identified using methods such as those described herein. The homologous coding nucleic acids, homologous antisense nucleic acids or homologous polypeptides may be used to identify compounds which inhibit the proliferation of these other pathogenic microorganisms using methods such as those described herein.

For example, the proliferation-required nucleic acids, antisense nucleic acids, and polypeptides from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia*

pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*,
5 *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or
10 *Yersinia pestis* described herein (including the nucleic acids of SEQ ID NOs.: 6214-42397, the antisense nucleic acids of SEQ ID NOs.: 1-6213, and the polypeptides of SEQ ID NOs.: 42398-78581) may be used to identify homologous coding nucleic acids, homologous antisense nucleic acids or homologous polypeptides required for proliferation in prokaryotes and eukaryotes. For example, nucleic acids or polypeptides required for the proliferation of protists, such as *Plasmodium* spp.;
15 plants; animals, such as *Entamoeba* spp. and *Contracaecum* spp.; and fungi including *Candida* spp., (e.g., *Candida albicans*), *Cryptococcus neoformans*, and *Aspergillus fumigatus* may be identified. In one embodiment of the present invention, monera, specifically bacteria, including both Gram positive and Gram negative bacteria, are probed in search of novel gene sequences required for proliferation. Likewise, homologous antisense nucleic acids which may be used to inhibit growth of these organisms.
20 or to identify antibiotics may also be identified. These embodiments are particularly important given the rise of drug resistant bacteria.

The number of bacterial species that are becoming resistant to existing antibiotics is growing. A partial list of these microorganisms includes: *Escherichia* spp., such as *E. coli*, *Enterococcus* spp, such as *E. faecalis*; *Pseudomonas* spp., such as *P. aeruginosa*, *Clostridium* spp., such as *C.*
25 *botulinum*, *Haemophilus* spp., such as *H. influenzae*, *Enterobacter* spp., such as *E. cloacae*, *Vibrio* spp., such as *V. cholera*; *Moraxella* spp., such as *M. catarrhalis*; *Streptococcus* spp., such as *S. pneumoniae*, *Neisseria* spp., such as *N. gonorrhoeae*; *Mycoplasma* spp., such as *Mycoplasma pneumoniae*; *Salmonella typhimurium*; *Helicobacter pylori*; *Escherichia coli*; and *Mycobacterium tuberculosis*. The genes and polypeptides identified as required for the proliferation of *Escherichia*
30 *coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium*
35 *diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella*

multocida, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*,
Salmonella typhi, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus*
mutans, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma*
urealyticum, *Vibrio cholerae* or *Yersinia pestis* (including the nucleic acids of SEQ ID NOs.: 6214-
5 42397, the sequences complementary to the nucleic acids of SEQ ID NOs.: 6214-42397, and the
polypeptides of SEQ ID NOs.: 42398-78581) can be used to identify homologous coding nucleic
acids or homologous polypeptides required for proliferation from these and other organisms using
methods such as nucleic acid hybridization and computer database analysis. Likewise, the
antisense nucleic acids which inhibit proliferation of *Escherichia coli*, *Staphylococcus aureus*,
10 *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*,
Acinetobacter baumannii, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia*
burgdorferi, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter*
jejuni, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
botulinum, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus*
15 *faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria*
monocytogenes, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
pneumoniae, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus*
mirabilis, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*,
20 *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus*
pneumoniae, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio*
cholerae or *Yersinia pestis* (including the antisense nucleic acids of SEQ ID NOs.: 1-6213 or the
sequences complementary thereto) may also be used to identify antisense nucleic acids which
inhibit proliferation of these and other microorganisms or cells using nucleic acid hybridization or
25 computer database analysis.

In one embodiment of the present invention, the nucleic acid sequences from *Escherichia coli*,
Staphylococcus aureus, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*,
Salmonella typhimurium, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*,
Bordetella pertussis, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*,
30 *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*,
Clostridium acetobutylicum, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium*
diphtheriae, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter*
pylori, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium*
avium, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma*
35 *genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella*
multocida, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*,
Salmonella typhi, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus*
mutans, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma*

urealyticum, *Vibrio cholerae* or *Yersinia pestis* (including the nucleic acids of SEQ ID NOs.: 6214-42397 and the antisense nucleic acids of SEQ ID NOs. 1-6213) are used to screen genomic libraries generated from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*,
5 *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*,
10 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*,
15 *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Yersinia pestis* and other bacterial species of interest. For example, the genomic library may be from Gram positive bacteria, Gram negative bacteria or other organisms including *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*,
25 *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*,
30 *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*,
35 *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species, including coagulase negative species of *Staphylococcus*. In some embodiments, the genomic

library may be from an organism other than *E. coli*. Standard molecular biology techniques are used to generate genomic libraries from various cells or microorganisms. In one aspect, the libraries are generated and bound to nitrocellulose paper. The identified exogenous nucleic acid sequences of the present invention can then be used as probes to screen the libraries for homologous sequences.

5 For example, the libraries may be screened to identify homologous coding nucleic acids or homologous antisense nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213, nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500
10 consecutive nucleotides of one of SEQ ID NOS. 1-6213, nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a nucleic acid complementary to one of SEQ ID NOS. 1-6213, nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of the sequence complementary to one of SEQ ID NOS. 1-
15 6213, nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a nucleic acid selected from the group consisting of SEQ ID NOS.: 6214-42397, nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of one of SEQ ID NOS.: 6214-42397, nucleic acids comprising nucleotide sequences
20 which hybridize under stringent conditions to a nucleic acid complementary to one of SEQ ID NOS.: 6214-42397, nucleic acids comprising nucleotide sequences which hybridize under stringent conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of the sequence complementary to one of SEQ ID NOS.: 6214-42397.

25 The libraries may also be screened to identify homologous nucleic coding nucleic acids or homologous antisense nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213, nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500
30 consecutive nucleotides of one of SEQ ID NOS. 1-6213, nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a nucleic acid complementary to one of SEQ ID NOS. 1-6213, nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of the sequence complementary to one of SEQ ID
35 NOS. 1-6213, nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a nucleic acid selected from the group consisting of SEQ ID NOS.: 6214-42397, nucleic acids comprising nucleic acid sequences which hybridize under moderate conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500

consecutive nucleotides of one of SEQ ID NOS.: 6214-42397, nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a nucleic acid complementary to one of SEQ ID NOS.: 6214-42397 and nucleic acids comprising nucleotide sequences which hybridize under moderate conditions to a fragment comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100,
5 150, 200, 300, 400, or 500 consecutive nucleotides of the sequence complementary to one of SEQ ID NOS.: 6214-42397.

The homologous coding nucleic acids, homologous antisense nucleic acids or homologous polypeptides identified as above can then be used as targets or tools for the identification of new, antimicrobial compounds using methods such as those described herein. In some embodiments, the
10 homologous coding nucleic acids, homologous antisense nucleic acids, or homologous polypeptides may be used to identify compounds with activity against more than one microorganism. [Placeholder]

For example, the preceding methods may be used to isolate homologous coding nucleic acids or homologous antisense nucleic acids comprising a nucleotide sequence with at least 97%, at least 95%, at least 90%, at least 85%, at least 80%, or at least 70% nucleotide sequence identity to a
15 nucleotide sequence selected from the group consisting of one of the sequences of SEQ ID NOS. 1-6213, fragments comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides thereof, and the sequences complementary thereto. The preceding methods may also be used to isolate homologous coding nucleic acids or homologous antisense nucleic acids comprising a nucleotide sequence with at least 97%, at least 95%, at least 90%, at least 85%, at
20 least 80%, or at least 70% nucleotide sequence identity to a nucleotide sequence selected from the group consisting of one of the nucleotide sequences of SEQ ID NOS.: 6214-42397, fragments comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides thereof, and the sequences complementary thereto. Identity may be measured using
25 BLASTN version 2.0 with the default parameters. (Altschul, S.F. et al. Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs, Nucleic Acid Res. 25: 3389-3402 (1997). For example, the homologous polynucleotides may comprise a coding sequence which is a naturally occurring allelic variant of one of the coding sequences described herein. Such allelic variants may have a substitution, deletion or addition of one or more nucleotides when compared to the nucleic acids of SEQ ID NOS.: 1-6213, SEQ ID NOS.: 6214-42397 or the
30 nucleotide sequences complementary thereto.

Additionally, the above procedures may be used to isolate homologous coding nucleic acids which encode polypeptides having at least 99%, 95%, at least 90%, at least 85%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40% or at least 25% amino acid identity or similarity to a polypeptide comprising the sequence of one of SEQ ID NOS.: 42398-78581 or to a polypeptide
35 whose expression is inhibited by a nucleic acid of one of SEQ ID NOS.: 1-6213 or fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids thereof as determined using the FASTA version 3.0t78 algorithm with the default parameters. Alternatively, protein identity or similarity may be identified using BLASTP with the default

parameters, BLASTX with the default parameters, or TBLASTN with the default parameters. (Altschul, S.F. et al. Gapped BLAST and PSI-BLAST: A New Generation of Protein Database Search Programs, Nucleic Acid Res. 25: 3389-3402 (1997).

Alternatively, homologous coding nucleic acids, homologous antisense nucleic acids or homologous polypeptides may be identified by searching a database to identify sequences having a desired level of nucleotide or amino acid sequence homology to a nucleic acid or polypeptide involved in proliferation or an antisense nucleic acid to a nucleic acid involved in microbial proliferation. A variety of such databases are available to those skilled in the art, including GenBank and GenSeq. In some embodiments, the databases are screened to identify nucleic acids with at least 97%, at least 95%, at least 90%, at least 85%, at least 80%, or at least 70% nucleotide sequence identity to a nucleic acid required for proliferation, an antisense nucleic acid which inhibits proliferation, or a portion of a nucleic acid required for proliferation or a portion of an antisense nucleic acid which inhibits proliferation. For example, homologous coding sequences may be identified by using a database to identify nucleic acids homologous to one of SEQ ID Nos. 1-6213, homologous to fragments comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides thereof, nucleic acids homologous to one of SEQ ID NOS.: 6214-42397, homologous to fragments comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of one of SEQ ID NOS.: 6214-42397, nucleic acids homologous to one of SEQ ID Nos. 1-6213, homologous to fragments comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides thereof or nucleic acids homologous to the sequences complementary to any of the preceding nucleic acids. In other embodiments, the databases are screened to identify polypeptides having at least 99%, 95%, at least 90%, at least 85%, at least 80%, at least 70%, at least 60%, at least 50%, at least 40% or at least 25% amino acid sequence identity or similarity to a polypeptide involved in proliferation or a portion thereof. For example, the database may be screened to identify polypeptides homologous to a polypeptide comprising one of SEQ ID NOs: 42398-78581, a polypeptide whose expression is inhibited by a nucleic acid of one of SEQ ID NOs: 1-6213 or homologous to fragments comprising at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of any of the preceding polypeptides. In some embodiments, the database may be screened to identify homologous coding nucleic acids, homologous antisense nucleic acids or homologous polypeptides from cells or microorganisms other than the *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,

Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* species from which they were obtained. For example the database may be screened to identify homologous coding nucleic acids, homologous antisense nucleic acids or homologous polypeptides from microorganisms such as *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species, including coagulase negative *Staphylococcus*. In some embodiments, the homologous coding nucleic acids, homologous antisense nucleic acids, or homologous polypeptides are from an organism other than *E. coli*.

In another embodiment, gene expression arrays and microarrays can be employed. Gene expression arrays are high density arrays of DNA samples deposited at specific locations on a glass chip, nylon membrane, or the like. Such arrays can be used by researchers to quantify relative gene expression under different conditions. Gene expression arrays are used by researchers to help identify optimal drug targets, profile new compounds, and determine disease pathways. An example of this technology is found in U.S. Patent No. 5,807,522.

It is possible to study the expression of all genes in the genome of a particular microbial organism using a single array. For example, the arrays may consist of 12 x 24 cm nylon filters containing PCR products corresponding to ORFs from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*,
 5 *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria*
 10 *monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus*
 15 *pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including the nucleic acids of SEQ ID NOs.: 6214-42397) . 10 ngs of each PCR product are spotted every 1.5 mm on the filter. Single stranded labeled cDNAs are prepared for hybridization to the array (no second strand synthesis or amplification step is done) and placed in contact with the filter. Thus the labeled cDNAs are of "antisense" orientation.
 20 Quantitative analysis is done by phosphorimager.

Hybridization of cDNA made from a sample of total cell mRNA to such an array followed by detection of binding by one or more of various techniques known to those in the art results in a signal at each location on the array to which cDNA hybridized. The intensity of the hybridization signal obtained at each location in the array thus reflects the amount of mRNA for that specific
 25 gene that was present in the sample. Comparing the results obtained for mRNA isolated from cells grown under different conditions thus allows for a comparison of the relative amount of expression of each individual gene during growth under the different conditions.

Gene expression arrays may be used to analyze the total mRNA expression pattern at various time points after induction of an antisense nucleic acid complementary to a proliferation-
 30 required gene. Analysis of the expression pattern indicated by hybridization to the array provides information on other genes whose expression is influenced by antisense expression. For example, if the antisense is complementary to a gene for ribosomal protein L7/L12 in the 50S subunit, levels of other mRNAs may be observed to increase, decrease or stay the same following expression of antisense to the L7/L12 gene. If the antisense is complementary to a different 50S subunit
 35 ribosomal protein mRNA (e.g. L25), a different mRNA expression pattern may result. Thus, the mRNA expression pattern observed following expression of an antisense nucleic acid comprising a nucleotide sequence complementary to a proliferation required gene may identify other proliferation-required nucleic acids. In addition, the mRNA expression patterns observed when the

bacteria are exposed to candidate drug compounds or known antibiotics may be compared to those observed with antisense nucleic acids comprising a nucleotide sequence complementary to a proliferation-required nucleic acid. If the mRNA expression pattern observed with the candidate drug compound is similar to that observed with the antisense nucleic acid, the drug compound may be a promising therapeutic candidate. Thus, the assay would be useful in assisting in the selection of promising candidate drug compounds for use in drug development.

In cases where the source of nucleic acid deposited on the array and the source of the nucleic acid being hybridized to the array are from two different cells or microorganisms, gene expression arrays can identify homologous nucleic acids in the two cells or microorganisms.

The present invention also contemplates additional methods for screening other microorganisms for proliferation-required genes. In one aspect of this embodiment, an antisense nucleic acid comprising a nucleotide sequence complementary to the proliferation-required sequences from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis*, or a portion thereof, is transcribed in an antisense orientation in such a way as to alter the level or activity of a nucleic acid required for proliferation of an autologous or heterologous cell or microorganism. For example, the antisense nucleic acid may be a homologous antisense nucleic acid such as an antisense nucleic acid homologous to the nucleotide sequence complementary to one of SEQ ID NOs.: 6214-42397, an antisense nucleic acid comprising a nucleotide sequence homologous to one of SEQ ID Nos.: 1-6213, or an antisense nucleic acid comprising a nucleotide sequence complementary to a portion of any of the preceding nucleic acids. The cell or microorganism transcribing the homologous antisense nucleic acid may be used in a cell-based assay, such as those described herein, to identify candidate antibiotic compounds. In another embodiment, the conserved portions of nucleotide sequences identified as proliferation-required can be used to generate degenerate primers for use in the polymerase chain reaction (PCR). The PCR technique is well known in the art. The successful production of a PCR product using degenerate primers generated from the nucleotide sequences identified herein indicates the presence of a homologous gene sequence in the species being screened.

This homologous gene is then isolated, expressed, and used as a target for candidate antibiotic compounds. In another aspect of this embodiment, the homologous gene (for example a homologous coding nucleic acid) thus identified, or a portion thereof, is transcribed in an autologous cell or microorganism or in a heterologous cell or microorganism in an antisense orientation in such a way as to alter the level or activity of a homologous gene required for proliferation in the autologous or heterologous cell or microorganism. Alternatively, a homologous antisense nucleic acid may be transcribed in an autologous or heterologous cell or microorganism in such a way as to alter the level or activity of a gene product required for proliferation in the autologous or heterologous cell or microorganism.

The nucleic acids homologous to the genes required for the proliferation of *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or the sequences complementary thereto may be used to identify homologous coding nucleic acids or homologous antisense nucleic acids from cells or microorganisms other than *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* to inhibit the proliferation of cells or microorganisms other than

Escherichia coli, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*,
Pseudomonas aeruginosa, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*,
Bacteroides fragilis, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*,
Burkholderia fungorum, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*,
5 *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*,
Corynebacterium diphtheriae, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus*
influenzae, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella*
catarrhalis, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium*
tuberculosis, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria*
10 *meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas*
syringae, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus*
haemolyticus, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*,
Treponema pallidum, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* by inhibiting the
activity or reducing the amount of the identified homologous coding nucleic acid or homologous
15 polypeptide in the cell or microorganism other than *Escherichia coli*, *Staphylococcus aureus*,
Enterococcus faecalis, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*,
Acinetobacter baumannii, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia*
burgdorferi, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter*
jejuni, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
20 *botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus*
faecium, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria*
monocytogenes, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
pneumoniae, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus*
25 *mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*,
Staphylococcus epidermidis, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus*
pneumoniae, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio*
cholerae or *Yersinia pestis* or to identify compounds which inhibit the growth of cells or
microorganisms other than *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*,
30 *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter*
baumannii, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*,
Burkholderia cepacia, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*,
Chlamydia pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
botulinum, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus*
35 *faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria*
monocytogenes, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
pneumoniae, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus*

mirabilis, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*,
Staphylococcus epidermidis, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus*
pneumoniae, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio*
cholerae or *Yersinia pestis* as described below. For example, the nucleic acids homologous to
5 proliferation-required genes from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*,
Klebsiella pneumoniae, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter*
baumannii, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*,
Burkholderia cepacia, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*,
Chlamydia pneumoniae, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium*
10 *botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus*
faecium, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria*
monocytogenes, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
pneumoniae, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus*
15 *mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*,
Staphylococcus epidermidis, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus*
pneumoniae, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio*
cholerae or *Yersinia pestis* or the sequences complementary thereto may be used to identify
compounds which inhibit the growth of *Acinetobacter baumannii*, *Anaplasma marginale*,
20 *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia*
burgdorferi, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter*
jejuni, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*,
Candida parapsilosis, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida*
pseudotropicalis), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*,
25 *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*,
Coccidioides immitis, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter*
cloacae, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*,
Helicobacter pylori, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*,
Listeria monocytogenes, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
30 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma*
pneumoniae, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella*
haemolytica, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,
Pseudomonas aeruginosa, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,
Salmonella choleraesuis, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella*
35 *typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
Staphylococcus aureus, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus*
pneumoniae, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma*
urealyticum, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*,

Yersinia pestis or any species falling within the genera of any of the above species. In some embodiments of the present invention, the nucleic acids homologous to proliferation-required sequences from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*,
 5 *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*,
 10 *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*,
 15 *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including nucleic acids homologous to one of SEQ ID NOs.: 6214-42397) or the sequences complementary thereto (including nucleic acids homologous to one of SEQ ID NOs.: 1-6213) are used to identify proliferation-required sequences in an organism other than *E. coli*.

In another embodiment of the present invention, antisense nucleic acids complementary to the
 20 sequences identified as required for proliferation or portions thereof (including antisense nucleic acids comprising a nucleotide sequence complementary to one of SEQ ID NOs.: 6214-42397 or portions thereof, such as the nucleic acids of SEQ ID NOs.: 1-6213) are transferred to vectors capable of function within a species other than the species from which the sequences were obtained. For example, the vector may be functional in *Acinetobacter baumannii*, *Anaplasma marginale*,
 25 *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*,
 30 *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
 35 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*,

Salmonella choleraesuis, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. In some embodiments of the present invention, the vector may be functional in an organism other than *E. coli*. As would be appreciated by one of ordinary skill in the art, vectors may contain certain elements that are species specific. These elements can include promoter sequences, operator sequences, repressor genes, origins of replication, ribosomal binding sequences, termination sequences, and others. To use the antisense nucleic acids, one of ordinary skill in the art would know to use standard molecular biology techniques to isolate vectors containing the sequences of interest from cultured bacterial cells, isolate and purify those sequences, and subclone those sequences into a vector adapted for use in the species of bacteria to be screened.

Vectors for a variety of other species are known in the art. For example, numerous vectors which function in *E. coli* are known in the art. Also, Pla et al. have reported an expression vector that is functional in a number of relevant hosts including: *Salmonella typhimurium*, *Pseudomonas putida*, and *Pseudomonas aeruginosa*. *J. Bacteriol.* 172(8):4448-55 (1990). Brunschwig and Darzins (Gene (1992) 111:35-4, described a shuttle expression vector for *Pseudomonas aeruginosa*. Vectors useful for the production of stabilized mRNA having an increased lifetime (including antisense RNA) in Gram negative organisms are described in U.S. Provisional Patent Application Serial Number 60/343,512, filed December 21, 2001. Similarly many examples exist of expression vectors that are freely transferable among various Gram positive microorganisms. Expression vectors for *Enterococcus faecalis* may be engineered by incorporating suitable promoters into a pAK80 backbone (Israelsen, H., S. M. Madsen, A. Vrang, E. B. Hansen and E. Johansen. 1995. *Appl. Environ. Microbiol.* 61:2540-2547. A number of vectors useful for nucleic acid expression (including antisense nucleic acid expression) in *Enterococcus faecalis*, *Staphylococcus aureus* as well as other Gram positive organisms are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001.

Following the subcloning of the antisense nucleic acids complementary to proliferation-required sequences from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,

Mycobacterium leprae, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or portions thereof into a vector functional in a second cell or microorganism of interest (i.e. a cell or microorganism other than the one from which the identified nucleic acids were obtained), the antisense nucleic acids are conditionally transcribed to test for bacterial growth inhibition. The nucleotide sequences of the nucleic acids from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diptheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* that, when transcribed, inhibit growth of the second cell or microorganism are compared to the known genomic sequence of the second cell or microorganism to identify the homologous gene from the second organism. If the homologous sequence from the second cell or microorganism is not known, it may be identified and isolated by hybridization to the proliferation-required *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diptheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio*

cholerae or *Yersinia pestis* sequence of interest or by amplification using PCR primers based on the proliferation-required nucleotide sequence of interest as described above. In this way, sequences which may be required for the proliferation of the second cell or microorganism may be identified. For example, the second microorganism may be *Acinetobacter baumannii*, *Anaplasma marginale*,
 5 *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*,
 10 *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
 15 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
 20 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. In some
 25 embodiments of the present invention, the second microorganism is an organism other than *E. coli*.

The homologous nucleic acid sequences from the second cell or microorganism which are identified as described above may then be operably linked to a promoter, such as an inducible promoter, in an antisense orientation and introduced into the second cell or microorganism. The techniques described herein for identifying *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus*
 30 *faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus*
 35 *faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus*

mirabilis, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* genes required for proliferation may thus be employed to determine whether the identified nucleotide sequences from a second cell or microorganism inhibit the proliferation of the second cell or microorganism. For example, the second microorganism may be *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. In some embodiments of the present invention, the second microorganism may be an organism other than *E. coli*.

Antisense nucleic acids required for the proliferation of microorganisms other than *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium*

tuberculosis, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*,
5 *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or the genes corresponding thereto, may also be hybridized to a microarray containing the *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*,
10 *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* (including the nucleic acids of SEQ ID NOs.: 6214-
20 42397) to gauge the homology between the *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*,
30 *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* sequences and the proliferation-required nucleic acids from other cells or microorganisms. For example, the proliferation-required nucleic acid may be from
35 *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida*

guilliermondii, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. In some embodiments of the present invention, the proliferation-required nucleotide sequences from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* or homologous nucleic acids are used to identify proliferation-required sequences in an organism other than *E. coli*. In some embodiments of the present invention, the proliferation-required sequences may be from an organism other than *E. coli*. The proliferation-required nucleic acids from a cell or microorganism other than *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium*, *Acinetobacter baumannii*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Chlamydia pneumoniae*,

Chlamydia trachomatis, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Corynebacterium diphtheriae*, *Enterobacter cloacae*, *Enterococcus faecium*, *Haemophilus influenzae*, *Helicobacter pylori*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Pasteurella multocida*, *Proteus mirabilis*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella paratyphi*, *Salmonella typhi*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus mutans*, *Streptococcus pneumoniae*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae* or *Yersinia pestis* may be hybridized to the array under a variety of conditions which permit hybridization to occur when the probe has different levels of homology to the nucleotide sequence on the microarray. This would provide an indication of homology across the cells or microorganisms as well as clues to other possible essential genes in these cells or microorganisms.

In some embodiments of the present invention, the essential gene products described herein are used in methods of identifying a target on which a compound that inhibits cellular proliferation acts. Such methods are described in the U.S. Patent Application entitled METHODS FOR IDENTIFYING THE TARGET OF A COMPOUND WHICH INHIBITS CELLULAR PROLIFERATION, filed February 8, 2002. As employed herein, some embodiments of methods used to identify a target on which a compound that inhibits cellular proliferation acts utilize collections or cultures of strains comprising strains which either overexpress a different gene product which is required for cellular proliferation (such as the gene products described herein) or underexpress a different gene product (such as the gene products described herein) which is required for cellular proliferation (i.e. at least some of the strains in the culture overexpress or underexpress a gene product required for cellular proliferation). In some embodiments, the present invention uses collections or cultures of strains comprising both strains which overexpress gene products required for cellular proliferation and strains which underexpress the same gene products required for cellular proliferation. Preferably, each of the strains present in the culture or collection either overexpresses or underexpresses a different gene product which is required for cellular proliferation (i.e. all of the strains in the culture overexpress or underexpress a gene product required for cellular proliferation). However, in some embodiments, the culture or collection may include one or more strains which do not overexpress or underexpress a gene product which is required for proliferation. The gene product which is overexpressed or underexpressed in each strain may be any gene product which is required for cellular proliferation, including a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a gene product whose activity or level is inhibited by a homologous

antisense nucleic acid, a gene product encoded by a homologous coding nucleic acid, and a gene product comprising a homologous polypeptide.

As used herein the term "culture" refers to a plurality of strains growing in a single aliquot of a liquid growth medium and the term "collection" refers to a plurality of strains each of which is growing in a separate aliquot of liquid growth medium or a different location on a solid growth medium.

In some embodiments, if desired, one or more of the strains in the culture or collection of strains may overexpress or underexpress more than one gene product described herein which is required for cellular proliferation. In this embodiment, the gene products which are overexpressed or underexpressed in one or more of the strains may be functionally related or functionally unrelated. This may facilitate the identification of compounds when two or more gene products share similar functions in the cell or where the cell has multiple biochemical pathways which lead to a particular end product.

Alternatively, if the gene product described herein to be overexpressed or underexpressed is encoded by a gene which is part of an operon containing a plurality of genes, the desired gene may be overexpressed or underexpressed while the remaining genes in the operon are expressed at levels where they do not impact the ability of the cell to grow in the presence of a particular compound. For example, the desired gene may be placed under the control of a regulatable promoter, a transcriptional terminator may be placed 3' of the desired gene and a promoter, preferably a constitutive promoter, may be placed 3' of the transcriptional terminator and 5' of the remaining genes in the operon.

In some embodiments, the culture or collection of strains may comprise a strain which overexpresses or underexpresses a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 1-6213.

In some embodiments, the culture or collection of strains may comprise strains which in aggregate overexpress or underexpress at least two gene products whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213, at least 10 gene products whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213, at least 20 gene products whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213, at least 30 gene products whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213, at least 50 gene products whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213, at least 100 gene products whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213, at least 300 gene products whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213 or more than 300 gene products whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOS.: 1-6213, wherein each strain in the culture or collection of strains overexpresses or underexpresses a single gene

product whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213. Alternatively, if desired, one or more of the strains in the culture or collection of strains may overexpress or underexpress more than one gene product whose activity or level is inhibited by a nucleic acid selected from the group consisting of SEQ ID NOs. 1-6213.

5 In other embodiments, the culture or collection of strains may comprise a strain which overexpresses or underexpresses a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397. In some embodiments, the culture or collection of strains may comprise strains which in aggregate overexpress or underexpress at least two gene products encoded by a nucleic acid comprising a nucleotide
10 sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, at least 10 gene products encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, at least 20 gene products encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, at least 30 gene products encoded by a nucleic acid comprising a nucleotide sequence selected from
15 the group consisting of SEQ ID NOs.: 6214-42397, at least 50 gene products encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, at least 100 gene products encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, at least 300 gene products encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of
20 SEQ ID NOs.: 6214-42397 or more than 300 gene products encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, wherein each strain in the culture or collection of strains overexpresses or underexpresses a single gene product encoded by a nucleic acid selected from the group consisting of SEQ ID NOs. 6214-42397. Alternatively, if desired, one or more strains in the culture or collection of strains may overexpress
25 or underexpress more than one gene product encoded by a nucleic acid selected from the group consisting of SEQ ID NOs. 6214-42397.

In some embodiments the culture or collection of strains comprises a strain in which a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 is overexpressed or underexpressed. In some embodiments, the culture or collection
30 of strains may comprise strains which in aggregate overexpress or underexpress at least two gene products comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581, at least 10 gene products comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581, at least 20 gene products comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581, at least 30 gene
35 products comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581, at least 50 gene products comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581, at least 100 gene products comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581, at least 300 gene

products comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581 or more than 300 gene products comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42938-78581, wherein each strain in the culture or collection of strains overexpresses or underexpresses a single gene product selected from the group consisting of SEQ ID NOs. 42938-78581. Alternatively, if desired one or more of the strains in the culture or collection of strains may overexpress or underexpress more than one gene product selected from the group consisting of SEQ ID NOs. 42938-78581.

In other embodiments, the culture or collection of strains comprises a strain in which at least one of the gene products encoded by a homologous coding nucleic acid as defined above is overexpressed or underexpressed. In some embodiments, the culture or collection of strains may comprise strains which in aggregate overexpress or underexpress at least 2, at least 10, at least 20, at least 30, at least 50, at least 100, at least 300 or more than 300 gene products encoded by a homologous coding nucleic acid as defined above. If desired the culture or collection of strains may comprise one or more strains which overexpress or underexpress more than one gene product encoded by a homologous coding nucleic acid. In further embodiments, the culture or collection of strains comprises a strain in which at least one, at least 10, at least 20, at least 30, at least 50, at least 100, at least 300 or more than 300 homologous polypeptides as defined above is overexpressed or underexpressed. If desired the culture or collection of strains may comprise one or more strains which overexpress or underexpress more than one homologous polypeptide.

For example, in some embodiments, the culture or collection of strains comprises a strain in which at least one gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed, wherein each strain overexpresses or underexpresses one gene product. In some

embodiments, the culture or collection of strains may comprise strains in which in aggregate at least 2, at least 10, at least 20, at least 30, at least 50, at least 100, at least 300, or more than 300 gene products selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 is overexpressed or underexpressed, wherein each strain overexpresses or underexpresses one gene product.

If desired, one or more of the strains in the culture or collection of strains may overexpress or underexpress more than one gene product selected from the group consisting of a gene product having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleic acid encoding a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product having at least 25% amino acid identity as determined using FASTA version 3.0t78 with the default parameters to a gene product whose expression is inhibited by an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under stringent conditions, a gene product encoded by a nucleic acid which hybridizes to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213 under moderate conditions, and a gene product whose activity may be complemented by the gene product whose activity is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213.

In further embodiments, the culture or collection of strains comprises a strain in which at least one gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed, wherein each strain overexpresses or underexpresses one gene product. In some embodiments, the culture or collection of strains comprises a strain or a group of strains in which in aggregate at least 2, at least 10, at least 20, at least 30, at least 50, at least 100, at least 300, or more than 300 gene products encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions is overexpressed or underexpressed, wherein each strain overexpresses or underexpresses one gene product.

If desired, one or more of the strains in the culture or collection of strains may overexpress or underexpress more than one gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of a nucleic acid comprising a nucleic acid having at least 70% nucleotide sequence identity as determined using BLASTN version 2.0 with the default parameters to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397, a nucleic acid comprising a nucleotide sequence which hybridizes to a sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under stringent conditions, and a nucleic acid comprising a nucleotide sequence which hybridizes to a nucleotide sequence selected from the group consisting of SEQ ID NOS.: 6214-42397 under moderate conditions.

In additional embodiments, the culture or collection of strains comprises a strain in which at least one gene product comprising a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOS.: 42938-78581 is overexpressed or underexpressed, wherein each strain overexpresses or underexpresses one gene product. In some embodiments, the culture or collection of strains comprises a strain or a group of strains in which in aggregate at least 2, at least 10, at least 20, at

least 30, at least 50, at least 100, at least 300, or more than 300 gene products comprising a polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented
 5 by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581 is overexpressed or underexpressed, wherein each strain overexpresses or underexpresses one gene product.

If desired, one or more of the strains in the culture or collection of strains may overexpress or underexpress more than one polypeptide selected from the group consisting of a polypeptide having at least 25% amino acid identity as determined using FASTA version 3.0t78 to a
 10 polypeptide selected from the group consisting of SEQ ID NOs.: 42938-78581 and a polypeptide whose activity may be complemented by a polypeptide selected from the group consisting of SEQ ID NOs: 42938-78581.

The methods of the present invention may be used to identify the targets of compounds which inhibit the proliferation of any desired cell or organism. In some embodiments, these
 15 methods are employed to identify the targets of compounds which inhibit the proliferation of bacteria, fungi, or protozoans. In further embodiments, these methods are employed to identify the targets of compounds which inhibit the growth of an organism selected from the group consisting of *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*,
 20 *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*,
 25 *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*,
 30 *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
 35 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species.

Overexpression may be obtained using a variety of techniques familiar to those skilled in the art. For example, overexpression may be obtained by operably linking a gene encoding a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a gene product whose activity or level is inhibited by a homologous antisense nucleic acid, a gene product encoded by a homologous coding nucleic acid, or a gene product comprising a homologous polypeptide to a promoter which transcribes a higher level of mRNA encoding or comprising the gene product than does a wild type cell.

A variety of promoters may be used to overexpress the gene product described herein, including a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a gene product whose activity or level is inhibited by a homologous antisense nucleic acid, a gene product encoded by a homologous coding nucleic acid, and a gene product comprising a homologous polypeptide. The promoters used to overexpress the gene product may be relatively strong promoters, promoters which possess a moderate level of activity, or relatively weak promoters and may be either constitutive or regulatable promoters. In some embodiments, several strains, each of which overexpresses the gene product to a different extent, may be used in order to optimize the degree of overexpression of the gene product.

In some embodiments, each of the gene products required for proliferation may be placed under the control of several different promoters of varying strengths to create several different strains which express the gene product at varying levels. The level of expression of the gene product in each of the strains is compared to that in wild type cells in order to identify a promoter which provides a desired level of expression relative to wild type cells (i.e. a desired level of overexpression or underexpression). The strain having the desired level of expression is then included in a culture or collection of strains to be contacted with a test compound as discussed below. Examples of suites of regulatable promoters having varying strengths that are useful for the expression of gene products at varying levels are described in U.S. Patent Application Serial Number 10/032,393, filed on December 21, 2002.

The promoter is selected to be active in the type of cell in which the gene product is to be expressed. For example, for overexpression of the gene product in mammalian cells, the gene encoding the gene product may be operably linked to promoters such as the SV40 promoter, the metallothionein promoter, the MMTV promoter, the RSV promoter, the tetP promoter, the adenovirus major late promoter or other promoters known to those skilled in the art. In yeast, the gene encoding the gene product may be operably linked to promoters such as the CYC1, ADHI,

ADHII, GAL1, GAL10, PHO5, PGK or other promoters used in the art. Similarly, in bacteria, the gene encoding the gene product may be operably linked to the , SP6, T3, trc promoter, lac promoter, temperature regulated lambda promoters, the *Bacillus* aprE and nprE promoters (U.S. Patent No. 5,387,521), the bacteriophage lambda P_L and P_R promoters (Renaut, et al., (1981) Gene 15: 81) the trp promoter (Russell, et al., (1982) Gene 20: 23), the tac promoter (de Boer et al., (1983) Proc. Natl. Acad. Sci. USA 80: 21), *B. subtilis* alkaline protease promoter (Stahl et al, (1984) J. Bacteriol. 158, 411-418) alpha amylase promoter of *B. subtilis* (Yang et al., (1983) Nucleic Acids Res. 11, 237-249) or *B. amyloliquefaciens* (Tarkinen, et al, (1983) J. Biol. Chem. 258, 1007-1013), the neutral protease promoter from *B. subtilis* (Yang et al, (1984) J. Bacteriol. 160, 15-21), T7 RNA polymerase promoter (Studier and Moffatt (1986) J Mol Biol. 189(1):113-30), *B. subtilis* xyl promoter or mutant tetR promoter active in bacilli (Geissendorfer & Hillen (1990) Appl. Microbiol. Biotechnol. 33:657-663), Staphylococcal enterotoxin D promoter (Zhang and Stewart (2000) J. Bacteriol. 182(8):2321-5), cap8 operon promoter from *Staphylococcus aureus* (Ouyang et al., (1999) J. Bacteriol. 181(8):2492-500), the lactococcal nisA promoter (Eichenbaum (1998) Appl Environ Microbiol. 64(8):2763-9), promoters from in *Acholeplasma laidlawii* (Jarhede et al., (1995) Microbiology 141 (Pt 9):2071-9), porA promoter of *Neisseria meningitidis* (Sawaya et al., (1999) Gene 233:49-57), the fbpA promoter of *Neisseria gonorrhoeae* (Forng et al., (1997) J. Bacteriol. 179:3047-3052), *Corynebacterium diphtheriae* toxin gene promoter (Schmitt and Holmes (1994) J. Bacteriol. 176(4):1141-9), the hasA operon promoter from Group A Streptococci (Alberti et al., (1998) Mol Microbiol 28(2):343-53), the rpoS promoter of *Pseudomonas putida* (Kojic and Venturi (2001) J. Bacteriol. 183:3712-3720), the *Acinetobacter baumannii* phosphate regulated *ppk* gene promoter (Gavigan et al., Microbiology 145:2931-7 (1999)); the *Acinetobacter baumannii* *adhC1* promoter which is induced under iron limitation and repressed when the cells are cultured in the presence of free inorganic iron (Echenique et al., Microbiology 147:2805-15 (2001)); the *flaB* promoter of pGK12 active in *Borrelia burgdorferi* (Sartakova et al., Proc Natl Acad Sci U S A. 97(9):4850-5 (2000)); the use of P_{trc} promoter results in strong inducer-dependent expression in *Burkholderia spp* (Santos et al., FEMS Microbiol Lett 195(1):91-6 (2001)); the iron regulated *sodA* promoter of *Bordetella pertussis* (Graeff-Wohlleben et al., J Bacteriol 179(7):2194-201 (1997)); UV-inducible *bcn* and *uviAB* promoters in *Clostridia spp* (Garnier and Cole Mol Microbiol 2(5):607-14 (1988)); the heat-inducible *clpB* promoter of *Campylobacter jejuni* (Thies et al., Gene 230(1):61-7 (1999)); promoters carrying bacteriophage C1 operator sites in *Klebsiella pneumoniae* (Schoefield et al, J Bacteriol 183(23):6947-50 (2001)); the *Proteus mirabilis* *ureR* promoter (Poore et al., J Bacteriol 183(15):4526-35 (2001)); and the heat-inducible *groESL* promoter in *Listeria monocytogenes*, and the IPTG inducible promoter in pLEX5BA (Krause et al., J. Mol. Biol. 274: 365 (1997). In another embodiment, which may be useful in *Staphylococcus aureus*, the promoter is a novel inducible promoter system, XylT5, comprising a modified T5 promoter fused to the *xylO* operator from the *xylA* promoter of *Staphylococcus aureus*. This promoter is described in U.S. Patent Application Serial Number 10/032,393. In another embodiment the promoter may be a two-

component inducible promoter system in which the T7 RNA polymerase gene is integrated on the chromosome and is regulated by *lacUV5/ lacO* (Brunschwig, E. and Darzins, A. 1992. Gene 111:35-41, and a T7 gene 10 promoter, which is transcribed by T7 RNA polymerase, is fused with a *lacO* operator. In another embodiment the promoter may be the promoters from the plasmids pEPEF3 or pEPEF14, which harbor xylose inducible promoters functional in *E. faecalis*, described in U.S. Patent Application Serial No. 10/032,393. Other promoters which may be used are familiar to those skilled in the art. In fungi, the gene encoding the gene product may be operably linked to the CaACT1 promoter (Morschhauser, Mol. Gen. Genet. 257: 412-420 (1998), or other promoters familiar to those skilled in the art. It will be appreciated that other combinations of organisms and promoters may also be used in the present invention.

In some embodiments, overexpression may be achieved by using homologous recombination to replace the natural promoter which drives expression of the proliferation-required genes described herein with a regulatable promoter. For example, the methods described in U.S. Patent Application 09/948,993 may be used to place the gene required for proliferation under the control of a regulatable promoter. Examples of gene products, which are encoded by genes that can be overexpressed by regulatable promoters introduced by such promoter replacement methods include a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a gene product whose activity or level is inhibited by a homologous antisense nucleic acid, a gene product encoded by a homologous coding nucleic acid, and a gene product comprising a homologous polypeptide.

Briefly, in some embodiments of these methods in which natural promoters are replaced by regulatable promoters, the cells may be haploid, such as bacterial cells. Regulatable promoters that are useful for promoter replacement in bacterial cells include, but are not limited to, the promoters described in U.S. Patent Application Serial Number 10/032,393 filed December 21, 2001. A linear promoter replacement cassette comprising a regulatable promoter flanked by nucleotide sequences having homology to the natural promoter is introduced into the cell. In some embodiments, the cassette also comprises a nucleotide sequence encoding a selectable marker or a marker whose expression is readily identified. The cassette may be a double stranded nucleic acid or a single stranded nucleic acid as described in U.S. Patent Application Serial Number 09/948,993. Upon homologous recombination, the natural promoter is replaced with the regulatable promoter, leaving the gene required for proliferation under the control of the regulatable promoter. Strains in which the gene required for proliferation is under control of the regulatable promoter are grown under conditions in which the regulatable promoter provides a level of the proliferation-required gene product which is above the level in a wild type cell. For example, the strains may be grown in the

presence of an inducer which induces expression from the regulatable promoter, or under conditions in which the action of a repressor on the regulatable promoter is reduced or eliminated.

Alternatively, rather than replacing the native promoters of each of the genes encoding a proliferation-required gene product described herein with a single desired replacement promoter, a plurality of replacement promoters which provide desired expression levels for the gene products to be overexpressed or underexpressed are used. The method is performed as described above except that rather than using a single labeled primer complementary to a nucleotide sequence within the single replacement promoter, a plurality of labeled primers complementary to suitable nucleotide sequences in the plurality of replacement promoters are used.

Alternatively, in embodiments in which the level or activity of proliferation-required gene products described herein is reduced by transcribing an antisense nucleic acid complementary to at least a portion of the genes encoding such gene products, the strains may be designed such that the length of the nucleotide sequence encoding the antisense nucleic acid is different for each gene. Amplification reactions are performed as described above using primers at each end of the gene encoding the antisense nucleic acid such that the amplification product corresponding to each gene has a unique length or a dye which allows it to be distinguished from other amplification products of the same length. Alternatively, the lengths of the nucleotide sequences encoding the antisense nucleic acids may not be unique for each gene, but the primers used in the amplification reaction may be selected such that the length of the amplification product corresponding to each gene is unique.

In another embodiment, the native promoters may be replaced with promoters which include therein or adjacent thereto a unique nucleotide sequence which is distinct from that present in the other replacement promoters in the strains in the culture or collection of strains. In this embodiment, each promoter includes or has adjacent thereto a unique "tag" which may be used to identify strains which proliferate more rapidly or more slowly in the culture or collection of strains. The tag may be detected using hybridization based methods or amplification based methods, including the amplification method which generates amplification products having a unique size for each proliferation required gene described above.

Alternatively, the native promoter which directs the transcription of the proliferation-required genes described herein may rendered regulatable by inserting a regulatory element into the chromosome of the cell via homologous recombination such that the regulatory element regulates the level of transcription from the promoter. Examples of gene products, which are encoded by genes that have promoters which can be rendered regulatable by regulatory elements inserted by such methods include a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a gene product whose activity or

level is inhibited by a homologous antisense nucleic acid, a gene product encoded by a homologous coding nucleic acid, and a gene product comprising a homologous polypeptide.

A variety of regulatory elements may be used to regulate the expression of essential gene products described herein. The regulatory element may be an operator which is recognized by a repressor (e.g. lac, tet, araBAD repressors) or a nucleotide sequence which is recognized by a transcriptional activator. In some embodiments, the regulatory element may be a transcriptional terminator, a nucleotide sequence which introduces a bend in the DNA or an upstream activating sequence. A linear regulatory element insertion cassette comprising a regulatory element flanked by nucleotide sequences having homology to the natural promoter is introduced into the cell. In some embodiments, the cassette also comprises a nucleotide sequence encoding a selectable marker or a marker whose expression is readily identified. The cassette may be a double stranded nucleic acid or a single stranded nucleic acid as described in U.S. Patent Application Serial Number 09/948,993. Upon homologous recombination, the regulatory element is inserted into the chromosome, leaving the gene required for proliferation under the control of the regulatory element. Strains in which the gene required for proliferation is under control of the regulatory element are grown under conditions in which the regulatable promoter provides a level of the proliferation-required gene product which is above the level in a wild type cell. For example, the strains may be grown in the presence of an inducer which induces expression from the promoter, or under conditions in which the action of a repressor on the promoter is reduced or eliminated. It will be appreciated that the amplification method which generates amplification products having a unique size for each proliferation required gene may be used to detect strains which are overrepresented or underrepresented in the culture or collection of strains. For example, if desired, primers complementary to a nucleotide sequence within the regulatory element may be used in the amplification reaction.

The promoter replacement cassette or regulatory element insertion cassette may be a double stranded nucleic acid, such as an amplicon generated through PCR or other amplification methods, or a single stranded nucleic acid, such as an oligonucleotide. For example, single stranded nucleic acids may be introduced into the chromosome using the methods described in Ellis et al., PNAS 98: 6742-6746, 2001.

In some embodiments, the cell into which the promoter replacement cassette or regulatory element insertion cassette is introduced has an enhanced frequency of recombination. For example, the cells may lack or have a reduced level or activity of one or more exonucleases which would ordinarily degrade the DNA to be inserted into the chromosome. In further embodiments, the cells may both lack or have reduced levels of exonucleases and express or overexpress proteins involved in mediating homologous recombination. For example, if the methods are performed in *Escherichia coli* or other enteric prokaryotes, cells in which the activity of exonuclease V of the RecBCD recombination pathway, which degrades linear nucleic acids, has been reduced or eliminated, such as recB, recC, or recD mutants may be used. In some embodiments, the cells have

mutations in more than one of the *recB*, *recC*, and *recD* genes which enhance the frequency of homologous recombination. For example the cells may have mutations in both the *recB* and *recC* genes.

The promoter replacement or regulatory element insertion methods may also be performed in *Escherichia coli* cells in which the activity of the RecET recombinase system of the Rac prophage has been activated, such as cells which carry an *sbcA* mutation. The *RecE* gene of the rac prophage encodes ExoVIII a 5'-3' exonuclease, while the *RecT* gene of the Rac prophage encodes a single stranded DNA binding protein which facilitates renaturation and D-loop formation. Thus, the gene products of the *RecE* and *RecT* genes or proteins with analogous functions facilitate homologous recombination. The *RecE* and *RecT* genes lie in the same operon but are normally not expressed. However, *sbcA* mutants activate the expression the *RecE* and *RecT* genes. In some embodiments, the methods may be performed in cells which carry mutations in the *recB* and *recC* genes as well as the *sbcA* mutation. The *RecE* and *RecT* gene may be constitutively or conditionally expressed. For example, the methods may be performed in *E. coli* strain JC8679, which carries the *sbcA23*, *recB21* and *recC22* mutations.

In some embodiments, the methods may be performed in *Escherichia coli* cells in which recombination via the *RecF* pathway has been enhanced, such as cells which carry an *sbcB* mutation.

It will be appreciated that the *RecE* and *RecT* gene products, or proteins with analogous functions may be conditionally or constitutively expressed in prokaryotic organisms other than *E. coli*. In some embodiments, these proteins may be conditionally or constitutively expressed in *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,

Staphylococcus aureus, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. For example, plasmids encoding these gene products may be introduced into the organism. If desired, the coding sequences encoding these gene products may be optimized to reflect the codon preferences of the organism in which they are to be expressed. Similarly, in some embodiments, the organism may contain mutations analogous to the *recB*, *recC*, *recD*, *sbcA* or *sbcB* mutations which enhance the frequency of homologous recombination.

In further embodiments, the promoter replacement or regulatory element insertion methods may be conducted in cells which utilize the Red system of bacteriophage lambda (λ) or analogous systems from other phages to enhance the frequency of homologous recombination. The Red system contains three genes, (γ , β and *exo* whose products are the Gam, Bet and Exo proteins (see Ellis et al. PNAS 98:6742-6746, 2001. The Gam protein inhibits the RecBCD exonuclease V, thus permitting Beta and Exo to gain access to the ends of the DNA to be integrated and facilitating homologous recombination. The Beta protein is a single stranded DNA binding protein that promotes the annealing of a single stranded nucleic acid to a complementary single stranded nucleic acid and mediates strand exchange. The Exo protein is a double-stranded DNA dependent 5'-3' exonuclease that leaves 3' overhangs that can act as substrates for recombination. Thus, constitutive or conditional expression of the λ Red proteins or proteins having analogous functions facilitates homologous recombination.

It will be appreciated that the λ Beta, Gam and Exo proteins, or proteins with analogous functions may be expressed constitutively or conditionally in prokaryotic organisms other than *E. coli*. In some embodiments, these proteins may be conditionally or constitutively expressed in *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*,

Pseudomonas aeruginosa, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*, *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. For example, plasmids encoding these gene products may be introduced into the organism. If desired, the coding sequences encoding these gene products may be optimized to reflect the codon preferences of the organism in which they are to be expressed.

In some embodiments, the cells may have an increased frequency of homologous recombination as a result of more than one of the aforementioned characteristics. In some embodiments, the enhanced frequency of recombination may be a conditional characteristic of the cells which depends on the culture conditions in which the cells are grown. For example, in some embodiments, expression of the λ Red Gam, Exo, and Beta proteins or recE and recT proteins may be regulated. Thus, the cells may have an increased frequency of homologous recombination as a result of any combination of the aforementioned characteristics. For example, in some embodiments, the cell may carry the sbcA and recBC mutations.

In some embodiments, a linear double stranded DNA to be inserted into the chromosome of the organism is introduced into an organism constitutively or conditionally expressing the recE and recT or the λ Beta, Gam and Exo proteins or proteins with analogous functions as described above. In some embodiments, the organism may be *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*, *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*, *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,

Staphylococcus aureus, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species. In some
 5 embodiments, the double stranded DNA may be introduced into an organism having the recBC and sbcA mutations or analogous mutations.

In other embodiments, a single stranded DNA to be inserted into the chromosome of the organism is introduced into an organism expressing the λ Beta protein or a protein with an analogous function. In some embodiments the single stranded DNA is introduced into an organism
 10 expressing both the λ Beta and Gam proteins or proteins with analogous functions. In further embodiments, the single stranded DNA is introduced into an organism expressing the λ Beta, Gam and Exo proteins or proteins with analogous functions. The λ proteins or analogous proteins may be expressed constitutively or conditionally. In some embodiments, the organism may be
 15 *Acinetobacter baumannii*, *Anaplasma marginale*, *Aspergillus fumigatus*, *Bacillus anthracis*, *Bacteroides fragilis*, *Bordetella pertussis*, *Borrelia burgdorferi*, *Burkholderia cepacia*, *Burkholderia fungorum*, *Burkholderia mallei*, *Campylobacter jejuni*, *Candida albicans*, *Candida glabrata* (also called *Torulopsis glabrata*), *Candida tropicalis*, *Candida parapsilosis*, *Candida guilliermondii*, *Candida krusei*, *Candida kefyr* (also called *Candida pseudotropicalis*), *Candida dubliniensis*, *Chlamydia pneumoniae*, *Chlamydia trachomatis*, *Clostridium acetobutylicum*,
 20 *Clostridium botulinum*, *Clostridium difficile*, *Clostridium perfringens*, *Coccidioides immitis*, *Corynebacterium diphtheriae*, *Cryptococcus neoformans*, *Enterobacter cloacae*, *Enterococcus faecalis*, *Enterococcus faecium*, *Escherichia coli*, *Haemophilus influenzae*, *Helicobacter pylori*, *Histoplasma capsulatum*, *Klebsiella pneumoniae*, *Legionella pneumophila*, *Listeria monocytogenes*, *Moraxella catarrhalis*, *Mycobacterium avium*, *Mycobacterium bovis*,
 25 *Mycobacterium leprae*, *Mycobacterium tuberculosis*, *Mycoplasma genitalium*, *Mycoplasma pneumoniae*, *Neisseria gonorrhoeae*, *Neisseria meningitidis*, *Nocardia asteroides*, *Pasteurella haemolytica*, *Pasteurella multocida*, *Pneumocystis carinii*, *Proteus mirabilis*, *Proteus vulgaris*, *Pseudomonas aeruginosa*, *Pseudomonas putida*, *Pseudomonas syringae*, *Salmonella bongori*, *Salmonella choleraesuis*, *Salmonella enterica*, *Salmonella paratyphi*, *Salmonella typhi*, *Salmonella typhimurium*, *Shigella boydii*, *Shigella dysenteriae*, *Shigella flexneri*, *Shigella sonnei*,
 30 *Staphylococcus aureus*, *Staphylococcus epidermidis*, *Staphylococcus haemolyticus*, *Streptococcus pneumoniae*, *Streptococcus mutans*, *Streptococcus pyogenes*, *Treponema pallidum*, *Ureaplasma urealyticum*, *Vibrio cholerae*, *Vibrio parahaemolyticus*, *Vibrio vulnificans*, *Yersinia enterocolitica*, *Yersinia pestis* or any species falling within the genera of any of the above species.

35 In some embodiments, the linear nucleic acid may be introduced into the chromosome of a first organism which has an enhanced frequency of homologous recombination and then transferred to a second organism which is less amenable to direct application of the present methods. For example, the linear nucleic acid may be introduced into the chromosome of *E. coli* and transferred

into a second organism via conjugation or transduction. After introduction into the second organism, the nucleic acid is inserted into the chromosome of the second organism via homologous recombination, thereby effectively transferring the regulatory element from the chromosome of the first organism into the corresponding location in the chromosome of the second organism.

5 In other embodiments, the cells may be diploid cells, such as fungal cells. In some embodiments, one copy of the gene encoding the proliferation-required gene product may be disrupted, rendering it inactive. In further embodiments, one copy of the gene encoding the proliferation-required gene product may be disrupted and the other copy of the gene encoding the proliferation-required gene product may be placed under the control of a regulatable promoter.

10 Such strains may be generated by disrupting the first copy of the gene encoding the proliferation-required gene product by homologous recombination using a disruption cassette comprising a nucleotide sequence encoding an expressible dominant selectable marker flanked on each side by nucleic acids homologous to the target sequence to be disrupted. The second copy of the gene encoding the proliferation-required gene product may be placed under the control of a regulatable

15 promoter by homologous recombination using a promoter replacement cassette comprising a regulatable promoter flanked on each side by nucleic acids homologous to the natural promoter for the proliferation-required gene. The promoter replacement cassette may also include a nucleotide sequence encoding a selectable marker located 5' of the regulatable promoter but between the nucleic acids homologous to the natural promoter.

20 In other embodiments, overexpression may be achieved by operably linking a proliferation-required gene product described herein to a desired promoter in a vector. The vector may be a vector which replicates extrachromosomally or a vector which integrates into the chromosome. For example, if the vector is to be used in bacterial cells, the vector may be a pBR322 based vector or a bacteriophage based vector such as P1 or lambda. If the vector is to be used in *Saccharomyces*

25 *cerevisiae*, it may be a vector based on the 2 micron circle or a vector incorporating a yeast chromosomal origin of replication. If the vector is to be used in mammalian cells, it may be a retroviral vector, SV40 based vector, a vector based on bovine papilloma virus, a vector based on adenovirus, or a vector based on adeno-associated virus. If the vector is to be used in *Candida albicans* it may be a vector comprising a promoter selected from the group consisting of the

30 CaPCK1, MET25, MAL2, PHO5, GAL1,10, STE2 or STE3 promoters. In some embodiments, the vectors described in the following publications may be used: Clp10, an efficient and convenient integrating vector for *Candida albicans*. Murad et al., Yeast 16(4):325-7 (2000); Transforming vector pCPW7, Kvaal et al., : Infect Immun 67(12):6652-62 (1999); Transforming vector pCWOP16, Kvaal et al., : Infect Immun 65(11):4668-75 (1997); double-ARS vector, pRM1, to be

35 used for direct cloning in Ca by complementation of the histidine auxotrophy of strain CA9, Pla et al., Gene 165(1):115-20 (1995); pMK16, that was developed for the transformation of *C. albicans* and carries an ADE2 gene marker and a *Candida* autonomously replicating sequence (CARS) element promoting autonomous replication (cited in Sanglard and Fiechter Yeast 8(12):1065-75

(1992); A plasmid vector (denoted pRC2312) was constructed, which replicates autonomously in *Escherichia coli*, *Saccharomyces cerevisiae* and *Candida albicans*. It contains LEU2, URA3 and an autonomously replicating sequence (ARS) from *C. albicans*, Cannon et al., Mol Gen Genet 235(2-3):453-7 (1992); Expression vector (CIp10-MAL2p) for use in *Candida albicans* has been
 5 constructed in which a gene of interest can be placed under the control of the CaMAL2 maltase promoter and stably integrated at the CaRP10 locus (Backen et al., Yeast 16(12):1121-9 (2000)); (Volker, R. S., A. Sonneborn, C. E. Leuker, and J. F. Ernst. 1997. Efg1p, an essential regulator of morphogenesis of the human pathogen *Candida albicans*, is a member of a conserved class of bHLH proteins regulating morphogenetic processes in fungi. EMBO 16:1982-1991.); and a *C.*
 10 *albicans* transformation vector containing the *C. albicans* URA3 gene, a Candida ARS sequence, and a portion of the *Saccharomyces cerevisiae* 2 microns circle containing the replication origin was constructed. Goshorn et al., Infect Immun 60(3):876-84 (1992). A variety of other vectors suitable for use in foregoing organisms or in any other organism in which the present invention is to be practiced are familiar to those skilled in the art.

15 Underexpression of a proliferation-required gene product described herein may be obtained in a variety of ways. For example, in one embodiment underexpression of the proliferation-required gene product may be achieved by providing an agent, such as an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, an antisense nucleic acid comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400,
 20 or 500 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a nucleic acid complementary to a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a nucleic acid complementary to a nucleic acid comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a nucleotide sequence selected from the group consisting of SEQ ID
 25 NOs.: 6214-42397, a nucleic acid complementary to a nucleic acid which encodes a polypeptide comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a nucleic acid complementary to a nucleic acid which encodes at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of a polypeptide sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a homologous antisense nucleic acid, an antisense
 30 nucleic acid comprising at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a homologous nucleic acid, a nucleic acid complementary to a homologous coding nucleic acid, a nucleic acid complementary to at least 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, 150, 200, 300, 400, or 500 consecutive nucleotides of a homologous coding nucleic acid, a nucleic acid complementary to a nucleic acid which encodes a homologous polypeptide, or a
 35 nucleic acid complementary to a nucleic acid which encodes at least 5, 10, 15, 20, 25, 30, 35, 40, 50, 75, 100, or 150 consecutive amino acids of a homologous polypeptide, which reduces the level or activity of the gene product within the cell. In one embodiment, the agent may comprise an antisense nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ

ID NOs.: 1-6213 which is complementary to a nucleic acid encoding the proliferation-required gene product or complementary to a portion of a nucleic acid encoding the proliferation-required gene product.

5 In one example of antisense-inhibition-based underexpression, a nucleic acid which encodes the antisense nucleic acid may be operably linked to a regulatable promoter. When grown under appropriate conditions, such as media containing an inducer of transcription or an agent which alleviates repression of transcription, the antisense nucleic acid is expressed in the cell, thereby reducing the level or activity of the gene product within the cell. In some embodiments, the concentration of the inducer of transcription or the agent which alleviates repression of transcription
10 may be varied to provide optimal results. Such methods have been described previously herein and in U.S. Patent Application Serial Number 09/815,242, U.S. Patent Application Serial Number 09/492,709, U.S. Patent Application Serial Number 09/711,164, or U.S. Patent Application Serial Number 09/741,669.

Alternatively, underexpression of a proliferation-required gene product described herein
15 may be achieved by constructing strains in which the expression of the gene product is under the control of a constitutive or regulatable promoter using methods such as those described above with respect to methods in which the gene product is overexpressed. To provide cells which underexpress the gene product, the cells are grown under conditions in which the gene product is expressed at a level lower than that of a wild type cell. For example, the cells may be grown under
20 conditions in which a repressor reduces the level of transcription from the regulatable promoter.

In other embodiments, underexpression may be achieved by operably linking the gene required for proliferation to a desired promoter in a vector as described above with respect to
embodiments in which gene products required for proliferation are overexpressed. In some
embodiments, the vector may be present in cells in which the chromosomal copy or copies of the
25 gene has been disrupted.

Examples of gene products, which are encoded by genes that can be underexpressed using methods such as those described above with respect to methods in which the gene product is overexpressed include a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a
30 gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a gene product whose activity or level is inhibited by a homologous antisense nucleic acid, a gene product encoded by a homologous coding nucleic acid, and a gene product comprising a homologous polypeptide.

35 One embodiment of the invention includes a method for identifying a gene product described herein on which a compound which inhibits the proliferation of an organism acts. The method employs a culture which comprises a mixture of strains of the organism. At least some of the strains in the culture overexpress a different gene product which is required for the proliferation

of the organism. Preferably, each of the strains in the culture overexpresses a different gene product which is required for proliferation of the organism (i.e. all of the strains in the culture overexpress a gene product which is required for proliferation of the organism). For example, the gene product which is overexpressed in each strain may be a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a gene product whose activity or level is inhibited by a homologous antisense nucleic acid, a gene product encoded by a homologous coding nucleic acid, and a gene product comprising a homologous polypeptide.

Strains that overexpress the proliferation-required gene product may be obtained using the methods described above. The culture may comprise any number of strains which overexpress a gene product required for proliferation. For example the culture may comprise at least two strains, at least 10 strains, at least 20 strains, at least 30, strains, at least 50 strains, at least 100 strains, at least 300 strains or more than 300 strains which overexpress a gene product required for proliferation. In some embodiments, the culture may comprise strains which in aggregate overexpress all or most of the gene products required for proliferation of the organism.

The culture is contacted with a compound which inhibits proliferation of the organism. The compound may be a candidate drug compound obtained from any source. For example, the compound may be a compound generated using combinatorial chemistry, a compound from a natural product library, or an impure or partially purified compound, such as a compound in a partially purified natural extract. The culture is contacted with a sufficient concentration of the compound to inhibit the proliferation of strains of the organism in the culture which do not overexpress the gene product on which the compound acts, such that strains which overexpress said gene product on which the compound acts proliferate more rapidly in the culture than strains which do not overexpress said gene product on which said compound acts. Thus, after a sufficient period of time, the strain which overexpresses the gene product on which the compound acts will be more prevalent in the culture than strains which do not overexpress the gene product on which the compound acts. In a preferred embodiment, the growth conditions and incubation period are selected so that only one strain, the strain overexpressing the target of the compound, is recovered from the culture. Thus, in one embodiment, a plurality of cultures containing a plurality of strains each of which overexpresses a different proliferation-required gene product may be grown in the presence of varying concentrations of the compound. In addition to varying the compound concentrations, in embodiments where expression of the proliferation-required gene product is under the control of a regulatable promoter, the plurality of cultures may be grown at varying concentrations of an agent which regulates the level of expression from the promoter, such as an inducer or an agent which reduces the effect of a repressor on transcription from the promoter. It

will be appreciated, that the cultures may be grown in liquid medium in the presence of the compound whose target is to be identified (and where appropriate in the presence of an agent which regulates the level of expression from the promoter) or alternatively, a liquid culture comprising the strains which overexpress the proliferation-required gene products may be grown in the absence of the compound whose target is to be identified and then introduced onto a solid medium containing the compound (and, where appropriate, also containing an agent which regulates the level of expression from the promoter).

The identity of the overexpressed gene product which is the target of the compound may be determined using a variety of methods. For example, in some embodiments of the present invention, the nucleic acids present in the culture or collection of strains which was contacted with the compound may be compared to the nucleic acids present in a control culture or collection of strains which was not contacted with the compound to identify nucleic acids which are overrepresented in the culture or collection of strains contacted with the test compound relative to the control culture or collection of strains. Alternatively, in some embodiments, the nucleic acids present in a culture or collection of strains contacted with the test compound may be analyzed to identify those nucleic acids which are present without comparison to a control culture or collection of strains.

In some embodiments, the strains which proliferated more rapidly in the culture or collection of strains, i.e. strains having an enhanced ability to proliferate in the presence of a test compound relative to other strains in the culture or collection of strains, are identified as follows. Amplification products which are correlated with each of the overexpressed genes and which are distinguishable from one another are obtained from a culture or collection grown in the presence of a test compound. The amplification products are distinguished from one another to determine whether a particular amplification product is overrepresented in the culture or collection of strains. In some embodiments, the amplification products corresponding to each of the gene products have lengths which permit them to be distinguished from one another. In another embodiment, one or more of the amplification products have similar or identical lengths but are distinguishable from one another based on a detectable agent, such as a dye, attached thereto. In some embodiments, amplification products which are overrepresented are identified by comparing the amplification products from the culture or collection of strains which was contacted with the test compound to the amplification products from a culture or collection of strains which was not contacted with the test compound. Alternatively, amplification products which are overrepresented may be identified by simply identifying the amplification products obtained from the culture or collection of strains contacted with the test compound (for example, only one or a few strains may have proliferated in the presence of the test compound). The above methods for generating distinguishable amplification products may be used in conjunction with any of the methods for generating strains which overexpress gene products required for proliferation described herein in order to facilitate the

identification of strains which proliferate more rapidly or more slowly in the presence of a test compound.

For example, in some embodiments of the present invention, each of the native promoters of each of the genes encoding gene product required for proliferation are replaced by a single
5 desired replacement promoter. After growth of the culture or collection of strains containing the strains in which the promoters have been replaced in the presence of a test compound for a desired period of time, an amplification reaction is performed on nucleic acids obtained from the culture as follows.

The nucleic acids from the culture or collection of strains may be divided into at least two
10 aliquots if desired. In a preferred embodiment the nucleic acids from the culture or collection of strains are divided into four aliquots. A single primer complementary to a nucleotide sequence within the replacement promoter, within the proliferation required genes, or within nucleic acid sequences adjacent to the promoter or proliferation required genes is divided into at least two portions, one portion for each aliquot of nucleic acids. Each portion of the primer is labeled with a
15 distinct detectable dye, such as the 6FAMTM, TETTM, VICTM, HEXTM, NEDTM, and PETTM dyes obtainable from Applied Biosystems (Foster City, CA). For example, the DS-31 or DS-33 dye sets available from Applied Biosystems (Foster City, CA) may be used to label the primers. Alternatively, the HEXTM, NED, JOE, TMR and TETTM dyes available from Amersham Biosciences may be used. Thus, if the nucleic acids from the culture are not divided into aliquots, a
20 single primer labeled with a single dye may be used. If the nucleic acids from the culture are divided into aliquots, at least 2, at least 3, at least 4 or more than 4 primers labeled with distinguishable dyes may be used. Each of the portions of labeled primers are added to each of the aliquots of the nucleic acids from the culture or collection of strains such that each aliquot of nucleic acid receives a single labeled primer with a single detectable dye thereon. In some
25 embodiments, the primers are divided into 3 portions, 4 portions or more than 4 portions, with each portion having a dye which is distinguishable from the dyes on the other portions thereon.

Each of the aliquots of nucleic acids also receives a set of unlabeled primers, with each of the unlabeled primers being complementary to a nucleotide sequence within the promoter, within a nucleotide sequence which is unique to one of the genes encoding gene products required for
30 proliferation which were placed under the control of the replacement promoter, or within nucleotide sequences adjacent to the promoter or proliferation required genes. Each of the aliquots receives primers unique to 1/N proliferation required genes which were placed under the control of the replacement promoter, where N is the number of aliquots (i.e. if the culture or collection of strains consisted of 100 strains in which a gene required for proliferation was placed under the control of
35 the replacement promoter and was divided into four aliquots, then each of the four aliquots of nucleic acids from the culture or collection of strains would receive primers complementary to 25 of the genes). The unlabeled primers are selected so that each will yield an amplification product having a length distinguishable from the length of the amplification product produced with the other

unlabeled primers. Preferably, the amplification products are between about 100-about 400 nucleotides in length, but any lengths which may be distinguished from each other may be used. In addition, in some of the embodiments some of the amplification products may have identical or very similar lengths but be distinguishable from one another due to labeling with distinguishable dyes.

A nucleic acid amplification reaction is conducted on each of the nucleic acid aliquots. The amplification products are then separated by length to identify amplification products having increased representation in the culture or collection of strains (i.e. amplification products derived from cells which proliferated more rapidly in the culture or collection of strains). The amplification products are then correlated with the corresponding genes to determine which strains proliferated more rapidly in the culture or collection of strains. If desired, amplification products having increased representation in the culture may be identified by comparing the amplification products obtained from a culture or collection of strains which was contacted with the compound to amplification products obtained from a control culture or collection of strains which was not contacted with the compound. Alternatively, if desired, the amplification products which are obtained from a culture which was contacted with the compound may be directly identified without comparison to a control culture which was not contacted with the compound.

For example, in some embodiments, the amplification products from each of the nucleic acid aliquots are pooled and subjected to capillary electrophoresis. The amplification products are detected by detecting the fluorescent dyes attached thereto and their lengths are determined to identify those amplification products having increased or decreased representation in the culture or collection of strains. Figures 2A and 2B illustrate one embodiment of this method in which the absence of an amplification product from an amplification reaction performed on a culture comprising a plurality of strains underexpressing genes required for proliferation indicates that a test compound acts on the gene corresponding to the missing amplification product. It will be appreciated that the method may also be used to identify an amplification product which is overrepresented in an amplification reaction conducted on a culture or collection of strains overexpressing genes required for proliferation because the test compound acted on the corresponding gene.

Alternatively, in another embodiment, a first amplification reaction is performed on nucleic acids obtained from a culture or collection of strains which was contacted with the compound using a first primer complementary to a nucleotide sequence present upstream or downstream of all of the overexpressed genes (such as a primer complementary to a nucleotide sequence in a replacement promoter upstream of all of the overexpressed genes) and a set of primers complementary to a nucleotide sequence unique to each of the strains (such as a primer complementary to a nucleotide sequence within each of the proliferation-required genes). One of the two amplification primers for each of the proliferation required genes is labeled with a dye as described above. Preferably, the common primer complementary to a nucleotide sequence upstream or downstream of all of the

overexpressed genes is labeled with the dye. The primers used in the amplification reaction are designed so that the amplification product corresponding to each proliferation-required gene has a unique length or a dye which allows it to be distinguished from other amplification products of the same length. A second amplification reaction is conducted on a control culture or collection of strains which was not contacted with the compound using the same primers as in the first amplification reaction. The amplification products from the first amplification reaction are compared to those from the second amplification reaction to identify one or more amplification products which are overrepresented in the culture or collection of strains. For example, the amplification products from the first amplification reaction may be run in a separate lane of a polyacrylamide gel or a separate capillary than the amplification products from the second amplification reaction and the two lanes or capillaries are compared to one another. If desired, in the embodiment where the amplification products from the first amplification reaction are run in a different lane or capillary than the amplification products from the second amplification reaction, the same dye may be used to label the primers in the first and second amplification reactions. Alternatively, if desired, different dyes may be used to label the primers in the first and second amplification reactions. If desired, in the embodiment where the amplification products from the first amplification reaction are run in a different lane or capillary than the amplification products from the second amplification reaction, the same dye may be used to label the primers in the first and second amplification reactions. Alternatively, if desired, different dyes may be used to label the primers in the first and second amplification reactions.

Alternatively, in some embodiments, the primers in the second amplification reaction are labeled with a different dye which is distinguishable from the dye used in the first amplification reaction. In this embodiment, the amplification reactions may be pooled and run in the same lane on a polyacrylamide gel or in the same capillary and the products from each amplification reaction are compared by comparing the amount of each dye present for each amplification product. Figures 3A and 3B illustrate one embodiment of this method in which the absence of an amplification product from the amplification reaction performed on a culture comprising a plurality of strains underexpressing genes required for proliferation which was contacted with the compound indicates that a test compound acts on the gene corresponding to the missing amplification product. It will be appreciated that the method may also be used to identify an amplification product which is overrepresented in an amplification reaction conducted on a culture or collection of strains overexpressing genes required for proliferation because the test compound acted on the corresponding gene.

If desired, rather than dividing the culture into aliquots, individual amplification reactions may be conducted on nucleic acids obtained from the culture or collection of strains. Each amplification reaction contains primers which will yield an amplification product specific for only one of the proliferation required genes. The resulting amplification products from each of the

individual amplification reactions are pooled and amplification products having increased representation in the culture are identified as described above.

In another embodiment, a culture or collection of strains in which gene products required for proliferation are overexpressed from regulatable promoters which replaced the native promoters of the genes encoding these gene products is allowed to grow in the presence of a test compound for a desired number of generations. Preferably, the culture or collection of strains is allowed to grow in the presence of the test compound for at least 20 generations. Nucleic acids are isolated from the culture or collection of strains and an amplification reaction is performed using a primer which is complementary to a nucleotide sequence within the replacement promoter(s) or a nucleotide sequence adjacent to the a 5' end thereof and primers which are complementary to a nucleotide sequence within the proliferation required genes or nucleotide sequences adjacent thereto. The resulting amplification product(s) is directly sequenced using a primer complementary to a nucleotide sequence within the replacement promoter.

In one embodiment of the present invention, the vector containing the nucleotide sequence encoding the proliferation-required gene product is obtained from a strain which proliferated more rapidly in the culture using methods such as plasmid preparation techniques. Nucleic acid sequencing techniques are then employed to determine the nucleotide sequence of the gene which was overexpressed.

Alternatively, the identity of the overexpressed gene product which is the target of the compound may be determined by performing a nucleic acid amplification reaction, such as a polymerase chain reaction (PCR), to identify the nucleotide sequence of the gene which was overexpressed. For example, aliquots of a nucleic acid preparation, such as a purified plasmid, from the strain which is recovered from the culture may each be contacted with pairs of PCR primers which would amplify a different proliferation-required gene to determine which pair of primers yields an amplification product.

An alternative method for determining the identity of the gene product described herein which is the target of the compound involves obtaining a nucleic acid array, such as a DNA chip, which contains each of the proliferation-required genes which were overexpressed in the strains in the culture. Each proliferation-required gene occupies a known location in the array. A nucleic acid preparation, such as a plasmid preparation, from the recovered strain is labeled with a detectable agent, such as radioactive or fluorescent moiety, and placed in contact with the nucleic acid array under conditions which permit the labeled nucleic acid to hybridize to complementary nucleic acids on the array. The location on the array to which the labeled nucleic acids hybridize is determined to identify the gene which was overexpressed in the recovered strain. If desired the hybridized nucleic acids from a culture which was contacted with the compound may be compared to the hybridized nucleic acids from a control culture which was not contacted with the compound. Alternatively, the hybridized nucleic acids from a culture which was contacted with the compound may be directly identified without comparison to nucleic acids from a control culture.

In some instances, more than one strain may proliferate more rapidly in the presence of the compound. This may result from a variety of causes. For example, the concentration of the compound may not have been high enough to restrict proliferation only to cells which overexpress one gene product (i.e. the target gene product). While strains which overexpress the target gene product will be the most prevalent strain in the culture, other strains may also have proliferated. In such instances, the identity of the gene product in the strain which is most prevalent in the culture may be identified by quantitating the levels of each of the genes encoding proliferation-required proteins in the culture. This may be accomplished by quantitative PCR, DNA sequencing, hybridization, or array technology as described above.

In other instances, multiple strains will exhibit more rapid proliferation in the culture as a result of a common functional attribute. For example, the strains which proliferate more rapidly may each overexpress a gene product with a common enzymatic activity, such as serine protease activity for example. Alternatively, the strains which proliferate more rapidly may each overexpress a gene product with a common functional domain, such as a cAMP binding domain. In such instances, the common attribute of the strains which proliferate more rapidly may provide information as to the mode of action of the compound or the biochemical activity of the target of the compound. For example, if all of the overexpressed genes in the strains which proliferated more rapidly are serine proteases, the compound acts by inhibiting serine protease activity and the target protein is a serine protease. If desired, the compound may be derivatized and the efficacy of the derivatized compound against each of the strains which proliferated more rapidly may be assessed as described herein in order to identify derivatives which are capable of interacting with a wide range of targets sharing a common activity or binding site (i.e. derivatives which have a greater ability to inhibit the proliferation of all the strains than the original compound) or to identify derivatives having greater specificity for a desired target (i.e. derivatives which have a greater specificity for one of the strains than the original compound). For example, it is possible that a nonessential gene product expressed in the cell might also bind to the initial test compound in addition to the gene product required for proliferation. In such an instance, it is desirable to obtain a derivative of the initial test compound which is specific for the gene product required for proliferation. In addition, it is possible that two gene products required for proliferation might bind to the initial test compound but specificity for one of the gene products is desired.

Rather than employing a single culture which contains multiple strains each of which overexpresses a proliferation-required gene product described herein, the methods of the present invention may be performed using an array of individual strains (i.e. a collection of strains) each of which overexpresses a different proliferation-required gene product. For example, individual strains each overexpressing a different proliferation-required gene product may be grown in different wells of a multiwell plate. Each well is contacted with the compound (and, where appropriate an agent which regulates the level of expression from the promoter). The level of proliferation of the strains in each of the wells is determined to identify a strain which proliferated

more rapidly. The identity of the overexpressed gene product in the strain that proliferated more rapidly is determined as described above.

In another embodiment, individual strains each overexpressing a different proliferation-required gene product (i.e. a collection of strains) are grown at different locations on a solid medium, such as an agar plate. The medium contains the compound and where appropriate an agent which regulates the level of expression from the promoter). The level of proliferation of each of the strains is determined to identify a strain which proliferated more rapidly. The identity of the overexpressed gene product in the strain that proliferated more rapidly is determined as described above.

The above methods may be used to prioritize compound development or to determine whether the compound has been previously identified or whether the target of the compound is the target of a previously identified drug. In particular, if the product is a natural product, it is advantageous to determine whether it has been previously identified prior to investing significant effort in developing it. Thus, in some embodiments of the present invention, the target of a partially purified or purified natural product or a compound produced by combinatorial chemistry is identified using the methods described above and compared to the targets of known drugs. If the target is identical to that of a known drug, further development of the compound is halted.

Alternatively, an array of strains each of which overexpresses a different gene product described herein (i.e. a collection of strains) is grown on solid medium containing a compound to be evaluated. The location of each strain in the array and the gene product overexpressed by that strain is known. The pattern of colonies which grow in the presence of the compound is evaluated and compared to the pattern of colonies which grow in the presence of previously identified drugs. If the pattern of colonies which grow in the presence of the compound being evaluated is the same as the pattern of colonies which grow in the presence of a previously identified drug, further development of the compound is halted.

Additionally in some embodiments, the sequence of the gene product in a strain which proliferated more rapidly in the assays described above is compared to the sequence of gene products from heterologous organisms to determine the likely spectrum of species whose growth would be inhibited by the compound. If the gene product has a high degree of homology to gene products from heterologous species, it is likely that the compound would also inhibit the growth of these heterologous species. Homology may be determined using any of a variety of methods familiar to those skilled in the art. For example, homology may be determined using a computer program such as BLASTP or FASTA. The ability of the compound to inhibit the growth of the heterologous species may then be confirmed by comparing the growth of cells of the heterologous species in the presence and absence of the compound.

Current methods for identifying the target of compounds which inhibit cellular proliferation are laborious and time consuming. The above methods may be employed to allow the targets of a large number of compounds to be rapidly identified. In such methods, the methods described above

are simultaneously performed for each of a large number of compounds. For example, the compounds may be members of a library of compounds generated using combinatorial chemistry or members of a natural product library. In such methods, a plurality of cultures each comprising a plurality of strains each of which overexpresses a different gene product required for proliferation
5 or a plurality of collections of individual strains each of which overexpresses a different gene product required for proliferation is obtained. Each culture or collection of strains is contacted with a different compound in the library and the target of the compound is identified as described above.

In another embodiment, the gene product described herein on which a compound which inhibits the proliferation of an organism acts is identified using a culture which comprises a mixture
10 of strains of the organism including strains which underexpress a different gene product which is required for proliferation of the organism (i.e. at least some of the strains in the culture underexpress a gene product which is required for proliferation of the organism). Preferably, each of the strains in the culture underexpress a different a gene product which is required for the proliferation of the organism (i.e. all of the strains in the culture underexpress a gene product which
15 is required for the proliferation of the organism). In some embodiments, the culture comprises at least one strain which underexpresses a gene product selected from the group consisting of a gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-
20 42397, a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a gene product whose activity or level is inhibited by a homologous antisense nucleic acid, a gene product encoded by a homologous coding nucleic acid, and a gene product comprising a homologous polypeptide.

Strains underexpressing the proliferation-required gene products described herein may be
25 obtained using the methods described above. The culture may comprise any number of strains. For example the culture may comprise at least two strains, at least 10 strains, at least 20 strains, at least 30, strains, at least 50 strains, at least 100 strains, at least 300 strains or more than 300 strains which underexpress a gene product required for proliferation. In some embodiments, the strains in the culture in aggregate may underexpress all or most of the gene products required for proliferation of
30 the organism.

The culture is contacted with a compound which inhibits proliferation of the organism. The compound may be a candidate drug compound obtained from any source. For example, the compound may be a compound generated using combinatorial chemistry, a compound from a natural product library, or an impure or partially purified compound, such as a compound in a
35 partially purified natural extract. The culture is contacted with a sufficient concentration of the compound to inhibit the proliferation of strains of the organism in the culture which underexpress the gene product on which the compound acts, such that strains which do not underexpress the gene product on which the compound acts proliferate more rapidly in the culture than strains which do

underexpress said gene product on which said compound acts. Thus, after a sufficient period of time, the strain which underexpresses the gene product on which the compound acts will be less prevalent in the culture than strains which do not underexpress the gene product on which the compound acts. In one embodiment, the growth conditions and incubation period are selected so that only one strain, the strain underexpressing the target of the compound, proliferates at a reduced rate in the culture. In another embodiment, the growth conditions may be selected so that the strain underexpressing the target of the compound is not recovered from the culture. Thus, in one embodiment, a plurality of cultures containing a plurality of strains each of which underexpresses a different proliferation-required gene product may be grown in the presence of varying concentrations of the compound. In addition to varying the compound concentrations, in embodiments where expression of the proliferation-required gene product is under the control of a regulatable promoter, the plurality of cultures may be grown at varying concentrations of an agent which regulates the level of expression from the promoter, such as an inducer or an agent which reduces the effect of a repressor on transcription from the promoter. It will be appreciated, that the cultures may be grown in liquid medium in the presence of the compound whose target is to be identified (and where appropriate in the presence of an agent which regulates the level of expression from the promoter) or alternatively, a liquid culture comprising the strains which underexpress the proliferation-required gene products may be grown in the absence of the compound whose target is to be identified and then introduced onto a solid medium containing the compound (and, where appropriate, also containing an agent which regulates the level of expression from the promoter).

The identity of the underexpressed gene product which is the target of the compound may be determined using a variety of methods. For example, in some embodiments of the present invention, the nucleic acids present in the culture or collection of strains which was contacted with the compound may be compared to the nucleic acids present in a control culture or collection of strains which was not contacted with the compound to identify nucleic acids which are underrepresented in the culture or collection of strains contacted with the test compound relative to the control culture or strains. Alternatively, in some embodiments, the nucleic acids present in a culture or collection of strains contacted with the test compound may be analyzed to identify those nucleic acids which are missing or present at reduced levels without comparison to a control culture or collection of strains.

In some embodiments of the present invention, the strains which proliferated more slowly in the culture or collection of strains, i.e. strains having an decreased ability to proliferate in the presence of a test compound or which do not proliferate in the presence of a test compound, are identified as follows. Amplification products which are correlated with each of the underexpressed genes and which are distinguishable from one another are obtained from a culture or collection grown in the presence of a test compound. The amplification products are distinguished from one another to determine whether a particular amplification product is underrepresented in the culture or collection of strains. In some embodiments, the amplification products corresponding to each of the

gene products have lengths which permit them to be distinguished from one another. In another embodiment, one or more of the amplification products have similar or identical lengths but are distinguishable from one another based on a detectable agent, such as a dye, attached thereto. In some embodiments, amplification products which are underrepresented are identified by comparing the amplification products from the culture or collection of strains which was contacted with the test compound to the amplification products from a culture or collection of strains which was not contacted with the test compound. Alternatively, amplification products which are underrepresented in the culture or collection of strains may be identified simply by determining which amplification products are missing or present at reduced levels in the culture or collection of strains. The above methods for generating distinguishable amplification products may be used in conjunction with any of the methods for generating strains which underexpress gene products required for proliferation described herein in order to facilitate the identification of strains which proliferate more slowly in the presence of a test compound.

For example, in some embodiments of the present invention, each of the native promoters of each of the genes encoding gene product required for proliferation are replaced by a single desired replacement promoter. After growth of the culture or collection of strains containing the strains in which the promoters have been replaced in the presence of a test compound for a desired period of time, an amplification reaction is performed on nucleic acids obtained from the culture as follows.

The nucleic acids from the culture or collection of strains are divided into at least two aliquots. In a preferred embodiment the nucleic acids from the culture or collection of strains are divided into four aliquots. A single primer complementary to a nucleotide sequence within the replacement promoter, within the proliferation required genes, or within nucleic acid sequences adjacent to the promoter or proliferation required genes is divided into four groups. Each group is labeled with a distinct detectable dye, such as the 6FAMTM, TETTM, VICTM, HEXTM, NEDTM, and PETTM dyes obtainable from Applied Biosystems (Foster City, CA). For example, the DS-31 or DS-33 dye sets available from Applied Biosystems (Foster City, CA) may be used to label the primers. Each of the groups of labeled primers are added to each of the aliquots of the nucleic acids from the culture or collection of strains such that each aliquot of nucleic acid receives a single labeled primer with a single detectable dye thereon.

Each of the aliquots of nucleic acids also receives a set of unlabeled primers, with each of the unlabeled primers being complementary to a nucleotide sequence within the promoter, within a nucleotide sequence which is unique to one of the genes encoding gene products required for proliferation which were placed under the control of the replacement promoter, or within nucleotide sequences adjacent to the promoter or proliferation required genes. Each of the aliquots receives primers unique to 1/N proliferation required genes which were placed under the control of the replacement promoter, where N is the number of aliquots (i.e. if the culture or collection of strains consisted of 100 strains in which a gene required for proliferation was placed under the control of the replacement promoter and was divided into four aliquots, then each of the four aliquots of

nucleic acids from the culture or collection of strains would receive primers complementary to 25 of the genes). The unlabeled primers are selected so that each will yield an amplification product having a length distinguishable from the length of the amplification product produced with the other unlabeled primers. Preferably, the amplification products are between about 100-about 400
5 nucleotides in length, but any lengths which may be distinguished from each other may be used. In addition, in some of the embodiments some of the amplification products may have identical or very similar lengths but be distinguishable from one another due to labeling with distinguishable dyes.

A nucleic acid amplification reaction is conducted on each of the nucleic acid aliquots. The
10 amplification products are then separated by length to identify amplification products decreased representation or which are absent in the culture or collection of strains. The amplification products are then correlated with the corresponding genes to determine which strains proliferated more slowly in the culture or collection of strains. If desired, amplification products having decreased representation in the culture may be identified by comparing the amplification products obtained
15 from a culture or collection of strains which was contacted with the compound to amplification products obtained from a control culture or collection of strains which was not contacted with the compound. Alternatively, if desired, the amplification products which are missing or present at reduced levels in a culture which was contacted with the compound may be directly identified without comparison to a control culture which was not contacted with the compound.

For example, in some embodiments, the amplification products from each of the nucleic
20 acid aliquots are pooled and subjected to capillary electrophoresis. The amplification products are detected by detecting the fluorescent dyes attached thereto and their lengths are determined to identify those amplification products having decreased representation in the culture or collection of strains. Figures 2A and 2B illustrate one embodiment of this method in which the absence of an
25 amplification product from an amplification reaction performed on a culture comprising a plurality of strains underexpressing genes required for proliferation indicates that a test compound acts on the gene corresponding to the missing amplification product.

Alternatively, in another embodiment, a first amplification reaction is performed on nucleic
acids obtained from a culture or collection of strains which was contacted with the compound using
30 a first primer complementary to a nucleotide sequence present upstream or downstream of all of the overexpressed genes (such as a primer complementary to a nucleotide sequence in a replacement promoter upstream of all of the overexpressed genes) and a set of primers complementary to a nucleotide sequence unique to each of the strains (such as a primer complementary to a nucleotide sequence within each of the proliferation-required genes). One of the two amplification primers for
35 each of the proliferation required genes is labeled with a dye as described above. Preferably, the common primer complementary to a nucleotide sequence upstream or downstream of all of the overexpressed genes is labeled with the dye. The primers used in the amplification reaction are designed so that the amplification product corresponding to each proliferation-required gene has a

unique length. A second amplification reaction is conducted on a control culture or collection of strains which was not contacted with the compound using the same primers as in the first amplification reaction. The amplification products from the first amplification reaction are compared to those from the second amplification reaction to identify one or more amplification products which are underrepresented in the culture or collection of strains. For example, the amplification products from the first amplification reaction may be run in a separate lane of a polyacrylamide gel or a separate capillary than the amplification products from the second amplification reaction and the two lanes or capillaries are compared to one another.

Alternatively, in some embodiments, the primers in the second amplification reaction are labeled with a different dye which is distinguishable from the dye used in the first amplification reaction. In this embodiment, the amplification reactions may be pooled and run in the same lane on a polyacrylamide gel or in the same capillary and the products from each amplification reaction are compared by comparing the amount of each dye present for each amplification product. Figures 3A and 3B illustrate one embodiment of this method in which the absence of an amplification product from the amplification reaction performed on a culture comprising a plurality of strains underexpressing genes required for proliferation which was contacted with the compound indicates that a test compound acts on the gene corresponding to the missing amplification product.

If desired, rather than dividing the culture into aliquots, individual amplification reactions may be conducted on nucleic acids obtained from the culture or collection of strains. Each amplification reaction contains primers which will yield an amplification product specific for only one of the proliferation required genes. The resulting amplification products from each of the individual amplification reactions are pooled and amplification products having decreased representation in the culture are identified as described above.

In an alternative embodiment, the representation of each strain in the culture may be assessed by hybridizing detectably labeled nucleic acids encoding the proliferation-required gene products, or portions thereof, obtained from the culture to an array comprising nucleic acids encoding the gene products required for proliferation or portions thereof. Each nucleic acid encoding a gene product required for proliferation or portion thereof occupies a known location on the array. The signal from each location on the array is quantitated to identify those nucleic acids encoding a proliferation-required gene product which are underrepresented in the culture. If desired the hybridized nucleic acids from a culture which was contacted with the compound may be compared to the hybridized nucleic acids from a control culture which was not contacted with the compound. Alternatively, the hybridized nucleic acids from a culture which was contacted with the compound may be directly analyzed without comparison to nucleic acids from a control culture.

In another alternative, each strain underexpressing a gene product required for proliferation may be constructed to contain a unique nucleic acid sequence (referred to herein as a "tag"). The tag may be included in the chromosome of each strain or in an extrachromosomal vector. For example, the tag could be included in a vector encoding an antisense nucleic acid complementary to

a gene encoding a gene product required for proliferation or a portion of such a gene or the tag may be included in the antisense nucleic acid itself. The representation of each strain in the culture may be assessed by performing an amplification reaction using primers complementary to each of the tags and quantitating the levels of the resulting amplification products to identify a tag which is underrepresented or absent from the culture. Since each tag corresponds to one strain, the strain which is underrepresented or absent from the culture may be identified. If desired the tags present in a culture which was contacted with the compound may be compared to the tags present in a control culture which was not contacted with the compound. Alternatively, the tags present in a culture which was contacted with the compound may be analyzed without comparison to a control culture.

It will be appreciated that, if desired, unique tags may also be used in embodiments in which gene products required for proliferation are overexpressed. In some aspects of such embodiments, the tags may be within or adjacent to the promoter which drives expression of the gene encoding the gene product. In such embodiments, the gene product which is overexpressed in strains which proliferate more rapidly in the culture may be identified by detecting the presence or amount of the unique tag corresponding to that gene product in the culture.

In some instances, more than one strain may proliferate less rapidly in the presence of the compound. This may result from a variety of causes. For example, the concentration of the compound may not have been high enough to reduce the proliferation only in cells which underexpress one gene product (i.e. the target gene product). While strains which underexpress the target gene product will be the least prevalent strain in the culture, other strains may also be underrepresented. In such instances, the identity of the gene product in the strain which is least prevalent in the culture (or not recovered from the culture) may be identified by quantitating the levels of each of the genes encoding proliferation-required proteins in the culture. This may be accomplished by quantitative PCR, DNA sequencing, hybridization, or array technology as described above.

In other instances, multiple strains will exhibit less rapid proliferation in the culture as a result of a common functional attribute. For example, the strains which proliferate less rapidly (or the strains which are not recovered from the culture) may each underexpress a gene product with a common enzymatic activity, such as serine protease activity for example. Alternatively, the strains which proliferate less rapidly (or the strains which are not recovered from the culture) may each underexpress a gene product with a common functional domain, such as a cAMP binding domain. In such instances, the common attribute of the strains which proliferate less rapidly (or the strains which are not recovered from the culture) may provide information as to the mode of action of the compound or the biochemical activity of the target of the compound. For example, if all of the underexpressed genes in the strains which proliferated less rapidly are serine proteases, the compound acts by inhibiting serine protease activity and the target protein is a serine protease. If desired, the compound may be derivatized and the efficacy of the derivatized compound against

each of the strains which proliferated more rapidly may be assessed as described herein in order to identify derivatives which are capable of interacting with a wide range of targets sharing a common activity or binding site (i.e. derivatives which have a greater ability to inhibit the proliferation of all the strains than the original compound) or to identify derivatives having greater specificity for a
5 desired target (i.e. derivatives which have a greater specificity for one of the strains than the original compound).

Rather than employing a single culture which contains multiple strains each of which underexpresses a proliferation-required gene product described herein, the methods of the present invention may be performed using an array of individual strains (i.e. a collection of strains) each of
10 which underexpresses a different proliferation-required gene product. For example, individual strains each underexpressing a different proliferation-required gene product may be grown in different wells of a multiwell plate. Each well is contacted with the compound (and, where appropriate an agent which regulates the level of expression from the promoter). The level of proliferation of the strains in each of the wells is determined to identify a strain which proliferated
15 less rapidly or which did not proliferate at all. The identity of the underexpressed gene product in the strain that proliferated less rapidly or which did not proliferate at all is determined as described above.

In another embodiment, individual strains each underexpressing a different proliferation-required gene product (i.e. a collection of strains) are grown at different locations on a solid
20 medium, such as an agar plate. The medium contains the compound and, where appropriate, an agent which regulates the level of expression from the promoter. The level of proliferation of each of the strains is determined to identify a strain which proliferated less rapidly (or a strain which is not recovered from the culture). The identity of the underexpressed gene product in the strain that proliferated less rapidly (or the strain which is not recovered from the culture) is determined as
25 described above.

The above methods may be used to prioritize compound development or to determine whether the compound has been previously identified or whether the target of the compound is the target of a previously identified drug. In particular, if the product is a natural product is advantageous to determine whether it has been previously identified prior to investing significant
30 effort in developing it. Thus, in some embodiments of the present invention, the target of a partially purified or purified natural product or a compound produced by combinatorial chemistry is identified using the methods described above and compared to the targets of known drugs. If the target is identical to that of a known drug, further development of the compound is halted.

Alternatively, an array of strains each of which underexpresses a different gene product
35 described herein (i.e. a collection of strains) is grown on solid medium containing a compound to be evaluated. The location of each strain in the array and the gene product underexpressed by that strain is known. The pattern of colonies which grow less rapidly or fail to grow in the presence of the compound is evaluated and compared to the pattern of colonies which grow less rapidly or fail

to grow in the presence of previously identified drugs. If the pattern of colonies which grow less rapidly or fail to grow in the presence of the compound being evaluated is the same as the pattern of colonies which grow less rapidly or fail to grow in the presence of a previously identified drug, further development of the compound is halted.

5 Additionally, the nucleotide sequence of the gene product described herein in a strain which proliferated less rapidly (or a strain which was not recovered from the culture) in the assays described above is compared to the nucleotide sequence of gene products from heterologous organisms to determine the likely spectrum of species whose growth would be inhibited by the compound. If the gene product has a high degree of homology to gene products from heterologous
10 species, it is likely that the compound would also inhibit the growth of these heterologous species. Homology may be determined using any of a variety of methods familiar to those skilled in the art. For example, homology may be determined using a computer program such as BLASTP or FASTA. The ability of the compound to inhibit the growth of the heterologous species may then be confirmed by comparing the growth of cells of the heterologous species in the presence and absence
15 of the compound.

 In other embodiments, the present invention uses collections or cultures of strains comprising both strains which overexpress gene products described herein required for cellular proliferation and strains which underexpress the same gene products required for cellular proliferation. The gene product which is overexpressed or underexpressed in each strain may be a
20 gene product whose activity or level is inhibited by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 1-6213, a gene product encoded by a nucleic acid comprising a nucleotide sequence selected from the group consisting of SEQ ID NOs.: 6214-42397, a gene product comprising an amino acid sequence selected from the group consisting of SEQ ID NOs.: 42398-78581, a gene product whose activity or level is inhibited by a homologous
25 antisense nucleic acid, a gene product encoded by a homologous coding nucleic acid, and a gene product comprising a homologous polypeptide.

 The culture or collection of strains is contacted with a compound and the nucleic acids present in the culture or collection of strains are analyzed. Preferably, nucleic acids derived from overexpressing strains can be distinguished from those derived from underexpressing strains. For
30 example, the overexpressing strains may be obtained using promoter replacement as described above while the underexpressing strains may be obtained by expressing antisense nucleic acids. Accordingly, in one embodiment, amplification primers may be designed which will uniquely amplify nucleic acids from the overexpressing strains or the underexpressing strains. If a compound acts on a gene product which was overexpressed and underexpressed in the culture, then
35 the amplification product obtained from the strain in the culture or collection which overexpressed gene product will be overrepresented in the culture or collection while the amplification product obtained from the strain which underexpressed the gene product will be underrepresented in the culture or collection. If desired, nucleic acids from a culture or collection which was contacted with

the compound may be compared to nucleic acids from a control culture or collection which was not contacted with the compound. Alternatively, nucleic acids from a culture or collection which was contacted with the compound may be directly analyzed without comparison to a control culture or collection.

5 In some embodiments, strains are constructed in which a nucleic acid complementary to a gene encoding a gene product described herein required for proliferation or a portion thereof is operably linked to a regulatable promoter. For example, in some embodiments, the strains may transcribe an antisense nucleic acid selected from the group consisting of SEQ ID NOs.: 1-6213 or fragments thereof which inhibit proliferation or reduce the activity or level of the gene product
10 encoded by the gene comprising a nucleotide sequence complementary to the antisense nucleic acid or homologous antisense nucleic acids or fragments thereof. In other embodiments, the strains may transcribe an antisense nucleic acid which reduces the activity or level of a gene product encoded by SEQ ID NOs.: 6214-42397, the polypeptides of SEQ ID NOs.: 42398-78581, homologous coding nucleic acids or homologous polypeptides. A culture comprising a plurality of such strains
15 wherein each strain expresses an antisense nucleic acid against a different gene product required for proliferation is grown in the presence of varying levels of a compound which inhibits proliferation and in the presence of varying levels of an agent which regulates the level of transcription from the regulatable promoter. Nucleic acids samples are obtained from the culture, detectably labeled and hybridized to a solid support comprising nucleic acids containing the genes encoding the
20 proliferation-required gene products or a portion thereof. The level of hybridization is quantitated for each nucleic acid encoding each of the proliferation-required gene products to determine the rate at which each of the strains proliferated in the culture. If the antisense nucleic acid expressed by a strain in the culture is not complementary to all or a portion of the gene encoding the target of the compound (i.e. a nonspecific strain), then the hybridization intensity for that strain will not be
25 correlated with the concentration of the compound (See Figure 4), while if the antisense nucleic acid expressed by a strain in the culture is complementary to all or a portion of the gene encoding the target of the compound, the hybridization intensity for that strain will be intimately correlated with the concentration of the compound (See Figure 5). In this manner, the target of the compound may be identified. It will be appreciated that, as described above, rather than growing the strains in
30 a single culture, each strain may be grown in a different location on a solid medium or in a different well of a multiwell plate.

 The methods described above can be simultaneously performed for each of a large number of compounds. For example, the compounds may be members of a library of compounds generated using combinatorial chemistry or members of a natural product library. In such methods, a plurality
35 of cultures each comprising a plurality of strains each of which overexpresses or underexpresses a different gene product required for proliferation or a plurality of collections of individual strains each of which overexpresses or underexpresses a different gene product required for proliferation is

obtained. Each culture or collection of strains is contacted with a different compound in the library and the target of the compound is identified as described above.

In still another embodiment, the antisense nucleic acids of the present invention (including the antisense nucleic acids of SEQ ID NOs. 1-6213 fragments thereof or homologous antisense nucleic acids or fragments thereof) that inhibit bacterial growth or proliferation can be used as antisense therapeutics for killing bacteria. The antisense sequences can be complementary to one of SEQ ID NOs.: 6214-42397 or fragments thereof, homologous coding nucleic acids or fragments thereof. Alternatively, antisense therapeutics can be complementary to operons in which proliferation-required genes reside (i.e. the antisense nucleic acid may hybridize to a nucleotide sequence of any gene in the operon in which the proliferation-required genes reside). Further, antisense therapeutics can be complementary to a proliferation-required gene or portion thereof with or without adjacent noncoding sequences, an intragenic sequence (i.e. a sequence within a gene), an intergenic sequence (i.e. a sequence between genes), a sequence spanning at least a portion of two or more genes, a 5' noncoding region or a 3' noncoding region located upstream or downstream from the actual sequence that is required for bacterial proliferation or an operon containing a proliferation-required gene.

In addition to therapeutic applications, the present invention encompasses the use of nucleic acids complementary to nucleic acids required for proliferation as diagnostic tools. For example, nucleic acid probes comprising nucleotide sequences complementary to proliferation-required sequences that are specific for particular species of cells or microorganisms can be used as probes to identify particular microorganism species or cells in clinical specimens. This utility provides a rapid and dependable method by which to identify the causative agent or agents of a bacterial infection. This utility would provide clinicians the ability to accurately identify the species responsible for the infection and administer a compound effective against it. In an extension of this utility, antibodies generated against proteins translated from mRNA transcribed from proliferation-required sequences can also be used to screen for specific cells or microorganisms that produce such proteins in a species-specific manner.

Other embodiments of the present invention include methods of identifying compounds which inhibit the activity of gene products required for cellular proliferation using rational drug design. As discussed in more detail below, in such methods, the structure of the gene product is determined using techniques such as x-ray crystallography or computer modeling. Compounds are screened to identify those which have a structure which would allow them to interact with the gene product or a portion thereof to inhibit its activity. The compounds may be obtained using any of a variety of methods familiar to those skilled in the art, including combinatorial chemistry. In some embodiments, the compounds may be obtained from a natural product library. In some embodiments, compounds having a structure which allows them to interact with the active site of a gene product, such as the active site of an enzyme, or with a portion of the gene product which interacts with another biomolecule to form a complex are identified. If desired, lead compounds may be identified and further optimized to provide compounds which are highly effective against the gene product.

The following examples teach the genes of the present invention and a subset of uses for the genes identified as required for proliferation. These examples are illustrative only and are not intended to limit the scope of the present invention.

EXAMPLES

5 The following examples are directed to the identification and exploitation of genes required for proliferation. Methods of gene identification are discussed as well as a variety of methods to utilize the identified sequences. It will be appreciated that any of the antisense nucleic acids, proliferation-required genes or proliferation-required gene products described herein, or portions thereof, may be used in the procedures described below, including the antisense nucleic acids of SEQ ID NOS.: 1-6213,
10 the nucleic acids of SEQ ID NOS.: 6214-42397, or the polypeptides of SEQ ID NOS.: 42398-78581. Likewise, homologous antisense nucleic acids, homologous coding nucleic acids, homologous polypeptides or portions of any of the above-mentioned nucleic acids or polypeptides, may be used in any of the procedures described below.

**Genes Identified as Required for Proliferation of *Escherichia coli*, *Staphylococcus aureus*,
15 *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Salmonella typhimurium*.**

Genomic fragments were operably linked to an inducible promoter in a vector and assayed for growth inhibition activity. Example 1 describes the examination of a library of genomic fragments cloned into vectors comprising inducible promoters. Upon induction with xylose or IPTG, the vectors
20 produced an RNA molecule corresponding to the subcloned genomic fragments. In those instances where the genomic fragments were in an antisense orientation with respect to the promoter, the transcript produced was complementary to at least a portion of an mRNA (messenger RNA) encoding a *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* or *Salmonella typhimurium* gene product such that they interacted with
25 sense mRNA produced from various *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* or *Salmonella typhimurium* genes and thereby decreased the translation efficiency or the level of the sense messenger RNA thus decreasing production of the protein encoded by these sense mRNA molecules. In cases where the sense mRNA encoded a protein required for proliferation, bacterial cells containing a vector from which transcription
30 from the promoter had been induced failed to grow or grew at a substantially reduced rate. Additionally, in cases where the transcript produced was complementary to at least a portion of a non-translated RNA and where that non-translated RNA was required for proliferation, bacterial cells containing a vector from which transcription from the promoter had been induced also failed to grow or grew at a substantially reduced rate. In contrast, cells grown under non-inducing conditions grow at a
35 normal rate.

The above method was used to identify genes required for cellular proliferation in *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Salmonella typhimurium*. Additionally, a number of genes required for cellular

proliferation in *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Salmonella typhimurium*, which have been described in the following U.S. Patent Applications: U.S. Patent Application Serial Number 09/492,709, filed January 27, 2000; U.S. Patent Application Serial Number 09/711,164, filed November 9, 2000; 5 U.S. Patent Application Serial Number 09/741,669, filed December 19, 2000 and U.S. Patent Application Serial Number 09/815,242 filed March 21, 2001, U.S. Provisional Patent Application Serial Number 60/342,923, filed October 25, 2001, have been previously identified using the above method.

EXAMPLE 1

10 Inhibition of Bacterial Proliferation after Induction of Antisense Expression

To identify genes required for proliferation of *E. coli*, random genomic fragments were cloned into the IPTG-inducible expression vector pLEX5BA (Krause et al., J. Mol. Biol. 274: 365 (1997) or a modified version of pLEX5BA, pLEX5BA-3' in which a synthetic linker containing a T7 terminator was ligated between the PstI and HindIII sites of pLEX5BA. In particular, to 15 construct pLEX5BA-3', the following oligonucleotides were annealed and inserted into the PstI and HindIII sites of pLEX5BA:

5' -GTCTAGCATAACCCCTTGGGGCCTCTAAACGGGTCCTTGAGGGGTTTTTTGA-3' (SEQ ID NO: 78584)

20 5' -AGCTTCAAAAAACCCCTCAAGGACCCGTTTAGAGGCCCAAGGGGTTAT
GCTAGACTGCA-3' (SEQ ID NO: 78585)

Random fragments of *E. coli* genomic DNA were generated by DNaseI digestion or sonication, filled in with T4 polymerase, and cloned into the SmaI site of pLEX5BA or pLEX5BA-3'. Upon activation or induction, the promoter transcribed the random genomic fragments.

A number of vectors which allow the production of transcripts which have an extended 25 lifetime in *E. coli* as well as other Gram negative bacteria can also be utilized in conjunction with these antisense inhibition experiments. Such vectors are described in U.S. Provisional Patent Application Serial Number 60/343,512, filed December 21, 2001. Briefly, the stabilized antisense RNA may comprise an antisense RNA which was identified as inhibiting proliferation as described above which has been engineered to contain at least one stem loop flanking each end of the 30 antisense nucleic acid. In some embodiments, the at least one stem-loop structure formed at the 5' end of the stabilized antisense nucleic acid comprises a flush, double stranded 5' end. In some embodiments, one or more of the stem loops comprises a rho independent terminator. In additional embodiments, the stabilized antisense RNA lacks a ribosome binding site. In further embodiments, the stabilized RNA lacks sites which are cleaved by one or more RNases, such as RNase E or 35 RNase III. In some embodiments, the stabilized antisense RNA may be transcribed in a cell which the activity of at least one enzyme involved in RNA degradation has been reduced. For example, the activity of an enzyme such as RNase E, RNase II, RNase III, polynucleotide phosphorylase, and poly(A) polymerase, RNA helicase, enolase or an enzyme having similar functions may be reduced in the cell.

To study the effects of transcriptional induction in liquid medium, growth curves were carried out by back diluting cultures 1:200 into fresh media with or without 1 mM IPTG and measuring the OD₄₅₀ every 30 minutes (min). To study the effects of transcriptional induction on solid medium, 10², 10³, 10⁴, 10⁵, 10⁶, 10⁷ and 10⁸ fold dilutions of overnight cultures were prepared. Aliquots of from 0.5 to 3 µl of these dilutions were spotted on selective agar plates with or without 1 mM IPTG. After overnight incubation, the plates were compared to assess the sensitivity of the clones to IPTG.

Of the numerous clones tested, some clones were identified as containing a sequence that inhibited *E. coli* growth after IPTG induction. Accordingly, the gene to which the inserted nucleic acid sequence corresponds, or a gene within the operon containing the inserted nucleic acid, is required for proliferation in *E. coli*.

Nucleic acids involved in proliferation of *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Salmonella typhimurium* were identified as follows. Randomly generated fragments of *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* or *Salmonella typhimurium* genomic DNA were transcribed from inducible promoters.

In the case of *Staphylococcus aureus*, a novel inducible promoter system, XylT5, comprising a modified T5 promoter fused to the *xylO* operator from the *xylA* promoter of *Staphylococcus aureus* was used. The promoter is described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001. Transcription from this hybrid promoter is inducible by xylose.

Randomly generated fragments of *Salmonella typhimurium* genomic DNA were transcribed from an IPTG inducible promoter in pLEX5BA (Krause et al., J. Mol. Biol. 274: 365 (1997) or a derivative thereof. Randomly generated fragments of *Klebsiella pneumoniae* genomic DNA were expressed from an IPTG inducible promoter in pLEX5BA-Kan. To construct pLEX5BA-kan, pLEX5BA was digested to completion with *ClaI* in order to remove the *bla* gene. Then the plasmid was treated with a partial *NotI* digestion and blunted with T4 DNA polymerase. A 3.2 kbp fragment was then gel purified and ligated to a blunted 1.3 kbp kan gene from pKan π . Kan resistant transformants were selected on Kan plates. Orientation of the kan gene was checked by *SmaI* digestion. A clone, which had the kan gene in the same orientation as the *bla* gene, was used to identify genes required for proliferation of *Klebsiella pneumoniae*. Randomly generated fragments of *Pseudomonas aeruginosa* genomic DNA were transcribed from a two-component inducible promoter system. Integrated on the chromosome was the T7 RNA polymerase gene regulated by *lacUV5/ lacO* (Brunschwig, E. and Darzins, A. 1992. Gene 111:35-41. On a separate plasmid, a T7 gene 10 promoter, which is transcribed by T7 RNA polymerase, was fused with a *lacO* operator followed by a multiple cloning site.

Should the genomic DNA downstream of the promoter contain, in an antisense orientation, at least a portion of an mRNA or a non-translated RNA encoding a gene product involved in proliferation, then induction of transcription from the promoter will result in detectable inhibition of proliferation.

5 In the case of *Staphylococcus aureus*, a shotgun library of *Staphylococcus aureus* genomic fragments was cloned into the vector pXyIT5-P15a, which harbors the XyIT5 inducible promoter. The vector was linearized at a unique *Bam*HI site immediately downstream of the XyIT5 promoter/operator. The linearized vector was treated with shrimp alkaline phosphatase to prevent reclosure of the linearized ends. Genomic DNA isolated from *Staphylococcus aureus* strain RN450
10 was fully digested with the restriction enzyme *Sau*3A, or, alternatively, partially digested with DNase I and "blunt-ended" by incubating with T4 DNA polymerase. Random genomic fragments between 200 and 800 base pairs in length were selected by gel purification. The size-selected genomic fragments were added to the linearized and dephosphorylated vector at a molar ratio of 0.1 to 1, and ligated to form a shotgun library.

15 The ligated products were transformed into electrocompetent *E. coli* strain XL1-Blue MRF' (Stratagene) and plated on LB medium supplemented with carbenicillin at 100 µg/ml. Resulting colonies numbering 5×10^5 or greater were scraped and combined, and were then subjected to plasmid purification.

The purified library was then transformed into electrocompetent *Staphylococcus aureus*
20 RN4220. Resulting transformants were plated on agar containing LB + 0.2% glucose (LBG medium) + chloramphenicol at 15 µg/ml (LBG+CM15 medium) in order to generate 100 to 150 platings at 500 colonies per plating. The colonies were subjected to robotic picking and arrayed into wells of 384 well culture dishes. Each well contained 100 µl of LBG + CM15 liquid medium. Inoculated 384 well dishes were incubated 16 hours at 37°C, and each well was robotically gridded
25 onto solid LBG + CM15 medium with or without 2% xylose. Gridded plates were incubated 16 hours at 37°C, and then manually scored for arrayed colonies that were growth-compromised in the presence of xylose.

Arrayed colonies that were growth-sensitive on medium containing 2% xylose, yet were able to grow on similar medium lacking xylose, were subjected to further growth sensitivity
30 analysis as follows: Colonies from the plate lacking xylose were manually picked and inoculated into individual wells of a 96 well culture dish containing LBG + CM15, and were incubated for 16 hours at 37°C. These cultures were robotically diluted 1/100 into fresh medium and allowed to incubate for 4 hours at 37°C, after which they were subjected to serial dilutions in a 384 well array and then gridded onto media containing 2% xylose or media lacking xylose. After growth for 16
35 hours at 37°C, the arrays that resulted on the two media were compared to each other. Clones that grew similarly at all dilutions on both media were scored as a negative and were no longer considered. Clones that grew on xylose medium but failed to grow at the same serial dilution on the non-xylose plate were given a score based on the differential, i.e. should the clone grow at a

serial dilution of 10^4 or less on the xylose plate and grow at a serial dilution of 10^8 or less on the non-xylose plate, then the corresponding clone received a score of "4" representing the log difference in growth observed.

For *Salmonella typhimurium* and *Klebsiella pneumoniae* growth curves were carried out by back diluting cultures 1:200 into fresh media containing 1 mM IPTG or media lacking IPTG and measuring the OD₄₅₀ every 30 minutes (min). To study the effects of transcriptional induction on solid medium, 10^2 , 10^3 , 10^4 , 10^5 , 10^6 , 10^7 and 10^8 fold dilutions of overnight cultures were prepared. Aliquots of from 0.5 to 3 μ l of these dilutions were spotted on selective agar plates with or without 1 mM IPTG. After overnight incubation, the plates were compared to assess the sensitivity of the clones to IPTG.

Nucleic acids involved in proliferation of *Pseudomonas aeruginosa* were identified as follows. Randomly generated fragments of *Pseudomonas aeruginosa* genomic DNA were transcribed from a two-component inducible promoter system. Integrated on the chromosome was the T7 RNA polymerase gene regulated by *lacUV5/ lacO* (Brunschwig, E. and Darzins, A. 1992. Gene 111:35-41). On an expression plasmid there was a T7 gene 10 promoter, which is transcribed by T7 RNA polymerase, fused with a *lacO* operator followed by a multiple cloning site. Transcription from this hybrid promoter is inducible by IPTG. Should the genomic DNA downstream of the promoter contain, in an antisense orientation, at least a portion of an mRNA encoding a gene product involved in proliferation, then induction of expression from the promoter will result in detectable inhibition of proliferation.

A shotgun library of *Pseudomonas aeruginosa* genomic fragments was cloned into the vectors pEP5, pEP5S, or other similarly constructed vectors which harbor the T7*lacO* inducible promoter. The vector was linearized at a unique *Sma*I site immediately downstream of the T7*lacO* promoter/operator. The linearized vector was treated with shrimp alkaline phosphatase to prevent reclosure of the linearized ends. Genomic DNA isolated from *Pseudomonas aeruginosa* strain PAO1 was partially digested with DNase I and "blunt-ended" by incubating with T4 DNA polymerase. Random genomic fragments between 200 and 800 base pairs in length were selected by gel purification. The size-selected genomic fragments were added to the linearized and dephosphorylated vector at a molar ratio of 2 to 1, and ligated to form a shotgun library.

The ligated products were transformed into electrocompetent *E. coli* strain XL1-Blue MRF' (Stratagene) and plated on LB medium with carbenicillin at 100 μ g/ml or Streptomycin 100 μ g/ml. Resulting colonies numbering 5×10^5 or greater were scraped and combined, and were then subjected to plasmid purification.

The purified library was then transformed into electrocompetent *Pseudomonas aeruginosa* strain PAO1. Resulting transformants were plated on LB agar with carbenicillin at 100 μ g/ml or Streptomycin 40 μ g/ml in order to generate 100 to 150 platings at 500 colonies per plating. The colonies were subjected to robotic picking and arrayed into wells of 384 well culture dishes. Each well contained 100 μ l of LB + CB 100 or Streptomycin 40 liquid medium. Inoculated 384 well

dishes were incubated 16 hours at room temperature, and each well was robotically gridded onto solid LB + CB100 or Streptomycin 40 medium with or without 1 mM IPTG. Gridded plates were incubated 16 hours at 37°C, and then manually scored for arrayed colonies that were growth-compromised in the presence of IPTG.

5 Arrayed colonies that were growth-sensitive on medium containing 1 mM IPTG, yet were able to grow on similar medium lacking IPTG, were subjected to further growth sensitivity analysis as follows: Colonies from the plate lacking IPTG were manually picked and inoculated into individual wells of a 96 well culture dish containing LB + CB100 or Streptomycin 40, and were incubated for 16 hours at 30°C. These cultures were robotically diluted 1/100 into fresh medium
10 and allowed to incubate for 4 hours at 37°C, after which they were subjected to serial dilutions in a 384 well array and then gridded onto media with and without 1 mM IPTG. After growth for 16 hours at 37°C, the arrays of serially diluted spots that resulted were compared between the two media. Clones that grew similarly at all dilutions on both media were scored as a negative and were no longer considered. Clones that grew on IPTG medium but failed to grow at the same serial
15 dilution on the non-IPTG plate were given a score based on the differential, i.e. should the clone grow at a serial dilution of 10^4 or less on the IPTG plate and grow at a serial dilution of 10^8 or less on the IPTG plate, then the corresponding clone received a score of "4" representing the log difference in growth observed.

 Following the identification of those vectors that, upon induction, negatively impacted
20 *Pseudomonas aeruginosa* growth or proliferation, the inserts or nucleic acid fragments contained in those vectors were isolated for subsequent characterization. Vectors of interest were subjected to nucleic acid sequence determination.

 Nucleic acids involved in proliferation of *E. faecalis* were identified as follows. Randomly generated fragments of genomic DNA were expressed from the vectors pEPEF3 or pEPEF14,
25 which contain the CP25 or P59 promoter, respectively, regulated by the xyl operator/repressor. These plasmids as well as other vectors useful for the expression of nucleic acids in *Enterococcus faecalis* and other Gram positive organisms are described in U.S. Patent Application Serial Number 10/032,393, filed December 21, 2001, the disclosure of which is incorporated herein by reference in its entirety. Should the genomic DNA downstream of the promoter contain, in an antisense
30 orientation, at least a portion of a mRNA encoding a gene product involved in proliferation, then induction of expression from the promoter will result in detectable inhibition of proliferation.

 A shotgun library of *E. faecalis* genomic fragments was cloned into the vector pEPEF3 or pEPEF14, which harbor xylose inducible promoters. The vector was linearized at a unique *Sma*I site immediately downstream of the promoter/operator. The linearized vector was treated with
35 alkaline phosphatase to prevent reclosure of the linearized ends. Genomic DNA isolated from *E. faecalis* strain OG1RF was partially digested with DNase I and "blunt-ended" by incubating with T4 DNA polymerase. Random genomic fragments between 200 and 800 base pairs in length were

selected by gel purification. The size-selected genomic fragments were added to the linearized and dephosphorylated vector at a molar ratio of 2 to 1, and ligated to form a shotgun library.

The ligated products were transformed into electrocompetent *E. coli* strain TOP10 cells (Invitrogen) and plated on LB medium with erythromycin (Erm) at 150 µg/ml. Resulting colonies
5 numbering 5×10^5 or greater were scraped and combined, and were then subjected to plasmid purification.

The purified library was then transformed into electrocompetent *E. faecalis* strain OG1RF. Resulting transformants were plated on Todd-Hewitt (TH) agar with erythromycin at 10 µg/ml in order to generate 100 to 150 platings at 500 colonies per plating. The colonies were subjected to
10 robotic picking and arrayed into wells of 384 well culture dishes. Each well contained 100 µl of THB + Erm 10 µg/ml. Inoculated 384 well dishes were incubated 16 hours at room temperature, and each well was robotically gridded onto solid TH agar + Erm with or without 5% xylose. Gridded plates were incubated 16 hours at 37°C, and then manually scored for arrayed colonies that were growth-compromised in the presence of xylose.

15 Arrayed colonies that were growth-sensitive on medium containing 5% xylose, yet were able to grow on similar medium lacking xylose, were subjected to further growth sensitivity analysis. Colonies from the plate lacking xylose were manually picked and inoculated into individual wells of a 96 well culture dish containing THB + Erm 10, and were incubated for 16 hours at 30°C. These cultures were robotically diluted 1/100 into fresh medium and allowed to
20 incubate for 4 hours at 37°C, after which they were subjected to serial dilution on plates containing 5% xylose or plates lacking xylose. After growth for 16 hours at 37°C, the arrays of serially diluted spots that resulted were compared between the two media. Colonies that grew similarly on both media were scored as a negative and corresponding colonies were no longer considered. Colonies on xylose medium that failed to grow to the same serial dilution compared to those on the non-
25 xylose plate were given a score based on the differential. For example, colonies on xylose medium that only grow to a serial dilution of -4 while they were able to grow to -8 on the non-xylose plate, then the corresponding transformant colony received a score of "4" representing the log difference in growth observed.

Following the identification of those vectors that, upon induction, negatively impacted *E.*
30 *faecalis* growth or proliferation, the inserts or nucleic acid fragments contained in those expression vectors were isolated for subsequent characterization. The inserts in the vectors of interest were subjected to nucleotide sequence determination.

It will be appreciated that other restriction enzymes and other endonucleases or methodologies may be used to generate random genomic fragments. In addition, random genomic
35 fragments may be generated by mechanical shearing. Sonication and nebulization are two such techniques commonly used for mechanical shearing of DNA.

EXAMPLE 2

Nucleotide Sequence Determination of Identified Clones Transcribing Nucleic Acid Fragments with Detrimental Effects on *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* or *Salmonella typhimurium* Proliferation

5 Plasmids from clones that received a dilution plating score of "2" or greater were isolated to obtain the genomic DNA insert responsible for growth inhibition as follows.

The nucleotide sequences of the nucleic acid sequences which inhibited the growth of *Escherichia coli* were determined using plasmid DNA isolated using QIAPREP (Qiagen, Valencia, CA) and methods supplied by the manufacturer. The primers used for sequencing the inserts were 5' -
 10 TGTTTATCAGACCGCTT - 3' (SEQ ID NO: 78586) and 5' - ACAATTTACACAGCCTC - 3' (SEQ ID NO: 78587). These sequences flank the polylinker in pLEX5BA.

The nucleotide sequences of the nucleic acid sequences which inhibited the growth of *Staphylococcus aureus* were determined as follows. *Staphylococcus aureus* were grown in standard laboratory media (LB or TB with 15 ug/ml Chloramphenicol to select for the plasmid). Growth
 15 was carried out at 37°C overnight in culture tubes or 2 ml deep well microtiter plates.

Lysis of *Staphylococcus aureus* was performed as follows. Cultures (2-5 ml) were centrifuged and the cell pellets resuspended in 1.5 mg/ml solution of lysostaphin (20 µl/ml of original culture) followed by addition of 250 µl of resuspension buffer (Qiagen). Alternatively, cell pellets were resuspended directly in 250 µl of resuspension buffer (Qiagen) to which 5-20 µl of a 1
 20 mg/ml lysostaphin solution were added.

DNA was isolated using Qiagen miniprep kits or Wizard (Qiagen) miniprep kits according to the instructions provided by the manufacturer.

The genomic DNA inserts were amplified from the purified plasmids by PCR as follows.

1 µl of Qiagen purified plasmid was put into a total reaction volume of 25 µl Qiagen Hot
 25 Start PCR mix. For *Staphylococcus aureus*, the following primers were used in the PCR reaction:
 pXyIT5F: CAGCAGTCTGAGTTATAAAATAG (SEQ ID NO: 78588)
 LexL TGTTTTATCAGACCGCTT (SEQ ID NO: 78589)

Similar methods were conducted for *Salmonella typhimurium* and *Klebsiella pneumoniae*. For *Salmonella typhimurium* and *Klebsiella pneumoniae* the following primers were used:

30 5' - TGTTTTATCAGACCGCTT - 3' (SEQ ID NO: 78589) and
 5'-ACAATTTACACAGCCTC-3' (SEQ ID NO: 78587)

PCR was carried out in a PE GenAmp with the following cycle times:

- Step 1. 95° C 15 min
- Step 2. 94° C 45 sec
- 35 Step 3. 54° C 45 sec
- Step 4. 72° C 1 minute
- Step 5. Return to step 2, 29 times
- Step 6. 72° C 10 minutes

Step 7. 4° C hold

The PCR products were cleaned using Qiagen Qiaquick PCR plates according to the manufacturer's instructions.

For *Pseudomonas aeruginosa*, plasmids from transformant colonies that received a dilution plating score of "2" or greater were isolated to obtain the genomic DNA insert responsible for growth inhibition as follows. *Pseudomonas aeruginosa* were grown in standard laboratory media (LB with carbenicillin at 100 µg/ml or Streptomycin 40 µg/ml to select for the plasmid). Growth was carried out at 30°C overnight in 100 ul culture wells in microtiter plates. To amplify insert DNA 2 ul of culture were placed into 25 ul Qiagen Hot Start PCR mix. PCR reactions were in 96 well microtiter plates. For plasmid pEP5S the following primers were used in the PCR reaction:

T7L1+: GTCGGCGATATAGGCGCCAGCAACCG (SEQ ID NO: 78590)

pStrA3: ATAATCGAGCATGAGTATCATACG (SEQ ID NO: 78591)

PCR was carried out in a PE GenAmp with the following cycle times:

Step 1. 95° C 15 min

Step 2. 94° C 45 sec

Step 3. 54° C 45 sec

Step 4. 72° C 1 minute

Step 5. Return to step 2, 29 times

Step 6. 72° C 10 minutes

Step 7. 4° C hold

The PCR products were cleaned using Qiagen Qiaquick PCR plates according to the manufacturer's instructions.

The purified PCR products were then directly cycle sequenced with Qiagen Hot Start PCR mix. The following primers were used in the sequencing reaction:

T7/L2: ATGCGTCCGGCGTAGAGGAT (SEQ ID NO: 78592)

PCR was carried out in a PE GenAmp with the following cycle times:

Step 1. 94° C 15 min

Step 2. 96° C 10 sec

Step 3. 50° C 5 sec

Step 4. 60 C 4 min

Step 5. Return to step 2, 24 times

Step 6. 4° C hold

The PCR products were cleaned using Qiagen Qiaquick PCR plates according to the manufacturer's instructions.

For *E. faecalis*, plasmids from transformant colonies that received a dilution plating score of "2" or greater were isolated to obtain the genomic DNA insert responsible for growth inhibition as follows. *E. faecalis* were grown in THB 10 µg/ml Erm at 30°C overnight in 100 ul culture wells

in microtiter plates. To amplify insert DNA 2 ul of culture were placed into 25 µl Qiagen Hot Start PCR mix. PCR reactions were in 96 well microtiter plates. The following primers were used in the PCR reaction:

pXylT5: CAGCAGTCTGAGTTATAAAATAG (SEQ ID NO: 78588) and the

5 pEP/pAK1 primer.

PCR was carried out in a PE GenAmp with the following cycle times:

Step 1. 95° C 15 min

Step 2. 94° C 45 sec

Step 3. 54° C 45 sec

10 Step 4. 72° C 1 minute

Step 5. Return to step 2, 29 times

Step 6. 72° C 10 minutes

Step 7. 4° C hold

The PCR products were cleaned using Qiagen Qiaquick PCR plates according to the manufacturer's
15 instructions.

The purified PCR products were then directly cycle sequenced with Qiagen Hot Start PCR mix. The following primers were used in the PCR reaction:

pXylT5: CAGCAGTCTGAGTTATAAAATAG (SEQ ID NO: 78588)

PCR was carried out in a PE GenAmp with the following cycle times:

20 Step 1. 94° C 15 min

Step 2. 96° C 10 sec

Step 3. 50° C 5 sec

Step 4. 60° C 4 min

Step 5. Return to step 2, 24 times

25 Step 6. 4° C hold

The PCR products were cleaned using Qiagen Qiaquick PCR plates according to the manufacturer's instructions.

The amplified genomic DNA inserts from each of the above procedures were subjected to automated sequencing. Sequence identification numbers (SEQ ID NOs) and clone names for the
30 identified inserts are listed in Table IA and discussed below.

TABLE IA

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
1	E3M10000001B01	1243	P33-1.C22	2485	E1M10000260G02	3727	P1M10000105C04	4969	S1M10000025G06
2	E3M10000001A02	1244	X3S107-17	2486	E1M10000260F04	3728	P1M10000105D04	4970	S1M10000025H06
3	E3M10000001B02	1245	P35-7	2487	E1M10000260A05	3729	P1M10000105C05	4971	S1M10000025H07
4	E3M10000001C02	1246	X3S118-9	2488	E1M10000260C05	3730	P1M10000105B06	4972	S1M10000025A08
5	E3M10000001D02	1247	X3S163-1	2489	E1M10000260E05	3731	P1M10000105C08	4973	S1M10000025D08
6	E3M10000001E02	1248	X3S204-7	2490	E1M10000260C07	3732	P1M10000105H08	4974	S1M10000025F08
7	E3M10000001F02	1249	X3S177-4	2491	E1M10000260G07	3733	P1M10000105D09	4975	S1M10000025H08
8	E3M10000001G02	1250	P342-3	2492	E1M10000260B08	3734	P1M10000110E01	4976	S1M10000025A09
9	E3M10000001H02	1251	SC21.1	2493	E1M10000260D08	3735	P1M10000110F01	4977	S1M10000025B09
10	E3M10000001E03	1252	SC17.1	2494	E1M10000260E08	3736	P1M10000110G01	4978	S1M10000025C09
11	E3M10000001G03	1253	SC13.1	2495	E1M10000260E09	3737	P1M10000110B02	4979	S1M10000025D09
12	E3M10000001H03	1254	MC9.6	2496	E1M10000260C10	3738	P1M10000110B03	4980	S1M10000025E09
13	E3M10000001D04	1255	Z60-P16	2497	E1M10000260D10	3739	P1M10000110F03	4981	S1M10000025F09
14	E3M10000001E04	1256	Z86-121	2498	E1M10000260E10	3740	P1M10000110G03	4982	S1M10000025A10
15	E3M10000001F04	1257	E1M10000109A02	2499	E1M10000260G10	3741	P1M10000110D04	4983	S1M10000025C10
16	E3M10000001G04	1258	E1M10000109A11	2500	E1M10000260H10	3742	P1M10000110F04	4984	S1M10000025D10
17	E3M10000001H04	1259	E1M10000101F05	2501	E1M10000260H11	3743	P1M10000110B05	4985	S1M10000025F10
18	E3M10000001B05	1260	E1M10000101D06	2502	E1M10000260B12	3744	P1M10000110E05	4986	S1M10000025G10
19	E3M10000001D05	1261	E1M10000101A07	2503	E1M10000260D12	3745	P1M10000110B07	4987	S1M10000025H10
20	E3M10000001G05	1262	E1M10000101H07	2504	E1M10000260G12	3746	P1M10000110B08	4988	S1M10000025C11
21	E3M10000001A06	1263	E1M10000101H09	2505	E1M10000261F01	3747	P1M10000110F08	4989	S1M10000025E11
22	E3M10000001F06	1264	E1M10000101C12	2506	E1M10000261B02	3748	P1M10000110A09	4990	S1M10000025B12
23	E3M10000001B08	1265	E1M10000103B04	2507	E1M10000261H02	3749	P1M10000110E09	4991	S1M10000025F12
24	E3M10000001E08	1266	E1M10000103D11	2508	E1M10000261G04	3750	P1M10000110F09	4992	S1M10000026C01
25	E3M10000001C09	1267	E1M10000110G01	2509	E1M10000261H05	3751	P1M10000100F01	4993	S1M10000026E01
26	E3M10000001D09	1268	E1M10000110H01	2510	E1M10000261G06	3752	P1M10000098A02	4994	S1M10000026F01
27	E3M10000001E09	1269	E1M10000110E09	2511	E1M10000261H06	3753	P1M10000098B02	4995	S1M10000026G01
28	E3M10000001B10	1270	E1M10000110A12	2512	E1M10000261D08	3754	P1M10000098A03	4996	S1M10000026H01
29	E3M100000004D01	1271	E1M10000112F05	2513	E1M10000261F08	3755	P1M10000098D03	4997	S1M10000026A02
30	E3M100000004G01	1272	E1M10000113F02	2514	E1M10000261C09	3756	P1M10000098E04	4998	S1M10000026B02
31	E3M100000004D02	1273	E1M10000113A11	2515	E1M10000261H09	3757	P1M10000098G04	4999	S1M10000026H02
32	E3M100000004C03	1274	E1M10000111C03	2516	E1M10000261E10	3758	P1M10000098A05	5000	S1M10000026B03
33	E3M100000004A04	1275	E1M10000111E04	2517	E1M10000262E01	3759	P1M10000098C05	5001	S1M10000026F03

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
34	E3M10000004F08	1276	E1M10000111F09	2518	E1M10000262C02	3760	P1M10000098G06	5002	S1M10000026G03
35	E3M10000004D10	1277	E1M10000115H01	2519	E1M10000262E02	3761	P1M10000098H06	5003	S1M10000026H03
36	E3M100000004F10	1278	E1M10000115G02	2520	E1M10000262F02	3762	P1M10000098C07	5004	S1M10000026A04
37	E3M100000004E11	1279	E1M10000115E03	2521	E1M10000262D03	3763	P1M10000098F07	5005	S1M10000026D04
38	E3M100000004H11	1280	E1M10000115G04	2522	E1M10000262G04	3764	P1M10000098A08	5006	S1M10000026F04
39	E3M100000005B01	1281	E1M10000115C06	2523	E1M10000262C05	3765	P1M10000098G08	5007	S1M10000026G04
40	E3M100000005C01	1282	E1M10000116B01	2524	E1M10000262A06	3766	P1M10000098H09	5008	S1M10000026H04
41	E3M100000005E01	1283	E1M10000106D02	2525	E1M10000262A07	3767	P1M10000098B11	5009	S1M10000026A05
42	E3M100000005E02	1284	E1M10000106G02	2526	E1M10000262E07	3768	P1M10000098C12	5010	S1M10000026B05
43	E3M100000005C03	1285	E1M10000106E04	2527	E1M10000262E08	3769	P1M10000099D01	5011	S1M10000026D05
44	E3M100000005D03	1286	E1M10000106F05	2528	E1M10000262B10	3770	P1M10000099G03	5012	S1M10000026F05
45	E3M100000005E03	1287	E1M10000106H05	2529	E1M10000262H10	3771	P1M10000099A09	5013	S1M10000026G05
46	E3M100000005C04	1288	E1M10000106H06	2530	E1M10000262G11	3772	P1M10000099A10	5014	S1M10000026H05
47	E3M100000005D04	1289	E1M10000106A08	2531	E1M10000262D12	3773	P1M10000099E10	5015	S1M10000026A06
48	E3M100000005H04	1290	E1M10000106E09	2532	E1M10000262G12	3774	P1M10000099F10	5016	S1M10000026B06
49	E3M100000005G05	1291	E1M10000106G10	2533	E1M10000263F01	3775	P1M10000099D11	5017	S1M10000026C06
50	E3M100000005A07	1292	E1M10000106D11	2534	E1M10000263H05	3776	P1M10000106D02	5018	S1M10000026D06
51	E3M100000005F07	1293	E1M10000122B03	2535	E1M10000263C06	3777	P1M10000106F03	5019	S1M10000026F06
52	E3M100000005B08	1294	E1M10000123D05	2536	E1M10000263G06	3778	P1M10000106H03	5020	S1M10000026G06
53	E3M100000005E08	1295	E1M10000123C09	2537	E1M10000263B07	3779	P1M10000106F04	5021	S1M10000026A07
54	E3M100000005D10	1296	E1M10000123E09	2538	E1M10000263F08	3780	P1M10000106D05	5022	S1M10000026B07
55	E3M100000005F10	1297	E1M10000123H10	2539	E1M10000263A10	3781	P1M10000106E07	5023	S1M10000026C07
56	E3M100000006C01	1298	E1M10000123F11	2540	E1M10000263A11	3782	P1M10000107E02	5024	S1M10000026D07
57	E3M100000006G02	1299	E1M10000107B02	2541	E1M10000263H11	3783	P1M10000107H02	5025	S1M10000026F07
58	E3M100000006B03	1300	E1M10000107E02	2542	E1M10000263C12	3784	P1M10000107C03	5026	S1M10000026G07
59	E3M100000006D03	1301	E1M10000107G02	2543	E1M10000263D12	3785	P1M10000107A04	5027	S1M10000026H07
60	E3M100000006F04	1302	E1M10000107B03	2544	E1M10000264B02	3786	P1M10000107C04	5028	S1M10000026A08
61	E3M100000006G04	1303	E1M10000107C03	2545	E1M10000264C02	3787	P1M10000107C09	5029	S1M10000026C08
62	E3M100000006H09	1304	E1M10000107H04	2546	E1M10000264F02	3788	P1M10000107C10	5030	S1M10000026D08
63	E3M100000006E11	1305	E1M10000107G08	2547	E1M10000264D03	3789	P1M10000107D10	5031	S1M10000026F08
64	E3M100000006C12	1306	E1M10000107F09	2548	E1M10000264F03	3790	P1M10000107H10	5032	S1M10000026G08
65	E3M100000006G12	1307	E1M10000107H09	2549	E1M10000264A04	3791	P1M10000108C01	5033	S1M10000026A09
66	E3M100000007F01	1308	E1M10000117C12	2550	E1M10000264B04	3792	P1M10000108A02	5034	S1M10000026E09
67	E3M100000007G01	1309	E1M10000118C04	2551	E1M10000264C04	3793	P1M10000108B02	5035	S1M10000026G09
68	E3M100000007A02	1310	E1M10000118B05	2552	E1M10000264E04	3794	P1M10000108A03	5036	S1M10000026H09
69	E3M100000007B02	1311	E1M10000118C05	2553	E1M10000264F04	3795	P1M10000108D04	5037	S1M10000026A10

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
70	E3M10000007B03	1312	E1M10000118G06	2554	E1M10000264B05	3796	P1M10000108G04	5038	S1M10000026B10
71	E3M10000007C03	1313	E1M10000119D02	2555	E1M10000264B06	3797	P1M10000108E05	5039	S1M10000026D10
72	E3M10000007D03	1314	E1M10000119D03	2556	E1M10000264G09	3798	P1M10000108F05	5040	S1M10000026E10
73	E3M10000007H03	1315	E1M10000119A04	2557	E1M10000264D11	3799	P1M10000108F06	5041	S1M10000026F10
74	E3M10000007C04	1316	E1M10000131H01	2558	E1M10000264F11	3800	P1M10000108G06	5042	S1M10000026G10
75	E3M10000007E05	1317	E1M10000131F04	2559	E1M10000264H11	3801	P1M10000109A02	5043	S1M10000026H10
76	E3M10000007F06	1318	E1M10000131C06	2560	E1M10000264B12	3802	P1M10000109C03	5044	S1M10000026A11
77	E3M10000008E02	1319	E1M10000131B07	2561	E1M10000264C12	3803	P1M10000109E03	5045	S1M10000026B11
78	E3M10000008H02	1320	E1M10000131C07	2562	E1M10000265A02	3804	P1M10000109D04	5046	S1M10000026C11
79	E3M10000008C03	1321	E1M10000131A10	2563	E1M10000265E02	3805	P1M10000109A05	5047	S1M10000026E11
80	E3M10000008G05	1322	E1M10000131G10	2564	E1M10000265G02	3806	P1M10000109B08	5048	S1M10000026B12
81	E3M10000008C08	1323	E1M10000135B02	2565	E1M10000265D04	3807	P1M10000109H09	5049	S1M10000026C12
82	E3M10000008D08	1324	E1M10000132C01	2566	E1M10000265F04	3808	P1M10000109E10	5050	S1M10000026D12
83	E3M10000008C09	1325	E1M10000132F02	2567	E1M10000265E05	3809	P1M10000109F10	5051	S1M10000026E12
84	E3M10000008G09	1326	E1M10000132H04	2568	E1M10000265H05	3810	P1M10000109E11	5052	S1M10000026F12
85	E3M10000009D01	1327	E1M10000132G08	2569	E1M10000265C09	3811	P1M10000109B12	5053	S1M10000026G12
86	E3M10000009E02	1328	E1M10000133A06	2570	E1M10000265E09	3812	S4M10000001C01	5054	S1M10000027G01
87	E3M10000009G02	1329	E1M10000133B08	2571	E1M10000265F09	3813	S4M10000002G04	5055	S1M10000027C02
88	E3M10000009E03	1330	E1M10000133D09	2572	E1M10000265H10	3814	S4M10000002B06	5056	S1M10000027D02
89	E3M10000009E05	1331	E1M10000144B01	2573	E1M10000265A11	3815	S4M10000002G08	5057	S1M10000027E02
90	E3M10000009H06	1332	E1M10000144C02	2574	E1M10000265B11	3816	S4M10000002B09	5058	S1M10000027F02
91	E3M10000009C07	1333	E1M10000144E03	2575	E1M10000265C11	3817	S4M10000019H06	5059	S1M10000027H02
92	E3M10000009C09	1334	E1M10000144F03	2576	E1M10000266D02	3818	S4M10000008H10	5060	S1M10000027D03
93	E3M10000010F01	1335	E1M10000144B06	2577	E1M10000266H02	3819	S4M10000009E03	5061	S1M10000027E03
94	E3M10000010H02	1336	E1M10000144G06	2578	E1M10000266F04	3820	S4M10000009C06	5062	S1M10000027G03
95	E3M10000010D05	1337	E1M10000144G07	2579	E1M10000266H04	3821	S4M10000009E07	5063	S1M10000027A04
96	E3M10000010G07	1338	E1M10000144A08	2580	E1M10000266H05	3822	S4M10000009G08	5064	S1M10000027C04
97	E3M10000010C08	1339	E1M10000144C10	2581	E1M10000266B06	3823	S4M10000009B11	5065	S1M10000027G04
98	E3M10000010G09	1340	E1M10000145E01	2582	E1M10000266F11	3824	S4M10000009F11	5066	S1M10000027H04
99	E3M10000010G10	1341	E1M10000146H01	2583	E1M10000267F01	3825	S4M10000009G11	5067	S1M10000027A05
100	E3M10000011H02	1342	E1M10000146D02	2584	E1M10000267E04	3826	S4M10000010F04	5068	S1M10000027C05
101	E3M10000011B03	1343	E1M10000146E05	2585	E1M10000267A05	3827	S4M10000010H04	5069	S1M10000027D05
102	E3M10000011D03	1344	E1M10000124E02	2586	E1M10000267B05	3828	S4M10000010B05	5070	S1M10000027E05
103	E3M10000011C07	1345	E1M10000124G03	2587	E1M10000267A07	3829	S4M10000010D07	5071	S1M10000027F05
104	E3M10000011A09	1346	E1M10000124G04	2588	E1M10000267H07	3830	S4M10000010D08	5072	S1M10000027G05
105	E3M10000011B09	1347	E1M10000124C05	2589	E1M10000267E09	3831	S4M10000010B09	5073	S1M10000027H05

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
106	E3M10000012B01	1348	E1M10000124F06	2590	E1M10000267G09	3832	S4M10000010C09	5074	S1M10000027B06
107	E3M10000012C01	1349	E1M10000124D09	2591	E1M10000267H09	3833	S4M10000010D09	5075	S1M10000027C06
108	E3M10000012B02	1350	E1M10000125A02	2592	E1M10000267A10	3834	S4M10000010D10	5076	S1M10000027D06
109	E3M10000012G02	1351	E1M10000125F07	2593	E1M10000267E10	3835	S4M10000011F05	5077	S1M10000027E06
110	E3M10000012F05	1352	E1M10000125F09	2594	E1M10000267C11	3836	S4M10000011D08	5078	S1M10000027F06
111	E3M10000012F06	1353	E1M10000120F01	2595	E1M10000267E11	3837	S4M10000011A09	5079	S1M10000027G06
112	E3M10000012B07	1354	E1M10000120F04	2596	E1M10000267B12	3838	S4M10000011F09	5080	S1M10000027H06
113	E3M10000012F07	1355	E1M10000120E05	2597	E1M10000267E12	3839	S4M10000011E10	5081	S1M10000027B07
114	E3M10000012G07	1356	E1M10000120A06	2598	E1M10000268F03	3840	S4M10000011F10	5082	S1M10000027D07
115	E3M10000012B08	1357	E1M10000120F06	2599	E1M10000268D04	3841	S4M10000011D11	5083	S1M10000027E07
116	E3M10000012D10	1358	E1M10000120A10	2600	E1M10000268E04	3842	S4M10000012H03	5084	S1M10000027G07
117	E3M10000012F10	1359	E1M10000120G10	2601	E1M10000268F06	3843	S4M10000012B06	5085	S1M10000027H07
118	E3M10000013D02	1360	E1M10000136C01	2602	E1M10000268E07	3844	S4M10000012B12	5086	S1M10000027A08
119	E3M10000013E02	1361	E1M10000136H01	2603	E1M10000268A08	3845	S4M10000013D02	5087	S1M10000027B08
120	E3M10000013H03	1362	E1M10000136E02	2604	E1M10000268B08	3846	S4M10000013H02	5088	S1M10000027C08
121	E3M10000013C05	1363	E1M10000136B03	2605	E1M10000268D08	3847	S4M10000014H02	5089	S1M10000027D08
122	E3M10000013F05	1364	E1M10000136D03	2606	E1M10000268G08	3848	S4M10000014B05	5090	S1M10000027E08
123	E3M10000013H05	1365	E1M10000121D01	2607	E1M10000268B09	3849	S4M10000014D07	5091	S1M10000027F08
124	E3M10000013A06	1366	E1M10000121G05	2608	E1M10000268E09	3850	S4M10000015E09	5092	S1M10000027G08
125	E3M10000013A07	1367	E1M10000121F06	2609	E1M10000268F09	3851	S4M10000015B11	5093	S1M10000027H08
126	E3M10000013D08	1368	E1M10000121E07	2610	E1M10000268G09	3852	S4M10000016A02	5094	S1M10000027B09
127	E3M10000013E08	1369	E1M10000129G04	2611	E1M10000268E10	3853	S4M10000020F08	5095	S1M10000027C09
128	E3M10000013D10	1370	E1M10000129F10	2612	E1M10000268A11	3854	S4M10000021E07	5096	S1M10000027D09
129	E3M10000013G10	1371	E1M10000129F11	2613	E1M10000268G11	3855	S4M10000022B02	5097	S1M10000027E09
130	E3M10000014G09	1372	E1M10000129F11	2614	E1M10000268G12	3856	S4M10000022D04	5098	S1M10000027F09
131	E3M10000014B12	1373	E1M10000126E08	2615	E1M10000269D01	3857	S4M10000022B05	5099	S1M10000027G09
132	E3M10000014E12	1374	E1M10000126F12	2616	E1M10000269B02	3858	S4M10000022G07	5100	S1M10000027H09
133	E3M10000015B04	1375	E1M10000127D03	2617	E1M10000269D03	3859	S4M10000022D12	5101	S1M10000027D10
134	E3M10000015B12	1376	E1M10000127C09	2618	E1M10000269D04	3860	S4M10000022E12	5102	S1M10000027H10
135	E3M10000015E12	1377	E1M10000127D09	2619	E1M10000269H04	3861	S4M10000024G01	5103	S1M10000027A11
136	E3M10000016A03	1378	E1M10000137C03	2620	E1M10000269B05	3862	S4M10000024G04	5104	S1M10000027B11
137	E3M10000016D03	1379	E1M10000137C04	2621	E1M10000269D05	3863	S4M10000024C06	5105	S1M10000027D11
138	E3M10000016A04	1380	E1M10000137E07	2622	E1M10000269H05	3864	S4M10000024F08	5106	S1M10000027E11
139	E3M10000016G05	1381	E1M10000137B08	2623	E1M10000269A06	3865	S4M10000024G09	5107	S1M10000027G11
140	E3M10000016H05	1382	E1M10000137G09	2624	E1M10000269E07	3866	S4M10000024C11	5108	S1M10000027H11
141	E3M10000016F06	1383	E1M10000137C11	2625	E1M10000269F07	3867	S4M10000025E02	5109	S1M10000028B01

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
142	E3M10000016F10	1384	E1M10000139B07	2626	E1M10000269E10	3868	S4M10000025E05	5110	S1M10000028E01
143	E3M10000016H10	1385	E1M10000139E10	2627	E1M10000269D11	3869	S4M10000025H07	5111	S1M10000028F01
144	E3M10000017A09	1386	E1M10000139B11	2628	E1M10000269C12	3870	S4M10000025A11	5112	S1M10000028G01
145	E3M10000017D09	1387	E1M10000140B05	2629	E1M10000269G12	3871	S4M10000025F12	5113	S1M10000028A02
146	E3M10000018E01	1388	E1M10000142H03	2630	E1M10000271F02	3872	S4M10000026C01	5114	S1M10000028B02
147	E3M10000018C02	1389	E1M10000142D05	2631	E1M10000271H02	3873	S4M10000026E03	5115	S1M10000028C02
148	E3M10000018H06	1390	E1M10000142F12	2632	E1M10000271E03	3874	S4M10000026D04	5116	S1M10000028G02
149	E3M10000018A07	1391	E1M10000143D03	2633	E1M10000271G03	3875	S4M10000026B10	5117	S1M10000028B03
150	E3M10000018G09	1392	E1M10000143A09	2634	E1M10000271B04	3876	S4M10000026E12	5118	S1M10000028D03
151	E3M10000019D02	1393	E1M10000143G09	2635	E1M10000271G04	3877	S4M10000027E02	5119	S1M10000028E03
152	E3M10000019E03	1394	E1M10000143A12	2636	E1M10000271B05	3878	S4M10000027C10	5120	S1M10000028F03
153	E3M10000019E04	1395	E1M10000147B03	2637	E1M10000271E05	3879	S4M10000029B12	5121	S1M10000028G03
154	E3M10000019B06	1396	E1M10000147D05	2638	E1M10000271C07	3880	S4M10000029D12	5122	S1M10000028H03
155	E3M10000020G04	1397	E1M10000148C02	2639	E1M10000271G07	3881	S4M10000030F06	5123	S1M10000028A04
156	E3M10000020H05	1398	E1M10000148D08	2640	E1M10000271G10	3882	S4M10000030F07	5124	S1M10000028B04
157	E3M10000021C03	1399	E1M10000148B09	2641	E1M10000271F11	3883	S4M10000032F01	5125	S1M10000028C04
158	E3M10000021C04	1400	E1M10000148H09	2642	E1M10000271E12	3884	S4M10000032G01	5126	S1M10000028D04
159	E3M10000021D04	1401	E1M10000155C02	2643	E1M10000271F12	3885	S4M10000032F03	5127	S1M10000028E04
160	E3M10000021G04	1402	E1M10000155F04	2644	E1M10000272F02	3886	S4M10000034A02	5128	S1M10000028F04
161	E3M10000021A08	1403	E1M10000155B05	2645	E1M10000272G03	3887	S4M10000034C05	5129	S1M10000028G04
162	E3M10000021C08	1404	E1M10000155A06	2646	E1M10000272A04	3888	S4M10000034H05	5130	S1M10000028B05
163	E3M10000021B10	1405	E1M10000155C06	2647	E1M10000272F05	3889	S4M10000034A06	5131	S1M10000028C05
164	E3M10000021E10	1406	E1M10000153B11	2648	E1M10000272A06	3890	S4M10000034A09	5132	S1M10000028D05
165	E3M10000021G10	1407	E1M10000155F12	2649	E1M10000272B06	3891	S4M10000034H09	5133	S1M10000028F05
166	E3M10000021A11	1408	E1M10000152B01	2650	E1M10000272H07	3892	S4M10000035B01	5134	S1M10000028G05
167	E3M10000021G11	1409	E1M10000152G01	2651	E1M10000272B08	3893	S4M10000035D01	5135	S1M10000028H05
168	E3M10000021H11	1410	E1M10000152G03	2652	E1M10000272C08	3894	S4M10000035F02	5136	S1M10000028A06
169	E3M10000022G02	1411	E1M10000152F04	2653	E1M10000272D08	3895	S4M10000035E03	5137	S1M10000028B06
170	E3M10000022A04	1412	E1M10000152H04	2654	E1M10000272G08	3896	S4M10000035B06	5138	S1M10000028C06
171	E3M10000022B04	1413	E1M10000152B05	2655	E1M10000272H08	3897	S4M10000035A09	5139	S1M10000028D06
172	E3M10000022D04	1414	E1M10000152B06	2656	E1M10000272C09	3898	S4M10000036F06	5140	S1M10000028F06
173	E3M10000022B05	1415	E1M10000152C08	2657	E1M10000272D09	3899	S4M10000036B09	5141	S1M10000028G06
174	E3M10000022C05	1416	E1M10000152H08	2658	E1M10000272G09	3900	S4M10000036H11	5142	S1M10000028D07
175	E3M10000022F05	1417	E1M10000152E09	2659	E1M10000272H09	3901	S4M10000037A03	5143	S1M10000028F07
176	E3M10000022C06	1418	E1M10000153H03	2660	E1M10000273E01	3902	S4M10000037A08	5144	S1M10000028H07
177	E3M10000022F06	1419	E1M10000153C04	2661	E1M10000273D02	3903	S4M10000037H09	5145	S1M10000028A08

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
178	E3M10000022B07	1420	E1M10000153E04	2662	E1M10000273E03	3904	S4M10000037E10	5146	S1M10000028B08
179	E3M10000022E08	1421	E1M10000153F05	2663	E1M10000273D05	3905	S4M10000037F10	5147	S1M10000028C08
180	E3M10000022F08	1422	E1M10000153A09	2664	E1M10000273E05	3906	S4M10000033G05	5148	S1M10000028D08
181	E3M10000022C09	1423	E1M10000156D07	2665	E1M10000273G05	3907	S4M10000033F08	5149	S1M10000028E08
182	E3M10000022A11	1424	E1M10000156B08	2666	E1M10000273C07	3908	S4M10000033G09	5150	S1M10000028G08
183	E3M10000022B11	1425	E1M10000156B09	2667	E1M10000273C08	3909	S4M10000033B10	5151	S1M10000028H08
184	E3M10000022G12	1426	E1M10000156G12	2668	E1M10000273G11	3910	S1M10000001D01	5152	S1M10000028B09
185	E3M10000023B02	1427	E1M10000157F01	2669	E1M10000273H11	3911	S1M100000001F01	5153	S1M10000028D09
186	E3M10000023D02	1428	E1M10000157B02	2670	E1M10000273B12	3912	S1M10000001D02	5154	S1M10000029F01
187	E3M10000023F02	1429	E1M10000157C04	2671	E1M10000273G12	3913	S1M10000001E02	5155	S1M10000029G01
188	E3M10000023G02	1430	E1M10000157B09	2672	E1M10000274C01	3914	S1M10000001F02	5156	S1M10000029H01
189	E3M10000023A03	1431	E1M10000160C02	2673	E1M10000274E01	3915	S1M10000001A04	5157	S1M10000029A02
190	E3M10000023C03	1432	E1M10000160F02	2674	E1M10000274G01	3916	S1M10000001E04	5158	S1M10000029B02
191	E3M10000023C04	1433	E1M10000160A03	2675	E1M10000274H05	3917	S1M10000001F04	5159	S1M10000029C02
192	E3M10000023D04	1434	E1M10000160C03	2676	E1M10000274D06	3918	S1M10000001A05	5160	S1M10000029D02
193	E3M10000023E04	1435	E1M10000160H03	2677	E1M10000274F06	3919	S1M10000001D06	5161	S1M10000029E02
194	E3M10000023G04	1436	E1M10000160H05	2678	E1M10000274F07	3920	S1M10000001D07	5162	S1M10000029F02
195	E3M10000023A06	1437	E1M10000160A06	2679	E1M10000274A08	3921	S1M10000001A08	5163	S1M10000029G02
196	E3M10000023B06	1438	E1M10000160D07	2680	E1M10000274D08	3922	S1M10000001F08	5164	S1M10000029A03
197	E3M10000023C06	1439	E1M10000160G07	2681	E1M10000274F08	3923	S1M10000001A09	5165	S1M10000029B03
198	E3M10000023A07	1440	E1M10000160B09	2682	E1M10000274F09	3924	S1M10000001E09	5166	S1M10000029C03
199	E3M10000023E07	1441	E1M10000160C09	2683	E1M10000274D10	3925	S1M10000001F09	5167	S1M10000029G03
200	E3M10000023C08	1442	E1M10000160E09	2684	E1M10000274D11	3926	S1M10000001A10	5168	S1M10000029A04
201	E3M10000023H08	1443	E1M10000160E10	2685	E1M10000274D12	3927	S1M10000001F10	5169	S1M10000029B04
202	E3M10000023A09	1444	E1M10000160B11	2686	E1M10000274G12	3928	S1M10000001G10	5170	S1M10000029F04
203	E3M10000023C09	1445	E1M10000160F11	2687	E1M10000275C01	3929	S1M10000001E11	5171	S1M10000029G04
204	E3M10000023E09	1446	E1M10000162C01	2688	E1M10000275E01	3930	S1M10000002B01	5172	S1M10000029B05
205	E3M10000023F10	1447	E1M10000162A03	2689	E1M10000275B02	3931	S1M10000002D01	5173	S1M10000029C05
206	E3M10000023G10	1448	E1M10000162F03	2690	E1M10000275A03	3932	S1M10000002E01	5174	S1M10000029D05
207	E3M10000024A03	1449	E1M10000162G05	2691	E1M10000275B03	3933	S1M10000002F01	5175	S1M10000029E05
208	E3M10000024A04	1450	E1M10000162H06	2692	E1M10000275G03	3934	S1M10000002A02	5176	S1M10000029G05
209	E3M10000024C06	1451	E1M10000162B08	2693	E1M10000275D04	3935	S1M10000002C02	5177	S1M10000029H05
210	E3M10000024A08	1452	E1M10000162A09	2694	E1M10000275H04	3936	S1M10000002D02	5178	S1M10000029B06
211	E3M10000024B08	1453	E1M10000162F12	2695	E1M10000275C05	3937	S1M10000002E02	5179	S1M10000029H06
212	E3M10000025B01	1454	E1M10000163H01	2696	E1M10000275E05	3938	S1M10000002F02	5180	S1M10000029C07
213	E3M10000025C01	1455	E1M10000163F02	2697	E1M10000275A06	3939	S1M10000002B03	5181	S1M10000029G07

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
214	E3M10000025D01	1456	E1M10000163A04	2698	E1M10000275C06	3940	S1M10000002D03	5182	S1M100000029B08		
215	E3M100000025B03	1457	E1M10000163C04	2699	E1M10000275G06	3941	S1M10000002G03	5183	S1M100000029G08		
216	E3M100000025C04	1458	E1M10000163B12	2700	E1M10000275A08	3942	S1M10000002B04	5184	S1M100000029H08		
217	E3M100000025F04	1459	E1M10000164A02	2701	E1M10000275D08	3943	S1M10000002B05	5185	S1M100000029A09		
218	E3M100000025B05	1460	E1M10000164F04	2702	E1M10000275F09	3944	S1M10000002D05	5186	S1M100000029C09		
219	E3M100000025C05	1461	E1M10000164H05	2703	E1M10000275D10	3945	S1M10000002G05	5187	S1M100000029D09		
220	E3M100000025A06	1462	E1M10000154F03	2704	E1M10000275G11	3946	S1M10000002B06	5188	S1M100000029F09		
221	E3M100000025F06	1463	E1M10000154H07	2705	E1M10000275B12	3947	S1M10000002G06	5189	S1M100000029H09		
222	E3M100000025C07	1464	E1M10000150E02	2706	E1M10000275C12	3948	S1M10000002B07	5190	S1M100000029A10		
223	E3M100000025E07	1465	E1M10000150G05	2707	E1M10000275G12	3949	S1M10000002D07	5191	S1M100000029B10		
224	E3M100000025G07	1466	E1M10000151C03	2708	E1M10000276E01	3950	S1M10000002E07	5192	S1M100000029C10		
225	E3M100000025C08	1467	E1M10000151C04	2709	E1M10000276F01	3951	S1M10000002F07	5193	S1M100000029D10		
226	E3M100000025E08	1468	E1M10000151G10	2710	E1M10000276A03	3952	S1M10000002D08	5194	S1M100000029E10		
227	E3M100000025F08	1469	E1M10000159F03	2711	E1M10000276B03	3953	S1M10000002G08	5195	S1M100000029F10		
228	E3M100000025C09	1470	E1M10000159F07	2712	E1M10000276A04	3954	S1M10000002A09	5196	S1M100000029H10		
229	E3M100000025F09	1471	E1M10000159A09	2713	E1M10000276D04	3955	S1M10000002B09	5197	S1M100000029A11		
230	E3M100000025G09	1472	E1M10000159C10	2714	E1M10000276G04	3956	S1M10000002C09	5198	S1M100000029E11		
231	E3M100000025B10	1473	E1M10000159C11	2715	E1M10000276H04	3957	S1M10000002E09	5199	S1M100000029F11		
232	E3M100000025D10	1474	E1M10000161D04	2716	E1M10000312C01	3958	S1M10000002F09	5200	S1M100000029A12		
233	E3M100000025F10	1475	E1M10000161A05	2717	E1M10000312B02	3959	S1M10000002A10	5201	S1M100000029C12		
234	E3M100000025C11	1476	E1M10000161E05	2718	E1M10000312D02	3960	S1M10000002C10	5202	S1M100000029D12		
235	E3M100000025E11	1477	E1M10000161C06	2719	E1M10000312F03	3961	S1M10000002G10	5203	S1M100000029F12		
236	E3M100000025F11	1478	E1M10000171E01	2720	E1M10000312A04	3962	S1M10000002B11	5204	S1M100000029G12		
237	E3M100000025E12	1479	E1M10000171E05	2721	E1M10000312D04	3963	S1M10000002C11	5205	S1M100000030B01		
238	E3M100000025F12	1480	E1M10000172C01	2722	E1M10000312F04	3964	S1M10000002E11	5206	S1M100000030D01		
239	E3M100000027G01	1481	E1M10000172C05	2723	E1M10000312H04	3965	S1M10000002A12	5207	S1M100000030F01		
240	E3M100000027A02	1482	E1M10000172C07	2724	E1M10000312E05	3966	S1M10000002C12	5208	S1M100000030H01		
241	E3M100000027C02	1483	E1M10000173B01	2725	E1M10000312C06	3967	S1M10000002D12	5209	S1M100000030A02		
242	E3M100000027C03	1484	E1M10000173D01	2726	E1M10000312B07	3968	S1M10000002E12	5210	S1M100000030B02		
243	E3M100000027D03	1485	E1M10000166G06	2727	E1M10000312G07	3969	S1M10000002F12	5211	S1M100000030C02		
244	E3M100000027H03	1486	E1M10000167E03	2728	E1M10000312H07	3970	S1M10000002G12	5212	S1M100000030D02		
245	E3M100000027H04	1487	E1M10000167F04	2729	E1M10000312E08	3971	S1M10000003A01	5213	S1M100000030E02		
246	E3M100000027D05	1488	E1M10000167G04	2730	E1M10000312D09	3972	S1M10000003E01	5214	S1M100000030H02		
247	E3M100000027A07	1489	E1M10000168H01	2731	E1M10000312E09	3973	S1M10000003A02	5215	S1M100000030B03		
248	E3M100000027B07	1490	E1M10000168B02	2732	E1M10000312F09	3974	S1M10000003F02	5216	S1M100000030C03		
249	E3M100000027H07	1491	E1M10000168F02	2733	E1M10000312G09	3975	S1M10000003A03	5217	S1M100000030D03		

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
250	E3M10000027B08	1492	E1M10000168G02	2734	E1M10000312A10	3976	S1M10000003G03	5218	S1M10000030G03
251	E3M10000027C08	1493	E1M10000168A03	2735	E1M10000313E01	3977	S1M10000003A04	5219	S1M10000030H03
252	E3M10000027D08	1494	E1M10000168A04	2736	E1M10000313F01	3978	S1M10000003E04	5220	S1M10000030C04
253	E3M10000027G08	1495	E1M10000169H02	2737	E1M10000313A02	3979	S1M10000003G04	5221	S1M10000030A05
254	E3M10000027A09	1496	E1M10000176C01	2738	E1M10000313D02	3980	S1M10000003A05	5222	S1M10000030B05
255	E3M10000027B09	1497	E1M10000176F01	2739	E1M10000313H02	3981	S1M10000003F05	5223	S1M10000030C05
256	E3M10000027D10	1498	E1M10000184C01	2740	E1M10000313A03	3982	S1M10000003A06	5224	S1M10000030D05
257	E3M10000028B01	1499	E1M10000184G02	2741	E1M10000313D03	3983	S1M10000003B06	5225	S1M10000030G05
258	E3M10000028C01	1500	E1M10000184C06	2742	E1M10000313G03	3984	S1M10000003C06	5226	S1M10000030H05
259	E3M10000028D01	1501	E1M10000184F08	2743	E1M10000313B04	3985	S1M10000003D06	5227	S1M10000030D06
260	E3M10000028E01	1502	E1M10000184G08	2744	E1M10000313D04	3986	S1M10000003F06	5228	S1M10000030E06
261	E3M10000028A02	1503	E1M10000184C09	2745	E1M10000313B05	3987	S1M10000003A07	5229	S1M10000030B07
262	E3M10000028B02	1504	E1M10000184F09	2746	E1M10000313A06	3988	S1M10000003C07	5230	S1M10000030D07
263	E3M10000028C02	1505	E1M10000184F10	2747	E1M10000313F06	3989	S1M10000003E07	5231	S1M10000030G07
264	E3M10000028D02	1506	E1M10000184G12	2748	E1M10000313A07	3990	S1M10000003F07	5232	S1M10000030H07
265	E3M10000028F02	1507	E1M10000185D01	2749	E1M10000313C07	3991	S1M10000003B08	5233	S1M10000030C08
266	E3M10000028A03	1508	E1M10000185A02	2750	E1M10000313F07	3992	S1M10000003D08	5234	S1M10000030F08
267	E3M10000028B03	1509	E1M10000185B03	2751	E1M10000313G07	3993	S1M10000003A09	5235	S1M10000030G08
268	E3M10000028E03	1510	E1M10000186A02	2752	E1M10000313D08	3994	S1M10000003B09	5236	S1M10000030A09
269	E3M10000028F03	1511	E1M10000186F03	2753	E1M10000313F08	3995	S1M10000003E09	5237	S1M10000030B09
270	E3M10000028A04	1512	E1M10000186G03	2754	E1M10000313F09	3996	S1M10000003A10	5238	S1M10000030C09
271	E3M10000028B04	1513	E1M10000186A04	2755	E1M10000313A10	3997	S1M10000003C10	5239	S1M10000030D09
272	E3M10000028C04	1514	E1M10000186A08	2756	E1M10000314F01	3998	S1M10000003D10	5240	S1M10000030F09
273	E3M10000028E04	1515	E1M10000186H10	2757	E1M10000314B02	3999	S1M10000003E10	5241	S1M10000030G09
274	E3M10000028H04	1516	E1M10000186E11	2758	E1M10000314H03	4000	S1M10000003A11	5242	S1M10000030H09
275	E3M10000028A05	1517	E1M10000186G12	2759	E1M10000314A04	4001	S1M10000003E11	5243	S1M10000030A10
276	E3M10000028B05	1518	E1M10000187D01	2760	E1M10000314H04	4002	S1M10000003B12	5244	S1M10000030C10
277	E3M10000028C05	1519	E1M10000187G04	2761	E1M10000314A05	4003	S1M10000003C12	5245	S1M10000030D10
278	E3M10000028D05	1520	E1M10000187D06	2762	E1M10000314B05	4004	S1M10000003F12	5246	S1M10000030F10
279	E3M10000028F05	1521	E1M10000187G06	2763	E1M10000314G05	4005	S1M10000004C01	5247	S1M10000030G10
280	E3M10000028G05	1522	E1M10000187G09	2764	E1M10000314D06	4006	S1M10000004D01	5248	S1M10000030H10
281	E3M10000028A06	1523	E1M10000187A10	2765	E1M10000314F06	4007	S1M10000004F01	5249	S1M10000030A11
282	E3M10000028B06	1524	E1M10000187G10	2766	E1M10000314G09	4008	S1M10000004G01	5250	S1M10000030D11
283	E3M10000028C06	1525	E1M10000187H10	2767	E1M10000314D10	4009	S1M10000004C02	5251	S1M10000030E11
284	E3M10000028D06	1526	E1M10000187F11	2768	E1M10000314G10	4010	S1M10000004F02	5252	S1M10000030G11
285	E3M10000028G06	1527	E1M10000187G11	2769	E1M10000314C11	4011	S1M10000004B03	5253	S1M10000030C12

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
286	E3M10000028B07	1528	E1M10000188B06	2770	E1M10000314E11	4012	S1M10000004D03	5254	S1M10000030E12
287	E3M10000028C07	1529	E1M10000188E07	2771	E1M10000314G11	4013	S1M10000004E03	5255	S1M10000030G12
288	E3M10000028E07	1530	E1M10000188G11	2772	E1M10000314B12	4014	S1M10000004G03	5256	S1M10000031B01
289	E3M10000028F07	1531	E1M10000188B12	2773	E1M10000314C12	4015	S1M10000004A04	5257	S1M10000031H01
290	E3M10000028G07	1532	E1M10000189A04	2774	E1M10000314E12	4016	S1M10000004B04	5258	S1M10000031B02
291	E3M10000028H07	1533	E1M10000189F05	2775	E1M10000315D01	4017	S1M10000004D04	5259	S1M10000031E02
292	E3M10000028A08	1534	E1M10000189H05	2776	E1M10000315G01	4018	S1M10000004E04	5260	S1M10000031F02
293	E3M10000028B08	1535	E1M10000189G10	2777	E1M10000315F03	4019	S1M10000004G05	5261	S1M10000031G02
294	E3M10000028C08	1536	E1M10000189C12	2778	E1M10000315F04	4020	S1M10000004A06	5262	S1M10000031H02
295	E3M10000028D08	1537	E1M10000189F12	2779	E1M10000315C05	4021	S1M10000004C06	5263	S1M10000031A03
296	E3M10000029B01	1538	E1M10000190D01	2780	E1M10000315G05	4022	S1M10000004D06	5264	S1M10000031E03
297	E3M10000029D01	1539	E1M10000190A03	2781	E1M10000315H06	4023	S1M10000004E06	5265	S1M10000031F03
298	E3M10000029E01	1540	E1M10000190D06	2782	E1M10000315G07	4024	S1M10000004F06	5266	S1M10000031G03
299	E3M10000029F01	1541	E1M10000190E07	2783	E1M10000315B08	4025	S1M10000004A07	5267	S1M10000031A04
300	E3M10000029G01	1542	E1M10000190D09	2784	E1M10000315C08	4026	S1M10000004D07	5268	S1M10000031B04
301	E3M10000029A02	1543	E1M10000190D10	2785	E1M10000315F08	4027	S1M10000004E07	5269	S1M10000031C04
302	E3M10000029B02	1544	E1M10000190E11	2786	E1M10000315D09	4028	S1M10000004F07	5270	S1M10000031E04
303	E3M10000029C02	1545	E1M10000191E05	2787	E1M10000315E10	4029	S1M10000004G07	5271	S1M10000031F04
304	E3M10000029H02	1546	E1M10000191G06	2788	E1M10000315G10	4030	S1M10000004B08	5272	S1M10000031G04
305	E3M10000029C03	1547	E1M10000191H06	2789	E1M10000315C12	4031	S1M10000004C08	5273	S1M10000031F05
306	E3M10000029D03	1548	E1M10000191A07	2790	E1M10000315F12	4032	S1M10000004D08	5274	S1M10000031D06
307	E3M10000029E03	1549	E1M10000191E07	2791	E1M10000316D01	4033	S1M10000004F08	5275	S1M10000031G06
308	E3M10000029A04	1550	E1M10000191A09	2792	E1M10000316B02	4034	S1M10000004B09	5276	S1M10000031H06
309	E3M10000029B04	1551	E1M10000191F10	2793	E1M10000316D02	4035	S1M10000004C09	5277	S1M10000031C07
310	E3M10000029C04	1552	E1M10000191F12	2794	E1M10000316E02	4036	S1M10000004F09	5278	S1M10000031D07
311	E3M10000029D04	1553	E1M10000192E03	2795	E1M10000316H04	4037	S1M10000004G09	5279	S1M10000031E07
312	E3M10000029G04	1554	E1M10000192F04	2796	E1M10000316A05	4038	S1M10000004C10	5280	S1M10000031A08
313	E3M10000029H04	1555	E1M10000192A05	2797	E1M10000316F05	4039	S1M10000004D10	5281	S1M10000031D08
314	E3M10000029A05	1556	E1M10000192B05	2798	E1M10000316G05	4040	S1M10000004A11	5282	S1M10000031E08
315	E3M10000029B05	1557	E1M10000192A06	2799	E1M10000316A08	4041	S1M10000004B11	5283	S1M10000031F08
316	E3M10000029C05	1558	E1M10000192B06	2800	E1M10000316H08	4042	S1M10000004C11	5284	S1M10000031C09
317	E3M10000029D05	1559	E1M10000192F06	2801	E1M10000316B09	4043	S1M10000004A12	5285	S1M10000031D09
318	E3M10000029E05	1560	E1M10000192D08	2802	E1M10000316E09	4044	S1M10000004C12	5286	S1M10000031G09
319	E3M10000029F05	1561	E1M10000192B09	2803	E1M10000316E11	4045	S1M10000004D12	5287	S1M10000031H09
320	E3M10000029G05	1562	E1M10000192D10	2804	E1M10000317C01	4046	S1M10000004E12	5288	S1M10000031A10
321	E3M10000029H05	1563	E1M10000192F10	2805	E1M10000317G02	4047	S1M10000004F12	5289	S1M10000031C10

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
322	E3M10000029B06	1564	E1M10000192C11	2806	E1M10000317D03	4048	S1M10000004G12	5290	S1M10000031E10
323	E3M10000029C06	1565	E1M10000192F11	2807	E1M10000317F03	4049	S1M10000005A01	5291	S1M10000031F10
324	E3M10000029D06	1566	E1M10000192B12	2808	E1M10000277D01	4050	S1M10000005C01	5292	S1M10000031G10
325	E3M10000029F06	1567	E1M10000193F01	2809	E1M10000277G01	4051	S1M10000005E01	5293	S1M10000031A11
326	E3M10000029C07	1568	E1M10000193G01	2810	E1M10000277F02	4052	S1M10000005B02	5294	S1M10000031B11
327	E3M10000029E07	1569	E1M10000193A02	2811	E1M10000277G03	4053	S1M10000005D02	5295	S1M10000031C11
328	E3M10000029G07	1570	E1M10000193F02	2812	E1M10000277A05	4054	S1M10000005E02	5296	S1M10000031F11
329	E3M10000029H07	1571	E1M10000193D04	2813	E1M10000277E05	4055	S1M10000005F02	5297	S1M10000031G11
330	E3M10000029B08	1572	E1M10000193G05	2814	E1M10000277C07	4056	S1M10000005A03	5298	S1M10000031H11
331	E3M10000029C08	1573	E1M10000193C06	2815	E1M10000277E07	4057	S1M10000005D03	5299	S1M10000031B12
332	E3M10000029D08	1574	E1M10000193F06	2816	E1M10000277G07	4058	S1M10000005F03	5300	S1M10000031C12
333	E3M10000029E08	1575	E1M10000193B07	2817	E1M10000277A08	4059	S1M10000005B04	5301	S1M10000031E12
334	E3M10000029G08	1576	E1M10000193C07	2818	E1M10000277C08	4060	S1M10000005D04	5302	S1M10000031F12
335	E3M10000029H08	1577	E1M10000193F07	2819	E1M10000277B10	4061	S1M10000005F04	5303	S1M10000032B01
336	E3M10000029C09	1578	E1M10000193C08	2820	E1M10000277G10	4062	S1M10000005C05	5304	S1M10000032C01
337	E3M10000029E09	1579	E1M10000193D08	2821	E1M10000277B11	4063	S1M10000005D05	5305	S1M10000032F01
338	E3M10000029F09	1580	E1M10000193B10	2822	E1M10000278G01	4064	S1M10000005E05	5306	S1M10000032H01
339	E3M10000029G09	1581	E1M10000193C10	2823	E1M10000278G02	4065	S1M10000005C06	5307	S1M10000032E02
340	E3M10000029A10	1582	E1M10000193G10	2824	E1M10000278B04	4066	S1M10000005D06	5308	S1M10000032G02
341	E3M10000029C10	1583	E1M10000193H11	2825	E1M10000278H06	4067	S1M10000005A07	5309	S1M10000032A03
342	E3M10000029E10	1584	E1M10000193G12	2826	E1M10000278A07	4068	S1M10000005B07	5310	S1M10000032C03
343	E3M10000029F10	1585	E1M10000194B03	2827	E1M10000278C07	4069	S1M10000005D07	5311	S1M10000032D03
344	E3M10000029G10	1586	E1M10000194F03	2828	E1M10000278C08	4070	S1M10000005A08	5312	S1M10000032E03
345	E3M10000029B11	1587	E1M10000194H03	2829	E1M10000278H10	4071	S1M10000005B08	5313	S1M10000032G03
346	E3M10000029G11	1588	E1M10000194D04	2830	E1M10000278B11	4072	S1M10000005D08	5314	S1M10000032C04
347	E3M10000029H11	1589	E1M10000194D05	2831	E1M10000278H11	4073	S1M10000005E08	5315	S1M10000032E04
348	E3M10000029B12	1590	E1M10000194F06	2832	E1M10000279G03	4074	S1M10000005B09	5316	S1M10000032F04
349	E3M10000029C12	1591	E1M10000194G06	2833	E1M10000279C05	4075	S1M10000005C09	5317	S1M10000032G04
350	E3M10000029D12	1592	E1M10000194H06	2834	E1M10000279G05	4076	S1M10000005D09	5318	S1M10000032H04
351	E3M10000029E12	1593	E1M10000194B07	2835	E1M10000279E07	4077	S1M10000005A10	5319	S1M10000032A05
352	E3M10000029F12	1594	E1M10000194H07	2836	E1M10000279H07	4078	S1M10000005A11	5320	S1M10000032B05
353	E3M10000029G12	1595	E1M10000194B08	2837	E1M10000279F08	4079	S1M10000005C11	5321	S1M10000032C05
354	E3M10000030E01	1596	E1M10000194G08	2838	E1M10000279A09	4080	S1M10000005D11	5322	S1M10000032F05
355	E3M10000030F01	1597	E1M10000194F09	2839	E1M10000279B09	4081	S1M10000005E11	5323	S1M10000032H05
356	E3M10000030G01	1598	E1M10000194B10	2840	E1M10000279C10	4082	S1M10000005B12	5324	S1M10000032A06
357	E3M10000030D02	1599	E1M10000194A11	2841	E1M10000279D10	4083	S1M10000005D12	5325	S1M10000032D06

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
358	E3M10000030E02	1600	E1M10000194F11	2842	E1M10000279E12	4084	S1M10000006F01	5326	S1M10000032E06
359	E3M10000030B03	1601	E1M10000194C12	2843	E1M10000280C01	4085	S1M10000006B02	5327	S1M10000032G06
360	E3M10000030C03	1602	E1M10000194G12	2844	E1M10000280G01	4086	S1M10000006E02	5328	S1M10000032A07
361	E3M10000030G03	1603	E1M10000195G02	2845	E1M10000280B02	4087	S1M10000006F02	5329	S1M10000032B07
362	E3M10000030H03	1604	E1M10000195B03	2846	E1M10000280C03	4088	S1M10000006G02	5330	S1M10000032C07
363	E3M10000030B04	1605	E1M10000195G03	2847	E1M10000280C05	4089	S1M10000006A03	5331	S1M10000032D07
364	E3M10000030C04	1606	E1M10000195A04	2848	E1M10000280E05	4090	S1M10000006B03	5332	S1M10000032F07
365	E3M10000030E04	1607	E1M10000195G05	2849	E1M10000280A06	4091	S1M10000006D03	5333	S1M10000032H07
366	E3M10000030F04	1608	E1M10000195D06	2850	E1M10000280B06	4092	S1M10000006E03	5334	S1M10000032A08
367	E3M10000030H04	1609	E1M10000195E07	2851	E1M10000280H06	4093	S1M10000006F03	5335	S1M10000032B08
368	E3M10000030A05	1610	E1M10000195A08	2852	E1M10000280A07	4094	S1M10000006G03	5336	S1M10000032D08
369	E3M10000030B05	1611	E1M10000195E09	2853	E1M10000280C07	4095	S1M10000006A04	5337	S1M10000032E08
370	E3M10000030D05	1612	E1M10000195D10	2854	E1M10000280G07	4096	S1M10000006B04	5338	S1M10000032G08
371	E3M10000030E05	1613	E1M10000195E10	2855	E1M10000280E08	4097	S1M10000006C04	5339	S1M10000032B09
372	E3M10000030B06	1614	E1M10000195D11	2856	E1M10000280F08	4098	S1M10000006E04	5340	S1M10000032C09
373	E3M10000030D06	1615	E1M10000195F11	2857	E1M10000280C09	4099	S1M10000006F04	5341	S1M10000032D09
374	E3M10000030F06	1616	E1M10000196B02	2858	E1M10000280H09	4100	S1M10000006G04	5342	S1M10000032E09
375	E3M10000030G06	1617	E1M10000196C02	2859	E1M10000280C10	4101	S1M10000006A05	5343	S1M10000032H09
376	E3M10000030H06	1618	E1M10000196E02	2860	E1M10000280C11	4102	S1M10000006D05	5344	S1M10000032A10
377	E3M10000030B07	1619	E1M10000196G02	2861	E1M10000280D11	4103	S1M10000006G05	5345	S1M10000032B10
378	E3M10000030F07	1620	E1M10000196A03	2862	E1M10000280H11	4104	S1M10000006C06	5346	S1M10000032C10
379	E3M10000030H07	1621	E1M10000196D03	2863	E1M10000280F12	4105	S1M10000006D06	5347	S1M10000032E10
380	E3M10000030A08	1622	E1M10000196A04	2864	E1M10000281B01	4106	S1M10000006F06	5348	S1M10000032F10
381	E3M10000030B08	1623	E1M10000196D05	2865	E1M10000281C02	4107	S1M10000006G06	5349	S1M10000032G10
382	E3M10000030D08	1624	E1M10000196E05	2866	E1M10000281C03	4108	S1M10000006A07	5350	S1M10000032B11
383	E3M10000030E08	1625	E1M10000196F05	2867	E1M10000281D04	4109	S1M10000006B07	5351	S1M10000032C11
384	E3M10000030G08	1626	E1M10000196D06	2868	E1M10000281E07	4110	S1M10000006C07	5352	S1M10000032D11
385	E3M10000030H08	1627	E1M10000196F06	2869	E1M10000281E08	4111	S1M10000006D07	5353	S1M10000032E11
386	E3M10000030A09	1628	E1M10000196H06	2870	E1M10000281H09	4112	S1M10000006E07	5354	S1M10000032F11
387	E3M10000030D09	1629	E1M10000196H07	2871	E1M10000281B10	4113	S1M10000006G07	5355	S1M10000032H11
388	E3M10000030E09	1630	E1M10000196C08	2872	E1M10000281D11	4114	S1M10000006A08	5356	S1M10000032B12
389	E3M10000030G09	1631	E1M10000196A10	2873	E1M10000281G11	4115	S1M10000006E08	5357	S1M10000032C12
390	E3M10000030B10	1632	E1M10000196B10	2874	E1M10000281D12	4116	S1M10000006A10	5358	S1M10000032E12
391	E3M10000030D10	1633	E1M10000196D11	2875	E1M10000281F12	4117	S1M10000006B10	5359	S1M10000032F12
392	E3M10000030E10	1634	E1M10000196D12	2876	E1M10000282D01	4118	S1M10000006C10	5360	S1M10000032G12
393	E3M10000030F10	1635	E1M10000197E02	2877	E1M10000282F01	4119	S1M10000006G10	5361	S1M10000033H01

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
394	E3M10000030H10	1636	E1M10000197G02	2878	E1M10000282D02	4120	S1M10000006B11	5362	S1M10000033A02
395	E3M10000030A11	1637	E1M10000197A03	2879	E1M10000282A03	4121	S1M10000006G11	5363	S1M10000033B02
396	E3M10000030B11	1638	E1M10000197D04	2880	E1M10000282F03	4122	S1M10000006A12	5364	S1M10000033D02
397	E3M10000030H11	1639	E1M10000197B05	2881	E1M10000282C04	4123	S1M10000006B12	5365	S1M10000033F02
398	E3M10000030B12	1640	E1M10000197E07	2882	E1M10000282E04	4124	S1M10000007F01	5366	S1M10000033H02
399	E3M10000030C12	1641	E1M10000197E08	2883	E1M10000282F04	4125	S1M10000007B02	5367	S1M10000033D03
400	E3M10000030D12	1642	E1M10000197H08	2884	E1M10000282H04	4126	S1M10000007F02	5368	S1M10000033F03
401	E3M10000030F12	1643	E1M10000197D09	2885	E1M10000282B05	4127	S1M10000007G02	5369	S1M10000033H03
402	E3M10000030G12	1644	E1M10000197D10	2886	E1M10000282F05	4128	S1M10000007A03	5370	S1M10000033C04
403	E3M10000031C01	1645	E1M10000197E10	2887	E1M10000282H05	4129	S1M10000007D03	5371	S1M10000033D04
404	E3M10000031A02	1646	E1M10000197F10	2888	E1M10000282A08	4130	S1M10000007G03	5372	S1M10000033E04
405	E3M10000031B02	1647	E1M10000197G10	2889	E1M10000282B08	4131	S1M10000007C04	5373	S1M10000033D05
406	E3M10000031F02	1648	E1M10000197H10	2890	E1M10000282D08	4132	S1M10000007E04	5374	S1M10000033G05
407	E3M10000031B03	1649	E1M10000197A11	2891	E1M10000282E08	4133	S1M10000007F04	5375	S1M10000033D06
408	E3M10000031D03	1650	E1M10000197C11	2892	E1M10000282F08	4134	S1M10000007C05	5376	S1M10000033F06
409	E3M10000031E03	1651	E1M10000197B12	2893	E1M10000282G08	4135	S1M10000007G05	5377	S1M10000033A07
410	E3M10000031G03	1652	E1M10000198C02	2894	E1M10000282H08	4136	S1M10000007C06	5378	S1M10000033B07
411	E3M10000031B04	1653	E1M10000198B03	2895	E1M10000282A09	4137	S1M10000007D06	5379	S1M10000033F07
412	E3M10000031C04	1654	E1M10000198E04	2896	E1M10000282C09	4138	S1M10000007E06	5380	S1M10000033G07
413	E3M10000031D04	1655	E1M10000198F04	2897	E1M10000282C11	4139	S1M10000007C07	5381	S1M10000033H07
414	E3M10000031E04	1656	E1M10000198A05	2898	E1M10000282D11	4140	S1M10000007E07	5382	S1M10000033A08
415	E3M10000031F04	1657	E1M10000198H05	2899	E1M10000282C12	4141	S1M10000007G07	5383	S1M10000033B08
416	E3M10000031G04	1658	E1M10000198D06	2900	E1M10000282E12	4142	S1M10000007C08	5384	S1M10000033H08
417	E3M10000031G05	1659	E1M10000198F06	2901	E1M10000282G12	4143	S1M10000007E08	5385	S1M10000033F09
418	E3M10000031H05	1660	E1M10000198H06	2902	E1M10000283D01	4144	S1M10000007F08	5386	S1M10000033G09
419	E3M10000031A06	1661	E1M10000198B09	2903	E1M10000283E01	4145	S1M10000007F09	5387	S1M10000033H09
420	E3M10000031C06	1662	E1M10000198C09	2904	E1M10000283A02	4146	S1M10000007D10	5388	S1M10000033A10
421	E3M10000031G06	1663	E1M10000198G09	2905	E1M10000283B02	4147	S1M10000007F10	5389	S1M10000033D10
422	E3M10000031H06	1664	E1M10000198C10	2906	E1M10000283H03	4148	S1M10000007B11	5390	S1M10000033E10
423	E3M10000031A07	1665	E1M10000198C12	2907	E1M10000283B04	4149	S1M10000007D11	5391	S1M10000033G10
424	E3M10000031E07	1666	E1M10000199F02	2908	E1M10000283B05	4150	S1M10000008F01	5392	S1M10000033H10
425	E3M10000031F07	1667	E1M10000199A05	2909	E1M10000283G05	4151	S1M10000008F02	5393	S1M10000033B11
426	E3M10000031G07	1668	E1M10000199G05	2910	E1M10000283A06	4152	S1M10000008G02	5394	S1M10000033F11
427	E3M10000031H07	1669	E1M10000199A06	2911	E1M10000283F06	4153	S1M10000008A03	5395	S1M10000033G11
428	E3M10000031A08	1670	E1M10000199C06	2912	E1M10000283A07	4154	S1M10000008B03	5396	S1M10000033H11
429	E3M10000031D08	1671	E1M10000199C08	2913	E1M10000283G07	4155	S1M10000008F03	5397	S1M10000033B12

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
430	E3M10000031G08	1672	E1M10000199E08	2914	E1M10000283A08	4156	S1M10000008G03	5398	S1M10000033D12
431	E3M10000031H08	1673	E1M10000199C09	2915	E1M10000283E08	4157	S1M10000008A04	5399	S1M10000033E12
432	E3M10000031B09	1674	E1M10000199G09	2916	E1M10000283F08	4158	S1M10000008B04	5400	S1M10000033G12
433	E3M10000031E09	1675	E1M10000199H09	2917	E1M10000283B10	4159	S1M10000008D05	5401	S1M10000034B01
434	E3M10000031F09	1676	E1M10000199B10	2918	E1M10000283H10	4160	S1M10000008E05	5402	S1M10000034D01
435	E3M10000031B10	1677	E1M10000199D10	2919	E1M10000283B11	4161	S1M10000008G05	5403	S1M10000034E01
436	E3M10000031C10	1678	E1M10000199F10	2920	E1M10000283E12	4162	S1M10000008B06	5404	S1M10000034F01
437	E3M10000031H10	1679	E1M10000199D11	2921	E1M10000302F01	4163	S1M10000008F06	5405	S1M10000034H01
438	E3M10000031B11	1680	E1M10000199E11	2922	E1M10000302G03	4164	S1M10000008A08	5406	S1M10000034A02
439	E3M10000031C11	1681	E1M10000199F11	2923	E1M10000302A05	4165	S1M10000008B08	5407	S1M10000034C02
440	E3M10000031F11	1682	E1M10000199B12	2924	E1M10000302C05	4166	S1M10000008C08	5408	S1M10000034E02
441	E3M10000031G11	1683	E1M10000199D12	2925	E1M10000302H07	4167	S1M10000008E08	5409	S1M10000034F02
442	E3M10000031H11	1684	E1M10000200G01	2926	E1M10000302C09	4168	S1M10000008F08	5410	S1M10000034G02
443	E3M10000031B12	1685	E1M10000200A02	2927	E1M10000302F10	4169	S1M10000008A09	5411	S1M10000034H02
444	E3M10000031C12	1686	E1M10000200B02	2928	E1M10000302H11	4170	S1M10000008B09	5412	S1M10000034B03
445	E3M10000032C01	1687	E1M10000200C02	2929	E1M10000303C01	4171	S1M10000008C09	5413	S1M10000034F03
446	E3M10000032D01	1688	E1M10000200A03	2930	E1M10000303A02	4172	S1M10000008E09	5414	S1M10000034G03
447	E3M10000032F01	1689	E1M10000200D03	2931	E1M10000303D02	4173	S1M10000008F09	5415	S1M10000034H03
448	E3M10000032G01	1690	E1M10000200B04	2932	E1M10000303A03	4174	S1M10000008B10	5416	S1M10000034A04
449	E3M10000032A02	1691	E1M10000200F04	2933	E1M10000303B03	4175	S1M10000008E10	5417	S1M10000034E04
450	E3M10000032C02	1692	E1M10000200C07	2934	E1M10000303H03	4176	S1M10000008F10	5418	S1M10000034F04
451	E3M10000032D02	1693	E1M10000200G07	2935	E1M10000303F04	4177	S1M10000008F11	5419	S1M10000034A05
452	E3M10000032F02	1694	E1M10000200D08	2936	E1M10000303B05	4178	S1M10000008A12	5420	S1M10000034B05
453	E3M10000032G02	1695	E1M10000200A09	2937	E1M10000303C05	4179	S1M10000009B01	5421	S1M10000034D05
454	E3M10000032B03	1696	E1M10000200B09	2938	E1M10000303F06	4180	S1M10000009C01	5422	S1M10000034E05
455	E3M10000032C03	1697	E1M10000200E10	2939	E1M10000303B07	4181	S1M10000009D01	5423	S1M10000034F05
456	E3M10000032D03	1698	E1M10000201G01	2940	E1M10000303F07	4182	S1M10000009F01	5424	S1M10000034A06
457	E3M10000032F03	1699	E1M10000201A02	2941	E1M10000303A08	4183	S1M10000009H01	5425	S1M10000034B06
458	E3M10000032A04	1700	E1M10000201B02	2942	E1M10000303F08	4184	S1M10000009A02	5426	S1M10000034C06
459	E3M10000032B04	1701	E1M10000201C02	2943	E1M10000303D11	4185	S1M10000009B02	5427	S1M10000034D06
460	E3M10000032E04	1702	E1M10000201E03	2944	E1M10000303D12	4186	S1M10000009C02	5428	S1M10000034E06
461	E3M10000032G04	1703	E1M10000201H03	2945	E1M10000304G01	4187	S1M10000009D02	5429	S1M10000034G06
462	E3M10000032B05	1704	E1M10000201D06	2946	E1M10000304H02	4188	S1M10000009E02	5430	S1M10000034H06
463	E3M10000032E05	1705	E1M10000201G06	2947	E1M10000304A03	4189	S1M10000009F02	5431	S1M10000034B07
464	E3M10000032F05	1706	E1M10000201H07	2948	E1M10000304C03	4190	S1M10000009G02	5432	S1M10000034C07
465	E3M10000032G05	1707	E1M10000201G08	2949	E1M10000304E03	4191	S1M10000009H02	5433	S1M10000034D07

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
466	E3M10000032H05	1708	E1M10000201F09	2950	E1M10000304F03	4192	S1M10000009B03	5434	S1M10000034E07
467	E3M10000032A06	1709	E1M10000201G09	2951	E1M10000304E05	4193	S1M10000009D03	5435	S1M10000034F07
468	E3M10000032C06	1710	E1M10000201H09	2952	E1M10000304G05	4194	S1M10000009F03	5436	S1M10000034G07
469	E3M10000032D06	1711	E1M10000201A10	2953	E1M10000304A06	4195	S1M10000009G03	5437	S1M10000034H07
470	E3M10000032G06	1712	E1M10000201G10	2954	E1M10000304F06	4196	S1M10000009H03	5438	S1M10000034A08
471	E3M10000032H06	1713	E1M10000201F12	2955	E1M10000304A08	4197	S1M10000009A04	5439	S1M10000034B08
472	E3M10000032A07	1714	E1M10000202C02	2956	E1M10000304B10	4198	S1M10000009B04	5440	S1M10000034D08
473	E3M10000032F07	1715	E1M10000202A05	2957	E1M10000305E01	4199	S1M10000009D04	5441	S1M10000034F08
474	E3M10000032G07	1716	E1M10000202C08	2958	E1M10000305C02	4200	S1M10000009B05	5442	S1M10000034G08
475	E3M10000032A08	1717	E1M10000202H08	2959	E1M10000305G04	4201	S1M10000009C05	5443	S1M10000034H08
476	E3M10000032B08	1718	E1M10000202C09	2960	E1M10000305G09	4202	S1M10000009D05	5444	S1M10000034A09
477	E3M10000032F08	1719	E1M10000202B10	2961	E1M10000305C10	4203	S1M10000009F05	5445	S1M10000034B09
478	E3M10000032H08	1720	E1M10000203D02	2962	E1M10000305B11	4204	S1M10000009G05	5446	S1M10000034C09
479	E3M10000032A09	1721	E1M10000203G04	2963	E1M10000305C11	4205	S1M10000009H05	5447	S1M10000034F09
480	E3M10000032C09	1722	E1M10000203C05	2964	E1M10000306C01	4206	S1M10000009B06	5448	S1M10000034G09
481	E3M10000032D09	1723	E1M10000203A08	2965	E1M10000306A03	4207	S1M10000009C06	5449	S1M10000034H09
482	E3M10000032H09	1724	E1M10000203F09	2966	E1M10000306G03	4208	S1M10000009E06	5450	S1M10000034B10
483	E3M10000032A10	1725	E1M10000203F10	2967	E1M10000306E04	4209	S1M10000009F06	5451	S1M10000034D10
484	E3M10000032E10	1726	E1M10000203E11	2968	E1M10000306H04	4210	S1M10000009G06	5452	S1M10000034E10
485	E3M10000032H10	1727	E1M10000203C12	2969	E1M10000306C05	4211	S1M10000009A07	5453	S1M10000034F10
486	E3M10000032A11	1728	E1M10000204E02	2970	E1M10000306H07	4212	S1M10000009B07	5454	S1M10000034H10
487	E3M10000032B11	1729	E1M10000204F02	2971	E1M10000306D09	4213	S1M10000009C07	5455	S1M10000034A11
488	E3M10000032C11	1730	E1M10000204E03	2972	E1M10000306H09	4214	S1M10000009D07	5456	S1M10000034D11
489	E3M10000032E11	1731	E1M10000204F03	2973	E1M10000306E11	4215	S1M10000009F07	5457	S1M10000034E11
490	E3M10000032F11	1732	E1M10000204B05	2974	E1M10000307G01	4216	S1M10000009G07	5458	S1M10000034G11
491	E3M10000032B12	1733	E1M10000204A06	2975	E1M10000307C02	4217	S1M10000009H07	5459	S1M10000034A12
492	E3M10000032C12	1734	E1M10000204A07	2976	E1M10000307D02	4218	S1M10000009A08	5460	S1M10000034B12
493	E3M10000032D12	1735	E1M10000204G07	2977	E1M10000307E03	4219	S1M10000009C08	5461	S1M10000034C12
494	E3M10000032E12	1736	E1M10000204E09	2978	E1M10000307B04	4220	S1M10000009E08	5462	S1M10000034D12
495	E3M10000032F12	1737	E1M10000204D10	2979	E1M10000307C04	4221	S1M10000009A09	5463	S1M10000034E12
496	E3M10000033B01	1738	E1M10000204H10	2980	E1M10000307E04	4222	S1M10000009C09	5464	S1M10000034F12
497	E3M10000033C01	1739	E1M10000204C12	2981	E1M10000307B05	4223	S1M10000009D09	5465	S1M10000034G12
498	E3M10000033D01	1740	E1M10000205F02	2982	E1M10000307C05	4224	S1M10000009E09	5466	S1M10000035B01
499	E3M10000033F01	1741	E1M10000205G03	2983	E1M10000307D05	4225	S1M10000009F09	5467	S1M10000035C01
500	E3M10000033B02	1742	E1M10000205D08	2984	E1M10000307E05	4226	S1M10000009G09	5468	S1M10000035D01
501	E3M10000033C02	1743	E1M10000205B10	2985	E1M10000307F05	4227	S1M10000009H09	5469	S1M10000035H01

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
502	E3M10000033E02	1744	E1M10000205F11	2986	E1M10000307A06	4228	S1M10000009A10	5470	S1M10000035C02
503	E3M10000033F02	1745	E1M10000205G11	2987	E1M10000307F06	4229	S1M10000009B10	5471	S1M10000035E02
504	E3M10000033G02	1746	E1M10000205H11	2988	E1M10000307H06	4230	S1M10000009C10	5472	S1M10000035G02
505	E3M10000033H02	1747	E1M10000205G12	2989	E1M10000307B07	4231	S1M10000009F10	5473	S1M10000035A03
506	E3M10000033A03	1748	E1M10000206B03	2990	E1M10000307C07	4232	S1M10000009G10	5474	S1M10000035B03
507	E3M10000033E03	1749	E1M10000206A04	2991	E1M10000307G07	4233	S1M10000009A11	5475	S1M10000035E03
508	E3M10000033F03	1750	E1M10000206D04	2992	E1M10000307F08	4234	S1M10000009B11	5476	S1M10000035F03
509	E3M10000033G03	1751	E1M10000206B05	2993	E1M10000307C09	4235	S1M10000009C11	5477	S1M10000035B04
510	E3M10000033A04	1752	E1M10000206G05	2994	E1M10000307A10	4236	S1M10000009D11	5478	S1M10000035C04
511	E3M10000033B04	1753	E1M10000206H05	2995	E1M10000307E10	4237	S1M10000009E11	5479	S1M10000035D04
512	E3M10000033D04	1754	E1M10000206A06	2996	E1M10000307F10	4238	S1M10000009G11	5480	S1M10000035E04
513	E3M10000033E04	1755	E1M10000206B06	2997	E1M10000307H10	4239	S1M10000009H11	5481	S1M10000035F04
514	E3M10000033F04	1756	E1M10000206F06	2998	E1M10000307A11	4240	S1M10000009B12	5482	S1M10000035C06
515	E3M10000033G04	1757	E1M10000206C09	2999	E1M10000307D11	4241	S1M10000009E12	5483	S1M10000035D06
516	E3M10000033H04	1758	E1M10000206E09	3000	E1M10000307G11	4242	S1M10000009G12	5484	S1M10000035H07
517	E3M10000033A05	1759	E1M10000206F09	3001	E1M10000307C12	4243	S1M10000011B01	5485	S1M10000035A08
518	E3M10000033B05	1760	E1M10000207E01	3002	E1M10000307E12	4244	S1M10000011C01	5486	S1M10000035B08
519	E3M10000033C05	1761	E1M10000207B03	3003	E1M10000307G12	4245	S1M10000011D01	5487	S1M10000035E08
520	E3M10000033D05	1762	E1M10000207E05	3004	E1M10000308C01	4246	S1M10000011E01	5488	S1M10000035H08
521	E3M10000033E05	1763	E1M10000207G05	3005	E1M10000308A02	4247	S1M10000011F01	5489	S1M10000035A09
522	E3M10000033F05	1764	E1M10000207C06	3006	E1M10000308B02	4248	S1M10000011G01	5490	S1M10000035D09
523	E3M10000033H05	1765	E1M10000207H06	3007	E1M10000308F02	4249	S1M10000011H01	5491	S1M10000035E09
524	E3M10000033A06	1766	E1M10000207F07	3008	E1M10000308H04	4250	S1M10000011A02	5492	S1M10000035F09
525	E3M10000033B06	1767	E1M10000207G07	3009	E1M10000308B05	4251	S1M10000011B02	5493	S1M10000035G09
526	E3M10000033D06	1768	E1M10000207C10	3010	E1M10000308E05	4252	S1M10000011D02	5494	S1M10000035H09
527	E3M10000033G06	1769	E1M10000207D12	3011	E1M10000308F06	4253	S1M10000011E02	5495	S1M10000035A10
528	E3M10000033A07	1770	E1M10000207G12	3012	E1M10000308B07	4254	S1M10000011H02	5496	S1M10000035H10
529	E3M10000033E07	1771	E1M10000208A04	3013	E1M10000308C07	4255	S1M10000011A03	5497	S1M10000035A11
530	E3M10000033F07	1772	E1M10000208A05	3014	E1M10000308A08	4256	S1M10000011B03	5498	S1M10000035B11
531	E3M10000033G07	1773	E1M10000208B05	3015	E1M10000308C08	4257	S1M10000011C03	5499	S1M10000035C11
532	E3M10000033H07	1774	E1M10000208B06	3016	E1M10000308D08	4258	S1M10000011E03	5500	S1M10000035G11
533	E3M10000033A08	1775	E1M10000208C06	3017	E1M10000308G09	4259	S1M10000011F03	5501	S1M10000035H11
534	E3M10000033B08	1776	E1M10000208B07	3018	E1M10000308H09	4260	S1M10000011G03	5502	S1M10000035A12
535	E3M10000033E08	1777	E1M10000208H07	3019	E1M10000308E10	4261	S1M10000011H03	5503	S1M10000035D12
536	E3M10000033F08	1778	E1M10000208F08	3020	E1M10000286D01	4262	S1M10000011A04	5504	S1M10000035E12
537	E3M10000033G08	1779	E1M10000208H10	3021	E1M10000286B02	4263	S1M10000011B04	5505	S1M10000035G12

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
538	E3M10000033H08	1780	E1M10000208D11	3022	E1M10000286G02	4264	S1M10000011D04	5506	S1M10000036C01
539	E3M10000033B09	1781	E1M10000209B01	3023	E1M10000286H02	4265	S1M10000011E04	5507	S1M10000036H01
540	E3M10000033C09	1782	E1M10000209F02	3024	E1M10000286A03	4266	S1M10000011F04	5508	S1M10000036A02
541	E3M10000033D09	1783	E1M10000209H02	3025	E1M10000286C03	4267	S1M10000011G04	5509	S1M10000036D02
542	E3M10000033E09	1784	E1M10000209D05	3026	E1M10000286C04	4268	S1M10000011H04	5510	S1M10000036H02
543	E3M10000033G09	1785	E1M10000209E05	3027	E1M10000286E04	4269	S1M10000011B05	5511	S1M10000036A03
544	E3M10000033H09	1786	E1M10000209A06	3028	E1M10000286C05	4270	S1M10000011C05	5512	S1M10000036C03
545	E3M10000033C10	1787	E1M10000209H08	3029	E1M10000286D05	4271	S1M10000011G05	5513	S1M10000036G03
546	E3M10000033D10	1788	E1M10000209C10	3030	E1M10000286E05	4272	S1M10000011A06	5514	S1M10000036H03
547	E3M10000033F10	1789	E1M10000209G10	3031	E1M10000286F05	4273	S1M10000011C06	5515	S1M10000036A04
548	E3M10000033H10	1790	E1M10000209E11	3032	E1M10000286H05	4274	S1M10000011D06	5516	S1M10000036B04
549	E3M10000033A11	1791	E1M10000209D12	3033	E1M10000286A06	4275	S1M10000011F06	5517	S1M10000036C04
550	E3M10000033C11	1792	E1M10000210G02	3034	E1M10000286G06	4276	S1M10000011G06	5518	S1M10000036H04
551	E3M10000033D11	1793	E1M10000210F03	3035	E1M10000286F07	4277	S1M10000012B01	5519	S1M10000036A05
552	E3M10000033E11	1794	E1M10000210B05	3036	E1M10000286B08	4278	S1M10000012C01	5520	S1M10000036C05
553	E3M10000033H11	1795	E1M10000210C05	3037	E1M10000286F08	4279	S1M10000012E01	5521	S1M10000036H05
554	E3M10000033C12	1796	E1M10000210G05	3038	E1M10000286H08	4280	S1M10000012G01	5522	S1M10000036B06
555	E3M10000033F12	1797	E1M10000210E07	3039	E1M10000286D09	4281	S1M10000012A02	5523	S1M10000036C06
556	E3M10000033G12	1798	E1M10000210B10	3040	E1M10000286F09	4282	S1M10000012E02	5524	S1M10000036D06
557	E3M10000034D01	1799	E1M10000210B11	3041	E1M10000286A10	4283	S1M10000012G02	5525	S1M10000036E06
558	E3M10000034E01	1800	E1M10000211C02	3042	E1M10000286F10	4284	S1M10000012C03	5526	S1M10000036F06
559	E3M10000034A02	1801	E1M10000211E04	3043	E1M10000286A11	4285	S1M10000012F03	5527	S1M10000036H06
560	E3M10000034B02	1802	E1M10000211F04	3044	E1M10000286C11	4286	S1M10000012G03	5528	S1M10000036A07
561	E3M10000034C02	1803	E1M10000211A05	3045	E1M10000286E12	4287	S1M10000012C04	5529	S1M10000036B07
562	E3M10000034D02	1804	E1M10000211F05	3046	E1M10000287B02	4288	S1M10000012D04	5530	S1M10000036C07
563	E3M10000034F02	1805	E1M10000211C06	3047	E1M10000287D02	4289	S1M10000012E04	5531	S1M10000036F07
564	E3M10000034G02	1806	E1M10000211C08	3048	E1M10000287F02	4290	S1M10000012F04	5532	S1M10000036G07
565	E3M10000034H02	1807	E1M10000211D11	3049	E1M10000287E03	4291	S1M10000012B05	5533	S1M10000036A08
566	E3M10000034A03	1808	E1M10000212B03	3050	E1M10000287A04	4292	S1M10000012C05	5534	S1M10000036B08
567	E3M10000034F03	1809	E1M10000212D05	3051	E1M10000287B05	4293	S1M10000012D05	5535	S1M10000036D08
568	E3M10000034G03	1810	E1M10000212H05	3052	E1M10000287C05	4294	S1M10000012H05	5536	S1M10000036E08
569	E3M10000034H03	1811	E1M10000212A08	3053	E1M10000287E05	4295	S1M10000012A06	5537	S1M10000036F08
570	E3M10000034A04	1812	E1M10000212G12	3054	E1M10000287G05	4296	S1M10000012B06	5538	S1M10000036G08
571	E3M10000034B04	1813	E1M10000213D01	3055	E1M10000287H05	4297	S1M10000012C06	5539	S1M10000036H08
572	E3M10000034C04	1814	E1M10000213B02	3056	E1M10000287A06	4298	S1M10000012D06	5540	S1M10000036B09
573	E3M10000034D04	1815	E1M10000213C04	3057	E1M10000287C06	4299	S1M10000012G06	5541	S1M10000036C09

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
574	E3M10000034E04	1816	E1M10000213A05	3058	E1M10000287A07	4300	S1M10000012B07	5542	S1M10000036F09		
575	E3M10000034F04	1817	E1M10000213F07	3059	E1M10000287A09	4301	S1M10000012D07	5543	S1M10000036A10		
576	E3M10000035B01	1818	E1M10000213G07	3060	E1M10000287A10	4302	S1M10000012E07	5544	S1M10000036C10		
577	E3M10000035C01	1819	E1M10000213A08	3061	E1M10000287C10	4303	S1M10000012F07	5545	S1M10000036D10		
578	E3M10000035F01	1820	E1M10000213C08	3062	E1M10000287B11	4304	S1M10000012G07	5546	S1M10000036F10		
579	E3M10000035A02	1821	E1M10000213F08	3063	E1M10000287F11	4305	S1M10000012A08	5547	S1M10000036A11		
580	E3M10000035D02	1822	E1M10000213E09	3064	E1M10000287G12	4306	S1M10000012B08	5548	S1M10000036B11		
581	E3M10000035F02	1823	E1M10000213F09	3065	E1M10000288B02	4307	S1M10000012D08	5549	S1M10000036D11		
582	E3M10000035G02	1824	E1M10000213G09	3066	E1M10000288D02	4308	S1M10000012E08	5550	S1M10000036E11		
583	E3M10000035B03	1825	E1M10000213H09	3067	E1M10000288H02	4309	S1M10000012F08	5551	S1M10000036F11		
584	E3M10000035C03	1826	E1M10000229B01	3068	E1M10000288A03	4310	S1M10000012G08	5552	S1M10000036G11		
585	E3M10000035D03	1827	E1M10000229D01	3069	E1M10000288B03	4311	S1M10000012H08	5553	S1M10000036H11		
586	E3M10000035E03	1828	E1M10000229C02	3070	E1M10000288F03	4312	S1M10000012A09	5554	S1M10000036A12		
587	E3M10000035F03	1829	E1M10000229B03	3071	E1M10000288C04	4313	S1M10000012D09	5555	S1M10000036B12		
588	E3M10000035H03	1830	E1M10000229E03	3072	E1M10000288D04	4314	S1M10000012F09	5556	S1M10000036D12		
589	E3M10000035A04	1831	E1M10000229G05	3073	E1M10000288A05	4315	S1M10000012H09	5557	S1M10000036E12		
590	E3M10000035C04	1832	E1M10000229H06	3074	E1M10000288H05	4316	S1M10000012A10	5558	S1M10000037G01		
591	E3M10000035D04	1833	E1M10000229E08	3075	E1M10000288A06	4317	S1M10000012F10	5559	S1M10000037A02		
592	E3M10000035E04	1834	E1M10000229E10	3076	E1M10000288G06	4318	S1M10000012G10	5560	S1M10000037E02		
593	E3M10000035G04	1835	E1M10000229F10	3077	E1M10000288C07	4319	S1M10000012H10	5561	S1M10000037F02		
594	E3M10000035A05	1836	E1M10000229C12	3078	E1M10000288G07	4320	S1M10000012A11	5562	S1M10000037G02		
595	E3M10000035C05	1837	E1M10000229D12	3079	E1M10000288E08	4321	S1M10000012B11	5563	S1M10000037H02		
596	E3M10000035D05	1838	E1M10000230C02	3080	E1M10000288D09	4322	S1M10000012C11	5564	S1M10000037A03		
597	E3M10000035E05	1839	E1M10000230A03	3081	E1M10000288E09	4323	S1M10000012F11	5565	S1M10000037B03		
598	E3M10000035G05	1840	E1M10000230F03	3082	E1M10000288E10	4324	S1M10000012H11	5566	S1M10000037E03		
599	E3M10000035A06	1841	E1M10000230B04	3083	E1M10000288F11	4325	S1M10000012C12	5567	S1M10000037F03		
600	E3M10000035C06	1842	E1M10000230C04	3084	E1M10000288H11	4326	S1M10000012D12	5568	S1M10000037G03		
601	E3M10000035F06	1843	E1M10000230E04	3085	E1M10000288D12	4327	S1M10000012E12	5569	S1M10000037H03		
602	E3M10000035H06	1844	E1M10000230F04	3086	E1M10000289D01	4328	S1M10000012F12	5570	S1M10000037B04		
603	E3M10000035B07	1845	E1M10000230B05	3087	E1M10000289F01	4329	S1M10000013E01	5571	S1M10000037D04		
604	E3M10000035C07	1846	E1M10000230D05	3088	E1M10000289G01	4330	S1M10000013G01	5572	S1M10000037F04		
605	E3M10000035E07	1847	E1M10000230H05	3089	E1M10000289G05	4331	S1M10000013A02	5573	S1M10000037B05		
606	E3M10000035F07	1848	E1M10000230A06	3090	E1M10000289B06	4332	S1M10000013B02	5574	S1M10000037C05		
607	E3M10000035A08	1849	E1M10000230H07	3091	E1M10000289D06	4333	S1M10000013E02	5575	S1M10000037D05		
608	E3M10000035B08	1850	E1M10000230A08	3092	E1M10000289G06	4334	S1M10000013F02	5576	S1M10000037F05		
609	E3M10000035C08	1851	E1M10000230A10	3093	E1M10000289E07	4335	S1M10000013A03	5577	S1M10000037H05		

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
610	E3M10000035E08	1852	E1M10000230F10	3094	E1M10000289G07	4336	S1M10000013B03	5578	S1M10000037A06
611	E3M10000035F08	1853	E1M10000230H10	3095	E1M10000289A08	4337	S1M10000013C03	5579	S1M10000037B06
612	E3M10000035G08	1854	E1M10000230B11	3096	E1M10000289H08	4338	S1M10000013F03	5580	S1M10000037C06
613	E3M10000035A09	1855	E1M10000230G11	3097	E1M10000289D09	4339	S1M10000013H03	5581	S1M10000037D06
614	E3M10000035C09	1856	E1M10000230C12	3098	E1M10000289C10	4340	S1M10000013B04	5582	S1M10000037E06
615	E3M10000035E09	1857	E1M10000231A02	3099	E1M10000289G10	4341	S1M10000013E04	5583	S1M10000037F06
616	E3M10000035F09	1858	E1M10000231C02	3100	E1M10000289B11	4342	S1M10000013G04	5584	S1M10000037G06
617	E3M10000035G09	1859	E1M10000231D02	3101	E1M10000289G11	4343	S1M10000013H04	5585	S1M10000037B07
618	E3M10000035H09	1860	E1M10000231A03	3102	E1M10000289E12	4344	S1M10000013A05	5586	S1M10000037C07
619	E3M10000035B10	1861	E1M10000231E03	3103	E1M10000290B01	4345	S1M10000013B05	5587	S1M10000037F07
620	E3M10000035D10	1862	E1M10000231H04	3104	E1M10000290G01	4346	S1M10000013C05	5588	S1M10000037H07
621	E3M10000035E10	1863	E1M10000231B05	3105	E1M10000290A02	4347	S1M10000013G05	5589	S1M10000037A08
622	E3M10000035F10	1864	E1M10000231F05	3106	E1M10000290B02	4348	S1M10000013H05	5590	S1M10000037B08
623	E3M10000035G10	1865	E1M10000231C06	3107	E1M10000290E02	4349	S1M10000013B06	5591	S1M10000037C08
624	E3M10000035A11	1866	E1M10000231A08	3108	E1M10000290F04	4350	S1M10000013E06	5592	S1M10000037E08
625	E3M10000035B11	1867	E1M10000231C09	3109	E1M10000290F05	4351	S1M10000013G06	5593	S1M10000037F08
626	E3M10000035C11	1868	E1M10000231G09	3110	E1M10000290D06	4352	S1M10000013A07	5594	S1M10000037G08
627	E3M10000035D11	1869	E1M10000231C10	3111	E1M10000290D08	4353	S1M10000013B07	5595	S1M10000037H08
628	E3M10000035E11	1870	E1M10000231E10	3112	E1M10000290E08	4354	S1M10000013C07	5596	S1M10000037A09
629	E3M10000035F11	1871	E1M10000231D11	3113	E1M10000290F08	4355	S1M10000013F07	5597	S1M10000037C09
630	E3M10000035G11	1872	E1M10000231E11	3114	E1M10000290B09	4356	S1M10000013G07	5598	S1M10000037D09
631	E3M10000035H11	1873	E1M10000231G11	3115	E1M10000290D10	4357	S1M10000013H07	5599	S1M10000037E09
632	E3M10000035B12	1874	E1M10000231C12	3116	E1M10000290E11	4358	S1M10000013A08	5600	S1M10000037F09
633	E3M10000035C12	1875	E1M10000231E12	3117	E1M10000291E01	4359	S1M10000013C08	5601	S1M10000037H09
634	E3M10000035E12	1876	E1M10000231G12	3118	E1M10000291B02	4360	S1M10000013D08	5602	S1M10000037B10
635	E3M10000035F12	1877	E1M10000214E01	3119	E1M10000291F02	4361	S1M10000013E08	5603	S1M10000037C10
636	E3M10000035B01	1878	E1M10000214F01	3120	E1M10000291A03	4362	S1M10000013F08	5604	S1M10000037E10
637	E3M10000035C01	1879	E1M10000214B02	3121	E1M10000291B04	4363	S1M10000013G08	5605	S1M10000037F10
638	E3M10000035E01	1880	E1M10000214E02	3122	E1M10000291E04	4364	S1M10000013A09	5606	S1M10000037G10
639	E3M10000035G01	1881	E1M10000214H02	3123	E1M10000291E05	4365	S1M10000013B09	5607	S1M10000037A11
640	E3M10000035B02	1882	E1M10000214E03	3124	E1M10000291G05	4366	S1M10000013C09	5608	S1M10000037B11
641	E3M10000035H02	1883	E1M10000214C04	3125	E1M10000291A06	4367	S1M10000013D09	5609	S1M10000037E11
642	E3M10000035A03	1884	E1M10000214G06	3126	E1M10000291B06	4368	S1M10000013E09	5610	S1M10000037H11
643	E3M10000035B03	1885	E1M10000214A07	3127	E1M10000291C06	4369	S1M10000013F09	5611	S1M10000037A12
644	E3M10000035C03	1886	E1M10000214D08	3128	E1M10000291D06	4370	S1M10000013H09	5612	S1M10000037B12
645	E3M10000035D03	1887	E1M10000214H11	3129	E1M10000291E07	4371	S1M10000013A10	5613	S1M10000037D12

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
646	E3M10000036H03	1888	E1M10000214F12	3130	E1M10000291A08	4372	S1M10000013C10	5614	S1M10000037E12
647	E3M10000036G03	1889	E1M10000215B01	3131	E1M10000291B08	4373	S1M10000013E10	5615	S1M10000038B01
648	E3M10000036H03	1890	E1M10000215F01	3132	E1M10000291F08	4374	S1M10000013F10	5616	S1M10000038C01
649	E3M10000036A04	1891	E1M10000215B03	3133	E1M10000291B10	4375	S1M10000013G10	5617	S1M10000038E01
650	E3M10000036D04	1892	E1M10000215F03	3134	E1M10000291E10	4376	S1M10000013H10	5618	S1M10000038G01
651	E3M10000036E04	1893	E1M10000215H03	3135	E1M10000291D11	4377	S1M10000013A11	5619	S1M10000038C02
652	E3M10000036F04	1894	E1M10000215B04	3136	E1M10000291F11	4378	S1M10000013B11	5620	S1M10000038D02
653	E3M10000036G04	1895	E1M10000215C05	3137	E1M10000291G11	4379	S1M10000013C11	5621	S1M10000038E02
654	E3M10000036H04	1896	E1M10000215D05	3138	E1M10000291H11	4380	S1M10000013D11	5622	S1M10000038B03
655	E3M10000036A05	1897	E1M10000215F06	3139	E1M10000291B12	4381	S1M10000013G11	5623	S1M10000038D03
656	E3M10000036E05	1898	E1M10000215A07	3140	E1M10000291F12	4382	S1M10000013H11	5624	S1M10000038E03
657	E3M10000036F05	1899	E1M10000215B07	3141	E1M10000293B01	4383	S1M10000013A12	5625	S1M10000038F03
658	E3M10000036H05	1900	E1M10000215C07	3142	E1M10000293B02	4384	S1M10000013F12	5626	S1M10000038G03
659	E3M10000036A06	1901	E1M10000215H07	3143	E1M10000293G02	4385	S1M10000013G12	5627	S1M10000038H03
660	E3M10000036B06	1902	E1M10000215F08	3144	E1M10000293A04	4386	S1M10000014B01	5628	S1M10000038A04
661	E3M10000036C06	1903	E1M10000215A09	3145	E1M10000293B04	4387	S1M10000014E01	5629	S1M10000038D04
662	E3M10000036D06	1904	E1M10000215G09	3146	E1M10000293A05	4388	S1M10000014A02	5630	S1M10000038E04
663	E3M10000036G06	1905	E1M10000215C10	3147	E1M10000293E05	4389	S1M10000014B02	5631	S1M10000038F04
664	E3M10000036H06	1906	E1M10000215D10	3148	E1M10000293G05	4390	S1M10000014F02	5632	S1M10000038G04
665	E3M10000036A07	1907	E1M10000215B12	3149	E1M10000293A06	4391	S1M10000014G02	5633	S1M10000038D05
666	E3M10000036B07	1908	E1M10000215F12	3150	E1M10000293H06	4392	S1M10000014H02	5634	S1M10000038E05
667	E3M10000036C07	1909	E1M10000216E01	3151	E1M10000293F07	4393	S1M10000014A03	5635	S1M10000038B06
668	E3M10000036E07	1910	E1M10000216B02	3152	E1M10000293C08	4394	S1M10000014B03	5636	S1M10000038C06
669	E3M10000036H07	1911	E1M10000216C02	3153	E1M10000293E08	4395	S1M10000014D03	5637	S1M10000038E06
670	E3M10000036A08	1912	E1M10000216G02	3154	E1M10000293G08	4396	S1M10000014F03	5638	S1M10000038F06
671	E3M10000036B08	1913	E1M10000216H02	3155	E1M10000293B09	4397	S1M10000014H03	5639	S1M10000038G06
672	E3M10000036C08	1914	E1M10000216B03	3156	E1M10000293G09	4398	S1M10000014B04	5640	S1M10000038A07
673	E3M10000036E08	1915	E1M10000216D03	3157	E1M10000293H09	4399	S1M10000014E04	5641	S1M10000038B07
674	E3M10000036F08	1916	E1M10000216C04	3158	E1M10000293A11	4400	S1M10000014F04	5642	S1M10000038D07
675	E3M10000036H08	1917	E1M10000216F04	3159	E1M10000293E11	4401	S1M10000014G04	5643	S1M10000038E07
676	E3M10000036A09	1918	E1M10000216E05	3160	E1M10000293F11	4402	S1M10000014H04	5644	S1M10000038H07
677	E3M10000036B09	1919	E1M10000216H05	3161	E1M10000293C12	4403	S1M10000014A05	5645	S1M10000038A08
678	E3M10000036C09	1920	E1M10000216E07	3162	E1M10000293D12	4404	S1M10000014B05	5646	S1M10000038B08
679	E3M10000036D09	1921	E1M10000216A09	3163	E1M10000295D01	4405	S1M10000014C05	5647	S1M10000038C08
680	E3M10000036F09	1922	E1M10000216B10	3164	E1M10000295G01	4406	S1M10000014E05	5648	S1M10000038D08
681	E3M10000036H09	1923	E1M10000216C11	3165	E1M10000295B02	4407	S1M10000014F05	5649	S1M10000038F08

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
682	E3M10000036A10	1924	E1M10000216E11	3166	E1M10000295E02	4408	S1M10000014H05	5650	S1M10000038G08
683	E3M10000036C10	1925	E1M10000216H11	3167	E1M10000295F02	4409	S1M10000014B06	5651	S1M10000038A09
684	E3M10000036D10	1926	E1M10000216D12	3168	E1M10000295H04	4410	S1M10000014C06	5652	S1M10000038B09
685	E3M10000036F10	1927	E1M10000217D02	3169	E1M10000295A07	4411	S1M10000014D06	5653	S1M10000038D09
686	E3M10000036G10	1928	E1M10000217E02	3170	E1M10000295B07	4412	S1M10000014G06	5654	S1M10000038F09
687	E3M10000036H10	1929	E1M10000217H02	3171	E1M10000295C07	4413	S1M10000014H06	5655	S1M10000038H09
688	E3M10000036B11	1930	E1M10000217C04	3172	E1M10000295D08	4414	S1M10000014A07	5656	S1M10000038C10
689	E3M10000036C11	1931	E1M10000217D06	3173	E1M10000295F08	4415	S1M10000014B07	5657	S1M10000038D10
690	E3M10000036D11	1932	E1M10000217B07	3174	E1M10000295G08	4416	S1M10000014C07	5658	S1M10000038E10
691	E3M10000036B12	1933	E1M10000217B08	3175	E1M10000295B09	4417	S1M10000014E07	5659	S1M10000038F10
692	E3M10000036D12	1934	E1M10000217G10	3176	E1M10000295F09	4418	S1M10000014G07	5660	S1M10000038G10
693	E3M10000037C01	1935	E1M10000217B11	3177	E1M10000295G09	4419	S1M10000014B08	5661	S1M10000038A11
694	E3M10000037E01	1936	E1M10000217C11	3178	E1M10000295D10	4420	S1M10000014D08	5662	S1M10000038C11
695	E3M10000037F01	1937	E1M10000217E11	3179	E1M10000295H10	4421	S1M10000014E08	5663	S1M10000038D11
696	E3M10000037G01	1938	E1M10000217G11	3180	E1M10000295B11	4422	S1M10000014F08	5664	S1M10000038F11
697	E3M10000037B02	1939	E1M10000218D01	3181	E1M10000295F11	4423	S1M10000014G08	5665	S1M10000038G11
698	E3M10000037C02	1940	E1M10000218F01	3182	E1M10000295G12	4424	S1M10000014H08	5666	S1M10000038H11
699	E3M10000037D02	1941	E1M10000218A02	3183	E1M10000312D11	4425	S1M10000014C09	5667	S1M10000038A12
700	E3M10000037E02	1942	E1M10000218D02	3184	E1M10000296B01	4426	S1M10000014D09	5668	S1M10000038B12
701	E3M10000037F02	1943	E1M10000218G03	3185	E1M10000296C02	4427	S1M10000014E09	5669	S1M10000038C12
702	E3M10000037G02	1944	E1M10000218E07	3186	E1M10000296D02	4428	S1M10000014F09	5670	S1M10000038D12
703	E3M10000037A03	1945	E1M10000218B08	3187	E1M10000296H02	4429	S1M10000014B10	5671	S1M10000038E12
704	E3M10000037B03	1946	E1M10000218H08	3188	E1M10000296C03	4430	S1M10000014C10	5672	S1M10000038F12
705	E3M10000037D03	1947	E1M10000218B09	3189	E1M10000296E03	4431	S1M10000014D10	5673	S1M10000038G12
706	E3M10000037E03	1948	E1M10000218C10	3190	E1M10000296H03	4432	S1M10000014E10	5674	S1M10000039B01
707	E3M10000037G03	1949	E1M10000218A11	3191	E1M10000296D04	4433	S1M10000014F10	5675	S1M10000039E01
708	E3M10000037C04	1950	E1M10000218B11	3192	E1M10000296G04	4434	S1M10000014A11	5676	S1M10000039A02
709	E3M10000037D04	1951	E1M10000218E11	3193	E1M10000296F05	4435	S1M10000014B11	5677	S1M10000039B02
710	E3M10000037C05	1952	E1M10000218B12	3194	E1M10000296G05	4436	S1M10000014C11	5678	S1M10000039D02
711	E3M10000037D05	1953	E1M10000218C12	3195	E1M10000296H05	4437	S1M10000014D11	5679	S1M10000039F02
712	E3M10000037E05	1954	E1M10000218E12	3196	E1M10000296A06	4438	S1M10000014H11	5680	S1M10000039H02
713	E3M10000037G05	1955	E1M10000218G12	3197	E1M10000296G07	4439	S1M10000014A12	5681	S1M10000039F03
714	E3M10000037H05	1956	E1M10000219C01	3198	E1M10000296H07	4440	S1M10000014B12	5682	S1M10000039G03
715	E3M10000037A06	1957	E1M10000219B04	3199	E1M10000296E08	4441	S1M10000014C12	5683	S1M10000039H03
716	E3M10000037C06	1958	E1M10000219E05	3200	E1M10000296F08	4442	S1M10000014E12	5684	S1M10000039C04
717	E3M10000037D06	1959	E1M10000219F05	3201	E1M10000296G08	4443	S1M10000014G12	5685	S1M10000039G04

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
718	E3M10000037F06	1960	E1M10000219H05	3202	E1M10000296H08	4444	S1M10000015C01	5686	S1M10000039H04		
719	E3M10000037G06	1961	E1M10000219B06	3203	E1M10000296A09	4445	S1M10000015F01	5687	S1M10000039A05		
720	E3M10000037B07	1962	E1M10000219C06	3204	E1M10000296B11	4446	S1M10000015G01	5688	S1M10000039F05		
721	E3M10000037C07	1963	E1M10000219G07	3205	E1M10000296E11	4447	S1M10000015A02	5689	S1M10000039H05		
722	E3M10000037E07	1964	E1M10000219H07	3206	E1M10000296F12	4448	S1M10000015B02	5690	S1M10000039B06		
723	E3M10000037F07	1965	E1M10000219A08	3207	E1M10000296G12	4449	S1M10000015C02	5691	S1M10000039C06		
724	E3M10000037G07	1966	E1M10000219A09	3208	E1M10000298C01	4450	S1M10000015D02	5692	S1M10000039H06		
725	E3M10000037H07	1967	E1M10000219E09	3209	E1M10000298G01	4451	S1M10000015E02	5693	S1M10000039A07		
726	E3M10000037A08	1968	E1M10000219A10	3210	E1M10000298G02	4452	S1M10000015F02	5694	S1M10000039B07		
727	E3M10000037B08	1969	E1M10000219E10	3211	E1M10000298C03	4453	S1M10000015G02	5695	S1M10000039C07		
728	E3M10000037E08	1970	E1M10000219D11	3212	E1M10000298D03	4454	S1M10000015A03	5696	S1M10000039F07		
729	E3M10000037G08	1971	E1M10000220B01	3213	E1M10000298H03	4455	S1M10000015C03	5697	S1M10000039G07		
730	E3M10000037A09	1972	E1M10000220C01	3214	E1M10000298E04	4456	S1M10000015D03	5698	S1M10000039H07		
731	E3M10000037D09	1973	E1M10000220D01	3215	E1M10000298H04	4457	S1M10000015E03	5699	S1M10000039A08		
732	E3M10000037A10	1974	E1M10000220F01	3216	E1M10000298C05	4458	S1M10000015F03	5700	S1M10000039C08		
733	E3M10000037E10	1975	E1M10000220F02	3217	E1M10000298D05	4459	S1M10000015G03	5701	S1M10000039E08		
734	E3M10000037G10	1976	E1M10000220A03	3218	E1M10000298C06	4460	S1M10000015A04	5702	S1M10000039F08		
735	E3M10000037H10	1977	E1M10000220B03	3219	E1M10000298D06	4461	S1M10000015D04	5703	S1M10000039H08		
736	E3M10000037B11	1978	E1M10000220F04	3220	E1M10000298G06	4462	S1M10000015F04	5704	S1M10000039C09		
737	E3M10000037C11	1979	E1M10000220G04	3221	E1M10000298B07	4463	S1M10000015G04	5705	S1M10000039D09		
738	E3M10000037D11	1980	E1M10000220B05	3222	E1M10000298C07	4464	S1M10000015H04	5706	S1M10000039E09		
739	E3M10000037G11	1981	E1M10000220E05	3223	E1M10000298G07	4465	S1M10000015A05	5707	S1M10000039F09		
740	E3M10000037C12	1982	E1M10000220H05	3224	E1M10000298B09	4466	S1M10000015C05	5708	S1M10000039B10		
741	E3M10000037E12	1983	E1M10000220B06	3225	E1M10000298D09	4467	S1M10000015D05	5709	S1M10000039C10		
742	E3M10000037F12	1984	E1M10000220D06	3226	E1M10000298D11	4468	S1M10000015G05	5710	S1M10000039D10		
743	E3M10000038D01	1985	E1M10000220F06	3227	E1M10000298F11	4469	S1M10000015A06	5711	S1M10000039E10		
744	E3M10000038B02	1986	E1M10000220A08	3228	E1M10000311F01	4470	S1M10000015C06	5712	S1M10000039F10		
745	E3M10000038C02	1987	E1M10000220C08	3229	E1M10000311C02	4471	S1M10000015D06	5713	S1M10000039G10		
746	E3M10000038D02	1988	E1M10000220A09	3230	E1M10000311E02	4472	S1M10000015E06	5714	S1M10000039A11		
747	E3M10000038E02	1989	E1M10000220D09	3231	E1M10000311A03	4473	S1M10000015F06	5715	S1M10000039C11		
748	E3M10000038G02	1990	E1M10000220G09	3232	E1M10000311C03	4474	S1M10000015G06	5716	S1M10000039E11		
749	E3M10000038H02	1991	E1M10000220A11	3233	E1M10000311D03	4475	S1M10000015H06	5717	S1M10000039A12		
750	E3M10000038A03	1992	E1M10000220H11	3234	E1M10000311H03	4476	S1M10000015E07	5718	S1M10000039B12		
751	E3M10000038B03	1993	E1M10000221B01	3235	E1M10000311D04	4477	S1M10000015F07	5719	S1M10000039F12		
752	E3M10000038C03	1994	E1M10000221E01	3236	E1M10000311E05	4478	S1M10000015G07	5720	S1M10000040B01		
753	E3M10000038E03	1995	E1M10000221B02	3237	E1M10000311F05	4479	S1M10000015B08	5721	S1M10000040D01		

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
754	E3M10000038G03	1996	E1M10000221F02	3238	E1M10000311D06	4480	S1M10000015C08	5722	S1M10000040E01
755	E3M10000038B04	1997	E1M10000222B02	3239	E1M10000311C07	4481	S1M10000015F08	5723	S1M10000040F01
756	E3M10000038D04	1998	E1M10000222D02	3240	E1M10000311E07	4482	S1M10000015G08	5724	S1M10000040G01
757	E3M10000038E04	1999	E1M10000222E05	3241	E1M10000311F07	4483	S1M10000015A09	5725	S1M10000040H01
758	E3M10000038F04	2000	E1M10000222F05	3242	E1M10000311D08	4484	S1M10000015B09	5726	S1M10000040E02
759	E3M10000038A05	2001	E1M10000222B09	3243	E1M10000311C09	4485	S1M10000015E09	5727	S1M10000040F02
760	E3M10000038B05	2002	E1M10000222B10	3244	E1M10000311F09	4486	S1M10000015F09	5728	S1M10000040G02
761	E3M10000038C05	2003	E1M10000222C12	3245	E1M10000311C10	4487	S1M10000015G09	5729	S1M10000040H02
762	E3M10000038E05	2004	E1M10000222E12	3246	E1M10000311E11	4488	S1M10000015B10	5730	S1M10000040B03
763	E3M10000038F05	2005	E1M10000222C04	3247	E1M10000311B12	4489	S1M10000015C10	5731	S1M10000040C03
764	E3M10000038H05	2006	E1M10000223F04	3248	E1M10000311F12	4490	S1M10000015E10	5732	S1M10000040D03
765	E3M10000038B06	2007	E1M10000223H05	3249	E1M10000292C05	4491	S1M10000015F10	5733	S1M10000040F03
766	E3M10000038F06	2008	E1M10000223H11	3250	E1M10000292D08	4492	S1M10000015G10	5734	S1M10000040G03
767	E3M10000038G06	2009	E1M10000224E05	3251	E1M10000292A09	4493	S1M10000015A11	5735	S1M10000040H03
768	E3M10000038H06	2010	E1M10000225G01	3252	E1M10000292C12	4494	S1M10000015C11	5736	S1M10000040A04
769	E3M10000038A07	2011	E1M10000225A02	3253	E1M10000294F01	4495	S1M10000015E11	5737	S1M10000040C04
770	E3M10000038B07	2012	E1M10000225C02	3254	E1M10000294C02	4496	S1M10000015G11	5738	S1M10000040E04
771	E3M10000038C07	2013	E1M10000225E02	3255	E1M10000294E02	4497	S1M10000015A12	5739	S1M10000040F04
772	E3M10000038E07	2014	E1M10000225F03	3256	E1M10000294G02	4498	S1M10000015C12	5740	S1M10000040G04
773	E3M10000038F07	2015	E1M10000225H03	3257	E1M10000294A04	4499	S1M10000015D12	5741	S1M10000040H04
774	E3M10000038G07	2016	E1M10000225F04	3258	E1M10000294C04	4500	S1M10000015E12	5742	S1M10000040A05
775	E3M10000038H07	2017	E1M10000225A06	3259	E1M10000294F04	4501	S1M10000016C01	5743	S1M10000040C05
776	E3M10000038A08	2018	E1M10000225B06	3260	E1M10000294H04	4502	S1M10000016D01	5744	S1M10000040D05
777	E3M10000038B08	2019	E1M10000225B07	3261	E1M10000294D05	4503	S1M10000016G01	5745	S1M10000040E05
778	E3M10000038D08	2020	E1M10000225E08	3262	E1M10000294F05	4504	S1M10000016B02	5746	S1M10000040F05
779	E3M10000038E08	2021	E1M10000225E09	3263	E1M10000294H05	4505	S1M10000016C02	5747	S1M10000040H05
780	E3M10000038H08	2022	E1M10000225H09	3264	E1M10000294C06	4506	S1M10000016D02	5748	S1M10000040C06
781	E3M10000038A09	2023	E1M10000225F10	3265	E1M10000294F06	4507	S1M10000016F02	5749	S1M10000040E06
782	E3M10000038B09	2024	E1M10000225D12	3266	E1M10000294G06	4508	S1M10000016A03	5750	S1M10000040F06
783	E3M10000038F09	2025	E1M10000225G12	3267	E1M10000294A08	4509	S1M10000016F03	5751	S1M10000040A07
784	E3M10000038H09	2026	E1M10000226E01	3268	E1M10000294B09	4510	S1M10000016G03	5752	S1M10000040B07
785	E3M10000038A10	2027	E1M10000226B02	3269	E1M10000294E09	4511	S1M10000016H03	5753	S1M10000040C07
786	E3M10000038C10	2028	E1M10000226C02	3270	E1M10000294F09	4512	S1M10000016A04	5754	S1M10000040E07
787	E3M10000038D10	2029	E1M10000226F02	3271	E1M10000294B10	4513	S1M10000016C04	5755	S1M10000040G07
788	E3M10000038F10	2030	E1M10000226D03	3272	E1M10000294G10	4514	S1M10000016D04	5756	S1M10000040H07
789	E3M10000038H10	2031	E1M10000226G03	3273	E1M10000294F11	4515	S1M10000016E04	5757	S1M10000040A08

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
790	E3M10000038A11	2032	E1M10000226F04	3274	E1M10000294B12	4516	S1M10000016G04	5758	S1M10000040B08
791	E3M10000038B11	2033	E1M10000226H04	3275	E1M10000294C12	4517	S1M10000016H04	5759	S1M10000040C08
792	E3M10000038D11	2034	E1M10000226H06	3276	E1M10000294E12	4518	S1M10000016B05	5760	S1M10000040D08
793	E3M10000038E11	2035	E1M10000226A08	3277	E1M10000300F05	4519	S1M10000016C05	5761	S1M10000040F08
794	E3M10000038F11	2036	E1M10000226D08	3278	E1M10000300E08	4520	S1M10000016D05	5762	S1M10000040G08
795	E3M10000038G11	2037	E1M10000226D09	3279	E1M10000300G09	4521	S1M10000016E05	5763	S1M10000040H08
796	E3M10000038H11	2038	E1M10000226B10	3280	E1M10000301F02	4522	S1M10000016F05	5764	S1M10000040D09
797	E3M10000038C12	2039	E1M10000226D10	3281	E1M10000301F03	4523	S1M10000016G05	5765	S1M10000040E09
798	E3M10000038D12	2040	E1M10000226E10	3282	E1M10000301G05	4524	S1M10000016A06	5766	S1M10000040F09
799	E3M10000039B01	2041	E1M10000226G11	3283	E1M10000301C06	4525	S1M10000016B06	5767	S1M10000040C10
800	E3M10000039E01	2042	E1M10000226B12	3284	E1M10000301F06	4526	S1M10000016C06	5768	S1M10000040D10
801	E3M10000039F01	2043	E1M10000226F12	3285	E1M10000301G08	4527	S1M10000016D06	5769	S1M10000040E10
802	E3M10000039G01	2044	E1M10000227E03	3286	E1M10000301C09	4528	S1M10000016E06	5770	S1M10000040G10
803	E3M10000039A02	2045	E1M10000227G03	3287	E1M10000301F09	4529	S1M10000016F06	5771	S1M10000040H10
804	E3M10000039C02	2046	E1M10000227E04	3288	E1M10000301D10	4530	S1M10000016A07	5772	S1M10000040A11
805	E3M10000039D02	2047	E1M10000227H04	3289	E1M10000301F10	4531	S1M10000016B07	5773	S1M10000040B11
806	E3M10000039E02	2048	E1M10000227C05	3290	E1M10000301G12	4532	S1M10000016E07	5774	S1M10000040C11
807	E3M10000039F02	2049	E1M10000227C07	3291	E1M10000309G01	4533	S1M10000016B08	5775	S1M10000040D11
808	E3M10000039G02	2050	E1M10000227G07	3292	E1M10000309A02	4534	S1M10000016C08	5776	S1M10000040E11
809	E3M10000039H02	2051	E1M10000227B08	3293	E1M10000309G02	4535	S1M10000016D08	5777	S1M10000040E12
810	E3M10000039B03	2052	E1M10000227D08	3294	E1M10000309A03	4536	S1M10000016E08	5778	S1M10000040F12
811	E3M10000039D03	2053	E1M10000227B09	3295	E1M10000309E03	4537	S1M10000016F08	5779	S1M10000040G12
812	E3M10000039E03	2054	E1M10000227D09	3296	E1M10000309G03	4538	S1M10000016H08	5780	S1M10000041G01
813	E3M10000039F03	2055	E1M10000227E11	3297	E1M10000309H04	4539	S1M10000016A09	5781	S1M10000041H01
814	E3M10000039B04	2056	E1M10000227C12	3298	E1M10000309H05	4540	S1M10000016B09	5782	S1M10000041B02
815	E3M10000039C04	2057	E1M10000227D12	3299	E1M10000309B06	4541	S1M10000016C09	5783	S1M10000041A03
816	E3M10000039D04	2058	E1M10000232H02	3300	E1M10000309B07	4542	S1M10000016D09	5784	S1M10000041B03
817	E3M10000039C05	2059	E1M10000232A03	3301	E1M10000309E07	4543	S1M10000016E09	5785	S1M10000041D03
818	E3M10000039E05	2060	E1M10000232B03	3302	E1M10000309B08	4544	S1M10000016F09	5786	S1M10000041E03
819	E3M10000039G05	2061	E1M10000232H03	3303	E1M10000309E08	4545	S1M10000016A10	5787	S1M10000041F03
820	E3M10000039A06	2062	E1M10000232C07	3304	E1M10000309G09	4546	S1M10000016B10	5788	S1M10000041H04
821	E3M10000039B06	2063	E1M10000232F07	3305	E1M10000309A10	4547	S1M10000016C10	5789	S1M10000041B05
822	E3M10000039C06	2064	E1M10000232G07	3306	E1M10000309G11	4548	S1M10000016D10	5790	S1M10000041G05
823	E3M10000039D06	2065	E1M10000232A08	3307	E1M10000309H11	4549	S1M10000016E10	5791	S1M10000041H05
824	E3M10000039F06	2066	E1M10000232G08	3308	E1M10000309F12	4550	S1M10000016H10	5792	S1M10000041B06
825	E3M10000039A07	2067	E1M10000232G12	3309	E1M10000310G01	4551	S1M10000016B11	5793	S1M10000041D06

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
826	E3M10000039B07	2068	E1M10000233C01	3310	E1M10000310C02	4552	S1M10000016C11	5794	S1M10000041E06
827	E3M10000039C07	2069	E1M10000233A03	3311	E1M10000310G02	4553	S1M10000016D11	5795	S1M10000041G06
828	E3M10000039E07	2070	E1M10000233B03	3312	E1M10000310D03	4554	S1M10000016E11	5796	S1M10000041B07
829	E3M10000039F07	2071	E1M10000233D03	3313	E1M10000310H03	4555	S1M10000016F11	5797	S1M10000041D07
830	E3M10000039G07	2072	E1M10000233H03	3314	E1M10000310A04	4556	S1M10000016A12	5798	S1M10000041H07
831	E3M10000039H07	2073	E1M10000233C04	3315	E1M10000310B04	4557	S1M10000016B12	5799	S1M10000041C08
832	E3M10000039A08	2074	E1M10000233G04	3316	E1M10000310C04	4558	S1M10000016C12	5800	S1M10000041D08
833	E3M10000039B08	2075	E1M10000233A05	3317	E1M10000310D04	4559	S1M10000016E12	5801	S1M10000041G08
834	E3M10000039C08	2076	E1M10000233C05	3318	E1M10000310A05	4560	S1M10000017C01	5802	S1M10000041H08
835	E3M10000039E08	2077	E1M10000233H05	3319	E1M10000310C05	4561	S1M10000017F01	5803	S1M10000041E09
836	E3M10000039F08	2078	E1M10000233D08	3320	E1M10000310A06	4562	S1M10000017A02	5804	S1M10000041H09
837	E3M10000039H08	2079	E1M10000233F08	3321	E1M10000310D06	4563	S1M10000017B02	5805	S1M10000041C10
838	E3M10000039B09	2080	E1M10000233A09	3322	E1M10000310F06	4564	S1M10000017G02	5806	S1M10000041D10
839	E3M10000039C09	2081	E1M10000233E09	3323	E1M10000310A07	4565	S1M10000017A03	5807	S1M10000041G10
840	E3M10000039G09	2082	E1M10000233F09	3324	E1M10000310B07	4566	S1M10000017C03	5808	S1M10000041C11
841	E3M10000039A10	2083	E1M10000233D10	3325	E1M10000310E07	4567	S1M10000017D03	5809	S1M10000041F11
842	E3M10000039C10	2084	E1M10000233H10	3326	E1M10000310A08	4568	S1M10000017A04	5810	S1M10000041G11
843	E3M10000039G10	2085	E1M10000234E01	3327	E1M10000310C09	4569	S1M10000017E04	5811	S1M10000041B12
844	E3M10000039A11	2086	E1M10000234B02	3328	E1M10000310H09	4570	S1M10000017F04	5812	S1M10000041D12
845	E3M10000039B11	2087	E1M10000234G02	3329	E1M10000310B11	4571	S1M10000017B05	5813	S1M10000041E12
846	E3M10000039H11	2088	E1M10000234C05	3330	E1M10000310F11	4572	S1M10000017C05	5814	S1M10000041F12
847	E3M10000040B01	2089	E1M10000234C07	3331	E1M10000310D12	4573	S1M10000017E05	5815	S1M10000042E01
848	E3M10000040F01	2090	E1M10000234C08	3332	E1M10000316D03	4574	S1M10000017F05	5816	S1M10000042F01
849	E3M10000040G01	2091	E1M10000234F08	3333	E1M10000316G03	4575	S1M10000017G05	5817	S1M10000042G01
850	E3M10000040B02	2092	E1M10000234H08	3334	E1M10000316C04	4576	S1M10000017F06	5818	S1M10000042B02
851	E3M10000040C02	2093	E1M10000234F09	3335	E1M10000316H05	4577	S1M10000017G06	5819	S1M10000042C02
852	E3M10000040G02	2094	E1M10000234D10	3336	E1M10000316D08	4578	S1M10000017A07	5820	S1M10000042F02
853	E3M10000040H02	2095	E1M10000234G10	3337	E1M10000316A11	4579	S1M10000017B07	5821	S1M10000042B03
854	E3M10000040A03	2096	E1M10000234B12	3338	E1M10000316D11	4580	S1M10000017A08	5822	S1M10000042E03
855	E3M10000040B03	2097	E1M10000235D01	3339	E1M10000280A04	4581	S1M10000017B08	5823	S1M10000042G03
856	E3M10000040D03	2098	E1M10000235A03	3340	E1M10000281E01	4582	S1M10000017C08	5824	S1M10000042A04
857	E3M10000040F03	2099	E1M10000235H03	3341	E1M10000281G01	4583	S1M10000017E08	5825	S1M10000042D04
858	E3M10000040H03	2100	E1M10000235E04	3342	E1M10000281E03	4584	S1M10000017B09	5826	S1M10000042A05
859	E3M10000040D04	2101	E1M10000235B06	3343	E1M10000281H03	4585	S1M10000017C09	5827	S1M10000042C05
860	E3M10000040G04	2102	E1M10000235F06	3344	E1M10000281C08	4586	S1M10000017D09	5828	S1M10000042F05
861	E3M10000040H04	2103	E1M10000235B08	3345	E1M10000281C11	4587	S1M10000017B10	5829	S1M10000042H05

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
862	E3M10000040A05	2104	E1M10000235E08	3346	E1M10000282A02	4588	S1M10000017C10	5830	S1M10000042A06
863	E3M10000040B05	2105	E1M10000235B09	3347	E1M10000284B01	4589	S1M10000017D10	5831	S1M10000042B06
864	E3M10000040C05	2106	E1M10000235H09	3348	E1M10000284A03	4590	S1M10000017A11	5832	S1M10000042C06
865	E3M10000040G05	2107	E1M10000235B10	3349	E1M10000284B03	4591	S1M10000017B11	5833	S1M10000042E06
866	E3M10000040H05	2108	E1M10000235A11	3350	E1M10000284H03	4592	S1M10000017C11	5834	S1M10000042F06
867	E3M10000040B06	2109	E1M10000235F12	3351	E1M10000284C05	4593	S1M10000017E11	5835	S1M10000042A07
868	E3M10000040C06	2110	E1M10000236E01	3352	E1M10000284E05	4594	S1M10000017F11	5836	S1M10000042B07
869	E3M10000040A07	2111	E1M10000236A02	3353	E1M10000284D06	4595	S1M10000017A12	5837	S1M10000042D07
870	E3M10000040C07	2112	E1M10000236E02	3354	E1M10000284H06	4596	S1M10000017B12	5838	S1M10000042H07
871	E3M10000040G07	2113	E1M10000236A03	3355	E1M10000284A08	4597	S1M10000017C12	5839	S1M10000042B08
872	E3M10000040H07	2114	E1M10000236D03	3356	E1M10000284D08	4598	S1M10000018C01	5840	S1M10000042E08
873	E3M10000040B08	2115	E1M10000236G03	3357	E1M10000284G11	4599	S1M10000018D01	5841	S1M10000042F08
874	E3M10000040C08	2116	E1M10000236A04	3358	E1M10000284C12	4600	S1M10000018E01	5842	S1M10000042G08
875	E3M10000040D08	2117	E1M10000236D04	3359	E1M10000284D12	4601	S1M10000018H01	5843	S1M10000042A09
876	E3M10000040F08	2118	E1M10000236G04	3360	E1M10000284G12	4602	S1M10000018B02	5844	S1M10000042B09
877	E3M10000040G08	2119	E1M10000236A05	3361	E1M10000285B03	4603	S1M10000018C02	5845	S1M10000042F09
878	E3M10000040A09	2120	E1M10000236F05	3362	E1M10000285D03	4604	S1M10000018D02	5846	S1M10000042G09
879	E3M10000040B09	2121	E1M10000236H06	3363	E1M10000285H03	4605	S1M10000018E02	5847	S1M10000042B10
880	E3M10000040C09	2122	E1M10000236D08	3364	E1M10000285F04	4606	S1M10000018H02	5848	S1M10000042C10
881	E3M10000040D09	2123	E1M10000236F09	3365	E1M10000285G04	4607	S1M10000018A03	5849	S1M10000042D10
882	E3M10000040F09	2124	E1M10000236C10	3366	E1M10000285D05	4608	S1M10000018B03	5850	S1M10000042F10
883	E3M10000040G09	2125	E1M10000236A11	3367	E1M10000285B07	4609	S1M10000018C03	5851	S1M10000042G10
884	E3M10000040H09	2126	E1M10000236C11	3368	E1M10000285G07	4610	S1M10000018D03	5852	S1M10000042A11
885	E3M10000040A10	2127	E1M10000236F12	3369	E1M10000285B08	4611	S1M10000018E03	5853	S1M10000042B11
886	E3M10000040B10	2128	E1M10000237A02	3370	E1M10000285D08	4612	S1M10000018F03	5854	S1M10000042C11
887	E3M10000040C10	2129	E1M10000237B02	3371	E1M10000285G08	4613	S1M10000018G03	5855	S1M10000042D11
888	E3M10000040E10	2130	E1M10000237E04	3372	E1M10000285D09	4614	S1M10000018A04	5856	S1M10000042F11
889	E3M10000040A11	2131	E1M10000237H04	3373	E1M10000285F09	4615	S1M10000018C04	5857	S1M10000042H11
890	E3M10000040B11	2132	E1M10000237G06	3374	E1M10000285D10	4616	S1M10000018D04	5858	S1M10000042A12
891	E3M10000040C11	2133	E1M10000237C07	3375	E1M10000285F10	4617	S1M10000018E04	5859	S1M10000042B12
892	E3M10000040E11	2134	E1M10000237G07	3376	E1M10000285G10	4618	S1M10000018F04	5860	S1M10000042G12
893	E3M10000040F11	2135	E1M10000237H07	3377	E1M10000285E11	4619	S1M10000018A05	5861	S1M10000043B01
894	E3M10000040G11	2136	E1M10000237A08	3378	E1M10000285F11	4620	S1M10000018B05	5862	S1M10000043D01
895	E3M10000040B12	2137	E1M10000237B08	3379	E1M10000285G11	4621	S1M10000018C05	5863	S1M10000043F01
896	E3M10000040C12	2138	E1M10000237D08	3380	E1M10000285F12	4622	S1M10000018E05	5864	S1M10000043G01
897	E3M10000040D12	2139	E1M10000237E08	3381	E1M10000286E03	4623	S1M10000018G05	5865	S1M10000043H01

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
898	E3M10000040E12	2140	E1M100000237B09	3382	E1M100000286C12	4624	S1M10000018A06	5866	S1M10000043A02
899	E3M10000040G12	2141	E1M100000237D10	3383	E1M100000287H06	4625	S1M10000018C06	5867	S1M10000043B02
900	E3M10000041C01	2142	E1M100000237E11	3384	E1M100000289D04	4626	S1M10000018F06	5868	S1M10000043C02
901	E3M10000041B02	2143	E1M100000238G01	3385	E1M100000289G12	4627	S1M10000018F07	5869	S1M10000043D02
902	E3M10000041C02	2144	E1M100000238A02	3386	E1M100000293B03	4628	S1M10000018G07	5870	S1M10000043E02
903	E3M10000041D02	2145	E1M100000238F03	3387	E1M100000293G03	4629	S1M10000018H07	5871	S1M10000043A03
904	E3M10000041E02	2146	E1M100000238B04	3388	E1M100000296H06	4630	S1M10000018A08	5872	S1M10000043E03
905	E3M10000041G02	2147	E1M100000238D04	3389	E1M100000299E01	4631	S1M10000018C08	5873	S1M10000043H03
906	E3M10000041A03	2148	E1M100000238F04	3390	E1M100000299E02	4632	S1M10000018E08	5874	S1M10000043A04
907	E3M10000041B03	2149	E1M100000238E05	3391	E1M100000299B03	4633	S1M10000018F08	5875	S1M10000043D04
908	E3M10000041D03	2150	E1M100000238F05	3392	E1M100000299E08	4634	S1M10000018G08	5876	S1M10000043G04
909	E3M10000041E03	2151	E1M100000238D06	3393	E1M100000300D10	4635	S1M10000018A09	5877	S1M10000043H04
910	E3M10000041F03	2152	E1M100000238F06	3394	E1M100000300H10	4636	S1M10000018B09	5878	S1M10000043E05
911	E3M10000041G03	2153	E1M100000238A07	3395	E1M100000300F11	4637	S1M10000018C09	5879	S1M10000043F05
912	E3M10000041C04	2154	E1M100000238A08	3396	E1M100000302H05	4638	S1M10000018D09	5880	S1M10000043G05
913	E3M10000041D04	2155	E1M100000238E08	3397	E1M100000306D03	4639	S1M10000018E09	5881	S1M10000043H05
914	E3M10000041G04	2156	E1M100000238B09	3398	E1M100000307A08	4640	S1M10000018F09	5882	S1M10000043A06
915	E3M10000041H04	2157	E1M100000238G09	3399	E1M100000308B03	4641	S1M10000018G09	5883	S1M10000043H06
916	E3M10000041A05	2158	E1M100000238H09	3400	E1M100000311A02	4642	S1M10000018H09	5884	S1M10000043A07
917	E3M10000041B05	2159	E1M100000238F12	3401	E1M100000311A07	4643	S1M10000018A10	5885	S1M10000043B07
918	E3M10000041D05	2160	E1M100000239B01	3402	E1M100000313E07	4644	S1M10000018B10	5886	S1M10000043C07
919	E3M10000041E05	2161	E1M100000239D01	3403	E1M100000314G03	4645	S1M10000018C10	5887	S1M10000043E07
920	E3M10000041F05	2162	E1M100000239D02	3404	E1M100000314F08	4646	S1M10000018D10	5888	S1M10000043F07
921	E3M10000041H05	2163	E1M100000239C03	3405	E1M100000317H03	4647	S1M10000018F10	5889	S1M10000043A08
922	E3M10000041B06	2164	E1M100000239E04	3406	E1M100000317C04	4648	S1M10000018G10	5890	S1M10000043B08
923	E3M10000041D06	2165	E1M100000239F04	3407	E1M100000317C05	4649	S1M10000018H10	5891	S1M10000043E08
924	E3M10000041F06	2166	E1M100000239C05	3408	K1M100000002F02	4650	S1M10000018A11	5892	S1M10000043F08
925	E3M10000041G06	2167	E1M100000239H05	3409	K1M100000003C01	4651	S1M10000018B11	5893	S1M10000043B09
926	E3M10000041H06	2168	E1M100000239H07	3410	K1M100000004F06	4652	S1M10000018C11	5894	S1M10000043F09
927	E3M10000041A07	2169	E1M100000239A08	3411	K1M100000007F01	4653	S1M10000018D11	5895	S1M10000043G09
928	E3M10000041C07	2170	E1M100000239D08	3412	K1M100000008C10	4654	S1M10000018E11	5896	S1M10000043H09
929	E3M10000041E07	2171	E1M100000239F08	3413	K1M10000013E04	4655	S1M10000018A12	5897	S1M10000043A10
930	E3M10000041F07	2172	E1M100000239H08	3414	K1M10000013E06	4656	S1M10000018C12	5898	S1M10000043B10
931	E3M10000041G07	2173	E1M100000239H10	3415	K1M10000015E05	4657	S1M10000018D12	5899	S1M10000043D10
932	E3M10000041A08	2174	E1M100000239G11	3416	K1M10000019D06	4658	S1M10000018E12	5900	S1M10000043E10
933	E3M10000041B08	2175	E1M100000239G12	3417	K1M100000020B02	4659	S1M10000018F12	5901	S1M10000043G10

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
934	E3M10000041C08	2176	E1M10000240B03	3418	K1M100000022C10	4660	S1M10000018G12	5902	S1M10000043H10
935	E3M10000041D08	2177	E1M10000240D03	3419	K1M10000030C03	4661	S1M10000019B01	5903	S1M10000043A11
936	E3M10000041F08	2178	E1M10000240A04	3420	K1M10000030C04	4662	S1M10000019C01	5904	S1M10000043C11
937	E3M10000041G08	2179	E1M10000240D06	3421	K1M10000030C07	4663	S1M10000019D01	5905	S1M10000043E11
938	E3M10000041H08	2180	E1M10000240G07	3422	K1M10000030E07	4664	S1M10000019E01	5906	S1M10000043H11
939	E3M10000041A09	2181	E1M10000240C08	3423	K1M10000032E11	4665	S1M10000019F01	5907	S1M10000043A12
940	E3M10000041B09	2182	E1M10000240F08	3424	K1M10000033E01	4666	S1M10000019A02	5908	S1M10000043B12
941	E3M10000041C09	2183	E1M10000240B10	3425	K1M10000033B02	4667	S1M10000019D02	5909	S1M10000043C12
942	E3M10000041D09	2184	E1M10000240B11	3426	K1M10000037D10	4668	S1M10000019E02	5910	S1M10000043D12
943	E3M10000041F09	2185	E1M10000240H11	3427	K1M10000038D04	4669	S1M10000019A03	5911	S1M10000043E12
944	E3M10000041G09	2186	E1M10000240B12	3428	K1M10000039A12	4670	S1M10000019B03	5912	S1M10000044B01
945	E3M10000041H09	2187	E1M10000241F01	3429	K1M10000043E02	4671	S1M10000019D03	5913	S1M10000044D01
946	E3M10000041A10	2188	E1M10000241A02	3430	K1M10000043D05	4672	S1M10000019B04	5914	S1M10000044E01
947	E3M10000041B10	2189	E1M10000241H02	3431	K1M10000043H10	4673	S1M10000019C04	5915	S1M10000044A02
948	E3M10000041C10	2190	E1M10000241A04	3432	K1M10000044G05	4674	S1M10000019D04	5916	S1M10000044B02
949	E3M10000041D10	2191	E1M10000241C06	3433	K1M10000045D10	4675	S1M10000019G04	5917	S1M10000044E02
950	E3M10000041E10	2192	E1M10000241F06	3434	P1M10000008G04	4676	S1M10000019A05	5918	S1M10000044F02
951	E3M10000041F10	2193	E1M10000241H07	3435	P1M10000008C06	4677	S1M10000019C05	5919	S1M10000044G02
952	E3M10000041G10	2194	E1M10000241A08	3436	P1M10000010C03	4678	S1M10000019D05	5920	S1M10000044C04
953	E3M10000041H10	2195	E1M10000241B08	3437	P1M10000015C09	4679	S1M10000019F05	5921	S1M10000044D04
954	E3M10000041A11	2196	E1M10000241E08	3438	P1M10000018B01	4680	S1M10000019H05	5922	S1M10000044B05
955	E3M10000041B11	2197	E1M10000241G08	3439	P1M10000018C01	4681	S1M10000019A06	5923	S1M10000044G05
956	E3M10000041C11	2198	E1M10000241A09	3440	P1M10000018E01	4682	S1M10000019C06	5924	S1M10000044H05
957	E3M10000041D11	2199	E1M10000241E09	3441	P1M10000019F01	4683	S1M10000019D06	5925	S1M10000044A06
958	E3M10000041E11	2200	E1M10000241H09	3442	P1M10000019E02	4684	S1M10000019F06	5926	S1M10000044B06
959	E3M10000041F11	2201	E1M10000241B11	3443	P1M10000021G03	4685	S1M10000019A07	5927	S1M10000044C06
960	E3M10000041H11	2202	E1M10000241E12	3444	P1M10000021G05	4686	S1M10000019B07	5928	S1M10000044D06
961	E3M10000041B12	2203	E1M10000242D06	3445	P1M10000022D09	4687	S1M10000019C07	5929	S1M10000044E06
962	E3M10000041C12	2204	E1M10000242F07	3446	P1M10000024H03	4688	S1M10000019D07	5930	S1M10000044F06
963	E3M10000041D12	2205	E1M10000242H07	3447	P1M10000024D06	4689	S1M10000019E07	5931	S1M10000044H06
964	E3M10000041G12	2206	E1M10000242F08	3448	P1M10000024E06	4690	S1M10000019G07	5932	S1M10000044C07
965	E3M10000042B01	2207	E1M10000242E11	3449	P1M10000025G07	4691	S1M10000019A08	5933	S1M10000044E07
966	E3M10000042D01	2208	E1M10000242H11	3450	P1M10000025H07	4692	S1M10000019B08	5934	S1M10000044H07
967	E3M10000042G01	2209	E1M10000242E12	3451	P1M10000026H02	4693	S1M10000019C08	5935	S1M10000044A08
968	E3M10000042A02	2210	E1M10000243F03	3452	P1M10000026F04	4694	S1M10000019F08	5936	S1M10000044B08
969	E3M10000042B02	2211	E1M10000243G03	3453	P1M10000026H05	4695	S1M10000019G08	5937	S1M10000044C08

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
970	E3M10000042C02	2212	E1M10000243B04	3454	P1M10000026E06	4696	S1M10000019H08	5938	S1M10000044D08		
971	E3M10000042D02	2213	E1M10000243F04	3455	P1M10000026E09	4697	S1M10000019A09	5939	S1M10000044F08		
972	E3M10000042A03	2214	E1M10000243F06	3456	P1M10000026G09	4698	S1M10000019B09	5940	S1M10000044G08		
973	E3M10000042C03	2215	E1M10000243F07	3457	P1M10000027B02	4699	S1M10000019D09	5941	S1M10000044H08		
974	E3M10000042D03	2216	E1M10000243H07	3458	P1M10000027G05	4700	S1M10000019F09	5942	S1M10000044A09		
975	E3M10000042B04	2217	E1M10000243F09	3459	P1M10000027A06	4701	S1M10000019G09	5943	S1M10000044D09		
976	E3M10000042C04	2218	E1M10000243B10	3460	P1M10000028B01	4702	S1M10000019B10	5944	S1M10000044E09		
977	E3M10000042E05	2219	E1M10000243E11	3461	P1M10000028E02	4703	S1M10000019G10	5945	S1M10000044H09		
978	E3M10000042G05	2220	E1M10000244F01	3462	P1M10000028A08	4704	S1M10000019A11	5946	S1M10000044D10		
979	E3M10000042D06	2221	E1M10000244C02	3463	P1M10000029G03	4705	S1M10000019B11	5947	S1M10000044E10		
980	E3M10000042H06	2222	E1M10000244E02	3464	P1M10000029H05	4706	S1M10000019C11	5948	S1M10000044F10		
981	E3M10000042G07	2223	E1M10000244H02	3465	P1M10000029A09	4707	S1M10000019F11	5949	S1M10000044G10		
982	E3M10000042A08	2224	E1M10000244B03	3466	P1M10000032F04	4708	S1M10000019G11	5950	S1M10000044H10		
983	E3M10000042B08	2225	E1M10000244E03	3467	P1M10000033F01	4709	S1M10000019A12	5951	S1M10000044A11		
984	E3M10000042G08	2226	E1M10000244F03	3468	P1M10000033A02	4710	S1M10000019B12	5952	S1M10000044B11		
985	E3M10000042H08	2227	E1M10000244A04	3469	P1M10000033E03	4711	S1M10000019C12	5953	S1M10000044C11		
986	E3M10000042B09	2228	E1M10000244D04	3470	P1M10000033D06	4712	S1M10000019D12	5954	S1M10000044D11		
987	E3M10000042D09	2229	E1M10000244E04	3471	P1M10000033B08	4713	S1M10000020E01	5955	S1M10000044E11		
988	E3M10000042A10	2230	E1M10000244G07	3472	P1M10000035A06	4714	S1M10000020F01	5956	S1M10000044G11		
989	E3M10000042B10	2231	E1M10000244D08	3473	P1M10000037B12	4715	S1M10000020G01	5957	S1M10000044H11		
990	E3M10000042C10	2232	E1M10000244E08	3474	P1M10000037G12	4716	S1M10000020H01	5958	S1M10000044A12		
991	E3M10000042E10	2233	E1M10000244G08	3475	P1M10000038G02	4717	S1M10000020B02	5959	S1M10000044B12		
992	E3M10000042B11	2234	E1M10000244B09	3476	P1M10000038C03	4718	S1M10000020H02	5960	S1M10000044C12		
993	E3M10000042D11	2235	E1M10000244E10	3477	P1M10000038F04	4719	S1M10000020B03	5961	S1M10000044D12		
994	E3M10000042F11	2236	E1M10000244E11	3478	P1M10000038C06	4720	S1M10000020D03	5962	S1M10000045B01		
995	E3M10000042G11	2237	E1M10000244F11	3479	P1M10000038B08	4721	S1M10000020E03	5963	S1M10000045D01		
996	E3M10000042H11	2238	E1M10000244C12	3480	P1M10000038A09	4722	S1M10000020D04	5964	S1M10000045A02		
997	E3M10000042D12	2239	E1M10000244E12	3481	P1M10000039G05	4723	S1M10000020E04	5965	S1M10000045B02		
998	E3M10000042E12	2240	E1M10000244F12	3482	P1M10000039G12	4724	S1M10000020H04	5966	S1M10000045C02		
999	E3M10000042F12	2241	E1M10000245C01	3483	P1M10000040C01	4725	S1M10000020A05	5967	S1M10000045B03		
1000	E3M10000042G12	2242	E1M10000245E02	3484	P1M10000040H03	4726	S1M10000020B05	5968	S1M10000045C03		
1001	E3M10000043B01	2243	E1M10000245E03	3485	P1M10000040C04	4727	S1M10000020F05	5969	S1M10000045D03		
1002	E3M10000043C01	2244	E1M10000245H03	3486	P1M10000040D04	4728	S1M10000020G05	5970	S1M10000045G03		
1003	E3M10000043D01	2245	E1M10000245A04	3487	P1M10000040D05	4729	S1M10000020A06	5971	S1M10000045C04		
1004	E3M10000043A02	2246	E1M10000245B04	3488	P1M10000040E10	4730	S1M10000020B06	5972	S1M10000045E04		
1005	E3M10000043B02	2247	E1M10000245D04	3489	P1M10000041E01	4731	S1M10000020D06	5973	S1M10000045F04		

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
1006	E3M10000043D02	2248	E1M10000245B05	3490	P1M10000041F01	4732	S1M10000020E06	5974	S1M10000045C05
1007	E3M10000043H02	2249	E1M10000245C05	3491	P1M10000041B02	4733	S1M10000020F06	5975	S1M10000045E05
1008	E3M10000043A03	2250	E1M10000245D05	3492	P1M10000041A12	4734	S1M10000020H06	5976	S1M10000045F05
1009	E3M10000043B03	2251	E1M10000245F06	3493	P1M10000042E08	4735	S1M10000020A07	5977	S1M10000045A06
1010	E3M10000043E03	2252	E1M10000245B07	3494	P1M10000042B12	4736	S1M10000020B07	5978	S1M10000045G06
1011	E3M10000043F03	2253	E1M10000245E09	3495	P1M10000043A03	4737	S1M10000020D07	5979	S1M10000045H06
1012	E3M10000043G03	2254	E1M10000245G09	3496	P1M10000043H04	4738	S1M10000020F07	5980	S1M10000045A07
1013	E3M10000043F04	2255	E1M10000245B11	3497	P1M10000043D06	4739	S1M10000020G07	5981	S1M10000045B07
1014	E3M10000043G04	2256	E1M10000245C11	3498	P1M10000044F07	4740	S1M10000020A08	5982	S1M10000045C07
1015	E3M10000043A05	2257	E1M10000245D11	3499	P1M10000046B03	4741	S1M10000020D08	5983	S1M10000045D07
1016	E3M10000043G05	2258	E1M10000245E11	3500	P1M10000046C07	4742	S1M10000020E08	5984	S1M10000045G07
1017	E3M10000043H05	2259	E1M10000245H11	3501	P1M10000046C08	4743	S1M10000020G08	5985	S1M10000045A08
1018	E3M10000043B06	2260	E1M10000245B12	3502	P1M10000046C09	4744	S1M10000020H08	5986	S1M10000045D08
1019	E3M10000043F06	2261	E1M10000245D12	3503	P1M10000046G11	4745	S1M10000020B09	5987	S1M10000045E08
1020	E3M10000043H06	2262	E1M10000245E12	3504	P1M10000047H02	4746	S1M10000020C09	5988	S1M10000045F08
1021	E3M10000043E07	2263	E1M10000246F01	3505	P1M10000047B04	4747	S1M10000020F09	5989	S1M10000045G08
1022	E3M10000043G07	2264	E1M10000246B02	3506	P1M10000047F07	4748	S1M10000020G09	5990	S1M10000045C09
1023	E3M10000043A08	2265	E1M10000246D03	3507	P1M10000047G10	4749	S1M10000020C10	5991	S1M10000045D09
1024	E3M10000043B08	2266	E1M10000246E03	3508	P1M10000047E11	4750	S1M10000020G10	5992	S1M10000045E09
1025	E3M10000043C08	2267	E1M10000246G03	3509	P1M10000048A03	4751	S1M10000020H10	5993	S1M10000045B10
1026	E3M10000043E08	2268	E1M10000246C05	3510	P1M10000049E08	4752	S1M10000020A11	5994	S1M10000045D10
1027	E3M10000043F08	2269	E1M10000246A06	3511	P1M10000049G10	4753	S1M10000020C11	5995	S1M10000045E10
1028	E3M10000043G08	2270	E1M10000246B06	3512	P1M10000050G11	4754	S1M10000020E11	5996	S1M10000045G10
1029	E3M10000043H08	2271	E1M10000246D06	3513	P1M10000051F01	4755	S1M10000020F11	5997	S1M10000045H10
1030	E3M10000043A09	2272	E1M10000246C07	3514	P1M10000051D11	4756	S1M10000020G11	5998	S1M10000045A11
1031	E3M10000043C09	2273	E1M10000246F07	3515	P1M10000052C03	4757	S1M10000020H11	5999	S1M10000045B11
1032	E3M10000043D09	2274	E1M10000246A08	3516	P1M10000052E04	4758	S1M10000020A12	6000	S1M10000045D11
1033	E3M10000043H09	2275	E1M10000246D09	3517	P1M10000052C12	4759	S1M10000020B12	6001	S1M10000045E11
1034	E3M10000043A10	2276	E1M10000246E10	3518	P1M10000053C02	4760	S1M10000020D12	6002	S1M10000045F11
1035	E3M10000043B10	2277	E1M10000246B11	3519	P1M10000053E07	4761	S1M10000020E12	6003	S1M10000045H11
1036	E3M10000043C10	2278	E1M10000246F11	3520	P1M10000053F08	4762	S1M10000020F12	6004	S1M10000045A12
1037	E3M10000043D10	2279	E1M10000247B01	3521	P1M10000053B12	4763	S1M10000020G12	6005	S1M10000045B12
1038	E3M10000043E10	2280	E1M10000247E01	3522	P1M10000055E05	4764	S1M10000021D01	6006	S1M10000045C12
1039	E3M10000043F10	2281	E1M10000247G01	3523	P1M10000055C08	4765	S1M10000021E01	6007	S1M10000045D12
1040	E3M10000043G10	2282	E1M10000247E02	3524	P1M10000055A11	4766	S1M10000021G01	6008	S1M10000045E12
1041	E3M10000043A11	2283	E1M10000247A03	3525	P1M10000056G01	4767	S1M10000021E02	6009	S1M10000045F12

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
1042	E3M10000043B11	2284	E1M10000247D03	3526	P1M10000056F02	4768	S1M10000021F02	6010	S1M10000045G12
1043	E3M10000043E11	2285	E1M10000247G03	3527	P1M10000056F05	4769	S1M10000021D03	6011	S1M10000046B01
1044	E3M10000043G11	2286	E1M10000247B04	3528	P1M10000056F06	4770	S1M10000021E03	6012	S1M10000046D01
1045	E3M10000043H11	2287	E1M10000247H04	3529	P1M10000056C07	4771	S1M10000021G03	6013	S1M10000046E01
1046	E3M10000043B12	2288	E1M10000247D05	3530	P1M10000058B07	4772	S1M10000021A04	6014	S1M10000046F01
1047	E3M10000043D12	2289	E1M10000247A06	3531	P1M10000061B04	4773	S1M10000021C04	6015	S1M10000046G01
1048	E3M10000043F12	2290	E1M10000247B06	3532	P1M10000061E04	4774	S1M10000021D04	6016	S1M10000046H01
1049	E3M10000043G12	2291	E1M10000247G06	3533	P1M10000061F04	4775	S1M10000021F04	6017	S1M10000046C02
1050	E3M10000044E01	2292	E1M10000247G07	3534	P1M10000062H01	4776	S1M10000021H04	6018	S1M10000046D02
1051	E3M10000044C02	2293	E1M10000247D08	3535	P1M10000062C03	4777	S1M10000021A05	6019	S1M10000046E02
1052	E3M10000045E07	2294	E1M10000247F09	3536	P1M10000062C04	4778	S1M10000021B05	6020	S1M10000046F02
1053	E3M10000046C04	2295	E1M10000247C11	3537	P1M10000062H04	4779	S1M10000021C05	6021	S1M10000046G02
1054	E3M10000047D02	2296	E1M10000247E11	3538	P1M10000062F06	4780	S1M10000021E05	6022	S1M10000046A03
1055	E3M10000047B08	2297	E1M10000247B12	3539	P1M10000062C07	4781	S1M10000021F05	6023	S1M10000046B03
1056	E3M10000047C08	2298	E1M10000248G01	3540	P1M10000062D07	4782	S1M10000021H05	6024	S1M10000046D03
1057	E3M10000047D08	2299	E1M10000248A02	3541	P1M10000062D08	4783	S1M10000021A06	6025	S1M10000046G03
1058	E3M10000050B01	2300	E1M10000248E04	3542	P1M10000062E08	4784	S1M10000021B06	6026	S1M10000046A04
1059	E3M10000050C01	2301	E1M10000248H04	3543	P1M10000062G11	4785	S1M10000021D06	6027	S1M10000046B04
1060	E3M10000050D01	2302	E1M10000248H05	3544	P1M10000062A12	4786	S1M10000021E06	6028	S1M10000046C04
1061	E3M10000050B02	2303	E1M10000248A06	3545	P1M10000062C12	4787	S1M10000021F06	6029	S1M10000046D04
1062	E3M10000050C02	2304	E1M10000248G06	3546	P1M10000063F02	4788	S1M10000021G06	6030	S1M10000046E04
1063	E3M10000050E02	2305	E1M10000248H08	3547	P1M10000063G02	4789	S1M10000021A07	6031	S1M10000046G04
1064	E3M10000050F02	2306	E1M10000248B12	3548	P1M10000063H02	4790	S1M10000021B07	6032	S1M10000046B05
1065	E3M10000050H04	2307	E1M10000249E01	3549	P1M10000064C02	4791	S1M10000021C07	6033	S1M10000046C05
1066	E3M10000050B05	2308	E1M10000249G01	3550	P1M10000064C03	4792	S1M10000021F07	6034	S1M10000046D05
1067	E3M10000050D05	2309	E1M10000249D02	3551	P1M10000064D03	4793	S1M10000021H07	6035	S1M10000046F05
1068	E3M10000050E05	2310	E1M10000249F02	3552	P1M10000064E05	4794	S1M10000021A08	6036	S1M10000046A06
1069	E3M10000050G05	2311	E1M10000249F03	3553	P1M10000064H07	4795	S1M10000021C08	6037	S1M10000046C06
1070	E3M10000050H05	2312	E1M10000249H04	3554	P1M10000064A10	4796	S1M10000021G08	6038	S1M10000046F06
1071	E3M10000050A06	2313	E1M10000249G05	3555	P1M10000064G12	4797	S1M10000021H08	6039	S1M10000046B07
1072	E3M10000050C06	2314	E1M10000249C06	3556	P1M10000065F01	4798	S1M10000021A09	6040	S1M10000046C07
1073	E3M10000050D06	2315	E1M10000249D06	3557	P1M10000065C03	4799	S1M10000021D09	6041	S1M10000046E07
1074	E3M10000050F06	2316	E1M10000249A07	3558	P1M10000065A04	4800	S1M10000021E09	6042	S1M10000046G07
1075	E3M10000050H06	2317	E1M10000249C07	3559	P1M10000065C05	4801	S1M10000021F09	6043	S1M10000046A08
1076	E3M10000050A07	2318	E1M10000249B08	3560	P1M10000065D06	4802	S1M10000021A10	6044	S1M10000046B08
1077	E3M10000050B07	2319	E1M10000249F08	3561	P1M10000065G06	4803	S1M10000021B10	6045	S1M10000046C08

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
1078	E3M10000050C07	2320	E1M10000249B09	3562	P1M10000065B07	4804	S1M10000021C10	6046	S1M10000046D08
1079	E3M10000050E07	2321	E1M10000249C09	3563	P1M10000065H07	4805	S1M10000021D10	6047	S1M10000046E08
1080	E3M10000050F07	2322	E1M10000249H09	3564	P1M10000066F04	4806	S1M10000021C11	6048	S1M10000046F08
1081	E3M10000050H07	2323	E1M10000249E10	3565	P1M10000066A10	4807	S1M10000021F11	6049	S1M10000046A09
1082	E3M10000050B08	2324	E1M10000249D11	3566	P1M10000066A11	4808	S1M10000021H11	6050	S1M10000046B09
1083	E3M10000050D08	2325	E1M10000249H11	3567	P1M10000067C01	4809	S1M10000021C12	6051	S1M10000046D09
1084	E3M10000050F08	2326	E1M10000250F02	3568	P1M10000067E01	4810	S1M10000021E12	6052	S1M10000046F09
1085	E3M10000050G08	2327	E1M10000250H02	3569	P1M10000067C04	4811	S1M10000021G12	6053	S1M10000046G09
1086	E3M10000050D09	2328	E1M10000250E03	3570	P1M10000067A05	4812	S1M10000022E01	6054	S1M10000046D10
1087	E3M10000050F09	2329	E1M10000250G03	3571	P1M10000067D05	4813	S1M10000022A02	6055	S1M10000046E10
1088	E3M10000050G09	2330	E1M10000250A04	3572	P1M10000067F05	4814	S1M10000022B02	6056	S1M10000046F10
1089	E3M10000050H09	2331	E1M10000250E04	3573	P1M10000067G05	4815	S1M10000022C02	6057	S1M10000046G10
1090	E3M10000050B10	2332	E1M10000250H04	3574	P1M10000067A06	4816	S1M10000022A03	6058	S1M10000046H10
1091	E3M10000051C01	2333	E1M10000250A05	3575	P1M10000067C06	4817	S1M10000022B03	6059	S1M10000046A11
1092	E3M10000051D01	2334	E1M10000250E05	3576	P1M10000067A08	4818	S1M10000022C03	6060	S1M10000046B11
1093	E3M10000051C03	2335	E1M10000250G07	3577	P1M10000068G01	4819	S1M10000022D03	6061	S1M10000046C11
1094	E3M10000051D03	2336	E1M10000250D09	3578	P1M10000068D04	4820	S1M10000022E03	6062	S1M10000046D11
1095	E3M10000051H03	2337	E1M10000250G09	3579	P1M10000068F04	4821	S1M10000022G03	6063	S1M10000046A12
1096	E3M10000051A04	2338	E1M10000250B10	3580	P1M10000068H05	4822	S1M10000022H03	6064	S1M10000046B12
1097	E3M10000051B04	2339	E1M10000250E10	3581	P1M10000068F08	4823	S1M10000022C04	6065	S1M10000046C12
1098	E3M10000051D04	2340	E1M10000250D11	3582	P1M10000068A09	4824	S1M10000022F04	6066	S1M10000046D12
1099	E3M10000051E04	2341	E1M10000250H11	3583	P1M10000069H02	4825	S1M10000022G04	6067	S1M10000046F12
1100	E3M10000051F04	2342	E1M10000250G12	3584	P1M10000069B05	4826	S1M10000022A05	6068	S1M10000047B01
1101	E3M10000051F05	2343	E1M10000251A02	3585	P1M10000069G06	4827	S1M10000022B05	6069	S1M10000047C01
1102	E3M10000051C06	2344	E1M10000251D04	3586	P1M10000069D09	4828	S1M10000022D05	6070	S1M10000047E01
1103	E3M10000051D06	2345	E1M10000251F04	3587	P1M10000070E03	4829	S1M10000022E05	6071	S1M10000047G01
1104	E3M10000051F06	2346	E1M10000251H04	3588	P1M10000070A05	4830	S1M10000022H05	6072	S1M10000047B02
1105	E3M10000051G06	2347	E1M10000251F05	3589	P1M10000070C06	4831	S1M10000022B06	6073	S1M10000047C02
1106	E3M10000051B07	2348	E1M10000251A07	3590	P1M10000070G06	4832	S1M10000022C06	6074	S1M10000047D02
1107	E3M10000051E07	2349	E1M10000251C07	3591	P1M10000070H06	4833	S1M10000022D06	6075	S1M10000047E02
1108	E3M10000051F07	2350	E1M10000251B08	3592	P1M10000070D08	4834	S1M10000022F06	6076	S1M10000047F02
1109	E3M10000051A08	2351	E1M10000251H08	3593	P1M10000070B10	4835	S1M10000022H06	6077	S1M10000047G02
1110	E3M10000051B08	2352	E1M10000251H09	3594	P1M10000070G12	4836	S1M10000022B07	6078	S1M10000047A03
1111	E3M10000051D08	2353	E1M10000251C10	3595	P1M10000071B01	4837	S1M10000022C07	6079	S1M10000047C03
1112	E3M10000051H08	2354	E1M10000251F11	3596	P1M10000071C01	4838	S1M10000022D07	6080	S1M10000047D03
1113	E3M10000051B09	2355	E1M10000251G11	3597	P1M10000071F01	4839	S1M10000022F07	6081	S1M10000047E03

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
1114	E3M10000051C09	2356	E1M10000251C12	3598	P1M10000071A03	4840	S1M10000022G07	6082	S1M10000047F03
1115	E3M10000051D09	2357	E1M10000251D12	3599	P1M10000071E04	4841	S1M10000022H07	6083	S1M10000047G03
1116	E3M10000051E09	2358	E1M10000251F12	3600	P1M10000073G03	4842	S1M10000022A08	6084	S1M10000047H03
1117	E3M10000051G09	2359	E1M10000252D01	3601	P1M10000073D04	4843	S1M10000022B08	6085	S1M10000047A04
1118	E3M10000051H09	2360	E1M10000252G02	3602	P1M10000073A06	4844	S1M10000022C08	6086	S1M10000047B04
1119	E3M10000051A10	2361	E1M10000252C03	3603	P1M10000073D09	4845	S1M10000022D08	6087	S1M10000047C04
1120	E3M10000051B10	2362	E1M10000252G03	3604	P1M10000073B10	4846	S1M10000022F08	6088	S1M10000047D04
1121	E3M10000051D10	2363	E1M10000252B04	3605	P1M10000074B01	4847	S1M10000022G08	6089	S1M10000047E04
1122	E3M10000051E10	2364	E1M10000252E04	3606	P1M10000074B04	4848	S1M10000022H08	6090	S1M10000047F04
1123	E3M10000051F10	2365	E1M10000252F04	3607	P1M10000074E04	4849	S1M10000022D09	6091	S1M10000047G04
1124	E3M10000051H10	2366	E1M10000252A05	3608	P1M10000074E09	4850	S1M10000022E09	6092	S1M10000047H04
1125	E3M10000051A11	2367	E1M10000252A06	3609	P1M10000074F10	4851	S1M10000022B10	6093	S1M10000047A05
1126	E3M10000051D11	2368	E1M10000252D06	3610	P1M10000074G12	4852	S1M10000022B11	6094	S1M10000047B05
1127	E3M10000051E11	2369	E1M10000252A07	3611	P1M10000075F02	4853	S1M10000022C11	6095	S1M10000047C05
1128	E3M10000051F11	2370	E1M10000252H07	3612	P1M10000075B03	4854	S1M10000022F11	6096	S1M10000047D05
1129	E3M10000051G11	2371	E1M10000252A09	3613	P1M10000075A04	4855	S1M10000022H11	6097	S1M10000047E05
1130	E3M10000051F12	2372	E1M10000252E09	3614	P1M10000075C04	4856	S1M10000022A12	6098	S1M10000047F05
1131	E3M10000050E01	2373	E1M10000252B10	3615	P1M10000075C05	4857	S1M10000022B12	6099	S1M10000047G05
1132	E3M10000050G01	2374	E1M10000252D10	3616	P1M10000075G05	4858	S1M10000022G12	6100	S1M10000047H05
1133	E3M10000050B03	2375	E1M10000252E10	3617	P1M10000076D05	4859	S1M10000022G12	6101	S1M10000047A06
1134	E3M10000050C03	2376	E1M10000252E11	3618	P1M10000076C08	4860	S1M10000023B01	6102	S1M10000047B06
1135	E3M10000050D03	2377	E1M10000252E12	3619	P1M10000076D10	4861	S1M10000023D01	6103	S1M10000047C06
1136	E3M10000050E03	2378	E1M10000253A02	3620	P1M10000077E04	4862	S1M10000023E01	6104	S1M10000047E06
1137	E3M10000050A04	2379	E1M10000253G02	3621	P1M10000077H05	4863	S1M10000023G01	6105	S1M10000047F06
1138	E3M10000050E04	2380	E1M10000253C04	3622	P1M10000077A08	4864	S1M10000023C02	6106	S1M10000047G06
1139	E3M10000050H08	2381	E1M10000253D04	3623	P1M10000077C08	4865	S1M10000023G02	6107	S1M10000047A07
1140	E3M10000052C01	2382	E1M10000253F04	3624	P1M10000096F01	4866	S1M10000023H02	6108	S1M10000047C07
1141	E3M10000052F01	2383	E1M10000253H05	3625	P1M10000096E04	4867	S1M10000023B03	6109	S1M10000047D07
1142	E3M10000052C02	2384	E1M10000253D08	3626	P1M10000096E12	4868	S1M10000023D03	6110	S1M10000047F07
1143	E3M10000052D02	2385	E1M10000253E08	3627	P1M10000097G05	4869	S1M10000023G03	6111	S1M10000047G07
1144	E3M10000052G02	2386	E1M10000253A09	3628	P1M10000059B04	4870	S1M10000023D04	6112	S1M10000047H07
1145	E3M10000052B03	2387	E1M10000253D09	3629	P1M10000059H08	4871	S1M10000023E04	6113	S1M10000047A08
1146	E3M10000052E03	2388	E1M10000253E09	3630	P1M10000059H09	4872	S1M10000023F04	6114	S1M10000047B08
1147	E3M10000052G03	2389	E1M10000253F09	3631	P1M10000059B10	4873	S1M10000023A05	6115	S1M10000047C08
1148	E3M10000052B04	2390	E1M10000253G09	3632	P1M10000059B11	4874	S1M10000023D05	6116	S1M10000047E08
1149	E3M10000052F04	2391	E1M10000253A10	3633	P1M10000059D11	4875	S1M10000023H05	6117	S1M10000047F08

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
1150	E3M10000052G04	2392	E1M10000253C10	3634	P1M10000060H02	4876	S1M10000023G06	6118	S1M10000047G08
1151	E3M10000052C05	2393	E1M10000253D10	3635	P1M10000060E03	4877	S1M10000023H06	6119	S1M10000047H08
1152	E3M10000052D05	2394	E1M10000253B11	3636	P1M10000060H04	4878	S1M10000023B07	6120	S1M10000047A09
1153	E3M10000052F05	2395	E1M10000253F11	3637	P1M10000079D01	4879	S1M10000023D07	6121	S1M10000047B09
1154	E3M10000052G05	2396	E1M10000253D12	3638	P1M10000079F06	4880	S1M10000023E07	6122	S1M10000047C09
1155	E3M10000052G06	2397	E1M10000253G12	3639	P1M10000079A10	4881	S1M10000023F07	6123	S1M10000047D09
1156	E3M10000052H06	2398	E1M10000254A03	3640	P1M10000079B10	4882	S1M10000023G07	6124	S1M10000047E09
1157	E3M10000052B07	2399	E1M10000254B03	3641	P1M10000079C10	4883	S1M10000023H07	6125	S1M10000047F09
1158	E3M10000052F08	2400	E1M10000254C03	3642	P1M10000079D10	4884	S1M10000023B08	6126	S1M10000047G09
1159	E3M10000052E09	2401	E1M10000254F03	3643	P1M10000080B01	4885	S1M10000023D08	6127	S1M10000047H09
1160	E3M10000052G09	2402	E1M10000254A04	3644	P1M10000080C01	4886	S1M10000023F08	6128	S1M10000047A10
1161	E3M10000052F10	2403	E1M10000254G05	3645	P1M10000080E04	4887	S1M10000023G08	6129	S1M10000047B10
1162	E3M10000052D11	2404	E1M10000254H05	3646	P1M10000080B06	4888	S1M10000023A09	6130	S1M10000047D10
1163	E3M10000052D12	2405	E1M10000254B06	3647	P1M10000080C06	4889	S1M10000023B09	6131	S1M10000047E10
1164	1008-H20	2406	E1M10000254A07	3648	P1M10000081G05	4890	S1M10000023D09	6132	S1M10000047F10
1165	1011-P20	2407	E1M10000254E07	3649	P1M10000081H05	4891	S1M10000023G09	6133	S1M10000047G10
1166	1053-37	2408	E1M10000254G07	3650	P1M10000081A06	4892	S1M10000023H09	6134	S1M10000047H10
1167	1010-C11	2409	E1M10000254A08	3651	P1M10000081D12	4893	S1M10000023B10	6135	S1M10000047A11
1168	1017-H1	2410	E1M10000254B09	3652	P1M10000082A02	4894	S1M10000023C10	6136	S1M10000047B11
1169	1067-16	2411	E1M10000254F10	3653	P1M10000082B04	4895	S1M10000023D10	6137	S1M10000047C11
1170	1083-27	2412	E1M10000254A11	3654	P1M10000082A05	4896	S1M10000023E10	6138	S1M10000047E11
1171	1065-12	2413	E1M10000254C11	3655	P1M10000082C05	4897	S1M10000023F10	6139	S1M10000047F11
1172	221-41	2414	E1M10000254E12	3656	P1M10000082D05	4898	S1M10000023H10	6140	S1M10000047H11
1173	B17-6.O10	2415	E1M10000255C01	3657	P1M10000082E05	4899	S1M10000023A11	6141	S1M10000047A12
1174	910-B20	2416	E1M10000255G02	3658	P1M10000083B01	4900	S1M10000023B11	6142	S1M10000047B12
1175	B18-2.N21	2417	E1M10000255H02	3659	P1M10000083A11	4901	S1M10000023C11	6143	S1M10000047C12
1176	971-B20	2418	E1M10000255A04	3660	P1M10000083B12	4902	S1M10000023E11	6144	S1M10000047D12
1177	D1-1.A15	2419	E1M10000255D05	3661	P1M10000083C12	4903	S1M10000023F11	6145	S1M10000047E12
1178	4-28.1	2420	E1M10000255F06	3662	P1M10000084D03	4904	S1M10000023G11	6146	S1M10000047F12
1179	D1-2.B13	2421	E1M10000255G06	3663	P1M10000084A04	4905	S1M10000023A12	6147	S1M10000048C01
1180	D1-2.P21	2422	E1M10000255B08	3664	P1M10000084E04	4906	S1M10000023B12	6148	S1M10000048D01
1181	Z56-D2	2423	E1M10000255D09	3665	P1M10000084F08	4907	S1M10000023C12	6149	S1M10000048G01
1182	PJMF55	2424	E1M10000255F09	3666	P1M10000084E11	4908	S1M10000023D12	6150	S1M10000048H01
1183	R1-15.A13	2425	E1M10000255B10	3667	P1M10000085D06	4909	S1M10000023F12	6151	S1M10000048A02
1184	R1-19.H1	2426	E1M10000255F01	3668	P1M10000086B01	4910	S1M10000024D01	6152	S1M10000048B02
1185	R1-55.M2	2427	E1M10000256B02	3669	P1M10000086E01	4911	S1M10000024A02	6153	S1M10000048C02

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
1186	Z45-F11	2428	E1M10000256D02	3670	P1M10000086A02	4912	S1M10000024C02	6154	S1M10000048D02
1187	Z8-B9	2429	E1M10000256A04	3671	P1M10000086D02	4913	S1M10000024D02	6155	S1M10000048E02
1188	E1M10000007B04	2430	E1M10000256C05	3672	P1M10000086E05	4914	S1M10000024F02	6156	S1M10000048F02
1189	227-10	2431	E1M10000256E07	3673	P1M10000087E04	4915	S1M10000024H02	6157	S1M10000048G02
1190	709-F23	2432	E1M10000256E09	3674	P1M10000087F04	4916	S1M10000024D03	6158	S1M10000048H02
1191	801-C15	2433	E1M10000256A10	3675	P1M10000087C09	4917	S1M10000024E03	6159	S1M10000048A03
1192	801-H19	2434	E1M10000256F10	3676	P1M10000087F09	4918	S1M10000024F03	6160	S1M10000048B03
1193	804-P6	2435	E1M10000256C12	3677	P1M10000087A11	4919	S1M10000024A04	6161	S1M10000048C03
1194	807-D20	2436	E1M10000257C01	3678	P1M10000088C04	4920	S1M10000024C04	6162	S1M10000048E03
1195	B13-17.G8	2437	E1M10000257G01	3679	P1M10000088A07	4921	S1M10000024D04	6163	S1M10000048F03
1196	B5-6.C8	2438	E1M10000257A02	3680	P1M10000089G08	4922	S1M10000024H04	6164	S1M10000048G03
1197	B8-2.D9	2439	E1M10000257D02	3681	P1M10000089D11	4923	S1M10000024B05	6165	S1M10000048H03
1198	B15-8.P13	2440	E1M10000257H02	3682	P1M10000090E01	4924	S1M10000024E05	6166	S1M10000048E04
1199	T13-5.A2	2441	E1M10000257C03	3683	P1M10000090F06	4925	S1M10000024F05	6167	S1M10000048G04
1200	T12-3.I11	2442	E1M10000257F04	3684	P1M10000090F08	4926	S1M10000024G05	6168	S1M10000048H04
1201	T20-15.D4	2443	E1M10000257G04	3685	P1M10000090B11	4927	S1M10000024B06	6169	S1M10000048A05
1202	T24-15.G6	2444	E1M10000257B05	3686	P1M10000091A09	4928	S1M10000024E06	6170	S1M10000048B05
1203	T24-17.C6	2445	E1M10000257D05	3687	P1M10000091E09	4929	S1M10000024G06	6171	S1M10000048C05
1204	244.B12	2446	E1M10000257F06	3688	P1M10000091G10	4930	S1M10000024H06	6172	S1M10000048F05
1205	1042-J1	2447	E1M10000257G07	3689	P1M10000092B02	4931	S1M10000024A07	6173	S1M10000048G05
1206	195.F5	2448	E1M10000257H07	3690	P1M10000092E02	4932	S1M10000024C07	6174	S1M10000048H05
1207	25.D5	2449	E1M10000257H08	3691	P1M10000092B04	4933	S1M10000024E07	6175	S1M10000048A06
1208	25.D6	2450	E1M10000257A09	3692	P1M10000092F05	4934	S1M10000024G07	6176	S1M10000048B06
1209	177.F3	2451	E1M10000257D09	3693	P1M10000092F06	4935	S1M10000024H07	6177	S1M10000048C06
1210	525.H11	2452	E1M10000257G10	3694	P1M10000092D09	4936	S1M10000024A08	6178	S1M10000048E06
1211	632.N2	2453	E1M10000257H10	3695	P1M10000092B10	4937	S1M10000024B08	6179	S1M10000048A07
1212	633.B7	2454	E1M10000257A11	3696	P1M10000092B12	4938	S1M10000024E08	6180	S1M10000048C07
1213	671.I20	2455	E1M10000257C11	3697	P1M10000093A03	4939	S1M10000024F08	6181	S1M10000048E07
1214	676.B12	2456	E1M10000257F11	3698	P1M10000093B03	4940	S1M10000024G08	6182	S1M10000048F07
1215	643.B19	2457	E1M10000257B12	3699	P1M10000093F03	4941	S1M10000024H08	6183	S1M10000048G07
1216	720.O16	2458	E1M10000257F12	3700	P1M10000093H07	4942	S1M10000024B09	6184	S1M10000048H07
1217	666.H12	2459	E1M10000258C01	3701	P1M10000093C08	4943	S1M10000024B10	6185	S1M10000048B08
1218	98.D4	2460	E1M10000258H02	3702	P1M10000093B09	4944	S1M10000024D10	6186	S1M10000048C08
1219	844.B21	2461	E1M10000258G03	3703	P1M10000093E09	4945	S1M10000024F10	6187	S1M10000048D08
1220	P31-25-F3	2462	E1M10000258A04	3704	P1M10000094H03	4946	S1M10000024G10	6188	S1M10000048E08
1221	P335-8.H8	2463	E1M10000258C04	3705	P1M10000094F04	4947	S1M10000024A11	6189	S1M10000048F08

SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name	SeqID	Clone Name
1222	P347.2	2464	E1M10000258G04	3706	P1M10000094H04	4948	S1M10000024D11	6190	S1M10000048H08
1223	P31-11.J20	2465	E1M10000258C05	3707	P1M10000094A10	4949	S1M10000024G12	6191	S1M10000048A09
1224	P336-14.F20	2466	E1M10000258D05	3708	P1M10000095C01	4950	S1M10000025B01	6192	S1M10000048C09
1225	P31-27-M1	2467	E1M10000258F05	3709	P1M10000095E04	4951	S1M10000025C01	6193	S1M10000048D09
1226	P338-4.M21	2468	E1M10000258G05	3710	P1M10000095G04	4952	S1M10000025D01	6194	S1M10000048E09
1227	P334-8.L7	2469	E1M10000258A06	3711	P1M10000095C09	4953	S1M10000025E01	6195	S1M10000048F09
1228	P31-2-E16	2470	E1M10000258D06	3712	P1M10000102E05	4954	S1M10000025B02	6196	S1M10000048H09
1229	P335-3.J14	2471	E1M10000258B07	3713	P1M10000102B07	4955	S1M10000025A03	6197	S1M10000048A10
1230	P334-5.H2	2472	E1M10000258G07	3714	P1M10000103B05	4956	S1M10000025B03	6198	S1M10000048B10
1231	P31-33-N2	2473	E1M10000258G08	3715	P1M10000103D06	4957	S1M10000025C03	6199	S1M10000048C10
1232	P332-11.C20	2474	E1M10000258B09	3716	P1M10000103E08	4958	S1M10000025D03	6200	S1M10000048D10
1233	869.A23	2475	E1M10000258D09	3717	P1M10000104A02	4959	S1M10000025F03	6201	S1M10000048E10
1234	P317-2.A3	2476	E1M10000258F10	3718	P1M10000104H02	4960	S1M10000025D04	6202	S1M10000048G10
1235	P326-9.K2	2477	E1M10000258C11	3719	P1M10000104A03	4961	S1M10000025E04	6203	S1M10000048H10
1236	P323-8.P1	2478	E1M10000258F11	3720	P1M10000104E03	4962	S1M10000025G04	6204	S1M10000048A11
1237	P35-8	2479	E1M10000259C03	3721	P1M10000104F07	4963	S1M10000025B05	6205	S1M10000048C11
1238	P36-13.E2	2480	E1M10000259B04	3722	P1M10000104D11	4964	S1M10000025C05	6206	S1M10000048D11
1239	P38-1.G20	2481	E1M10000259E04	3723	P1M10000105D01	4965	S1M10000025F05	6207	S1M10000048F11
1240	P327-50.M10	2482	E1M10000259E05	3724	P1M10000105E02	4966	S1M10000025H05	6208	S1M10000048G11
1241	P328-8.D21	2483	E1M10000259B12	3725	P1M10000105C03	4967	S1M10000025B06	6209	S1M10000048H11
1242	P328-20.P20	2484	E1M10000260E02	3726	P1M10000105G03	4968	S1M10000025D06	6210	S1M10000048A12

EXAMPLE 3

Comparison Of Isolated Nucleic Acids to Known Sequences

The nucleotide sequences of the subcloned fragments from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* and *Salmonella typhimurium* obtained from the expression vectors discussed above were compared to known sequences from *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa*, *Salmonella typhimurium* and other microorganisms as follows. First, to confirm that each clone originated from one location on the chromosome and was not chimeric, the nucleotide sequences of the selected clones were compared against the *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* or *Salmonella typhimurium* genomic sequences to align the clone to the correct position on the chromosome. The NCBI BLASTN v 2.0.9 program was used for this comparison, and the incomplete *Staphylococcus aureus* genomic sequences licensed from TIGR, as well as the NCBI nonredundant GenBank database were used as the source of genomic data. *Salmonella typhimurium* sequences were compared to sequences available from the Genome Sequencing Center (<http://genome.wustl.edu/gsc/salmonella.shtml>), and the Sanger Centre (http://www.sanger.ac.uk/projects/S_typhi). *Pseudomonas aeruginosa* sequences were compared to a proprietary database and the NCBI GenBank database. The *E. faecalis* sequences were compared to a proprietary database.

The BLASTN analysis was performed using the default parameters except that the filtering was turned off. No further analysis was performed on inserts which resulted from the ligation of multiple fragments.

In general, antisense molecules and their complementary genes are identified as follows. First, all possible full length open reading frames (ORFs) are extracted from available genomic databases. Such databases include the GenBank nonredundant (nr) database, the unfinished genome database available from TIGR and the PathoSeq database developed by Incyte Genomics. The latter database comprises over 40 annotated bacterial genomes including complete ORF analysis. If databases are incomplete with regard to the bacterial genome of interest, it is not necessary to extract all ORFs in the genome but only to extract the ORFs within the portions of the available genomic sequences which are complementary to the clones of interest. Computer algorithms for identifying ORFs, such as GeneMark, are available and well known to those in the art. Comparison of the clone DNA to the complementary ORF(s) allows determination of whether the clone is a sense or antisense clone. Furthermore, each ORF extracted from the database can be compared to sequences in well annotated databases including the GenBank (nr) protein database, SWISSPROT and the like. A description of the gene or of a closely related gene in a closely related microorganism is often available in these databases. Similar methods are used to identify antisense clones corresponding to genes encoding non-translated RNAs.

In order to generate the gene identification data compiled in Table IB, each of the cloned nucleic acid sequences discussed above corresponding to SEQ ID NO.s 1-6213 was used to identify the corresponding *Escherichia coli*, *Staphylococcus aureus*, *Enterococcus faecalis*, *Klebsiella pneumoniae*, *Pseudomonas aeruginosa* or *Salmonella typhimurium* ORFs in the PathoSeq v.4.1 (March 2000 release) database of microbial genomic sequences. For this purpose, the NCBI BLASTN 2.0.9 computer algorithm was used. The default parameters were used except that filtering was turned off. The default parameters for the BLASTN and BLASTX analyses were:

Expectation value (e)=10
 Alignment view options: pairwise
 10 Filter query sequence (DUST with BLASTN, SEG with others)=T
 Cost to open a gap (zero invokes behavior)=0
 Cost to extend a gap (zero invokes behavior)=0
 X dropoff value for gapped alignment (in bits) (zero invokes behavior)=0
 Show GI's in deflines=F
 15 Penalty for a nucleotide mismatch (BLASTN only)=!3
 Reward for a nucleotide match (BLASTN only)=1
 Number of one-line descriptions (V)=500
 Number of alignments to show (B)=250
 Threshold for extending hits=default
 20 Perform gapped alignment (not available with BLASTX)=T
 Query Genetic code to use=1
 DB Genetic code (for TBLAST[nx] only)=1
 Number of processors to use=1
 SeqAlign file
 25 Believe the query defline=F
 Matrix=BLOSUM62
 Word Size= default
 Effective length of the database (use zero for the real size)=0
 Number of best hits from a region to keep=100
 30 Length of region used to judge hits=20
 Effective length of the search space (use zero for the real size)=0
 Query strands to search against database (for BLAST[nx] and TBLASTX), 3 is both, 1 is top, 2 is bottom=3
 Produce HTML output=F
 35

Alternatively, ORFs were identified and refined by conducting a survey of the public and private data sources. Full-length gene protein and nucleotide sequences for these organisms were assembled from various sources. For *Pseudomonas aeruginosa*, gene sequences were adopted from the *Pseudomonas* genome sequencing project (downloaded from <http://www.pseudomonas.com>).
 40 For *Klebsiella pneumoniae*, *Staphylococcus aureus*, *Streptococcus pneumoniae* and *Salmonella typhi*, genomic sequences from PathoSeq v 4.1 (Mar 2000 release) was reanalyzed for ORFs using the gene finding software GeneMark v 2.4a, which was purchased from GenePro Inc. 451 Bishop St., N.W., Suite B, Atlanta, GA, 30318, USA.

Antisense clones were identified as those clones for which transcription from the inducible
 45 promoter would result in the expression of an RNA antisense to a complementary ORF, intergenic

or intragenic sequence. Those clones containing single inserts and that caused growth sensitivity upon induction are listed in Table IA.

5 The gene descriptions in the PathoSeq database derive from annotations available in the public sequence databases described above. Where a clone was found to share significant sequence identity to two or more adjacent ORFs, it was listed once for each ORF and the PathoSeq
information for each ORF was compiled in Table IB.

10 Table IA lists the SEQ ID NOs. and clone names of the inserts which inhibited proliferation. This information was used to identify the ORFs (SEQ ID NOs.: 6214-42397) whose gene products (SEQ ID NOs. 42398-78581) were inhibited by the nucleic acids comprising the nucleotide sequences of SEQ ID NOs. 1-6213. Table IB lists the clone name and the PathoSeq Locus containing the clone.

TABLE IB

Clone Name	Gene LocusID	Clone Name	Gene LocusID	Clone Name	Gene LocusID
E3M10000001B01	EFA205257	E1M10000233C05	ECO103161	S1M10000005E05	SAU802496
E3M10000001B01	EFA205258	E1M10000233H05	ECO103224	S1M10000005C06	SAU802121
E3M10000001A02	EFA205257	E1M10000233H05	ECO103225	S1M10000005D06	SAU801183
E3M10000001A02	EFA205258	E1M10000233D08	ECO103185	S1M10000005D06	SAU801184
E3M10000001B02	EFA205225	E1M10000233F08	ECO103265	S1M10000005A07	SAU800967
E3M10000001B02	EFA201977	E1M10000233F08	ECO103266	S1M10000005B07	SAU802496
E3M10000001B02	EFA203137	E1M10000233A09	ECO104092	S1M10000005D07	SAU801264
E3M10000001C02	EFA200840	E1M10000233A09	ECO104093	S1M10000005A08	SAU802496
E3M10000001D02	EFA202003	E1M10000233E09	ECO103238	S1M10000005B08	SAU800548
E3M10000001E02	EFA200840	E1M10000233E09	ECO103239	S1M10000005D08	SAU800607
E3M10000001F02	EFA200807	E1M10000233F09	ECO103886	S1M10000005E08	SAU802496
E3M10000001G02	EFA205257	E1M10000233D10	ECO103242	S1M10000005B09	SAU800122
E3M10000001G02	EFA205258	E1M10000233D10	ECO103243	S1M10000005C09	SAU801481
E3M10000001H02	EFA200811	E1M10000233H10	ECO100094	S1M10000005D09	SAU800542
E3M10000001E03	EFA201987	E1M10000234E01	ECO103884	S1M10000005A10	SAU801723
E3M10000001E03	EFA205258	E1M10000234B02	ECO103886	S1M10000005A10	SAU801722
E3M10000001G03	EFA201987	E1M10000234G02	ECO103233	S1M10000005A11	SAU801644
E3M10000001G03	EFA205258	E1M10000234G02	ECO103234	S1M10000005C11	SAU801113
E3M10000001H03	EFA201987	E1M10000234C05	ECO103181	S1M10000005D11	SAU800547
E3M10000001H03	EFA205258	E1M10000234C07	ECO103844	S1M10000005E11	SAU800155
E3M10000001D04	EFA201980	E1M10000234C08	ECO103878	S1M10000005B12	SAU802160
E3M10000001D04	EFA201981	E1M10000234C08	ECO204942	S1M10000005B12	SAU603460
E3M10000001D04	EFA205229	E1M10000234F08	ECO103461	S1M10000005D12	SAU801644
E3M10000001E04	EFA201028	E1M10000234H08	ECO103226	S1M10000006F01	SAU801264
E3M10000001F04	EFA200811	E1M10000234F09	ECO103055	S1M10000006B02	SAU800381
E3M10000001G04	EFA201993	E1M10000234D10	ECO100876	S1M10000006E02	SAU802496
E3M10000001H04	EFA201980	E1M10000234G10	ECO100886	S1M10000006F02	SAU802160
E3M10000001H04	EFA201981	E1M10000234B12	ECO104010	S1M10000006G02	SAU802125
E3M10000001H04	EFA205229	E1M10000235D01	ECO102233	S1M10000006A03	SAU802496
E3M10000001B05	EFA201993	E1M10000235A03	ECO100798	S1M10000006B03	SAU802655
E3M10000001D05	EFA201974	E1M10000235H03	ECO103886	S1M10000006D03	SAU801740
E3M10000001D05	EFA201975	E1M10000235E04	ECO103236	S1M10000006E03	SAU801256
E3M10000001G05	EFA202001	E1M10000235B06	ECO103886	S1M10000006F03	SAU801434
E3M10000001G05	EFA202003	E1M10000235F06	ECO103481	S1M10000006G03	SAU801275
E3M10000001A06	EFA201028	E1M10000235B08	ECO103885	S1M10000006A04	SAU801139
E3M10000001F06	EFA201028	E1M10000235E08	ECO103161	S1M10000006B04	SAU802496
E3M10000001B08	EFA201028	E1M10000235B09	ECO101848	S1M10000006C04	SAU802158
E3M10000001E08	EFA200807	E1M10000235H09	ECO103481	S1M10000006E04	SAU801089
E3M10000001C09	EFA200839	E1M10000235H09	ECO103482	S1M10000006F04	SAU801644
E3M10000001D09	EFA201987	E1M10000235B10	ECO100886	S1M10000006G04	SAU801740
E3M10000001D09	EFA205258	E1M10000235A11	ECO102299	S1M10000006A05	SAU802224
E3M10000001E09	EFA201987	E1M10000235F12	ECO103233	S1M10000006A05	SAU802223
E3M10000001E09	EFA205258	E1M10000235F12	ECO103234	S1M10000006D05	SAU802496
E3M10000001B10	EFA205257	E1M10000236E01	ECO100095	S1M10000006G05	SAU801256
E3M10000001B10	EFA205258	E1M10000236A02	ECO102340	S1M10000006C06	SAU800331
E3M10000004D01	EFA201985	E1M10000236E02	ECO103878	S1M10000006C06	SAU800332
E3M10000004D01	EFA201984	E1M10000236E02	ECO204942	S1M10000006D06	SAU802496
E3M10000004D01	EFA202953	E1M10000236A03	ECO103287	S1M10000006F06	SAU800548
E3M10000004G01	EFA200839	E1M10000236D03	ECO102556	S1M10000006G06	SAU800006
E3M10000004D02	EFA202022	E1M10000236G03	ECO102655	S1M10000006A07	SAU800967
E3M10000004D02	EFA202028	E1M10000236A04	ECO103186	S1M10000006B07	SAU801760

Clone Name	Gene LocusID	Clone Name	Gene LocusID	Clone Name	Gene LocusID
E3M10000004D02	EFA202536	E1M10000236D04	ECO103481	S1M10000006C07	SAU800546
E3M10000004C03	EFA200412	E1M10000236G04	ECO103510	S1M10000006D07	SAU801105
E3M10000004A04	EFA201981	E1M10000236A05	ECO102847	S1M10000006E07	SAU802496
E3M10000004A04	EFA205229	E1M10000236F05	ECO103181	S1M10000006G07	SAU801731
E3M10000004F08	EFA201977	E1M10000236F05	ECO103182	S1M10000006A08	SAU802496
E3M10000004F08	EFA203137	E1M10000236H06	ECO103242	S1M10000006E08	SAU802238
E3M10000004D10	EFA201999	E1M10000236H06	ECO103243	S1M10000006A10	SAU802496
E3M10000004D10	EFA201997	E1M10000236D08	ECO103669	S1M10000006B10	SAU802240
E3M10000004F10	EFA200624	E1M10000236F09	ECO103228	S1M10000006C10	SAU802496
E3M10000004E11	EFA200624	E1M10000236C10	ECO102227	S1M10000006G10	SAU802247
E3M10000004H11	EFA205225	E1M10000236A11	ECO102986	S1M10000006G10	SAU802248
E3M10000004H11	EFA201977	E1M10000236C11	ECO101088	S1M10000006B11	SAU801618
E3M10000004H11	EFA203137	E1M10000236F12	ECO101355	S1M10000006G11	SAU802119
E3M10000005B01	EFA201984	E1M10000237A02	ECO103161	S1M10000006G11	SAU802118
E3M10000005B01	EFA201983	E1M10000237B02	ECO101830	S1M10000006A12	SAU800548
E3M10000005C01	EFA200839	E1M10000237E04	ECO103217	S1M10000006B12	SAU802558
E3M10000005E01	EFA201977	E1M10000237E04	ECO103218	S1M10000007F01	SAU801256
E3M10000005E01	EFA203137	E1M10000237H04	ECO103624	S1M10000007B02	SAU800591
E3M10000005E02	EFA201977	E1M10000237H04	ECO103625	S1M10000007B02	SAU800592
E3M10000005E02	EFA203137	E1M10000237G06	ECO103232	S1M10000007F02	SAU801366
E3M10000005C03	EFA200811	E1M10000237G06	ECO103233	S1M10000007G02	SAU801138
E3M10000005C03	EFA200812	E1M10000237C07	ECO103886	S1M10000007A03	SAU801899
E3M10000005D03	EFA200811	E1M10000237G07	ECO103263	S1M10000007D03	SAU802496
E3M10000005D03	EFA200812	E1M10000237H07	ECO102267	S1M10000007G03	SAU800967
E3M10000005E03	EFA200811	E1M10000237A08	ECO103217	S1M10000007C04	SAU801740
E3M10000005E03	EFA200812	E1M10000237A08	ECO103216	S1M10000007E04	SAU802496
E3M10000005C04	EFA200660	E1M10000237B08	ECO101185	S1M10000007F04	SAU800478
E3M10000005C04	EFA200661	E1M10000237B08	ECO101186	S1M10000007C05	SAU800547
E3M10000005D04	EFA200839	E1M10000237D08	ECO103217	S1M10000007G05	SAU800548
E3M10000005H04	EFA200839	E1M10000237D08	ECO103216	S1M10000007C06	SAU801900
E3M10000005G05	EFA201977	E1M10000237E08	ECO103262	S1M10000007D06	SAU800547
E3M10000005G05	EFA203137	E1M10000237E08	ECO103878	S1M10000007E06	SAU801113
E3M10000005A07	EFA200811	E1M10000237E08	ECO204942	S1M10000007C07	SAU801904
E3M10000005A07	EFA200812	E1M10000237B09	ECO101844	S1M10000007E07	SAU801618
E3M10000005F07	EFA200839	E1M10000237D10	ECO102060	S1M10000007G07	SAU802638
E3M10000005B08	EFA201977	E1M10000237D10	ECO102061	S1M10000007C08	SAU800482
E3M10000005B08	EFA203137	E1M10000237E11	ECO100169	S1M10000007E08	SAU800700
E3M10000005E08	EFA202276	E1M10000238G01	ECO103451	S1M10000007F08	SAU802261
E3M10000005D10	EFA201977	E1M10000238A02	ECO103514	S1M10000007F09	SAU800210
E3M10000005D10	EFA203137	E1M10000238F03	ECO101939	S1M10000007D10	SAU800537
E3M10000005F10	EFA201977	E1M10000238B04	ECO103262	S1M10000007F10	SAU802240
E3M10000005F10	EFA203137	E1M10000238B04	ECO103878	S1M10000007B11	SAU802177
E3M10000006C01	EFA201982	E1M10000238B04	ECO204942	S1M10000007B11	SAU802176
E3M10000006C01	EFA201981	E1M10000238D04	ECO104147	S1M10000007D11	SAU801900
E3M10000006G02	EFA202214	E1M10000238F04	ECO103224	S1M10000008F01	SAU802160
E3M10000006G02	EFA202216	E1M10000238F04	ECO103225	S1M10000008F01	SAU603460
E3M10000006B03	EFA201999	E1M10000238E05	ECO103263	S1M10000008F02	SAU800519
E3M10000006B03	EFA201997	E1M10000238F05	ECO100194	S1M10000008G02	SAU802643
E3M10000006D03	EFA201982	E1M10000238F05	ECO100195	S1M10000008A03	SAU802177
E3M10000006D03	EFA201981	E1M10000238D06	ECO101185	S1M10000008A03	SAU802176
E3M10000006F04	EFA200811	E1M10000238D06	ECO101186	S1M10000008B03	SAU800023
E3M10000006F04	EFA200812	E1M10000238F06	ECO103229	S1M10000008F03	SAU800753
E3M10000006G04	EFA201999	E1M10000238F06	ECO103230	S1M10000008G03	SAU802369

Clone Name	Gene LocusID	Clone Name	Gene LocusID	Clone Name	Gene LocusID
E3M10000006G04	EFA201997	E1M10000238A07	ECO103236	S1M10000008A04	SAU800478
E3M10000006H09	EFA201028	E1M10000238A07	ECO103237	S1M10000008B04	SAU802496
E3M10000006E11	EFA200811	E1M10000238A08	ECO101628	S1M10000008D05	SAU800517
E3M10000006E11	EFA200812	E1M10000238E08	ECO103237	S1M10000008D05	SAU202623
E3M10000006C12	EFA205225	E1M10000238E08	ECO103238	S1M10000008E05	SAU801183
E3M10000006C12	EFA201977	E1M10000238B09	ECO102213	S1M10000008G05	SAU800305
E3M10000006C12	EFA203137	E1M10000238G09	ECO103242	S1M10000008B06	SAU802225
E3M10000006G12	EFA201999	E1M10000238H09	ECO101324	S1M10000008F06	SAU800381
E3M10000006G12	EFA201997	E1M10000238F12	ECO100179	S1M10000008A08	SAU800195
E3M10000007F01	EFA201999	E1M10000238F12	ECO100180	S1M10000008B08	SAU801900
E3M10000007F01	EFA201997	E1M10000239B01	ECO104091	S1M10000008C08	SAU800006
E3M10000007G01	EFA201999	E1M10000239B01	ECO104092	S1M10000008E08	SAU800548
E3M10000007G01	EFA201997	E1M10000239D01	ECO102636	S1M10000008F08	SAU801618
E3M10000007A02	EFA201999	E1M10000239D02	ECO103885	S1M10000008A09	SAU800381
E3M10000007A02	EFA201997	E1M10000239C03	ECO103222	S1M10000008B09	SAU801193
E3M10000007B02	EFA201999	E1M10000239C03	ECO103223	S1M10000008C09	SAU802238
E3M10000007B02	EFA201997	E1M10000239E04	ECO104090	S1M10000008E09	SAU801698
E3M10000007B03	EFA201999	E1M10000239F04	ECO104243	S1M10000008F09	SAU802496
E3M10000007B03	EFA201997	E1M10000239F04	ECO104242	S1M10000008B10	SAU801740
E3M10000007C03	EFA201982	E1M10000239C05	ECO102827	S1M10000008E10	SAU801621
E3M10000007C03	EFA201981	E1M10000239C05	ECO102828	S1M10000008F10	SAU800537
E3M10000007D03	EFA201999	E1M10000239H05	ECO103697	S1M10000008F11	SAU802502
E3M10000007D03	EFA201997	E1M10000239H07	ECO101139	S1M10000008A12	SAU801740
E3M10000007H03	EFA202214	E1M10000239A08	ECO103886	S1M10000009B01	SAU802397
E3M10000007H03	EFA202216	E1M10000239D08	ECO103886	S1M10000009C01	SAU801516
E3M10000007C04	EFA201028	E1M10000239F08	ECO104187	S1M10000009C01	SAU801515
E3M10000007E05	EFA201980	E1M10000239H08	ECO103885	S1M10000009D01	SAU802189
E3M10000007E05	EFA201981	E1M10000239H10	ECO103226	S1M10000009F01	SAU802507
E3M10000007E05	EFA205229	E1M10000239H10	ECO103227	S1M10000009H01	SAU802397
E3M10000007F06	EFA201999	E1M10000239G11	ECO103886	S1M10000009A02	SAU801286
E3M10000007F06	EFA201997	E1M10000239G12	ECO102425	S1M10000009B02	SAU801286
E3M10000008E02	EFA200360	E1M10000240B03	ECO103239	S1M10000009C02	SAU800118
E3M10000008H02	EFA200766	E1M10000240B03	ECO103240	S1M10000009D02	SAU801362
E3M10000008C03	EFA200805	E1M10000240D03	ECO103228	S1M10000009E02	SAU801516
E3M10000008G05	EFA201999	E1M10000240D03	ECO103229	S1M10000009E02	SAU801515
E3M10000008G05	EFA201997	E1M10000240A04	ECO100198	S1M10000009F02	SAU802139
E3M10000008C08	EFA201637	E1M10000240D06	ECO100179	S1M10000009G02	SAU801516
E3M10000008D08	EFA200805	E1M10000240D06	ECO100180	S1M10000009G02	SAU801515
E3M10000008C09	EFA201986	E1M10000240G07	ECO103242	S1M10000009H02	SAU802632
E3M10000008C09	EFA205255	E1M10000240C08	ECO101259	S1M10000009B03	SAU802397
E3M10000008G09	EFA200839	E1M10000240C08	ECO101258	S1M10000009D03	SAU800118
E3M10000008G09	EFA200840	E1M10000240F08	ECO100095	S1M10000009F03	SAU800476
E3M10000009D01	EFA201986	E1M10000240B10	ECO101259	S1M10000009G03	SAU802502
E3M10000009D01	EFA205255	E1M10000240B10	ECO101258	S1M10000009H03	SAU800176
E3M10000009E02	EFA201986	E1M10000240B11	ECO103624	S1M10000009H03	SAU800177
E3M10000009E02	EFA205255	E1M10000240B11	ECO103625	S1M10000009A04	SAU801013
E3M10000009G02	EFA200805	E1M10000240H11	ECO103161	S1M10000009B04	SAU801193
E3M10000009E03	EFA202001	E1M10000240B12	ECO100886	S1M10000009D04	SAU801013
E3M10000009E05	EFA200805	E1M10000241F01	ECO103885	S1M10000009B05	SAU800542
E3M10000009H06	EFA200495	E1M10000241A02	ECO103263	S1M10000009C05	SAU800542
E3M10000009C07	EFA202216	E1M10000241H02	ECO103624	S1M10000009D05	SAU802511
E3M10000009C07	EFA104836	E1M10000241H02	ECO103625	S1M10000009F05	SAU800542
E3M10000009C09	EFA200807	E1M10000241A04	ECO103263	S1M10000009G05	SAU800542

Clone Name	Gene LocusID	Clone Name	Gene LocusID	Clone Name	Gene LocusID
E3M10000010F01	EFA201976	E1M10000241C06	ECO101232	S1M10000009H05	SAU800230
E3M10000010F01	EFA201977	E1M10000241C06	ECO101233	S1M10000009B06	SAU801139
E3M10000010H02	EFA201976	E1M10000241F06	ECO103265	S1M10000009C06	SAU800259
E3M10000010D05	EFA201523	E1M10000241H07	ECO103263	S1M10000009E06	SAU801760
E3M10000010G07	EFA201993	E1M10000241A08	ECO103607	S1M10000009F06	SAU800542
E3M10000010C08	EFA200807	E1M10000241B08	ECO103263	S1M10000009G06	SAU801257
E3M10000010G09	EFA202012	E1M10000241E08	ECO100777	S1M10000009A07	SAU800153
E3M10000010G10	EFA202007	E1M10000241G08	ECO103265	S1M10000009B07	SAU800357
E3M10000011H02	EFA200811	E1M10000241A09	ECO101834	S1M10000009C07	SAU800306
E3M10000011B03	EFA202007	E1M10000241E09	ECO102593	S1M10000009D07	SAU801094
E3M10000011D03	EFA201987	E1M10000241H09	ECO103481	S1M10000009D07	SAU801095
E3M10000011D03	EFA205258	E1M10000241B11	ECO102588	S1M10000009F07	SAU800252
E3M10000011C07	EFA200307	E1M10000241E12	ECO102144	S1M10000009G07	SAU801511
E3M10000011A09	EFA200840	E1M10000242D06	ECO101089	S1M10000009H07	SAU802711
E3M10000011B09	EFA200805	E1M10000242F07	ECO103264	S1M10000009A08	SAU802100
E3M10000012B01	EFA201028	E1M10000242H07	ECO100663	S1M10000009A08	SAU802098
E3M10000012C01	EFA201028	E1M10000242F08	ECO102610	S1M10000009A08	SAU802099
E3M10000012B02	EFA201888	E1M10000242E11	ECO101932	S1M10000009C08	SAU802100
E3M10000012G02	EFA201993	E1M10000242H11	ECO103243	S1M10000009E08	SAU802539
E3M10000012F05	EFA201999	E1M10000242H11	ECO103244	S1M10000009E08	SAU202590
E3M10000012F06	EFA205257	E1M10000242E12	ECO101048	S1M10000009A09	SAU800006
E3M10000012B07	EFA201986	E1M10000243F03	ECO100245	S1M10000009C09	SAU801205
E3M10000012B07	EFA205255	E1M10000243G03	ECO102512	S1M10000009D09	SAU801507
E3M10000012B07	EFA201985	E1M10000243B04	ECO102277	S1M10000009D09	SAU801508
E3M10000012F07	EFA201981	E1M10000243B04	ECO102278	S1M10000009D09	SAU200470
E3M10000012F07	EFA205229	E1M10000243F04	ECO101684	S1M10000009E09	SAU801011
E3M10000012G07	EFA201986	E1M10000243F04	ECO101685	S1M10000009F09	SAU802496
E3M10000012G07	EFA205255	E1M10000243F06	ECO101714	S1M10000009G09	SAU801680
E3M10000012B08	EFA205257	E1M10000243F07	ECO100465	S1M10000009H09	SAU800543
E3M10000012D10	EFA200805	E1M10000243H07	ECO102922	S1M10000009A10	SAU802100
E3M10000012F10	EFA201986	E1M10000243F09	ECO101575	S1M10000009A10	SAU802099
E3M10000012F10	EFA205255	E1M10000243B10	ECO101152	S1M10000009B10	SAU802244
E3M10000013D02	EFA202001	E1M10000243B10	ECO101153	S1M10000009B10	SAU802243
E3M10000013E02	EFA201028	E1M10000243E11	ECO103488	S1M10000009C10	SAU802610
E3M10000013H03	EFA201985	E1M10000244F01	ECO100404	S1M10000009F10	SAU800189
E3M10000013C05	EFA202001	E1M10000244C02	ECO103233	S1M10000009G10	SAU800463
E3M10000013C05	EFA205285	E1M10000244C02	ECO103234	S1M10000009A11	SAU801011
E3M10000013F05	EFA200811	E1M10000244E02	ECO101475	S1M10000009B11	SAU802654
E3M10000013H05	EFA201997	E1M10000244E02	ECO101476	S1M10000009C11	SAU802606
E3M10000013A06	EFA202003	E1M10000244E02	ECO201962	S1M10000009D11	SAU802503
E3M10000013A07	EFA202001	E1M10000244H02	ECO103160	S1M10000009D11	SAU802502
E3M10000013D08	EFA201983	E1M10000244H02	ECO103161	S1M10000009E11	SAU802230
E3M10000013E08	EFA200805	E1M10000244B03	ECO101475	S1M10000009G11	SAU800942
E3M10000013D10	EFA201987	E1M10000244B03	ECO101476	S1M10000009H11	SAU802230
E3M10000013D10	EFA205258	E1M10000244B03	ECO201962	S1M10000009B12	SAU800001
E3M10000013G10	EFA200842	E1M10000244E03	ECO103160	S1M10000009E12	SAU801516
E3M10000014G09	EFA201204	E1M10000244E03	ECO103161	S1M10000009G12	SAU700396
E3M10000014B12	EFA205225	E1M10000244F03	ECO102669	S1M10000011B01	SAU802249
E3M10000014B12	EFA201977	E1M10000244A04	ECO102336	S1M10000011B01	SAU802248
E3M10000014B12	EFA203137	E1M10000244D04	ECO103218	S1M10000011C01	SAU802510
E3M10000014E12	EFA205257	E1M10000244E04	ECO101987	S1M10000011D01	SAU801677
E3M10000014E12	EFA201986	E1M10000244G07	ECO103697	S1M10000011F01	SAU801618
E3M10000015B04	EFA201611	E1M10000244D08	ECO100169	S1M10000011G01	SAU800490

Clone Name	Gene LocusID	Clone Name	Gene LocusID	Clone Name	Gene LocusID
E3M10000015B12	EFA201999	E1M10000244E08	ECO100850	S1M10000011H01	SAU801741
E3M10000015E12	EFA201987	E1M10000244G08	ECO103885	S1M10000011A02	SAU800517
E3M10000015E12	EFA205258	E1M10000244B09	ECO103181	S1M10000011B02	SAU801179
E3M10000016A03	EFA201946	E1M10000244E10	ECO104266	S1M10000011D02	SAU800517
E3M10000016D03	EFA201512	E1M10000244E10	ECO305338	S1M10000011E02	SAU802275
E3M10000016A04	EFA205257	E1M10000244E11	ECO102588	S1M10000011E02	SAU802276
E3M10000016G05	EFA205288	E1M10000244F11	ECO100453	S1M10000011H02	SAU802713
E3M10000016G05	EFA203140	E1M10000244C12	ECO101372	S1M10000011A03	SAU801139
E3M10000016H05	EFA202001	E1M10000244E12	ECO103244	S1M10000011B03	SAU801580
E3M10000016F06	EFA200544	E1M10000244F12	ECO103223	S1M10000011C03	SAU802713
E3M10000016F10	EFA201986	E1M10000245C01	ECO101259	S1M10000011E03	SAU800453
E3M10000016F10	EFA205255	E1M10000245E02	ECO101067	S1M10000011F03	SAU800593
E3M10000016H10	EFA205257	E1M10000245E03	ECO101258	S1M10000011G03	SAU801487
E3M10000017A09	EFA205285	E1M10000245H03	ECO100169	S1M10000011G03	SAU801490
E3M10000017A09	EFA201999	E1M10000245A04	ECO101067	S1M10000011H03	SAU800539
E3M10000017D09	EFA201985	E1M10000245B04	ECO103074	S1M10000011A04	SAU802240
E3M10000018E01	EFA200839	E1M10000245B04	ECO103075	S1M10000011B04	SAU801514
E3M10000018C02	EFA201028	E1M10000245D04	ECO102815	S1M10000011B04	SAU801513
E3M10000018H06	EFA201981	E1M10000245B05	ECO103885	S1M10000011D04	SAU802162
E3M10000018A07	EFA202007	E1M10000245C05	ECO100179	S1M10000011E04	SAU801516
E3M10000018G09	EFA203904	E1M10000245C05	ECO100180	S1M10000011F04	SAU801252
E3M10000019D02	EFA202022	E1M10000245D05	ECO103514	S1M10000011G04	SAU801139
E3M10000019E03	EFA200807	E1M10000245F06	ECO103884	S1M10000011H04	SAU802448
E3M10000019E04	EFA200805	E1M10000245B07	ECO103878	S1M10000011B05	SAU802448
E3M10000019B06	EFA201888	E1M10000245B07	ECO204942	S1M10000011C05	SAU800539
E3M10000020G04	EFA200807	E1M10000245E09	ECO103262	S1M10000011G05	SAU800593
E3M10000020H05	EFA200840	E1M10000245E09	ECO103878	S1M10000011A06	SAU801514
E3M10000021C03	EFA200805	E1M10000245E09	ECO204942	S1M10000011A06	SAU801513
E3M10000021C04	EFA205285	E1M10000245G09	ECO103218	S1M10000011C06	SAU800593
E3M10000021D04	EFA200807	E1M10000245B11	ECO102040	S1M10000011D06	SAU800743
E3M10000021G04	EFA201974	E1M10000245C11	ECO103242	S1M10000011F06	SAU801230
E3M10000021A08	EFA201999	E1M10000245C11	ECO103243	S1M10000011F06	SAU801231
E3M10000021A08	EFA201997	E1M10000245D11	ECO101628	S1M10000011G06	SAU802710
E3M10000021C08	EFA202001	E1M10000245E11	ECO103221	S1M10000012B01	SAU801301
E3M10000021B10	EFA201997	E1M10000245E11	ECO103222	S1M10000012C01	SAU801900
E3M10000021E10	EFA202006	E1M10000245E11	ECO103223	S1M10000012E01	SAU801471
E3M10000021G10	EFA201028	E1M10000245H11	ECO103232	S1M10000012E01	SAU801470
E3M10000021A11	EFA201981	E1M10000245H11	ECO103233	S1M10000012G01	SAU801193
E3M10000021G11	EFA201997	E1M10000245B12	ECO103181	S1M10000012A02	SAU802565
E3M10000021H11	EFA201997	E1M10000245D12	ECO103227	S1M10000012A02	SAU802564
E3M10000022G02	EFA202298	E1M10000245D12	ECO103228	S1M10000012E02	SAU800329
E3M10000022A04	EFA201986	E1M10000245E12	ECO103116	S1M10000012G02	SAU800422
E3M10000022B04	EFA201986	E1M10000246F01	ECO103481	S1M10000012C03	SAU800276
E3M10000022D04	EFA201985	E1M10000246B02	ECO103886	S1M10000012F03	SAU802332
E3M10000022B05	EFA201986	E1M10000246D03	ECO100850	S1M10000012F03	SAU802333
E3M10000022B05	EFA205255	E1M10000246E03	ECO101184	S1M10000012G03	SAU300404
E3M10000022C05	EFA202001	E1M10000246G03	ECO103185	S1M10000012C04	SAU800276
E3M10000022C05	EFA205285	E1M10000246G03	ECO103186	S1M10000012D04	SAU800357
E3M10000022F05	EFA200805	E1M10000246C05	ECO102253	S1M10000012E04	SAU800345
E3M10000022C06	EFA201975	E1M10000246A06	ECO102091	S1M10000012F04	SAU802238
E3M10000022F06	EFA205285	E1M10000246B06	ECO101712	S1M10000012B05	SAU801515
E3M10000022F06	EFA201999	E1M10000246D06	ECO100672	S1M10000012C05	SAU801741
E3M10000022B07	EFA202012	E1M10000246C07	ECO103217	S1M10000012D05	SAU800424